Nanotechnology for the delivery of vaccines by Wilkinson, Alexander
DOCTOR OF PHILOSOPHY
Nanotechnology for the delivery of
vaccines
Alexander Wilkinson
2014
Aston University
  
 
 Some pages of this thesis may have been removed for copyright restrictions. 
 
If you have discovered material in AURA which is unlawful e.g. breaches copyright, (either 
yours or that of a third party) or any other law, including but not limited to those relating to 
patent, trademark, confidentiality, data protection, obscenity, defamation, libel, then please 
read our Takedown Policy and contact the service immediately 
  
1 
 
 
 
 
 
 
 
 
NANOTECHNOLOGY FOR THE DELIVERY OF VACCINES 
 
 
Alexander Wilkinson 
Doctor of Philosophy 
 
 
 
ASTON UNIVERSITY 
September 2013 
 
 
©Alexander Wilkinson 2013 
Alexander Wilkinson asserts his moral right to be identified as the author of this thesis 
 
 
 
 
 
This copy of the thesis has been supplied on condition that anyone who consults it is 
understood to recognise that its copyright rests with its author and that no quotation from 
the thesis and no information derived from it may be published without proper 
acknowledgement 
2 
 
Aston University  
Nanotechnology for the delivery of vaccines 
Alexander Wilkinson 
Doctor of Philosophy 
2013 
Summary 
Liposomes offer an ideal platform for the delivery of subunit vaccines, due to their versatility and 
flexibility, which allows for antigen as well as immunostimulatory lipids and TLR agonists to become 
associated with these bilayered vesicles. Liposomes have the ability to protect vaccine antigen, as 
well as enhance delivery to antigen presenting cells, whilst the importance of cationic surface charge 
for delivery of TB subunit vaccines and formation of an ‘antigen depot’ may play a key role in 
boosting cell-mediated immunity and Th1 immune responses. The rational design of vaccine 
adjuvants requires the thorough investigation into the physicochemical characteristics that dictate 
the function of a liposomal adjuvant. Within this thesis, physicochemical characteristics were 
investigated in order to show any effects on the biodistribution profiles and the ensuing immune 
responses of these formulations.  
Initially the role of liposome charge within the formulation was investigated and subsequently their 
efficacy as vaccine adjuvants in combination with their biodistribution was measured to allow the 
role of formulation in vaccine function to be considered. These results showed that cationic surface 
charge, in combination with high loading of H56 vaccine antigen through electrostatic binding, was 
crucial in the promotion of the ‘depot-effect’ at the injection site which increases the initiation of 
Th1 cell-mediated immune responses that are required to offer protection against tuberculosis. To 
further investigate this, different methods of liposome production were also investigated where 
antigen incorporation within the vesicles as well as surface adsorption were adopted. Using the 
dehydration-rehydration (DRV) method (where liposomes are freeze-dried in the presence of 
antigen to promote antigen encapsulation) and the double emulsion (DE) method, a range of 
liposomes entrapping antigen were formulated. Variation in the liposome preparation method can 
lead to antigen entrapment within the delivery system which has been shown to be greater for DRV-
formulated liposomes compared to their DE-counterparts. This resulted in no significant effect on 
the vaccine biodistribution profile, as well as not significantly altering the efficacy of cationic 
liposomal adjuvants. To further enhance the efficacy of these systems, the addition of TLR agonists 
either at the vesicle surface as well as within the delivery system has been displayed through 
variation in the preparation method.  
Anionic liposomal adjuvants have been formulated, which displayed rapid drainage from the 
injection site to the draining lymph nodes and displayed a reduction in measured Th1 immune 
responses. However, variation in the preparation method can alter the immune response profile for 
anionic liposomal adjuvants with a bias in immune response to Th2 responses being noted. Through 
the use of high shear mixing and stepwise incorporation, the efficient loading of TLR agonist within 
liposomes has been shown. However, interestingly the conjugation between lipid and non-
electrostatically bound TLR agonist, followed by insertion into the bilayer of DDA/TDB resulted in 
localised agonist retention at the injection site and further stimulation of the Th1 immune response 
at the SOI, spleen and draining lymphatics as well as enhanced antibody titres. 
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1.1. Historical Background  
1.1.1. Vaccination 
 
The groundwork of modern vaccination was put down in the 18th century by Edward Jenner. He 
discovered that patients with smallpox could be protected with the mild related form of the disease, 
cowpox. This ultimately led to the development of an effective vaccine against smallpox, and laid the 
foundation for the treatment and protection against other contagious diseases (Plotkin, 2005). The 
idea behind vaccination can be traced back as early as 430 BC, when survivors of smallpox were used 
to nurse sufferers of this disease, however it was not until the 10th century AD and over the 
following few centuries that efforts were made in China to transfer smallpox infection to susceptible 
individuals, with the aim of combating this disease in a process termed inoculation (Gross and 
Sepkowitz, 1998). 
The basic theory behind vaccination is the attainment of immunity against an infectious agent 
without the prior need for an initial infection against the specific disease. The initial innate immune 
response is unable to counteract the initial major disease symptoms. However, the memory cells 
involved in the adaptive immune response ‘remember’ the first encounter with the disease 
pathogen. This results in the rapid onset of protective reactions against a specific disease (Bramwell 
and Perrie, 2005b, 2006, Perrie et al., 2007). For a vaccine to be deemed effective it must pass a 
certain number of aspects in that it is able to generate increased immune responses, as well as offer 
an enhanced safety profile and provide a safe form of health care. There are a range of vaccine types 
currently available or in clinical trials which will be described in more detail in Section 1.2. Subunit 
vaccines offer several advantages over live vaccines, however they tend to lack efficacy therefore 
adjuvants are often employed to improve immune responses. 
 
1.1.2. Liposomes 
 
Liposomes were originally described in the mid 1960s by Bangham and colleagues who observed 
that smears of lipid (egg lecithin) were able to react with water to form intricate vesicular structures, 
and following analysis by electron microscopy the spontaneous formation of vesicles was observed 
(Bangham et al., 1965). Following their discovery, in the initial years of liposome research these 
vesicles were used as models for artificial membranes (due to their similar membrane bilayer 
structure) in order to simulate cellular systems for the investigation of transport functions and 
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permeation properties (Bangham et al., 1967, Papahadjopoulos and Watkins, 1967). Furthermore, 
initial pioneering work on liposomes was undertaken by Gregoriadis and colleagues in the 1970s and 
80s who described their ability to act as delivery systems for drugs (Gregoriadis and Ryman, 1971, 
Allison and Gregoriadis, 1974, Gregoriadis, 1988). Simultaneously, liposomes were shown to have 
the ability to change the in vivo biodistribution of drugs (Poste and Papahadjopoulos, 1976, Poste et 
al., 1976), as well as enhance the drug loading and subsequent controlled release in order to 
increase bioavailability, and also increase entrapment efficiency (Szoka and Papahadjopoulos, 1978).  
Many of the advantages of liposomes as drug delivery systems can be applied in their use as vehicles 
for the delivery of vaccine antigens, through adsorption at the liposome surface or entrapment 
within (Gregoriadis and Ryman, 1971, Allison and Gregoriadis, 1974, Gregoriadis et al., 1987, 
Gregoriadis, 1989, 1994, Gregoriadis et al., 1999). Therefore, the delivery of vaccine antigens within 
liposome delivery systems will be primarily addressed during this thesis. 
 
1.2. Current vaccine strategies against Tuberculosis (TB) 
1.2.1. Types of Vaccines 
 
There are three main sub-categories of vaccines: live, inactivated and sub-unit. The adjuvant 
capability of live vaccines is based on the sustained ability of the immune system to detect signals of 
hazardous microbes. The application of live vaccines has been shown to reduce the effects of 
disease; however, there are certain disadvantages such as virus reversion, perseverance and 
production issues. As described in more detail in Section 1.2, an example of a live vaccine is the TB 
vaccine, Bacille-Calmette Guerin (BCG). This vaccine is fairly cost-effective and economical and 
provides high efficacy against TB for infants. However BCG had markedly reduced efficacy in adults, 
due to the inability to protect against the pulmonary form of this disease in adults (Delogu and 
Fadda, 2009). 
In terms of vaccine subtypes, subunit vaccines have the best safety profile (Perrie et al., 2008). This 
vaccine subset provide several key advantages in that they contain pure recombinant antigens which 
have the ability to decrease disease-associated side effects and generate an increased safety profile 
(Black et al., 2010). Although there are several drawbacks to these vaccines including reduced 
potency, requirement of more doses, the induction of unneeded host reactions and the limited 
nature of the produced level of immunity only resulting in humoural responses. However, 
administration of subunit vaccines alone lack the inherent immunogenicity themselves to produce 
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an effective immune response. Therefore, these vaccines require the combined presence of an 
adjuvant delivery system to increase and lengthen the levels of protective immunity (Bramwell and 
Perrie, 2005a, O'Hagan and De Gregorio, 2009, Reed et al., 2009).  
Even though there have been many successes and breakthroughs in the fields of vaccination and 
disease prevention, there remains a requirement for the development of vaccines against malaria 
and human immunodeficiency virus (HIV) and new effective TB vaccines, amongst others. Therefore 
ongoing research into vaccine formulation and technology is crucial to provide safe effective 
vaccines against infectious diseases (Martin, 2005, Delogu and Fadda, 2009, Reed et al., 2009). 
 
1.2.2. Success criteria for vaccines 
 
Vaccination is one of the primary methods that can be used in order to control the spread of disease 
and infection (especially tuberculosis, HIV, and malaria) by the introduction of antigenic material to 
stimulate the immune system of an individual. The main objective of a vaccine is to ‘promote long-
term immunological protection against the establishment of a specific infection’ (Perrie et al., 2007). 
There are some general criteria that a vaccine must satisfy, or a vaccine would significantly benefit 
from. A good vaccine must be able to elicit an appropriate immune response required for vaccine 
efficacy in order to control and eradicate a specific infectious disease. The vaccine must also be safe 
to administer, cost-effective and be administered in a stable and reproducible formulation (Perrie et 
al., 2007). If these criteria are satisfied this could have dramatic implications in the development of a 
successful vaccine. For a vaccine delivery system to be effective it requires the ability to ‘prime’ the 
immune system so that it can respond quickly and efficiently to limit infection to a specific pathogen 
in the vaccinated host organism (Altin and Parish, 2006). 
 
1.2.3. Tuberculosis 
 
As mentioned, tuberculosis (TB) remains a major global healthcare concern. TB is an airborne 
disease and is one of the commonest serious infectious diseases worldwide with about 8.8 million 
new cases diagnosed worldwide, with 1.4 million people dying in 2010 (WHO, 2011). This infection is 
out of control in developing and poverty-stricken regions such as Africa, where HIV-infection is also a 
serious problem. There is a clear synergistic relationship between M. tuberculosis and the human 
immunodeficiency virus (HIV), as individuals with active tuberculosis (TB) are more likely to become 
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immunodeficient to the HIV virus, thus causing increased mortality (Toossi et al., 2001, Corbett et al., 
2003). Control strategies and antibiotics against TB increasingly rely on at least three drugs for long 
periods of time; however, resistance to these drugs and difficulties with patient compliance has 
limited the control of this disease (Martin, 2005). 
The only current available vaccine against this disease is the nearly century-old Bacille-Calmette-
Guerin (BCG) vaccine, which is based on an attenuated form of the Mycobacterium bovis strain. This 
vaccine is able to protect against childhood forms of TB, but it struggles to protect against 
pulmonary TB in adults (Delogu and Fadda, 2009, Dheda et al., 2010). Although greater than 90 % of 
individuals infected with TB are able to effectively contain infection in the latent or subclinical stage, 
this huge number of latently infected individuals leads to a high number of active TB cases later in 
life (Ottenhoff and Kaufmann, 2012). 
This vaccine is unable to confer protection against TB in adults due to the existence of many strains 
of TB in the world today, including multidrug-resistant-TB (MDR-TB) and extremely drug resistant-TB 
(XDR-TB) strains. All of these strains have genetic differences which have resulted in this vaccine 
being unable to protect against all forms of this disease. Also, these strains have many antigenic and 
immunological differences (Delogu and Fadda, 2009) that lead to their potential reduction in efficacy 
against TB. Therefore it is of critical importance to develop an improved vaccine formulation against 
all forms of this disease. This vaccine must be capable of eliciting an appropriate immune response 
in individuals at high risk of developing TB. Therefore this situation ‘emphasises the need for a 
vaccine that can reduce, or even prevent transmission of TB’ (Ottenhoff et al., 2010). The first new-
generation TB vaccines are currently involved in clinical trials. These vaccines are summarised in 
Table 1.1. 
The lung is the point of entry of the M. tuberculosis (M. tb) bacterium as it enters the body through 
the airways whilst this infection is firmly established in macrophages, local dendritic cells and 
epithelial cells of the distal alveolar compartment before being recognised by CD4+ and CD8+ T-cells 
in order to generate levels of protective immunity (Martin, 2005, Reece and Kaufmann, 2008). M. tb 
organisms are able to be transmitted through aerosols originating from the lungs of individuals with 
active TB and have the unique ability to establish infection while also delaying the onset of adaptive 
immune responses by 2-3 weeks (Wolf et al., 2008). This strategy allows M. tb to establish infection 
resulting in the formation of two populations of these microorganisms; dormant (or latent) 
organisms which can be retained in a low metabolic state and resuscitate later in life, or active 
metabolically active bacterium which stimulate the local immune response but also lead to 
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pathological hallmarks of TB including the formation of necrotic lesions (Reece and Kaufmann, 
2012). 
The host immunity to mycobacterial infections is dependent on IFN-γ and IL-12, therefore showing 
the importance of a Th1-mediated immunity against M. tuberculosis. The most effective vaccination 
strategies against TB involve the stimulation of CD4 and CD8 T-cell responses in order to produce 
cytokines associated with the Th1 (cell mediated immune or CMI) response, such as IFN-γ and IL-2. 
Table 1.1. Current TB vaccine candidates in clinical trials 
Vaccine Strategy Vaccine Candidate Vaccine Description Clinical trials? 
Pre-exposure prime 
vaccination using 
recombinant BCG VPM 1002 
rBCG-expressing listeriolysin 
and urease deletion Phase IIa 
  rBCG30 rBCG-expressing Ag85B Phase I 
  Aeras-422 
rBCG-expressing perfringolysin 
and Ag85A, B, Rv3407 
Phase I 
terminated due 
to side effects 
Pre-exposure booster 
vaccination using viral 
vectors Aeras-485 
Modified vaccinia Ankara-
expressing Ag85A Phase IIb ongoing 
  Aeras-402 
Ad35-expressing Ag85A, B and 
TB10.4 Phase IIb ongoing 
  AdAg85A Ad5-expressing Ag85A Phase I 
Pre-exposure booster 
vaccination using fusion 
protein in adjuvants 
Hybrid1 in 
combination with 
IC31 
Fusion of Ag85B and ESAT6 in 
IC31 adjuvant Phase I/IIa 
  
Hybrid56 in 
combination with 
IC31 
Fusion of Ag85B, ESAT6 and 
Rv2660c in IC31 adjuvant Phase I 
  
Hybrid1 in 
combination with 
CAF01 
Fusion of Ag85B and ESAT6 in 
CAF01 adjuvant Phase I 
  Aeras-404 
Fusion of Ag85B and TB10.4 in 
IC31 adjuvant Phase I 
Therapeutic vaccination 
using whole bacteria RUTI Detoxified M. Tb in liposomes Phase IIa 
 
1.2.4. Mycobacterial antigens and their potential as vaccine candidates 
 
Whereas mycobacterial whole cell vaccines are highly immunogenic, vaccines based on sub-unit 
antigens rely on effective adjuvants or delivery systems in order to promote their immune response. 
However, vaccines based on these simplified sub-units have an increased profile when it comes to 
safety and quality control (Perrie et al., 2007, Perrie et al., 2008). During the past several years, the 
combination between antigen and adjuvant has been used extensively in order to provoke specific 
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immune responses against mycobacteria in a tuberculosis vaccine model (Davidsen et al., 2005). 
Subunit vaccines for TB, in the majority, are based on recombinant proteins in combination with 
proper adjuvants. The aim of TB subunit vaccines is often considered for them to be to used as 
‘booster vaccines’ in able to initiate strong, long-lived immune responses in already primed 
individuals (Ottenhoff and Kaufmann, 2012) who have been immunised with BCG- or M. tb priming 
vaccines. 
Over the past decade, a number of TB vaccine research groups have screened more than 250 
mycobacterial antigens for their potential as vaccine candidates, diagnostic tools or biomarkers 
(Christensen et al., 2009). The most recent approach towards the discovery of antigens has focussed 
on the identification of antigens that are preferentially recognized in hosts latently infected with 
mycobacteria with the purpose of using such antigens in future vaccines (Aagaard et al., 2011). To 
date, a number of antigen candidates have been identified for the purpose of identifying a subunit-
based TB vaccine; two of these are preventive vaccines, and the other is a post-exposure vaccine 
candidate (Figure 1.1). This is important as up to one third (1/3) of the population is estimated to be 
infected with TB, either in the active form or the latent form. So an effective vaccine must be 
capable of producing a sufficient immune response to both forms of this disease. 
 
Figure 1-1. Pre- and post-exposure TB-vaccine candidates [A: H1 (Ag85B-ESAT6); B: H4 (Ag85B-TB10.4); C: 
H56 (Ag85B-ESAT6-Rv2660c) which have been used in combination with liposomes in a TB vaccine model. 
 
The first of these vaccine candidates is termed Hybrid1 (H1) which is a fusion of the two proteins 
Ag85B and ESAT6 (Figure 1.1). Both of these proteins have been shown to have immunogenicity by 
themselves (as vaccine antigens), but when in combination (as Hybrid 1) these have a greater effect 
on the immune response (Weinrich Olsen et al., 2001). 
The second of these candidates is referred to as Hyvac (H4), which is a fusion of the two proteins 
Ag85B and TB10.4, which is also expressed by BCG (Elvang et al., 2009). Whereas the post-exposure 
vaccine candidate, termed H56, consists of the Ag85B-ESAT6 fusion protein attached to the latency 
antigen Rv2660c (Figure 1.1). The strategy for this post-exposure vaccine candidate is to selectively 
target the mycobacteria in the dormant stage of infection so therefore this antigen candidate can be 
preferentially expressed as the bacteria adapt to long-term persistence in the immune host, 
Ag85B Ag85B Ag85B ESAT-6 ESAT-6 Rv2660c TB10.4 
H1 H4 H56 
A B C 
34 
 
particularly against late chronic infection (Aagaard et al., 2011). The Rv2660c gene had been 
selected for use in this subunit vaccine combination due to its strong upregulation under starvation 
conditions. 
Both H1 and H56 vaccine antigens have been included in cationic liposome formulations based on 
DDA in combination with TDB. In 2005, Davidsen et al (Davidsen et al., 2005) showed that by 
associating this promising TB-fusion protein antigen, Ag85B-ESAT6 (Weinrich Olsen et al., 2001) with 
DDA/TDB liposomes this could initiate both a strong Th1-immune response and an antibody 
response. This antigen is highly anionic (negatively charged) and has a low isoelectric point (pI) value 
of around 4.0. Therefore high adsorption of this fusion protein antigen is able to occur to cationic 
DDA/TDB liposomes, due to the opposite charge of these components and this interaction is likely to 
be electrostatic in nature.  This subunit protein antigen has been used in subsequent studies in order 
to investigate the importance of various physicochemical characteristics of liposomal adjuvants, with 
strong Th1 immune responses also being initiated (Henriksen-Lacey et al., 2011b, Kaur et al., 2012). 
This formulation, in combination with H1, is currently in phase 1 clinical trials in humans. 
In further studies by Christensen et al (Christensen et al., 2007a, Christensen et al., 2009) freeze-
dried DDA/TDB liposomes have been shown to retain their ability to generate antigen-specific 
immune responses, and this was shown after the immunisation of mice with Ag58B-ESAT6 with this 
trehalose-stabilised adjuvant. Aagaard and colleagues (2011) have investigated the H56 antigen in 
combination with DDA/TDB. In these studies, this combination has been shown to generate a 
significantly better immune response than the BCG vaccine against tuberculosis (TB). This H56 
vaccine is able to promote a T-cell response against all protein components that is characterised by a 
very high proportion of polyfunctional CD4+ T-cells. This vaccine candidate has also been shown to 
be almost ten times more efficient in reducing the bacterial load than the H1 fusion protein (Aagaard 
et al., 2011) and this has been shown in two separate mouse models. These promising results have 
led to the recent advancement of the H56 vaccine into a number of clinical trials. 
Subunit vaccines can also be delivered through viral vector delivery systems with several systems 
currently involved in phase IIb clinical trials. These include the modified vaccine virus Ankara (MVA) 
expressing the subunit antigen Ag85A, which is highly immunogenic in both naive and BCG-primed 
individuals (McShane et al., 2004, Pathan et al., 2007). Also, replication-deficient adeneoviral 
systems (Ad5 or Ad35) containing the subunit antigens Ag85A, B and TB10.4 induce highly strong 
CD4+ and CD8+ T-cell responses as characterised by IFNγ production, therefore showing high 
immunogenicity in humans (Radosevic et al., 2007). 
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1.2.5. Live “Priming” Vaccines 
 
Another avenue of research into TB vaccines is to replace the Bacille-Calmette-Guerin (BCG) vaccine 
with recombinant BCG or genetically attenuated M. tb strains. This can be achieved through the 
overexpression of antigens (such as Ag85A, B, TB10.4 or RD1) that BCG already expresses by itself, 
but not in high enough quantities throughout infection. An example being the recombinant BCG30 
vaccine (rBCG30) which overexpresses Ag85B in BCG and offers improved protection against TB 
(Tullius et al., 2008). 
The second group of live TB vaccines are genetically attenuated M. tb derivatives, which can be 
attained through deletion of essential virulence genes that are involved in the metabolism of 
essential nutrients for these organisms. Examples of these vaccines include ΔRD1 ΔpanCD and ΔPhoP 
Δfad M. tb strains which lead to the induction of protective immunity in normal and 
immunocompromised mice and boast improved safety (Martin et al., 2006, Sambandamurthy et al., 
2006). 
A further vaccine in Phase IIa trials is termed RUTI, which is produced from Mycobacterium 
tuberculosis fragmented into tiny particles and detoxified in order to eliminate the toxic substances 
produced by the bacillus, and delivered in liposomes. This resulted in the induction of T-cell 
responses and shortens the treatment of latent TB infection (Cardona, 2006). 
 
1.3. Components of the immune system 
1.3.1 Adaptive Immunity 
 
It is important to understand how the human immune system responds to combat a specific 
infection, and how it responds to vaccination. As shown in Figure 1.2, the human immune system 
consists of three types of cells (Dendritic cells, T-lymphocytes and B-lymphocytes) that work in 
conjunction in order to provoke a specific immune response (Sprent and Webb, 1987). 
Dendritic cells, such as macrophages, are involved in taking up foreign antigens (derived from 
pathogens) by endocytosis or phagocytosis. Upon uptake, antigen can be broken down by lysosomes 
before they then be presented at the cell surface of T-cells, with Class II MHCs (Major 
Histocompatability Complexes) in association with CD4 glycoproteins (Nordly et al., 2009). These 
cells can then migrate from the site of infection to the regional lymph nodes. At this site, the antigen 
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can then be presented to naïve T-lymphocytes, which causes the secretion of various interleukins 
depending on whether the cellular or humoural arm of the immune response is activated. These 
signals (interleukins) result in the activation of B-lymphocytes; which in turn causes the formation of 
plasma cells and subsequently the secretion of antibodies specific to the antigen presented during 
the initial stage (infection). This leads to an antigen-specific immune response being activated in 
response to the specific antigen used during vaccination (Perrie et al., 2007). 
Figure 1-2. The three cell types that act together to induce an effective immune response [(A) Uptake of 
foreign antigen by dendritic cells such as macrophages before (B) presentation of antigen at the surface of T-
cells at the lymph nodes which causes interleukin secretion which (C) activates B-lymphocytes and hence 
leading to antibody secretion (Perrie et al., 2007). 
 
When an individual encounters a specific antigen for the first time, the immune response is generally 
slow to react because the immune system does not know how to deal with this pathogen, which 
leaves the human body susceptible to infection. During this initial encounter with this specific 
antigen the body can develop an acquired immunity. Therefore, a number of T- and B-lymphocytes 
can survive and differentiate into highly reactive memory and plasma cells accordingly, so upon re-
infection the body can respond in a quicker fashion in order to provide a stronger immune response 
(Figure 1.3). The process of vaccination (with antigen) negates the need for a specific infection in an 
individual in order to cause appropriate immunity to that pathogen, so a quicker immune response 
can be activated when that certain individual encounters infection (for the first time) without that 
individual developing symptoms of that disease (Figure 1.3). 
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Figure 1-3. The development of an immune response after natural infection or vaccination. 
 
CD4+ T-cells can be subdivided into a number of different subsets depending on the cytokines they 
produce and the specific function they perform (Figure 1.4). The early events in an immune response 
can stimulate cytokine production therefore directing the development of these T-cell subsets to a 
distinct lineage, which is strongly dictated by the type of microorganism or antigen which is invading 
the host and also depends strongly on antigen dose and vaccine administration route (Mosmann et 
al., 1986, O'Garra, 1998). Th1 cells can be characterised by their production of interferon-gamma 
(IFN-γ) which is primarily responsible for the eradication of intracellular pathogens, such as M. tb, 
whereas Th2 cells can be characterised by their production of interleukins 4, 5 and 10 which are 
responsible for B-cell growth and differentiation. A further distinct lineage of Th cells can be 
characterised by the production of interleukin-17 (IL-17) and have, therefore, been termed Th17 
cells (Harrington et al., 2005). These cells are important in mediating autoimmune pathology, which 
was previously thought to be a role for Th1 cells. These three separate Th cell lineages can be 
regulated depending on the cytokine milieu with IL-12 and IL-4 previously being shown to regulate 
Th1 and Th2 differentiation respectively, with the differentiation of Th17 cells (Bettelli et al., 2006) 
from naive CD4+ T-cells being shown to be due to IL-6, IL-23 and tumour growth factor-beta (TGF-β). 
A further subset of T-cells, termed regulatory T-cells (Treg), have been shown to be crucial for 
promoting ‘immunological homeostasis’ as well as maintaining the tolerance to self-antigens and 
also curtailing immune responses against pathogens (Cooke, 2006). Treg cells, therefore, shut down 
the immune response after the successful elimination of invading organisms such as Mycobacterium 
tuberculosis. 
Immunity 
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These CD4+ T-cells (often referred to as helper cells) express the CD4 receptor and, therefore, aid in 
immune responses, whereas a further sub-population of T-cells expressing the CD8 receptor are 
termed CD8+ T-cells (or cytotoxic T-lymphocytes). This further T-cell subpopulation recognise antigen 
that is presented on the surface of MHC class I molecules, therefore leading to their destruction 
(Guy, 2007). Antigen when formulated within liposome-TLR agonist adjuvants further results in the 
enhanced delivery of antigen and the stimulation of innate immunity through a process called ‘cross-
priming’ in which the antigen can be presented to CD8+ T-cells (Zaks et al., 2006). 
 
 
 
 
 
 
 
Figure 1-4. Initiation of T-cell responses by pathogen-associated molecular patterns (PAMPs), which are 
present on TLR agonists (SIGNAL 0). The antigen is presented at the surface of APCs (macrophages) and is 
taken up at the surface of T-cells (SIGNAL 1). This will provide the simultaneous delivery of co-stimulatory 
molecules (SIGNAL 2) to the APC. This has the ability to activate several distinct lineages of T-cells; Th1 and 
Th2, Th17 and Treg. 
 
1.3.2 Innate Immunity 
 
The innate immune system plays an important role as the first line of defence against pathogens. 
The main components of this system are phagocytes including macrophages, neutrophils and 
dendritic cells. Phagocyctes can kill these pathogens by engulfing and digesting them. The main 
function of these phagocytes is the discrimination between self and other pathogens, which is 
helped via the family of Toll-Like Receptors (TLRs) (Akira et al., 2003, Akira and Takeda, 2004). The 
stimulation of TLRs results in the activation of dendritic cells leading to the production of cytokines 
(interleukins), indicating a role for these receptors in adaptive immunity as well as innate immunity. 
The innate immune system is known to rely on receptors encoded by the germline in the detection 
of pathogenic or microbial stimuli that takes place during the processes involving cellular stress. All 
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receptors of the TLR family are characterised by containing an extracellular amino-terminal (-NH2) 
domain which comprises a number of leucine rich repeats, as well as a globular cytoplasmic domain 
termed the Toll/interleukin 1 receptor (or TIR) domain. These TLRs can either recognize their specific 
ligands on the cell surface (E.g. TLRs 1, 2, 4, 5, 6, 10 and 11) or intracellularly (TLRs 3, 7, 8,and 9); 
with TLRs located at the cell surface being able to recognise microbial cell wall components such as 
lipopolysaccharides (LPS). In contrast, TLRs can also be localised to intracellular membranes 
(phagosomes and endosomes) where they can recognise viral or microbial nucleic acids (ligands) 
such as dsRNA and ssRNA (Figure 1.5). 
 
In response to the activation of Toll-Like Receptors (TLRs) by their specific molecules or agonists, the 
activation of the downstream signal transduction pathway is largely dependent on a number of 
signalling and adaptor proteins. Upon activation of the majority of TLRs (with the exception of TLR3 
and TLR4), the initial interaction event is with the Toll interleukin1 receptor (TIR) -containing adaptor 
molecule (Figure 1.5), myeloid differentiation factor (Myd88) (Akira et al., 2001). This has been 
shown by the fact that Myd88-deficient mice (Myd88-/-) are unable to produce inflammatory 
cytokines, including IL12 and TNF-α, which are required in the production of a downstream immune 
response (Akira and Hoshino, 2003). These Myd88-deficient (KO) mice are more susceptible to 
infection by various mycobacterial infections, such as M. tb (Scanga et al., 2004). The activation of 
Myd88 in turn leads to the induction of a downstream signalling pathway including the association 
with members of the IL-1 receptor-associated kinase-1 (IRAK) family, such as IRAK-1 and IRAK-4 
(Figure 1.5). This will lead to activation of the TNF Receptor-associated Factor (TRAF6) and 
subsequently the association with the transcription factor Nuclear Factor Kappa-B (NF-κB), which is 
able to translocate into the cytoplasm which causes the increased production of cytokines and 
chemokines (Suzuki et al., 2002, Akira and Takeda, 2004). This complex TLR signal transduction 
therefore causes the initiation of various intracellular signalling pathways which results in the 
activation of the innate immune response (Figure 1.6), as well as modulating the adaptive immune 
response (Quesniaux et al., 2004). 
 
 
 
 
40 
 
Figure 1-5. Toll–like receptors and their ligands and an overview of major TLR signalling pathways 
(Quesniaux et al., 2004). 
 
With regards to signalling via Toll-Like Receptors 3 and 4, upon activation these require the TIR 
domain-containing adaptor-inducing interferon-β (TRIF) and/or the TRIF/TRIF-related adaptor 
molecule (Quesniaux et al, 2004). These pathways are crucial in the activation and maturation of 
antigen presenting cells (APCs) and dendritic cells as well as the subsequent activation of IRF-3 (IFN-
regulated factor3). This causes the late activation of the transcription factor, NF-κB, as well as the 
increased production of IFN- β. Therefore, these key adaptor proteins, along with TLRs, play a key 
role in the induction of innate immunity. These TLR agonists will be described in more detail in 
Section 1.6. 
 
 
 
Figure 1-6. The human immune system consists of two separate barriers in order to respond to foreign 
pathogen or antigen. 
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1.4. The importance of particulate delivery systems for vaccine delivery 
 
Most of the vaccines which are currently available are based on live organisms, due to their strong 
potency. In most cases, these vaccines are safe and effective but they also have associated risks and 
cause adverse symptoms (Perrie et al., 2007).  
In terms of an increased safety profile, vaccines can be administered as synthetic peptides or sub-
unit proteins (Perrie et al., 2008). Adjuvants are substances or formulations which can non-
specifically enhance or modify the immune response to a specific antigen. Many typical adjuvants 
which are currently in use are particulate-based. These particulates are passively targeted to antigen 
presenting cells (APCs) and have specific ability to provide persistent antigen due to slow 
degradation, due to association within the particulate delivery system. Examples of these delivery 
systems include mineral salts (aluminium-based adjuvants), saponins, liposomes, cationic lipid-based 
systems, niosomes (non-ionic surfactants), virosomes, immunostimulatory complexes (ISCOMs), 
polymer-based systems (E.g. PLGA microspheres), emulsions and combination systems. 
Formulation of antigens in particulate delivery systems leads to a number of advantages including 
antigen protection against degradation, uptake by antigen presenting cells (APCs), as well as the co-
delivery of antigen and adjuvant (Perrie et al., 2008). This co-delivery of both of these components 
to the same APC, therefore can direct the specific immune response generated. These APCs 
(dendritic cells and macrophages) are able to capture pathogens, pathogen-associated molecular 
patterns (PAMPs) contained on TLR agonists and particulate material by phagocytosis therefore 
being able to process antigens for presentation as described previously in Section 1.3 (Figure 1.4).  
 
1.4.1. Mechanisms of adjuvant action by particulate delivery systems 
 
Adjuvants (coming from the latin word adjuvare, meaning to help or aid) can be described as 
particles or molecules which can non-specifically enhance the immune response. Adjuvants, when 
used as substances in combination with antigen are able to produce more robust immune responses 
than antigen alone. Schijns et al (Schijns, 2000) have displayed the most common grouping for the 
classification of adjuvants, which is based on the five concepts of immunogenicity shown by Storni et 
al (2005) and in Figure 1.7 (Henriksen-Lacey et al., 2011c). 
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Figure 1-7. Concepts of immunogenicity (A) and methods of adjuvant action (B) by liposomes and 
particulate-based delivery systems, as explained by Storni et al, 2005. 
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to enhance the movement of antigen from the site of injection (SOI) towards the draining lymphatics 
(nearest to where the immunisation was administered).  This enables sufficient amount of antigen to 
be delivered to the lymphoid tissue (Nordly et al., 2009) in order to mount an extensive immune 
response. The use of various particulate delivery systems can increase the mode of adjuvant action, 
as these systems are increasingly recognised by APCs. These adjuvant delivery systems can also 
function by causing the up-regulation of co-stimulatory molecules on the surface of APCs. Therefore, 
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inflammatory cytokines and the generation of an enhanced immune response [Figure 1.4; (Schijns, 
2000)]. These adjuvants and particulate delivery systems can, therefore, induce additional 
characteristics to an antigen in order to generate a sufficient immune response based on these 
concepts of immunogenicity ((Figure 1.7; (Storni et al., 2005)). 
 
The uptake of liposomes, as well as the associated antigen (either surface adsorbed or entrapped), 
by dendritic cells  leads to the processing of pathogen-derived antigen and selection of T-cell clones 
in vivo (Steinman, 2008b, a). This processing step results in the breakdown of protein antigen into 
smaller peptide fragments (Schijns and Lavelle, 2011). This allows the efficient formation of peptide-
MHC complexes at the cell surface, before these dendritic cells migrate to the lymphoid tissue and 
immune organs in order to join an immune cell network of dendritic cells (Steinman, 2007) by 
continuously probing the local environment. These dendritic cells (DCs) are located at the most 
commonly-used injection sites (i.m and s.c) and can scan the local area and follow chemotactic 
stimuli in order to be on alert to the presence of extracellular material and injected antigen (Schijns 
and Lavelle, 2011). 
Particulate vaccines (associated with antigen) have a significant advantage over soluble (free) 
antigen due to their increased uptake by antigen-presenting cells (APCs) and their increased ability 
to ‘mimic’ pathogenic material. The uptake of particulate-based vaccine delivery systems will ideally 
follow the same route as the pathogen against which you are vaccinating; initially via phagocytosis 
to create an early-organelle termed the phagosome which enable and are important in the cross-
presentation of antigen (Ackerman et al., 2003). Further intracellular vesicles are involved in the 
processing of these particulate systems, with phagosome maturation leading to the fusion with the 
endosome which activates the formation of a phagolysosome. This sequential processing of antigen-
loaded particulate delivery systems leads to the acquisition of increasing degradative conditions, 
which leads to the generation and subsequent presentation of antigen.  
The interaction of antigen-bearing dendritic cells (containing liposomes) leads to the interaction of 
the peptide-MHC complex with T-cells (T-helper cells) at the lymphoid tissue which is referred to as 
‘signal 1’. When antigen is delivered to the lymphoid tissue this will lead to a selected T-cell 
response, including an increase in the clonal expansion of a T-cell population (Hawiger et al., 2001), 
which allows these T-cells to acquire their specific function. These T-cells have the ability to acquire 
memory (production of memory T-cells), so that upon reinfection with pathogen-derived antigen, 
these immune cells can produce an effective immune response. The complete activation of T-cells 
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requires the induction of a second signal event (termed signal 2), which is provided by the release 
and recognition of costimulatory molecules (such as CD80/86) on APC. 
Another important group of molecules involved in the activation of the immune response are 
chemokines. These chemokines act as stimuli for activation of inflammatory cells, such as 
macrophages and monocytes, with these chemoattractive molecules being involved in the 
regulation of immune cell traffic and the interaction of these antigen presenting cells (APCs) with T-
lymphocyes in secondary lymphoid organs and tissues (Sallusto et al., 1999a, Sallusto et al., 1999b, 
Moser, 2003). Therefore, the release of chemokines leads to the attraction of dendritic cells which 
constantly monitor their environment for any changes in the levels of these stimuli (Yan et al., 2007). 
A recent study by Yan et al (2007), has investigated the premise of the use of liposomes of varying 
charge and composition for the induction of chemokine activation in the activation of the immune 
response. These studies have shown that positively-charged liposomes, including DOTAP, leads to 
increased production and levels of the CCL-2 chemokine (Yan et al., 2007). 
 
1.4.2. The use of liposomes as drug delivery systems and vaccine adjuvants  
 
Liposomes are closed spherical vesicles consisting of an aqueous inner core surrounded by one or 
more concentrically arranged bilayer membranes (Perrie and Rades, 2010). In general, phospholipids 
are used to formulate these liposomes. Lipids from this group can be derived from natural and 
synthetic sources. Phospholipids are amphiphilic in nature, in the fact that they have a polar 
(hydrophilic) head group and a hydrophobic tail. The polar head group that is present in these lipids 
confers the surface charge of the liposomes (for example, phosphoserine and phosphatidylcholine 
are anionic and neutral in charge respectively). The phospholipid tail is also very important in the 
formation, as well as the packing and assembly of these liposomes (Figure 1.8). Liposomes are an 
ideal platform for drug delivery systems and vaccine adjuvants due to their versatility and flexibility 
in formulation, therefore allowing the incorporation of a large range of drugs and immunogenic 
molecules. A list of commercially available liposomal-based drugs available on the market is 
summarised in Table 1.2.  
Liposomes were the first delivery system to be described as being able to act as immunological 
adjuvants (Allison and Gregoriadis, 1974). These vesicles have been extensively tested and utilised as 
effective delivery systems for a wide variety of disease antigens (Gregoriadis et al., 1987, Christensen 
et al., 2007b). The ability of liposomes to act as adjuvants for protein-based vaccines (using subunit 
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antigens) can occur due to the incorporation (Perrie and Gregoriadis, 2000) or association (May et 
al., 2000, McNeil et al., 2010) of protein antigen into the liposome membrane or bilayer. These 
liposomes can function as adjuvants due to their specific ability to fuse with the cell membrane of 
APCs in order to deliver vaccines. 
Liposomes are an ideal vaccine delivery system due to their particulate nature, versatility and 
flexibility in formulation and it is these parameters that can be used to promote a range of immune 
responses (Foged et al., 2004). This is due to the ability of liposomes as delivery systems to render 
soluble antigen into a particulate form, thereby leading to the lengthening of their in vivo retention 
(Henriksen-Lacey et al., 2011c). The surface charge of liposomes has also been shown to have a 
positive effect on the immune response, with cationic liposomes having an advantage over their 
neutral and anionic counterparts (Henriksen-Lacey et al., 2011c). The importance of charge, antigen 
isoelectric point (pI) and buffer pH for liposomes offers an important platform for antigen adsorption 
due to electrostatic interaction between oppositely charged liposome and antigen components.  
 
 
Figure 1-8. Liposome constructs: when dispersed in an aqueous phase, lipids can form bilayer vesicles which 
can be prepared with varying physicochemical characteristics, including size (Perrie et al., 2013). 
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Table 1.2. Liposome-based drugs currently on the market 
Liposome Formulation Drug Name Company Target disease Delivery Route 
Liposomal Amphotericin B Abelcet Enzon Pharmaceutical Fungal infection i.v 
Liposomal Amphotericin B AmBisome Gilead Sciences 
Fungal/protozoal 
infection i.v 
Liposomal Cytorabine DepoCyt 
Skye Pharma/Enzon 
Pharmaceutical 
Malignant 
lymphomatous 
meningitis Spinal injection 
Liposomal Daunorubicin DaunoXome Galen 
HIV-related 
Kaposi's 
Sarcoma i.v 
Liposomal Doxorubicin Myocet Zeneus Pharma 
Metastatic 
breast cancer i.v 
Liposomal IRIV Vaccine Epaxal Berna Biotech Hepatitis A i.m 
Liposomal IRIV Vaccine Inflexal V Crucell Influenza i.m or s.c.  
Liposomal Morphine DepoDur 
Pacira 
Pharmaceuticals/Skye 
Pharma 
Post-surgical 
analgesia Epidural 
Liposomal Verteporfin Visudyne Novartis 
Macular 
degeneration i.v 
Liposome PEG-Doxorubicin Doxil 
Schering Plough, Ortho 
Biotech 
HIV-related 
Kaposi's 
Sarcoma, Breast 
& Ovarian 
Cancers i.v 
 
Liposomes have been shown to partly act through a mechanism of action termed the ‘depot effect’ 
and they act through this mechanism due to their retention at the site of injection, which leads to 
the sustained release of antigen to the immune cells at this site. This release of antigen can then 
drain to the lymph nodes in order to activate APCs and initiate T-cells to activate a Th1 cell-mediated 
immune response. This ‘depot effect’ has been shown to be the mechanism of action for cationic 
liposomes (Vangasseri et al., 2006, Henriksen-Lacey et al., 2010a, Henriksen-Lacey et al., 2010c, 
2011a). The liposome composition, such as the lipid head-group structure and membrane fluidity, as 
well as the cationic surface charge have been shown to play an important role in the retention of 
vaccine at the site of injection in order to initiate a vaccine-specific immune response. This has been 
shown using various cationic lipids, including dimethyldioctadecylammonium (DDA) bromide, 1,2- 
dioleoyl-3-trimetylammonium propane (DOTAP) and 3β-[N-(N-N-dimetylaminoethane)carbomyl] 
cholesterol (DC-Chol) in combination with the immunostimulatory glycolipid trehalose 6,6’- 
dibehenate (TDB).  
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1.4.3. The promise of cationic adjuvant formulations  
 
The immunological properties of cationic lipids has been described since 1966 when Gall and 
colleagues (Gall, 1966) described the lipid, dimethyldioctadecylammonium (DDA) bromide to have 
these properties. The adjuvant properties of cationic lipids, including DDA, has been shown to be 
due to the presence of quaternary ammonium ion head groups and long alkyl chains, which enables 
the formation of liposomes upon exposure to an aqueous buffer environment. 
DDA is a cationic surfactant which has the ability to promote a weak Th1 immune response 
(Weinrich Olsen et al., 2001). DDA contains a quaternary ammonium group and two methyl groups 
which make up the polar head group. This lipid also has two carbon-alkyl chains (18 carbons in 
length) which make up the hydrophobic tail region of the lipid. Although liposomes based on solely 
DDA alone are effective adjuvants for the generation of humoural and cell-mediated immune 
responses, these liposomes are physically unstable, which has limited their development as adjuvant 
delivery systems (Davidsen et al., 2005). 
This limitation of these liposomes can be substantially improved by the addition of 
immunostimulatory molecules within these cationic delivery systems, such as trehalose 6,6’ – 
dibehenate (TDB). This inclusion of TDB into DDA-based liposomes leads to an increasingly stable 
(Christensen et al., 2007a, Christensen et al., 2009) and efficient adjuvant delivery system, which has 
the advantage of greatly improving the Th1-mediated cell immune response and the antibody 
response (Davidsen et al., 2005). The enhanced stability of this cationic adjuvant formulation 
(CAF01) is caused by the interaction of the glucose headgroups of TDB with the surrounding aqueous 
buffer which is used to hydrate the liposomes (Christensen et al., 2007a, Christensen et al., 2008). 
These cationic-based liposomes have a selective advantage over other particulate delivery systems, 
such as niosomes (Vangala et al., 2006) and PLGA microspheres (Kirby et al., 2008a) which shows the 
importance of cationic liposomes compared to other delivery systems. The positive head group of 
DDA confers the immunogenic properties of this formulation, with these liposomes able to target 
the negatively-charged cell membrane of APCs which leads to the enhanced uptake of protein 
antigen (Korsholm et al., 2007). The incorporation of TDB into DDA-based liposomes confers an 
increased immune response against various sub-unit vaccine antigens due to the binding of TDB to a 
C-type Lectin Mincle Receptor (Ishikawa et al., 2009, Werninghaus et al., 2009, Schoenen et al., 
2010) which can activate the TLR-independent FcR-Syk-Card9 pathway in APCs in order to cause a 
sufficient innate immune response, characterised by protective Th1- and Th17-immunity. 
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Due to the successful passage of cationic DDA/TDB liposomes into clinical trials (NCT 00922363), in 
combination with the tuberculosis vaccine antigen, Ag85B-ESAT6 (H1), this adjuvant delivery system 
has been combined with antigens against a variety of other disease models.  This subunit vaccine 
approach builds on the concept of boosting the immune response to these selected antigens in the 
form of a recombinant antigen, such as Ag85B-ESAT6 (Holten-Andersen et al., 2004). These subunit 
vaccines offer great advantages such as safety and quality control when compared to vaccines based 
on live or attenuated microbes, but require to be delivered within effective delivery systems in order 
to exert their effect on the immune response. Research studies by Vangala et al (Vangala et al., 
2006, Vangala et al., 2007) investigated the potential and efficacy of this liposome delivery system in 
combination with the hepatitis B surface antigen (HbsAg) or malarial antigens (MSP1 and GLURP). 
These studies showed that these adjuvants had the ability to increase antigen-specific splenocyte 
proliferation and T-cell responses characterised by high production of interferon-gamma (IFN-γ) in 
order to generate an efficient cell-mediated immune response. 
The trivalent influenza vaccine (Vaxigrip; Sanofi Pasteur MSD), when administered with DDA/TDB, is 
able to generate an efficient cell-mediated immune response (characterised by the production of 
interferon-γ (IFN- γ), when delivered by the intranasal (i.n.) route, rather than without adjuvant 
alone. During this research using an in vitro study with the Calu-3 cell culture model has shown that 
CAF01 is able to increase the permeability through the ciliated mucus layer and the epithelium 
(Christensen et al., 2010). More recently, CAF01 has been developed and optimised as a dry powder 
vaccine formulation which can be administered via spray drying (Vehring, 2008, Ingvarsson et al., 
2013). The development of a dried powder vaccine formulation is advantageous due to enhanced 
storage stability and the ability upon rehydration for original particle characteristics to be 
maintained. These studies have shown that upon immunisation with the spray-dried CAF01 with 
associated H1 TB antigen (in combination with the stabiliser, trehalose) results in the preservation in 
vivo of the adjuvant activity of this vaccine. 
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1.5. Further particulate delivery systems for use in vaccine formulation 
1.5.1. Aluminium-based adjuvants 
 
To date the most common and successful adjuvants in vaccine development are aluminium-based 
mineral salts (alum) which have a proven track record in terms of their safety profile and use in 
vaccines, however these adjuvants are only capable of producing humoural immune responses 
(Brewer, 2006, Christensen et al., 2007b). Aluminium compounds were originally identified as 
adjuvants around 80-90 years ago (Glenny et al, 1926), and remain one of the major adjuvants in 
vaccine design. It is widely accepted that physical association between both aluminium and antigen 
components is required for these vaccines to retain their adjuvanticity (Brewer, 2006). 
The continued development of aluminium-based compounds for use in vaccines has been restricted 
by these adjuvants lacking the ability to promote a cell-mediated immune (CMI) response. These 
adjuvants have the ability to stimulate Th2 immune response and hence the production of IL-4 and 
IL-5 cytokines, as well as B-cell production of antibodies. Therefore, these aluminium-based 
adjuvants are unable to be used in vaccines against diseases such as TB, malaria and HIV which 
primarily require a Th1-immune response (Seder and Hill, 2000). Until recently, the 
immunostimulatory activity of alum-adjuvants was attributed due to its ability to retain antigen at 
the injection site (Glenny et al., 1926). However in the recent literature, several studies have 
challenged this theory, reasoning that Alum is likely to elicit Th2 responses independent of a depot 
formation at the injection site (Romero Mendez et al., 2007, Noe et al., 2010, Hutchison et al., 2012). 
 
1.5.2. Niosomes and virosomes 
 
Non-ionic surfactant vesicles (or niosomes) are potentially a more stable delivery vesicles compared 
to liposomes, with advantages including their relative chemical stability, low toxicity (Brewer and 
Alexander, 1992) and reduced costs. These factors make niosomes an attractive delivery system for 
antigenic components. The most commonly investigated niosome vesicles consists of monopalmitoyl 
glycerol, cholesterol and dicetyl phosphate (Baillie et al., 1985), with these delivery systems 
combined with antigen being able to provide higher production of cytokines, such as IFN-γ. 
Virosomes are composed of naturally occurring phospholipids (70 %) and phospholipids originating 
from the influenza virus (30 %; (Perrie et al., 2007)). These vesicles have been used as systems for 
the delivery of entrapped antigen against infections such as Hepatitis B and Influenza. 
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Following oral vaccine administration, liposomes and niosomes can be destabilised due to the 
presence of intestinal bile salts in the gastrointestinal (GI) tract which leads to subsequent disruption 
of the membrane causing release of macromolecules or antigen prior to reaching the intended site 
of action. Incorporation of bile salts into the vesicle bilayer membrane has been shown to protect 
liposomes (and associated antigen) to digestion by enzymes present in the GI tract (Schubert et al., 
1983, Shukla et al., 2008, Wilkhu et al., 2011). Oral vaccines can be targetted to specialised M-cells 
which are located in the follicle-associated epithelium of intestinal Peyer’s patches for uptake of 
particulate vaccine antigen in order to improve immune responses  (Brayden and Baird, 2004, 
Brayden et al., 2005, Wilkhu et al., 2011). 
 
1.5.3. Microparticles 
 
Microparticles also have the potential to be used as delivery vesicles with microspheres consisting of 
polylactides, polyglycolides and their copolymers (PLGA) being used in the field of drug and vaccine 
delivery for the delivery of promising sub-unit vaccines such as Ag85B-ESAT6 (Kirby et al., 2008a, b). 
Although the microsphere formulations induced a cell-mediated immune response, this was reduced 
in comparison to the same DDA/TDB formulation prepared as a liposome adjuvant system (Kirby et 
al., 2008b). 
 
1.5.4. Immune-stimulating complexes (ISCOMs) 
 
ISCOMs are particulate delivery systems, closely related to liposomes, which consist of phospholipids 
and cholesterol as well as a built-in immuostimulatory saponin vaccine adjuvant (Morein et al., 1984, 
Nordly et al., 2009). Therefore this combination within a delivery system is enough to reduce the 
cytotoxic effect associated with the saponin adjuvant. The incorporation of antigen, including 
tumour and viral antigens, within these spherical hollow assemblies is powerful and can induce both 
cellular and humoural immune responses (Cox and Coulter, 1997, Cox et al., 1998). The mechanism 
of antigen association within these systems is by insertion into the membrane bilayer or entrapment 
within the structure itself.  
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1.5.5. Oil in Water Emulsions 
 
The successfully licensed oil in water emulsion (o/w) termed MF59 was licensed in the late 1990’s in 
the influenza vaccine (Novartis, Italy) Fluad® (O'Hagan and De Gregorio, 2009). MF59 is composed of 
5 % squalene (oil) combined with two surfactants, sorbitan trioleate and polyoxyethylenesorbitan 
monooleate. This adjuvant has been shown to have an enhanced safety profile in humans. Mosca 
and colleagues have noted that MF59 induces cell recruitment to the injection site, renders soluble 
antigen to a particulate form and enhances the trafficking of antigen to the draining lymph nodes 
(Mosca et al., 2008). This also leads to increased antigen uptake by dendritic cells (Dupuis et al., 
2001). 
 
1.5.6. Further particulate systems 
 
Another promising liposome formulation contains the TLR4 ligand MPL and QS21 (a derivative of 
saponin), and is termed AS01B (GlaxoSmithKilne). This liposome contains the TB vaccine antigen 
Mtb72F (fusion protein), which comprises the Rv1196 and Rv0125 antigens. This vaccine has been 
shown to enhance the immune response, and can be used to boost the BCG vaccine (Brandt et al., 
2004). A modified heat-labile toxin derived from E. coli in combination with the Ag85B-ESAT6 fusion 
protein has been developed for nasal immunisation, called LTK63. This formulation has led to a 
significant immune response, with marked increases in IgG2 Ag85B-ESAT6 specific antibody titres 
(Palma et al., 2008). 
 
1.5.7. Currently licensed adjuvants used in vaccine formulation 
 
To date there are only a relatively small number of licensed adjuvant systems, which include a 
number of aluminium-based systems such as aluminium hydroxide or phosphate (Perrie et al., 2008) 
which have been used in vaccine formulations for Tetanus and Hepatitis B. The adjuvants have been 
demonstrated to have a good track record in terms of safety (Clements and Griffiths, 2002). 
More recently licensed adjuvant systems (AS) include AS03 and AS04, which have been developed by 
GlaxoSmithKline (Garcon et al., 2007, Henriksen-Lacey et al., 2011c). The adjuvant system AS04 is 
composed of aluminium hydroxide in combination with the TLR4 agonist monophosphoryl lipid A 
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(MPL) and is currently in vaccines for hepatitis B and human papillomavirus (HPV). Whereas, AS03 is 
similar to the MF59 adjuvant, consisting of a squalene oil-in-water emulsion (w/o) and is included in 
an influenza vaccine (Pandemrix). However, disease targets such as TB, HIV and malaria require the 
strong induction of Th1 immune responses; whereas these currently licensed adjuvants lack the 
ability to produce these effects on the immune response.  
 
1.6. Investigation into the combination of TLR agonists within vaccine 
formulations 
 
The addition of TLR agonists into liposome-based vaccine formulations results in the increase in 
immunostimulatory profile of these particulate delivery systems in order to cause a more diverse 
immune response. This has been of increased interest in the past several years with a number of 
experimental liposome-based vaccine formulations being tested (Nordly et al., 2011b, Nordly et al., 
2011c). Adjuvants are substances and molecules which can directly enhance the immune response 
and these can be split into two distinct groups, vaccine delivery systems and immunopotentiators 
(Nordly et al., 2009). The delivery system ensures the efficient delivery of antigen to antigen 
presenting cells (including macrophages), whereas immunopotentiators (such as TLR agonists) are 
able to activate the various cells of the immune system, through various intracellular pathways. The 
flexibility and versatility of liposomes allows these vesicles to be used as delivery systems, in 
combination with antigen, and also for the inclusion of immunostimulatory molecules into the 
membrane bilayer. Thus, the inclusion of these molecules into a liposome formulation will be of 
increased interest in the synergistic presentation of antigen, as well as immunopotentiators to the 
same antigen presenting cell (APC), and hence broaden the immune profile of the vaccine 
formulation in question. An alternative approach may also be to physically link antigen with TLR 
agonist (for example, flagellin) in order to provide synergistic delivery to the same APC (Guy, 2007, 
Eckl-Dorna and Batista, 2009). Of the candidate TLR agonists, a number have been used in liposome 
vaccine formulations including Monophosphoryl Lipid A (MPL), unmethylated CpG (cytosine-
phosphate-guanine) DNA, polyinosinic-polycytidylic acid [poly(I:C)], di- and triacylated lipopeptides, 
lipopolysaccharides (LPS) and imidazoquinolines (Figure 1.5). The combination of TLR agonist and 
adjuvant delivery vesicles (liposomes) is a novel prospect in the field of drug delivery and during the 
past decade a number of these combinations have been tested, in terms of their ability to deliver 
vaccine formulations which are known to engage TLR signalling. These combination systems will be 
reviewed in the following section in relation to the production of an appropriate immune response. 
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1.6.1. Monophosphoryl Lipid A (MPL) 
 
MPL is a synthetic and slightly modified version of the lipopolysaccharides (lipid A) derived from the 
cell surface of Gram-negative bacteria. MPL acts through the TLR4 agonist located at the cell 
membrane which results in the activation of downstream intracellular pathways leading to the 
transcription of co-stimulatory molecules and cytokines. MPL has been licensed in a number of 
adjuvant systems by GlaxoSmithKline, in which this TLR4 agonist is combined with a secondary 
adjuvant such as liposomes (AS01), QS21 (AS02) and aluminium hydroxide (AS04).Therefore the 
ability of these adjuvants to act through TLRs demonstrates that these adjuvants can act as 
pathogens therefore leading to the initiation of the immune response. 
The inclusion of MPL within the cationic liposome formulation, DDA/TDB, results in a significant 
decrease in the main phase transition temperature for this delivery system, as well as leading to an 
increase in surface pressure at the final collapse point (when the monolayer was fully compressed) 
and reduction in the mean molecular area. These factors demonstrated that this TLR4 agonist was 
inserting into the bilayer membrane of the liposome delivery system, therefore affecting the packing 
properties of the membrane (Nordly et al., 2011a). The inclusion of MPL within the delivery system 
also resulted in an enhanced antigen-specific immune response, as shown by a higher population of 
CD8+ T-cells. This increased T-cell population led to a significant increase in the production of the 
cytokine interferon-gamma (IFN-γ), so this liposome formulation can activate a number of signalling 
pathways in the production of a Th1 immune response (Nordly et al., 2011a). 
The development of new sub-unit protein vaccines against diseases such as TB has been an urgent 
research priority in the past decade. With this in mind, a number of adjuvants were developed 
including the liposome formulation, DDA/MPL. The cationic surfactant, DDA, alone achieves low 
levels of immunity (as originally described by Gall et al in 1966) but these adjuvants inherently lack 
stability in terms of their characteristics (Davidsen et al., 2005). The inclusion of the TLR4 ligand 
monophosphoryl lipid A (MPL) within this liposome formulation and combined with TB subunit 
antigen is able to initiate significant levels of immunity characterised by a stable deposition of 
antigen and a strong Th1 immune response characterised by production of interferon-gamma 
(Holten-Andersen et al., 2004). 
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1.6.2. Polyinosinic:polycytidylic acid (polyI:C) 
 
The combination of liposome delivery systems (DDA/TDB) with the CD8-inducing 
immunopotentiator, polyI:C, has been investigated in a number of research studies in the literature 
(Schlosser et al., 2008, Nordly et al., 2011c, Milicic et al., 2012). These studies have demonstrated 
the inclusion of polyI:C within the liposome membrane due to electrostatic binding to cationic lipid 
head groups, as well as resulting in a monolayer expansion of DDA/TDB. The inclusion of this agonist 
within the liposome formulation (using OVA as model antigen and C57/BL6 as mouse strain) results 
in an enhanced immune response (as shown by a CD8+ T-cell response), due to the synergistic 
delivery of both antigen and immunopotentiator to the same antigen presenting cell, which leads to 
the activation of further intracellular signalling pathways within the APC causing a more broad 
immune profile of the liposome formulation. Recent studies within our laboratory have 
demonstrated the immunostimulatory ability of polyI:C following incorporation within liposome 
vaccine adjuvants (Milicic et al., 2012). Addition of polyI:C significantly increased the adjuvant 
capability of DDA/TDB liposomes formed as multilamellar vesicles (MLVs) and antigen-entrapping 
dehydration rehydration vesicles (DRVs). However, DDA/TDB formed as small unilamellar vesicles 
(SUVs) offered enhanced adjuvant capacity without the addition of TLR agonists to the system. 
 
1.6.3. Unmethylated CpG DNA 
 
The ability of adjuvants to initiate a CD8+ T-cell response is crucial in the field of vaccine 
immunology. An example of an agonist is unmethylated CpG-containing oligodeoxynucleotides (CpG 
ODN) which is able to activate TLR9 located in the cytoplasmic compartment of the cell. This TLR9 
agonist contains regions and repeats of nucleotides of DNA with a cytosine next to guanine 
separated by only one phosphate (which is part of the phosphodiester backbone of DNA). The ability 
of CpG ODN and its use as a vaccine adjuvant has been shown through the activation of natural killer 
(NK) T-cells, which in turn leads to the production of type 1 interferons (Suzuki et al., 2004). 
Therefore, the optimisation of cationic adjuvant formulations by the inclusion of CpG-containing 
ODN in the formulation is a viable option as a vaccine adjuvant with the possibility of increasing 
CD8+ T-cell responses (Gursel et al., 2001). 
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1.6.4. Imidazoquinolines  
 
During the early 1980’s, effort was going into the identification of small molecules which were able 
to inhibit infection by herpes simplex virus-2 (HSV-2) (Bernstein and Harrison, 1989, Miller et al., 
1999, Wagner et al., 1999). This led to the identification of a family of low molecular weight 
molecules including imiquimod, resiquimod and gardiquimod (Figure 1.9) which have been shown to 
activate dendritic cells (DCs) therefore leading to the secretion and production of cytokines and 
chemokines (IFN-γ, IL-6, IL-18 and IL-10) (Wagner et al., 1999). These imidazoquinoloine molecules 
are also able to activate B-cells to proliferate and differentiate into antibody-secreting cells 
therefore leading to enhanced antibody production (Bishop et al., 2000, Tomai et al., 2000). This 
family of molecules are able to activate both Toll-like receptor (TLR) 7 and 8 agonists leading to the 
skewing of immunity towards a Th1 immune response (Jurk et al., 2002). These molecules present in 
the imidazoquinolines are termed synthetic immune response modifiers (IRM) due to their ability to 
selectively activate these specific TLRs. These TLRs are located within the endosomal compartment 
of the cell and are able to recognise guanosine- and uridine-rich single stranded (ss)RNA (Diebold et 
al., 2004, Heil et al., 2004, Gorden et al., 2006) as well as IRM such as imidazoquinolines. Therefore 
activation of these TLRs occurs at the endosome, which has been shown to be due to activation of 
these TLRs (by imiquimod and resiquimod), leading to endosomal acidification and downstream 
events, leading to the activation of the specific immune response (Tomai et al., 2007). This has been 
further demonstrated by agents that are able to block acidification of endosomes and hence block 
the subsequent activation of the immune response (Hart et al., 2005). 
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Figure 1-9. Members of the imidazoquinoline family of Toll-like receptor (TLR) agonists [A- Resiquimod; B – 
Imiquimod; C- Gardiquimod) 
 
Even though these Toll-like receptors are closely related they seem to be activated to a different 
degree by their natural ssRNA ligands as well as by IRMs in which they stimulate the human forms of 
TLR7 and TLR8, as well as the mouse TLR7 but not mouse TLR8. This is due to TLR8 in mice being 
A B C 
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non-functional as has been shown by its response to ssRNA and immune response modifiers that are 
usually activated through TLR8 (Hemmi et al., 2002, Jurk et al., 2002, Gorden et al., 2006).  
The first member of the imidazoquinoline family to become commercially available was imiquimod 
in 1997, which has generally been used in the form of a cream (ALDARA™) for treatment against 
anogenital warts (caused by human papilloma virus infection) and actinic keratosis (Abramovits and 
Gupta, 2004, Swanson et al., 2010). These clinical studies have shown that topical application of 
both imiquimod and resiquimod and their synthetic analogues is a safe and effective method in 
which to locally activate the immune response. This kind of treatment can be considered as a form 
of endogenous vaccination in which the virus acts as the antigen and the TLR agonists act to boost 
the antigen-specific immune response (Tomai et al., 2007).  
However, in subsequent studies another member of the imidazoquinoline family of molecules, 
resiquimod (or R848), has been discovered to be a more potent and soluble analogue which is able 
to produce an increased cytokine response compared to imiquimod (Tomai et al., 1995). Resiquimod 
is able to exert its immunostimulatory activity via activation of mouse TLR7 and human TLRs 7 and 8. 
Therefore resiquimod has shown great promise as a vaccine adjuvant and has been included in 
further vaccine formulations. The adjuvant activity of these TLR agonists has also been studied by 
vaccination in animal models in which imiquimod has been used in combination with herpes simplex 
virus (HSV) glycoprotein, which has led to increased levels of response to HSV challenge (Bernstein et 
al., 1993), both prophylactically and therapeutically. The resiquimod TLR7 agonist has also been used 
in animal mouse models in combination with viral antigen in order to show enhanced T-cell and 
antibody responses (Otero et al., 2004, Wille-Reece et al., 2005). 
Resiquimod has been investigated as a vaccine adjuvant in initial studies (Vasilakos et al., 2000) using 
ovalbumin (OVA) as a model protein antigen. This was shown to lead to enhanced Th1 antibody 
(IgG2) and cytokine (IFN-γ) production, as well as inhibition of Th2 antibody and cytokine production 
(IgE and IL5). These studies also showed that secondary immunisation of this vaccine (resiquimod, in 
combination with model antigen OVA) in combination with the alum delivery system leads to a more 
effective primary memory response, thus showing the importance of a delivery system for retaining 
both TLR agonist and antigen. In further studies resiquimod has been compared with the TLR9 
agonist CpG ODN DNA for their ability to act as vaccine adjuvants. Both of these TLR agonists (in 
combination with the hepatitis B surface antigen) were experimentally tested in vaccine 
formulations in mice with CpG ODN giving a superior immune response to its resiquimod alternative. 
This was hypothesised to be due to resiquimod having a smaller molecular weight (Mw) than CpG 
ODN, therefore upon vaccination it will more likely be distributed more quickly throughout the body 
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rather than remain at the vaccination site, whereas CpG ODN is more likely to remain at this site 
(Weeratna et al., 2005, McCluskie et al., 2006).  
Although resiquimod and other analogues (which activate through TLR7 and/or TLR8) have been 
demonstrated as effective vaccine adjuvants in a number of model systems, several other studies 
have given mixed success in their ability to act as vaccine adjuvants (Wille-Reece et al., 2005). The 
short half-life, in combination with small size and high water solubility, may lead to the rapid 
distribution throughout the body rather than staying at the injection site which is not ideal for the 
local activation of dendritic cells at the injection site. Therefore, these TLR7/8 agonists may need to 
be colocalised with other stimuli (antigen) at the injection site in order to offer enhanced immunity 
(Ahonen et al., 2004). Therefore for optimal vaccine adjuvant formulation it may be required to 
retain the TLR agonist at the site of injection in order to induce local adjuvant effects without 
inducing systemic cytokines which may give side effects. This could be achieved by formulating the 
agonist within a delivery system such as liposomes. 
 
1.6.5. Lipopolysaccharides 
 
The bacterium Mycobacterium tuberculosis is able to regulate APCs due to TLR2 signalling. This 
occurs via lipoproteins which are present in the cell wall of this bacterium, including LpqH, LprA and 
PhoS1. These lipoproteins are able to regulate the functions of APCs, therefore leading to 
downstream cytokine production and further innate immune responses (Drage et al., 2009). During 
these responses TLR2 either associates with TLR1 or TLR6 in order to form a heterodimer, therefore 
leading to these downstream signalling effects. Both of these heterodimers can bind to different 
forms of lipid from the mycobacterial cell wall, with TLR1 leading to the recognition of triacylated 
peptides whilst TLR6 leads to diacyl peptide recognition (Schroder et al., 2004, Buwitt-Beckmann et 
al., 2005, Kang et al., 2009). 
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1.6.6. Flagellin 
 
Flagellin is present in the flagellar structure of many bacteria (Gram positive and Gram negative), is 
recognised by TLR5. Activation of the TLR5 receptor, through bacterial flagellin, leads to the 
stimulation of proinflammatory cytokines through signalling the adaptor protein Myeloid 
differentiation primary response gene 88 (Myd88) which activates downstream pathways to activate 
the immune response (Gewirtz et al., 2001, Hayashi et al., 2001, Smith and Ozinsky, 2002). The 
immunisation of animals with a recombinant fusion protein containing flagellin has been shown to 
generate significant antigen specific CD8+ T-cell responses. This occurs through stimulation of 
antigen presenting cells (APCs), thus resulting in the subsequent maturation of these cells leading to 
the secretion of proinflammatory cytokines. 
 
1.6.7. Modified TLR agonists through chemical conjugation to lipids 
 
An important characteristic of antigen-loaded vaccine adjuvants is the specific ability to target 
professional antigen presenting cells (APCs) by the targeting of pattern recognition receptors, such 
as Toll-like receptors (TLRs). The association of TLR agonist to the liposome bilayer can be achieved 
by one of two different methods; physical adsorption or chemical conjugation (Demento et al., 
2011). 
Physical adsorption of pathogen-associated molecular patterns (PAMPs), such as TLR agonists, to the 
liposome surface can be achieved by electrostatic interactions, hydrogen bonding and weak 
intermolecular interactions (such as Van der Waals). This occurs due to electrostatic interactions 
between cationic delivery system and anionic TLR agonist. However these systems may be inherently 
unstable. Delivery of PAMPs can also occur by entrapment of TLR agonist, polyI:C or CpG, within the 
delivery system itself (Gursel et al., 2001, Gursel et al., 2002, Nordly et al., 2011c). 
However, an interesting approach towards coupling of PAMPs to lipids is through chemical 
conjugation. This can occur through simple covalent bonding or chemical coupling between adjacent 
functional groups between lipid and PAMP. Chemical coupling between amine and carboxylate can 
lead to ‘ester formation’ between these two components (Hermanson, 2008, Demento et al., 2011). 
This approach of chemical and bioconjugation, although intriguing, may have a drawback in that the 
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interaction with serum proteins might mask the efficacy of the agonist and its ability to target its 
specific receptor.  
An interesting study by Andrews and colleagues (2011) has shown that immunostimulatory CpG 
oligodeoxynucleotides (ODN) can be chemically conjugated to lipid and incorporated into liposomes 
as a means to enhance the delivery of TLR agonist to the TLR9 receptor and, therefore, generate an 
increased immune response (Andrews et al., 2011). 
 
1.6.8. Synthetic TLR agonists 
 
Encapsulation of TLR agonists within liposome formulations (in combination with protein antigen) 
has been studied previously as a means of enhancing the immune response (Gursel et al., 2001, 
Nordly et al., 2011c). Also synthetic TLR7 ligands such as 3M-019 and 3M-052 (synthesised by 3M 
Pharmaceuticals) have been used and prepared in liposome vaccine formulations (Johnston et al., 
2007, Smirnov et al., 2011). Johnston and colleagues (2007) demonstrated that the imidazoquinoline 
derivative, 3M-019, was able to effectively modulate the immune response to the model vaccine 
antigen ovalbumin (OVA). This immune response, in terms of IgG2a antibody production, was 
further increased upon encapsulation of the TLR agonist into the liposome formulation in 
comparison to TLR agonist or antigen alone thus showing the importance of a delivery system 
(Johnston et al., 2007). Another synthetic IRM, 3M-052 was designed and synthesised with the aim 
of forming a depot and sustained release of compound and for incorporation into the bilayer of 
liposomes. Upon formulation of this agonist within neutral liposomes composed of PC 
(phosphatidylcholine) this resulted in increased immune responses compared to vaccination using 
antigen or agonist alone (Smirnov et al., 2011).  
Also in other recent studies, some compounds have been specifically developed in order to activate 
TLRs 7 and 8 (Smits et al., 2008). Activation of TLR7 has been shown to occur due to action by 
ligands, 3M-001 and 852A. Whereas TLR8-mediated activation occurs through the action of the 
specific ligand, 3M-002 (or CL075), in order to activate the downstream cellular immune response 
(Gorden et al., 2006, Dudek et al., 2007, Harrison et al., 2007). 
In further studies (Chan et al., 2009) another group of low molecular weight TLR7 activators termed 
purine-like molecules has been investigated, including 9-benzyl-8-hydroxy-2-(2-methoxyethoxy) 
adenine (otherwise termed SM360320). This compound has been shown to be a specific TLR7 
agonist (Kurimoto et al., 2004). Upon conjugation of this agonist to phosphatidylethanolamine (PE) 
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this leads to the production of an increased immune response as shown by enhanced antibody 
production (when compared to agonist alone) upon immunisation (Chan et al., 2009). 
 
1.6.9. The inclusion of non-TLR agonists within liposome formulations 
 
TDB is a synthetic analogue of the mycobacterial ‘cord factor’, otherwise termed as trehalose 
dimycolate (TDM) and shows less toxicity in vivo whilst retaining immunogenic properties. This is 
due to the reduced number of mycolate chains which results in a shorter chain length (Matsunaga 
and Moody, 2009). These properties allow for the successful inclusion of TDB into cationic liposome 
delivery systems, with an optimal ratio of 11 mol % (8:1 M/M) shown to display the highest titres of 
antibody (Davidsen et al., 2005) in order to generate the optimal immune response. 
A growing number of studies have investigated the role of further mycobacterial-derived lipids in the 
process of interaction between mycobacteria such as (M.tb) and dendritic cells (DCs) at the host-
pathogen interface. Initial studies have identified mycobacterial cell envelope components such as 
phosphatidylinositol mannoside and lipoarabionmannan as having the ability to have an 
immunopotentiary effect on the immune response (Sprott et al., 2004). Also, further studies 
(Andersen et al., 2009a, Andersen et al., 2009b) have indicated monomycoloyl glycerol (MMG) as a 
prominent glycolipid from the mycobacterial cell wall, which has an enhanced effect on the immune 
response. Formulation of the cationic liposome system, with the addition of MMG (in combination 
with the TB antigen H1) within the liposome bilayer, has been shown to lead to an increase in 
antigen-specific immunity. MMG was identified as an important lipid in this process following the 
extraction of apolar and polar lipid fractions from M. bovis BCG (Andersen et al., 2009b). Following 
isolation and extraction of MMG from the apolar lipid fraction, this lipid was formulated within a 
cationic DDA-based liposome delivery system. This delivery system, in combination with the Ag85B-
ESAT6 fusion protein (Hybrid 1) was found to be highly efficient in the activation of APCs (by MMG) 
and the production of a Th1-biassed immune response, as characterised by high levels of interferon-
gamma (IFN-γ) and IL-2 as well as neglible levels of Th2 cytokines IL-4 and IL-5. This has been studied 
previously using complex mycobacterial extracts delivered with cationic liposomes which have given 
enhanced immune responses in combination with TB antigen (Rosenkrands et al., 2005). 
A number of research groups have also used synthetic analogues of monomycoloyl glycerol (MMG) 
to show the effect on the resulting immune response (Andersen et al., 2009a, Bhowruth et al., 2009, 
Nordly et al., 2011b). A synthetic C32 MMG analogue has been produced by the coupling of C32 
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mycolic acid with isopropylidene glycerol. This liposome adjuvant system has been shown to give 
comparable immune responses to both the CAF01 and CAF04 delivery system (Andersen et al., 
2009b). A further synthetic MMG  analogue, termed MMG-1, has been shown to have a stabilising 
effect on cationic DDA-based liposomes as well as stimulating the Th1/Th17 immune response of 
this adjuvant system as characterised by increased production of interferon-gamma (IFN-γ) and IL-2. 
Also in further studies this liposome vaccine formulation, DDA/MMG (otherwise known as CAF04) 
has been delivered in combination with the TLR3 agonist polyI:C in order to increase the CD4/CD8 T-
cell immune response. 
A number of research studies have suggested that several vaccine adjuvants may function in a TLR-
independent pathway; molecules including NOD-like receptors, retinoic acid inducible gene (RIG)-
like receptors, scavenger receptors, neuronal apoptosis inhibitory proteins (NAIP5) as well as Dectin-
1 like receptors have been shown to play a role in activating the immune response (Lahiri et al., 
2008).  
Double stranded (ds) RNA and its synthetic analogues including polyI:C have been shown to be 
potent inducers of innate immunity, as well as acting through Toll-Like Receptor 3 (TLR3) and RIG1-
like receptors which causes the production of key cytokines (including IFN-γ and IL-12). This enables 
the cross presentation of antigen to MHCI complexes in order to enhance the CD8+ T-cell response. 
The nucleotide-binding oligomerisation domain (NOD) receptors are localised in the cytoplasm and 
are able to recognise components of the bacterial peptidoglycan, such as muramyldipeptide (MDP) 
and diaminopimelic acid (DAP). These NOD-like proteins are able play key roles in innate immunity 
against a number of pathogens, including Chlamydia trachomatis (Fritz et al., 2006, Shaw et al., 
2008). 
 
1.6.10. The role of the inflammasome in innate immunity 
 
The inflammasome is a multi-protein complex that is involved in the promotion of an innate immune 
response, specifically the activation of caspase-I which promotes the processing and secretion of 
proinflammatory cytokines (Ogura et al., 2006) including IL-1β. Inflammation is the response of the 
host to ‘danger signals’, tissue damage and infectious agents (Stutz et al., 2009). These inflammatory 
responses are extensively co-ordinated by cells of the innate immune system, with cytokines and 
chemokines playing a significant role as mediators of the downstream signalling cascades. The 
inflammasome becomes activated in response to external extracellular stimuli leading to caspase-I 
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activation, which was initially known as the IL1-converting enzyme due to its ability to proteolytically 
cleave pro IL-1β into the bioactive cytokine IL-1β. This process occurs due to the recruitment and 
oligomerisation of pro-caspase-1 upon stimulation of the inflammasome complex. 
This proinflammatory cytokine, IL-1β, is important as it activates lymphocytes in the initiation of the 
immune response. The activation of caspase-I (and hence secretion of cytokines) is a highly 
regulated event which involves the priming and maturation of this complex. Several other cytokines 
are processed by the inflammasome including IL-18 and IL-33, which are important in IFN-γ induction 
and activation of natural killer (NK) T-cells. The activation of the cytokines IL-18 and IL-33 has been 
shown to be also due to cleavage caused by activation of the caspase-1 enzyme, with the latter of 
these cytokines inactivated by caspase-1 and actually activated by the calpain enzyme (Cayrol and 
Girard, 2009, Luthi et al., 2009). 
 
1.7. Enhancing liposomal adjuvants: Investigating the effect of 
physicochemical characteristics on the function of liposomal adjuvants  
 
Key advantages of these particulate delivery systems lie in the fact that they have the ability to be 
tailored to achieve desired physicochemical properties through variation of lipid components as well 
as the method of preparation. This versatility of liposomes allows protein antigen, peptides, nucleic 
acids and immunomodulatory components including Toll-like receptor (TLR) and non-TLR agonists to 
be incorporated within the system (Perrie et al., 2013). Therefore liposomes can be used as efficient 
delivery vehicles for the delivery of vaccines with these vesicles being able to differ in size and 
lamellarity as well as their membrane fluidity and surface charge (Figure 1.10). The importance of 
these physicochemical parameters, in terms of enhancing immune responses, will be described 
below. 
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Figure 1-10. Liposome formulation parameters have the ability to influence specific immune responses. 
These include membrane surface charge (A), bilayer fluidity (B) and vesicle size (C).  
 
1.7.1. The role of liposome surface charge in vaccine delivery and formulation 
 
The role of surface charge of liposome delivery systems in vaccine delivery and formulation has been 
investigated in a number of research studies. As described previously (Henriksen-Lacey et al., 2010c), 
cationic liposomes have an advantage over their neutral and anionic counterparts due to their ability 
to adsorb anionic antigen to their surface and thus enabling the formation of an ‘antigen depot 
effect’. Therefore these particulate vaccine carriers have an increased adjuvant activity and are more 
likely to deliver antigen to T-cells in the lymphoid tissue. Original studies by Allison and Gregoriadis 
in 1974 demonstrated the use of diphtheria toxoid in combination with negatively-charged 
liposomes caused a significantly elevation in the levels of antibody in comparison to positively-
charged liposomes (Allison and Gregoriadis, 1974). In addition, other studies (Nakanishi et al., 1999, 
Foged et al., 2004, Henriksen-Lacey et al., 2010c) have shown that cationic liposomes (in 
combination with anionic antigen) are more potent inducers of antigen-specific immune responses 
compared to neutral and anionic liposomes. The use of liposomes of varying charge has also been 
investigated by Yanasarn et al, in which some negatively-charged liposomes (including the anionic 
lipid DOPA) are able to generate strong and functional antibody responses, as well as up-regulating 
gene expression related to the activation and maturation of dendritic cells (Yanasarn et al., 2011). 
This occurred due to the simple mixing of pre-formed negatively charged liposomes with antigens. 
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1.7.2. The role of liposome vesicle size and administration route on vaccine delivery and 
formulation 
 
The vaccine administration route of particulate delivery systems may be importance as particles in 
the sub-micron range can be naturally phagocytosed by antigen presenting cells (APCs). These 
particulate vesicles can also be formulated in order to control their characteristics so as to target 
specific tissues or cells (Mohanan et al., 2010), including the draining lymphatics so as to stimulate 
and regulate adaptive immune responses (O'Hagan and De Gregorio, 2009). Bachmann and 
colleagues (2010) have investigated the role of vesicle size on targeting to the lymph nodes by 
several administration routes. Particulates of less than 200 nm in size have the ability to self-drain to 
the lymphatics without the need for uptake by APCs before being taken up by lymphoid-organ 
resident dendritic cells (Joffre et al., 2012), however larger particulates (500-1000 nm) require to be 
previously taken up by APCs before transport into the LN (Bachmann and Jennings, 2010, Joffre et 
al., 2012). However drainage of liposomes is also charge-dependent, with neutral DSPC/TDB 
liposomes (Henriksen-Lacey et al., 2010c) draining rapidly from the injection site due to low 
retention at this site (which is not size-dependent). However for cationic formulations, drainage of 
liposomes at early timepoints to the lymph nodes was shown to be size-dependent, thus suggesting 
increased uptake of larger liposomes by macrophages at the site of injection before subsequent 
drainage to lymph nodes (Manolova et al., 2008, Henriksen-Lacey et al., 2011b). 
A number of various factors have been investigated which may affect the immune response; 
including the route of vaccine administration, inclusion of Toll-Like Receptor (TLR) ligands, and the 
amount of antigen and delivery system administered (Mohanan et al., 2010). The route of 
administration is the site at which an individual or experimental animal are vaccinated. During a 
recent study (Mohanan et al., 2010), various administration routes were investigated and the 
ensuing immune response was shown. Each administration route requires a different volume of 
vaccine, and the antigen drains to the various lymph nodes where an immune response is generated. 
These routes of vaccine administration, via injection, possess various safety risks with an increased 
risk of injury from sharp needles (Pruss-Ustun et al., 2005). 
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Most vaccines are administered via subcutaneous (s.c) or intramuscular (i.m) injection due to 
relatively cheap cost and ease of administration; however, during recent studies the mucosal, 
transdermal, intralymphatic and vaginal routes have been a major focus of investigation. These 
alternative administration routes have been used to increase patient compliance, control and 
prevent disease at the site of infection and to target the vaccines to local lymphoid tissue. Vaccine 
administration via the mucosal route is a promising topic in the field of vaccine development, with 
the use of lipid-based particulate delivery systems being of increased focus (Christensen et al., 
2010). The major properties of a vaccine to be delivered via the mucosal route are the ability to 
penetrate through the mucosal tissue and to be delivered across the epithelium in order to interact 
with APCs. The trivalent influenza vaccine, when administered with DDA/TDB (CAF01), is able to 
generate an efficient cell-mediated immune response [characterised with production of interferon-γ 
(IFN-γ)] when delivered by the intranasal (i.n.) route, rather than without adjuvant alone. A stronger 
immune response may be expected the closer a vaccine is administered to the lymph node. With this 
in mind, vaccines administered via the intralymphatic (i.ln) route are able to increase the amount of 
protein antigen in the lymph node as well as increase cell-mediated and humoural immune 
responses (Johansen et al., 2010).  
 
1.7.3. The role of liposome preparation method on vaccine delivery and formulation 
 
By varying the preparation method, liposomes (cationic, anionic and neutral) can be formed in a 
number of ways (Bangham et al., 1965, Gregoriadis et al., 1999). In order to act as efficient delivery 
systems, liposomes must become associated with antigen in order to induce an effective immune 
response as these systems are able to protect antigen from degradation (McNeil et al., 2011) 
Antigen can either become adsorbed at the liposome surface, associated within the phospholipid 
bilayer or become entrapped within the liposome itself. In order for antigen to become associated at 
the liposome surface, both of these components have to be opposite in charge in order to associate 
via electrostatic interactions. Antigen can also become entrapped within the liposome, and this 
interaction itself can be devoid of electrostatic interactions, therefore allowing the association of 
similarly charged liposomal and antigenic components (Henriksen-Lacey et al., 2011c). This 
entrapment procedure often yields low levels of antigen entrapment, but antigen is protected from 
degradation by protease enzymes (Gregoriadis, 1990, 1994). Many of the initial studies into 
liposome-based vaccines compared encapsulated antigens with surface-conjugated antigens with 
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the main findings showing improved antibody production and immune responses when antigen is 
exposed on the liposome surface and can attach to B-cell receptors (White et al., 1995).  
Various studies have shown that depending on the antigen location and its subsequent physical 
association with the liposome, the type and strength of the immune system is varied. Fortin and 
colleagues (1996) have demonstrated that these different locations can influence on the route in 
which antigen is processed within antigen presenting cells and thus dictate the immune response 
(Fortin et al., 1996). Antigen may be entrapped within dehydration-rehydration vesicles which gives 
rise to high antigen entrapment efficiency and subsequent improved immunogenicity (Kirby and 
Gregoriadis, 1984), however various other studies suggest that the physical location of the antigen 
has no bearing on the subsequent immune response (Gregoriadis et al., 1987, Kaur et al., 2011). 
 
1.7.4. The role of liposome membrane fluidity in vaccine delivery and formulation 
 
The role of membrane fluidity has been extensively reviewed in the literature. The general trend is 
for high transition temperature lipids to have an advantage over their low transition temperature 
counterparts when formulated within liposomal vaccine adjuvants, with Yasuda et al (1977) 
demonstrating that higher transition lipids gave rise a 4-fold increase in anti-DNP antibody responses 
(Yasuda et al., 1977). Also, mixed compositions of DSPC (high transition temperature) and DOPC (low 
transition temperature) led to enhanced antibody responses upon increased titration of DSPC lipid 
within the formulation (Dancey et al., 1978). More recent studies have compared liposomes 
formulated using either the high transition lipid DDA or the low transition lipid DODA 
(dimethyldioleoylammonium bromide) in combination with the immunostimulatory glycolipid TDB. 
Rigid DDA/TDB liposomes retained a higher percentage of antigen at the injection than their fluid 
DODA/TDB liposome counterparts, thus leading to significantly higher Th1 responses (100-fold) thus 
confirming that membrane fluidity plays an important role in the immunogenicity of liposome 
adjuvants (Christensen et al., 2012). 
So to conclude, liposomes consisting of high transition temperature lipids give rise to vesicles of 
greater rigidity which leads to enhanced antibody and cell-mediated immune (CMI) responses to a 
number of surface-adsorbed and encapsulated protein antigens (Watson et al., 2012), whereas low 
transition temperature lipids give rise to more fluid liposomes which lead to a significant reduction 
in Th1 immune responses. 
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1.7.5. Enhanced targeting of liposomal vaccines to the draining lymphatics 
 
Lymph nodes are the primary peripheral lymphoid organs that are essential for vaccine-induced 
immune responses. These draining lymph nodes are strategically positioned in order for the immune 
response to be initiated after coming into contact with foreign antigens (Roozendaal et al., 2009). 
The enhanced targeting of liposome-bound antigen is not fully understood in terms of improving the 
efficiency of cationic liposome-formulated vaccines. Previous studies have shown the role of vesicle 
size and surface charge as well as membrane fluidity on the retention of liposome at the vaccination 
site and their subsequent draining to the popliteal lymph nodes (PLN). These studies suggested that 
as cationic liposomes led to vesicle aggregation at the vaccination site, however neutral DSPC/TDB 
liposomes are less well retained at this site therefore are more likely to drain to the LN (Henriksen-
Lacey et al., 2010c). 
Liposome drainage to the lymph nodes has also been investigated by Kaur et al (2011) and Zhuang et 
al (2011) by incorporating varying concentrations of polyethylene glycol (PEG) within the 
formulation. These studies have demonstrated that incorporating PEG into the formulation led to 
the blockage of the ‘depot effect’ due to ‘masking’ of the cationic surface charge and, therefore, 
subsequently led to increased liposome drainage to the LN (Kaur et al., 2011). However, this did not 
correlate with antigen retention at this site, with no significant differences noted between 
formulations and a subsequent reduction in immune responses observed. However in terms of 
design for the manufacture of adjuvants, the promotion of a strong liposome depot also leads to the 
potentiation of strong Th1 immune responses (Perrie et al., 2013). 
 
Zhuang and colleagues demonstrated that PEGylation is important in the modification of liposome 
vaccine formulations. Incorporation of PEG could shield the surface charge of nanoparticles and 
reduce non-specific absorption by the extracellular matrix, thereby effectively accelerating the 
drainage of nanoparticles into the lymphatic system (Zhuang et al., 2011). Further studies have been 
carried out including the PEGylation of cationic liposomal adjuvants (Kaur et al., 2012). These studies 
indicated that size reduction of liposomes (to around 150 nm) and PEGylation of these liposome 
adjuvants led to enhanced drainage to the popliteal lymph nodes (PLN) and also led to earlier 
antibody responses. Carstens and colleagues (2011) also noted an enhanced lymphatic drainage of 
liposomal DNA vaccine carriers following subcutaneous injection, however this did not correlate with 
enhanced immune responses (Carstens et al., 2011). 
The draining lymph nodes are functionally partitioned into various compartments which contain 
areas that are high in cell content for B- and T-cells respectively (Roozendaal et al., 2009, Gonzalez et 
68 
 
al., 2010) . Therefore these cellular interactions in distinct compartments of the LN are able to direct 
both the cell-mediated immune response and humoural immunity. B-cells are able to circulate 
throughout secondary lymphoid organs, such as the spleen, in an effort to become more susceptible 
to encounter with antigen. These B-cells then are able to concentrate and become activated in the 
follicular region of the lymph nodes due to chemotactic migration in response to CXCL13, where 
they accumulate at the T-cell/B-cell border in order to interact with T-cells. 
 
In general, the lymphatic draining of cationic liposome vaccine formulations is inefficient, which has 
been previously demonstrated in the literature. This is due to their increased retention at the 
vaccination site due to non-specific electrostatic binding between the delivery system and 
extracellular matrix proteins (Foged et al., 2004). However, these vaccine formulations have still 
been shown to be immunopotent and capable of increasing levels of immunity as characterised by 
high production of interferon-gamma (IFN-γ) which is required for effective Th1 immunity. 
Therefore, these cationic liposome vaccine formulations are immunostimulatory but future 
challenges in research will be to augment enhanced lymphatic targeting of these systems in order to 
induce better immunoprotection by vaccination. 
 
 
1.8. Aims and Objectives 
 
A liposomal adjuvant currently shown to offer strong potential as an adjuvant for sub-unit vaccines 
including those for TB is composed of the cationic lipid DDA and the immunostimulatory glycolipid 
TDB (CAF01). Through previous studies, one contributing mechanism of action of this vaccine 
formulation is termed the ‘depot effect’. However, further information on the downstream immune 
responses elicited by this adjuvant remain unclear. With this in mind, the aim of this of this work was 
to further investigate these cationic liposome formulations in order to better understand the 
controlling link of formulation and function. To achieve this aim, the main objectives of these studies 
were to: 
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1. Formulate and characterise a high transition temperature anionic formulation. 
2. Develop and formulate an optimised liposome formulation, which maintains nanoscale 
properties. 
 
3. Investigate the role of surface charge in liposome vaccine formulation, stability, 
biodistribution and vaccine efficacy. 
4. Investigate the role of liposome preparation method in formulation, stability, biodistribution 
and vaccine efficacy. 
5. Identify TLR and non-TLR ligands we should consider in the context of liposome vaccine 
formulations. 
6. Optimise liposome vaccine formulations through inclusion of surface-bound or entrapped 
TLR agonists or insertion of bacterial-derived glycolipids within the bilayer. 
7. Reduce the particle size of liposome adjuvants through high shear mixing, with the aim of 
further inclusion of TLR agonists within the system. 
8. Conjugate a TLR agonist to lipid and incorporate within the CAF01 liposome system and 
investigate the subsequent effect on vesicle characteristics, agonist and antigen loading, 
biodistribution profile and immunogenicity. 
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Chapter 2: Materials and Methods 
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2.1. Materials 
 
Dimethyldioctadecylammonium bromide (DDA), 1,2 - distearoyl-sn-glycero-3-phospho-L-serine 
sodium salt (DSPS), 1,2 – disteraoyl-sn-glycero-3-phosphocholine (DSPC), 1,2 - distearoyl-sn-glycero-
3-phospho-L-ethanolamine (DSPE) and trehalose 6,6′-dibehenate (TDB) were purchased from Avanti 
Polar Lipids Inc. (Figure 2.1; Alabaster, USA). Monomycoloyl glycerol (MMG), Ag85B-ESAT6-Rv2660 
(H56 TB antigen) and Ag85B-ESAT6 (H1 TB antigen) at concentrations of 1.2 mg/ml and 1.6 mg/mL 
respectively were obtained from Statens Serum Institute (Copenhagen, Denmark). 
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Figure 2-1. Lipids required in studies in order to make liposome formulations. 
 
Lysozyme (from chicken egg white), hydrogen peroxide, resiquimod, Sephadex™ G-75 and G100, 
bicinchoninic acid protein assay (BCA) components, crystal sky blue (Pontamine blue), Phospho-
buffered saline (PBS) tablets, trypsin (from bovine pancreas), succinic anhydride, diisopropyl 
azodicarboxylate (DIAD), triphenylphosphine (TPP), sodium chloride, protease inhibition mixture, 
potassium chloride, potassium dihydrogen phosphate, sodium orthophosphate, citric acid, azino-
bis(3-ethylbenzthiazoline-6-sulfonic acid) [ABTS] tablets, Tween-20, Triton X-100 phosphate-citrate 
buffer tablets, dimethylsulfoxide (DMSO), sodium azide, bovine serum albumin (BSA), concanavalin 
A (conA), succinic anhydride, tetramethylbenzidine (TMB) tablets, Brilliant Blue R, glycine, 
cyclohexane and sodium dodecyl sulphate (SDS) were purchased from Sigma-Aldrich UK. 
Glacial acetic acid, diethylether, ethanol, propan-2-ol, methanol and chloroform (both HPLC grade) 
were purchased from Fisher Scientific UK (Leicestershire, UK). Dialysis tubing (3.5 kDa MWCO, 45 
kDa MWCO and 100 kDa MWCO) were obtained from Biodesign and Spectrapor respectively. 
The TLR3 agonist poly(I:C) oligodeoxynucleotide (ODN) DNA, agonists was purchased from Source 
Life Sciences (Nottingham, UK). Ovalbumin (OVA) was bought from Calbiochem (La Jolla, USA). 
Foetal Calf serum (FCS), and RPMI (without L-glutamine) were obtained from BioSera. Tritium-
labelled cholesterol (3H-Cholesterol) was obtained from GE Healthcare (Amersham, UK). IODOGEN® 
pre-coated iodination tubes were purchased from Pierce Biotechnology (Rockford, IL, USA). 
3H-thymidine (tritium-labelled thymidine), 125I (NaI in NaOH solution),  32P- ATP, SOLVABLE™ and 
UltimaGold™ scintillation fluid were purchased from Perkin Elmer (Waltham, MA, USA). 
Trehalose 6,6′-dibehenate (TDB) 
Monomycoloyl Glycerol (MMG) 
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Tris-base was obtained from IDN Biomedical Inc. (Aurora, OH, USA) and used to make Tris buffer and 
adjusted to pH 7.4 or pH 4.0 using HCl; unless stated otherwise Tris buffer was used at 10mM, pH 
7.4. Pre-cast 12 % and 18 % Tris-glycine gels (12 wells), penicillin streptomycin glutamate (PSG; 100 X 
liquid] and BenchMark ™ pre-stained protein ladder were bought from Invitrogen Ltd (Paisley, UK). 
Trehalose [D-Trehalose (99 %) anhydrous] was obtained from Acros Organics. Isotype-specific 
immunoglobulins (Goat anti-mouse IgG, IgG1, IgG2a and IgG2b) were purchased from AbD Serotec. 
All plastic wear for use in cell culture experiments and assays was purchased from Greiner BioOne. 
Mouse duoset capture cytokine analysis kits (IFN-γ, IL17, IL1-β, IL33, IL2, IL5, IL6 and IL10) and ELISA 
assay components were purchased from RnD (Abingdon, UK). Dried skimmed milk powder was 
purchased from Marvel. TLC plates and silica were obtained from Merck Chemicals Ltd. Deuteriated 
chloroform and DMSO were purchased from Cambridge Isotope Laboratories. 
 
2.2. Methods in liposome formulation 
2.2.1. Lipid Film Hydration Method for the production of multilamellar vesicles (MLV) 
 
Liposomes were prepared using the previously described lipid film hydration method (Bangham et 
al., 1965). For individual formulations, weighed amounts of DDA (10 mg/ml), DSPS (10 mg/ml) and 
TDB (2 mg/ mL) were each dissolved in chloroform/methanol (9:1 by volume). These lipids were 
added together to a final concentration of either 1.98 mM DDA or DSPS in combination with 0.25 
mM TDB (8:1 M/M) added in the case of DDA/TDB and DSPS/TDB liposomes. The organic solvent 
was extracted using a roto-evaporator followed by flushing with N2 to form a thin lipid film on the 
bottom of a round bottom flask (rbf). The lipid film was hydrated using 10 mM Tris buffer at pH 7.4 
(unless otherwise stated) and at ~ 20 ˚C above the transition temperature for the main lipid in the 
formulation; e.g. for DDA and DDA/TDB liposomes the hydration buffer was pre-heated to 60 ºC. For 
DSPS/TDB liposomes, the hydration buffer was pre-heated to greater than 80 °C in order for these 
vesicles to assemble. For each of the formulations, the hydrated lipid film was vortexed every 5 
minutes (for 20 minutes) in order to form liposomes (Figure 2.2) before being left to cool for 30 
minutes. Subsequently, protein antigen, vaccine or TLR agonist could be added in order to 
investigate vesicle characteristics. 
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Figure 2-2. Preparation of lipid stocks in organic solvent (9:1 chlorofom/methanol), and preparation of 
multilamellar vesicles using the lipid film hydration method. 
 
2.2.2. Formulation of small unilamellar vesicles (SUV) 
 
For each liposome formulation, the particle size was reduced using a sonication procedure. The 
suspension of MLV was sonicated (at 10 psi for 2 minutes) using a titanium probe (MSE PG100 
probe) slightly immersed into the solution. This sonication procedure causes the breaking of the lipid 
bilayer of liposomes, converting a slightly milky suspension of MLV into a clear suspension of SUV 
(Figure 2.3A). These vesicles were left to stand for 30 minutes before characterisation of the size, 
polydispersity and zeta potential. These vesicle systems were either characterised empty or with the 
addition of varying concentrations of protein [either OVA (anionic), lysozyme (cationic) or H56 TB 
antigens (anionic)] or TLR agonist. 
 
2.2.3. Preparation of dehydration-rehydration vesicles (DRV)  
 
Vesicles were prepared by the dehydration-rehydration method as previously described (Senior and 
Gregoriadis, 1989, Gregoriadis et al., 1999) at the same composition and molar ratios (8:1 M/M 
ratio) as for SUV as described in section 2.2.2.  
These vesicle suspensions were then placed in glass vials covered with parafilm (with small holes) 
before being placed in the freezer at - 70 ˚C for 10 minutes. The liposome samples were then placed 
LIPOSOME 
FORMATION 
Evaporation of organic solvent, using rotary 
evaporation followed by a gentle stream of 
nitrogen yields a thin lipid film at the bottom of 
round-bottomed flask.  
 
Addition of hydration buffer 
Hydration of lipid film with Tris (10 mM, pH 7.4) 
buffer above the phase transition temperature of 
the main lipid in formulation, followed by 
frequent vortexing leads to the formation of 
liposomes.  
 
Addition of lipids (dissolved 
in 9:1 chloroform:methanol 
Addition of 
protein/TLR agonist 
post-lipid film 
hydration 
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in a freeze drier overnight, at - 40 ˚C under vacuum conditions (Figures 2.3A and B) with vacuum to 
40 mbars. Controlled rehydration (using deionised water) of the dried powder (lipid cake) led to the 
formation of antigen containing DRV. Controlled rehydration was achieved by addition of 10% of the 
final volume which was standardised at 900 μl, twice at 30 min intervals (followed by vortexing), 
before addition of the remaining volume of deionised water. 
 
 
 
Figure 2-3. (A) Preparation of liposomes by the dehydration-rehydration vesicle (DRV) method [Gregoriadis 
and Kirby, 1984]; (B) Diagrammatical representation of each stage of the DRV liposome preparation process. 
 
2.2.4. Preparation of double emulsion (DE) vesicles  
 
The same molar ratio was used between formulations, using these various liposome preparation 
methods, in order to serve as a direct comparison between cationic DDA/TDB and anionic DSPS/TDB 
liposome formulations. The organic solvent was extracted using a roto-evaporator (at 40 ˚C) 
followed by flushing with N2 to yield a thin lipid film on the bottom of a round-bottomed flask or 
glass vial as described in section 2.2.1. Subsequently, 2.1 ml organic phase (o) consisting of 
diethylether and cyclohexane (5:1 v/v) was added to this lipid film before being dispersed by tip 
sonication. To this volume, 350 µl Tris buffer was added (inner water phase, w1) containing the 
A 
B 
1 
2 
3 4 
5 
1 2 3 4 5 
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desired amount of protein (OVA, lysozyme or H56 antigen) before being sonicated using a titanium 
probe (MSE PG100 probe; Soniprep 150) slightly immersed into the solution. For in vivo 
formulations, the dose concentration of 5 μg (or 0.1 mg/mL) was added in the w1 inner water phase.  
Under vigorous magnetic stirring, the primary w1/o emulsion was introduced (using a Hamilton 
syringe) into a second water phase (w2) consisting of 10 ml Tris buffer, 10 ml MilliQ water and 8.5 ml 
of the co-solvent ethanol (30 % v/v) in order to form a double (w1/o/w2) emulsion (Figure 2.4). 
Under slow magnetic stirring, this rbf was then placed in a water bath at 35 ˚C in order for solvent 
evaporation to take place. After a few hours evaporation, a gentle stream of air/N2 was introduced 
to facilitate the evaporation process. The organic phase and co-solvent should evaporate after 
around 5 hours. To further improve the quality of the formulation, the w1/o/w2 emulsion was 
sonicated for 2 minutes every 30 minutes during the evaporation process using a bath sonicator 
(Nordly et al., 2011c). 
 
 
 
 
 
 
Figure 2-4. Schematic illustration of the double emulsion solvent evaporation method, used in the 
preparation of double emulsion (DE) liposomes. 
 
2.2.5. Formulation of liposomes by the high shear mixing (HSM) homogenisation method 
 
As with the lipid-film hydration (LH) method, the thin lipid film was formed as described previously 
in Section 2.2.1. Again Tris buffer (10 mM; pH 7.4) was added to the lipid film, which was then placed 
and mounted in a 60 °C water bath (for DDA-based formulations). The use of an Ultraturax™ Silent 
Crusher M at 24,000 rpm (for 15 minutes) was optimal to produce a homogenous population of 
Addition of 
2.1 mL organic 
(o) phase 
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inner water 
phase 
containing 
protein (w1) 
Evaporation of organic solvent, followed by 
dispersion of lipid film in organic phase consisting 
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followed by sonication to produce a primary w1/0 
emulsion 
Under fast magnetic stirring, 
introduction of primary w1/o 
emulsion to outer water phase (w2) 
to form a secondary water in oil 
emulsion (w1/0/w2). 
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emulsion liposomes. 
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vesicles (Figure 2.5). Following formulation of CAF01 (DDA/TDB) or CAF04 (DDA/MMG) by high shear 
mixing (HSM), subsequently polyI:C was added in steps of 5 μL, in order to form CAF05 or CAF09 
respectively. This was followed by high shear mixing at a temperature of 60 °C for 60 seconds. This 
was continued until the final concentration of poly(I:C) within the formulation was reached.  
 
Figure 2-5. Schematic illustration of the high shear mixing homogenisation method used in the formation of 
liposomes with reduced vesicle size [with or without incorporation of poly(I:C)]. 
 
2.2.6. Removal of unincorporated protein from liposome-bound protein 
 
For all liposome formulations (prepared by all of the above methods) with the addition of protein in 
the preparation process, the liposome-entrapped protein is separated from non-entrapped protein 
using ultracentrifugation at 125,000 x g (at 4 ˚C for 30 minutes). The supernatant is then decanted, 
and the liposome pellet is resuspended in Tris buffer (10 mM; pH 7.4).  
 
2.3. Characterisation of liposomal systems 
2.3.1. Determination of vesicle size and surface charge, by dynamic light scattering and 
zeta potential 
 
The particle size distribution and polydispersity (PDI) of the liposome suspensions were determined 
by dynamic light scattering (DLS). PDI is a measure of the distribution of the particle size. Samples of 
100 μL were diluted 10-fold with Tris buffer (1 mM, pH 7.4) before measuring to ensure the 
concentration of particles was sufficient. Particle size measurement took place using a Malvern 
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Zetasizer Nano-ZS (Malvern Instruments, Worcs., UK). Triplicate samples were measured three times 
each at 25 °C. The vesicle surface charge (as indicated by zeta potential) of the formulations were 
measured using the same instrument at 25 °C in a clear zeta potential cuvette. Each sample was also 
measured three times (in triplicate). 
During a size measurement of the various liposome systems if the particles are illuminated with a 
laser, the intensity of the scattered light fluctuates at a rate that is dependent upon the size of the 
particles. Smaller particles are moved further by the solvent molecules and move more rapidly. 
Analysis of these intensity fluctuations yields the velocity of the Brownian motion and hence the 
particle size using the Stokes-Einstein relationship. These particles in suspension move under 
‘Brownian motion’ which is the motion induced by the bombardment by solvent molecules that 
themselves are moving due to their thermal energy. During a particle size measurement the laser 
acts as the light source (at an angle of 90o), therefore light is scattered by the particles at all angles. 
The scattered light is then able to be converted into electrical pulses by a photon detector which 
feeds into a digital correlator and gives data analysis of the particle size. 
The zeta potential is defined as the electrical potential that exists at the hydrodynamic plane of 
shear (or slipping plane), which is the area of the diffuse layer where ions can no longer interact. The 
zeta potential can be used to measure the charge stability of a disperse system and also assist in the 
formulation of stable products. So, the zeta potential can act as an indirect measurement of the 
surface charge of a particle (in the case of these studies, liposomes). The zeta potential can be 
measured by applying an electrical field across the dispersion. During this measurement, particles 
with a zeta potential will migrate towards the electrode of opposite charge with a velocity 
proportional to that of the zeta potential. 
During this thesis, a number of stability studies were carried out in order to ensure that liposome 
vesicle size and surface charge characteristics maintained constant over a 28-day period at storage 
temperatures of 4 ˚C or 25 ˚C. The size, zeta potential and polydispersity of these liposomes (without 
and with antigen) were measured at a number of different timepoints (Days 0, 3, 7, 14, 21 and 28) in 
order to show if the liposome formulation remains stable. Also, at each timepoint a visual inspection 
of the sample was undertaken to check for aggregation, along with a photograph of the specific 
liposome formulation.  
Further stability studies were also undertaken to investigate the long term storage conditions of 
liposome vaccine formulations over a 6-month study period (Chapter 6). These liposomes were all 
formulated with the H56 TB vaccine antigen at a concentration of 5 μg (0.1 mg/mL), and also with 
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and without addition of the TLR3 agonist polyI:C (50 μg). The protein integrity of antigen within 
these vaccine formulations was also visualised by SDS-PAGE, which will be described in Section 2.3.6. 
 
2.3.2. Cryo-Transmission Electron Microscopy (Cryo-TEM) 
 
Cryo-electron microscopy involves forming a thin aqueous film on a bare specimen grid (3–4 mm 
thick, with a fine 700 mesh honeycomb pattern of bars) by pipetting 5-10 µl of the liposome 
suspension onto the grid. After blotting the suspension-coated grid on filter paper, the thin film 
produced was rapidly (1 s) vitrified by plunging the grid into ethane and cooled to its melting point 
with liquid nitrogen. Preparation and blotting of thin films was carried out in a controlled 
environment using a fully automated system (PC-controlled, up to vitrification). The vitrified film was 
mounted in a cryo-holder (Gatan 626) and observed at 170 °C in a transmission microscope (Philips 
CM12) operating at 120 kV. Micrographs were taken using low-dose conditions. 
 
2.3.3. Adsorption of protein antigen to liposomal formulations 
 
Once the liposomes (MLV) had been formulated by one of the preparation methods described in 
Section 2.2, they were mixed with various concentrations of protein/antigen (OVA, lysozyme or 
H56). Adsorption of protein to these liposomes occurred due to frequent mixing of the eppendorf 
tube over a time period of 45 minutes. 1 mL of 10 mM Tris buffer (pH 7.4) was added to this mixture 
before a number of different total protein assays were undertaken. This procedure was also 
undertaken for the adsorption of radiolabelled protein to liposome formulations, as described in 
Section 2.4, with the addition of varying concentrations of protein. 
 
2.3.4. Measuring the amount of total protein using a Bicinchonic Acid (BCA) Assay 
 
This assay is based on the colourimetric detection of a purple-coloured BCA-Cu+ reaction complex (at 
562nm) to determine the total amount of protein in a sample, based on the method carried out by 
Smith (1985). This protocol combines the reduction of copper ions (Cu2+  Cu+) by a protein in an 
alkaline medium (termed the Biuret reaction), with the ability of a single Cu+ ion to be able to chelate 
with two molecules of BCA in order to form the purple-coloured reaction complex. 
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Protein (present in sample) + Cu2+(green/blue)                         tetradentate-Cu+ complex (purple) 
 
This reaction complex has a strong absorbance at 562nm, which increases in a linear fashion over 
increasing concentrations of protein. During this study, a BCA total protein assay was used to 
determine the amount of protein which was present in the supernatant fraction from the liposomes 
(DDA, DDA/TDB, DSPC/TDB and DSPS/TDB) in order to determine the amount of protein which 
remained unadsorbed to these liposomes. In order to obtain supernatant fractions from the 
liposomal formulations, these protein-adsorbed liposome samples (as prepared previously in Section 
2.2) were centrifuged for 30 minutes at 10,000 x g (using a Sanyo MSE Micocentaur centrifuge). The 
supernatant fractions for each of the liposomes were then decanted and stored in a new set of 
eppendorf tubes. The remaining liposome pellet was resuspended in 1 mL Tris 10mM buffer (pH 7.4) 
and this process was repeated several times for each formulation. 
This same protocol was repeated in a subsequent experiment, with the exception that the protein-
adsorbed liposome samples were separated from free protein using ultracentrifugation [using a 
Optima Max-XP Ultracentrifuge (Beckman-Coulter Inc., Fullerton, CA)] for 30 minutes at 125,000 x g 
at a temperature of 4 °C. Again this step was repeated to gain a series of supernatant fractions. A 
standard protein curve of 0-1 mg/mL OVA or lysozyme, in triplicate wells, was set up in order to 
compare to the protein concentration in both these supernatant fractions for various liposome 
formulations. For these formulations, 25 μL of supernatant, in triplicate wells, were placed in 
separate wells on a 96-well plate - and then 200 μL of BCA reagent was added to each of these wells. 
The 96-well plate was then incubated for 30 minutes at 37 °C before the absorbance of this plate 
was read at an absorbance of 562 nm using a BioRad™ plate reader. 
 
2.3.5. Trypsin Digestion Assay to show the localisation of antigen in regards to the delivery 
system 
 
Liposomes were prepared as in Sections 2.2, with the addition of protein antigen in the preparation 
method [lipid-film hydration (LH) method, dehydration-rehydration vesicle (DRV) method or double 
emulsion (DE) solvent evaporation method]. Post-liposome preparation, these vesicles were 
subjected to conditions of varying concentrations of trypsin (100, 200 and 400 μg/mL respectively). 
Trypsin is a serine protease enzyme located in the digestive system of many vertebrates, where it 
hydrolyses proteins. This enzyme is able to function by cleaving peptide chains mainly at the 
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carboxyl side of the amino acids lysine or arginine, except when either is followed by proline. 
Therefore if the antigen is surface-adsorbed to the liposome delivery system then trypsin will be able 
to remove this protein. However, if the protein antigen remains entrapped within the delivery 
system, the trypsin enzyme will be unable to perform its function. This is due to the fact that trypsin 
is unable to pass through the liposome bilayer. 
Post-assay, these preparations will then be separated by ultracentrifuge (125,000 x g; for 30 minutes 
at 4 ˚C using a Optima Max-XP Ultracentrifuge; Beckman-Coulter Inc., Fullerton, CA) in order to 
produced a defined liposome pellet. The supernatant (S1) was decanted, and the liposome pellet 
resuspended in Tris buffer (10 mM; pH 7.4). This process was repeated in order to gain a second 
supernatant fraction (S2). These fractions were then ran on an SDS-PAGE gel and the protocol was 
followed as per Section 2.3.6. 
In order to quantitatively establish the extent of antigen adsorbed compared with antigen entrapped 
within the the liposome delivery system, DDA/TDB and DSPS/TDB liposomes (in combination with 
radiolabelled protein antigen) prepared by either the LH method, DRV method or the double 
emulsion (DE) solvent evaporation method were subjected to surface digestion of antigen using 
trypsin and antigen retention measured (Kaur et al., 2011). The % radioactivity within the pellet 
fraction was quantified as the percentage of adsorbed protein, therefore being a direct 
measurement of antigen retained with the delivery system, as described in Section 2.4. 
 
2.3.6. SDS-PAGE to determine the adsorption or entrapment of protein antigen to 
liposomal formulations 
 
Preparation of Tris/ Glycine/ SDS running buffer was achieved by the mixing of Tris (15 g), glycine (72 
g) and SDS (5 g) - before being made up to 1 L with deionised H20. The samples containing the 
proteins of interest were separated on a 12 % Tris-glycine (Invitrogen) gel, and this was run in Tris/ 
glycine/ SDS running buffer using Novex Mini Cell gel apparatus (Invitrogen). These samples 
containing the proteins of interest, from the supernatant and pellet fraction, of various liposomal 
formulations were compared against 10 μL of a protein marker. Prior to loading, all of these samples 
were heated at 90 °C for 3 minutes in order to denature the protein present in the sample. A volume 
of 10 μL of each pellet and supernatant sample were loaded into each specific lane of the gel. The 
gel was run for about 90 minutes at a constant 30 mA per gel, until the dye had just reached the end 
of the gel. The gel was subsequently stained using Coomassie Blue overnight, followed by a period of 
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destaining for several hours. A photograph was then taken of each gel using a GeneFlash gel 
photoimager (Syngene bioimaging). 
 
2.4. Techniques for Protein, TLR Agonist and Liposome Detection  
2.4.1. Preparation of radiolabelled liposomes  
 
To follow the movement of liposomes in vivo, a stable radioactive tracer component (3H-Chol) was 
added to the liposomes which can integrate into the lipid bilayer (Figure 2.9). Each liposome 
formulation (DDA/TDB or DSPS/TDB) was made in a similar manner (in a 8:1 M/M ratio) as described 
previously by the lipid film hydration method (Figure 2.2), but tritium-labelled cholesterol (3H-Chol) 
was added to the rbf at the same time for each separate formulation. 3H-Chol was added at a 
radioactivity of 2 MBq (100 kBq/ dose) to each liposome formulation (so the equivalent of 20 doses; 
1 mL in order to track the in vivo fate of liposomes as vaccine components during biodistribution 
studies. The amount of 3H-Chol added was based on the radioactivity (3H) and the concentration of 
Cholesterol in the liposomes (0.17 nM) so that the physicochemical liposomal properties were not 
altered. The high ratio of 3H-Cholesterol was ideal for biodistribution work as both factors - high 
radioactivity and low levels of cholesterol - were fulfilled. 3H-Cholesterol was incorporated into 
liposomes at 3H-Cholesterol:lipid weight ratio of 1:10,000. This is equivalent to 25 ng 
Cholesterol/dose with an approximate radioactivity of between 100-200 kBq. 
The membrane stability of liposome delivery systems was determined by means of the incorporation 
of trace amounts of tritium (3H) radiolabelled cholesterol within the liposome formulation. 
Therefore, the presence of this radiolabelled lipid either in the liposome or leaked into surrounding 
media can be measured. With this in mind, dialysis was used to study the retention of 3H-Cholesterol 
within the liposome membrane. Liposomes were prepared by the lipid-film hydration (LH) method, 
dehydration-rehydration vesicle (DRV) or double emulsion method as described in Sections 2.2, with 
the inclusion of trace amounts of 3H-Cholesterol. This liposome preparation was placed in dialysis 
tubing (MWCO; 3 kDa) and subsequently placed in dialysis media which simulates the in vivo 
environment (FCS/Tris; 50/50 v/v). Aliquots of dialysis media were removed (1 mL) at various time 
points (30 minutes, 1 h, 3 h, 5 h, 18 h, 48 h and 96 h). In order to maintain ‘sink’ conditions, this 
volume is replaced with new dialysis media. These aliquots were added with 10 mL Ultima Gold 
scintillation fluid before being measured by standard scintillation counting procedures using a 
1600TR Liquid Scintillation Counter. 
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2.4.2. Radiolabelling of protein antigen 
 
Known volumes of either lysozyme or OVA (both at 10 mg/mL), H56 (at a concentration of 1.2 or 1.6 
mg/mL) in combination with 125I were added into an IODO-GEN® tube and left for 1 hour with 
intermittent swirling to allow the specific protein to be radiolabelled. Typical volumes for the 
production of 1 mL radiolabelled lysozyme would require the mixing of 100 µl lysozyme (10 mg/mL) 
with the addition of 9 MBq of 125I. Whereas typical volumes for the production of 1 mL radiolabelled 
OVA would require the mixing of 100 μL OVA (10 mg/mL) with the addition of 3 MBq of 125I. During 
subsequent experiments the H56 TB antigen was radiolabelled for used in adsorption and 
biodistribution studies. This would require the mixing of 0.2 mL H56 antigen (1.6 mg/mL) with 3 MBq 
125I. These IODO-GEN® tubes contain an oxidizing reagent, which can convert NaI into a reactive 
iodine molecule – which can subsequently insert into the tyrosol group of amino acids in all proteins, 
or the aromatic residues of other molecules (Figure 2.6). Therefore this leads to the protein or 
antigen being able to be radiolabelled with Iodine-125 (125I). Lysozyme is known to contain 3 tyrosine 
residues (iodinatable sites), whereas OVA has 9 tyrosine amino acids. 
Na-125I  Na- + 125I-                                     +  125I-                    + Na- 
Figure 2-6. Diagram showing iodination of the amino acid tyrosine using Pierce oxidizing reagent present in 
Pierce iodination tubes. Two possible iodination sites exist on tyrosine at the ortho ring position either side 
of the hydroxyl group  (Adapted from (Salacinski et al., 1981)). 
 
2.4.3. Separation of bound from free I125 using a Sephadex gel filtration column 
 
A gel filtration column (with a column volume of 8 cm3) containing Sephadex G-75 beads was made 
in order to separate bound from free 125I (Figure 2.7). In order to make the column, 1g of Sephadex 
G-75 was rehydrated at 90 ˚C for 1-2 hours with 20 mL Tris (10 mM) buffer (at either pH 4.0 for 
lysozyme or pH 7.4 for OVA and H56 antigen). In order to act as a stopper, a small amount of cotton 
wool was placed at the bottom of a 5 mL glass pipette – and placed in a clamp and stand. This bead 
slurry of Sephadex G-75 was then poured into this 5 ml glass pipette, in order to minimise protein 
binding to the column. The 125I /lysozyme (or OVA) solution (~ 100 μL) or H56 (~ 500 μL)  was then 
added to the column and elucidated using 10 mM Tris buffer (at either pH 4.0 for lysozyme or pH 7.4 
Iodination 
Reagent 
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for OVA and H56) – this was in order to maintain a steady flow of buffer through the column in order 
to separate bound from free I125. Aliquots of 0.25 mL were then collected at 1 minute intervals for 40 
minutes. These aliquots were collected and analysed for 125I content using a Cobra CPM Auto-
Gamma counter. Verification of the presence of protein (lysozyme, OVA or H56) was carried out in 
separate BCA assays and the absorbance results (at 562 nm) were compared against a standard 
curve (0-1 mg/mL) for that specific protein which was prepared at the same time (as described 
previously in Section 2.3.4). The samples with the highest protein content and 125I content (Figure 
2.7) were collected, pooled together and diluted for future experimental use as radiolabelled protein 
in antigen adsorption/entrapment, release and biodistribution studies. 
Figure 2-7. Separation of radiolabelled protein (OVA) from free radiolabel using a Sephadex G-75 Column. 
Aliquots high in protein and gamma counts (radiolabelled protein) are pooled together and diluted for 
future use. 
 
2.4.4. Adsorption of radiolabelled protein antigen to liposomes 
 
In order to show the degree of protein antigen adsorption to both cationic and anionic liposomes, 
125I-labelled lysozyme, OVA or H56 was added to each liposome formulation (DDA/TDB and 
DSPS/TDB) at an in vivo concentration of 5 μg per dose. In order for adsorption to take place this 
mixture was left for 1 hour with intermittent swirling. This sample was then made up to 1 mL (1:5 
dilution) using Tris 10 mM buffer (pH 7.4) and a 100 µL aliquot was used in order to determine the 
total amount of radioactivity present in the sample. The remaining sample was centrifuged at 45,000 
rpm for 45 minutes at 4 °C  (using an Optima MAX-XP ultracentrifuge (Beckman Coulter Inc., 
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Fullerton, CA)) in order to separate free protein (in supernatant) from bound protein (in liposome 
pellet). After two washes (with Tris 10 mM pH 7.4), the 125I recovery in the pellet and supernatant 
was measured using a Cobra CPM Auto-Gamma counter. The percentage of protein adsorbed to 
liposomal formulations was calculated as a percentage of the radioactivity recovered from both the 
supernatant (free protein) and pellet (bound protein) as well as the total amount of radioactivity 
present in the sample. 
 
2.4.5. Protein entrapment by DRV and double emulsion vesicles of cationic DDA/TDB and 
anionic DSPS/TDB liposomes 
 
In order to measure the proportion of protein, either entrapped within the liposomes (bound 
protein) or within the supernatant (free protein), radiolabelled (125I) protein was added in the 
preparation process; either in the inner water phase (for the double emulsion method) or with the 
sonicated liposomes (for the dehydration-rehydration method). For these liposome preparation 
methods which involve the entrapment of antigen, an aliquot of the sample was taken (200 µL) and 
this was made up to 1 mL using Tris buffer (10 mM; pH 7.4) and 100 µL of the sample will be 
aliquotted to determine the total amount of radioactivity present. The percentage of entrapped 
(liposome-bound) protein will then be determined as in Section 2.4.4. 
The formation of a more pronounced liposome pellet can be achieved using a solution of OVA (1 
mg/mL) in Tris buffer (10 mM;pH 7.4) during these studies. This was in order so that supernatant can 
be efficiently removed without disturbing the liposome pellet, thus enabling efficient measuring of 
radiolabelled protein associated with each fraction (liposome pellet or supernatant). 
 
2.4.6. Antigen release kinetics in simulated in vivo conditions 
 
Antigen release from liposomal formulations (multilamellar vesicles, double emulsion liposomes, 
small unilamellar vesicles and dehydration-rehydration vesicles) was measured in simulated in vivo 
conditions (FCS/Tris; 50:50 v/v) as well as being measured in control conditions (Tris buffer; 10 mM 
pH 7.4) over a 96 hour time period. Aliquots of each formulation, consisting of equal volumes of 
liposome with radiolabelled antigen, were diluted 1:5 in either FCS/Tris (50:50 v/v) or Tris, and 
incubated in a shaking water bath at 37 °C for 96 hours. 
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The % antigen loading and release was determined at selected timepoints (0 h, 1 h, 3 h, 5 h, 18 h, 48 
h and 96 h) using the centrifuge method as described previously in Section 2.4.4. At these selected 
time points, the eppendorf tube was removed from the water bath and processed as described 
previously in Sections 2.4.4 and 2.4.5 in order to determine the % antigen retention with the 
liposome delivery system. 
 
2.4.7. Radiolabelling of resiquimod and subsequent separation of radiolabelled TLR 
agonist from free radiolabel 
 
During this investigation, it was required to determine the agonist loading and also to track the 
biodistribution of TLR agonist in vivo. Resiquimod or DSPE conjugated resiquimod is radiolabelled 
with 125I in an IODO-GEN® tube and left for 1 hour with intermittent swirling (Figure 2.7). Resiquimod 
can be radiolabelled due to the presence of aromatic residues within this TLR agonist. 
Due to the radiolabelling procedure not being 100 % efficient there may still be some free 125I. This 
was removed by using sodium thiosulphate (Na2SO3), which will convert free iodine to iodide (I2  
2I-). As a control during this study, radiolabelled resiquimod (125I) was added post lipid film-hydration 
(LH) to the CAF01 formulation (with incorporation of DSPE within the bilayer) in order to determine 
agonist loading. Also the radiolabelled lipid-TLR conjugate was incorporated within the CAF01 
delivery system during the initial process so that TLR agonist can be retained by the delivery system. 
The percentage loading and release kinetics of resiquimod TLR agonist, when associated within 
these liposome formulations, can also take place in simulated in vivo or control conditions, using the 
method described in Section 2.4.6. Through radiolabelling of these novel vaccine formulations we 
were able to track the biodistribution of resiquimod agonist in vivo as will be described in Section 
2.6. 
 
2.4.8. Radiolabelling of PolyI:C and subsequent separation of radiolabelled TLR agonist 
from free radiolabel 
 
It was required to radiolabel polyI:C in order to determine whether loading of agonist has a 
subsequent effect on vesicle characteristics (whole dose or stepwise addition of polyI:C) or whether 
vesicle size and zeta potential remain constant. In an initial reaction, polyI:C was added with 
thermosensitive alkaline phosphatise (TSAP), Tris-HCl (70 mM; pH 7.6) and dithreitol (DTT; 5 mM) 
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before being incubated at 37 °C for 30 minutes. Subsequently polyI:C was radiolabelled through heat 
inactivation of TSAP in which dephosphorylated polyI:C was reacted with MgCl2 (10 mM), 
polynucleotide kinase (5 mM) and 32P-ATP (1.35 µM). This reaction mixture was incubated at 74 °C 
for 15 minutes, before being transferred to a water bath for incubation for 5 minutes (at 37 °C). This 
was followed by polyI:C purification through repeated centrifugation steps (at 10,000 x g) in order to 
obtain highly pure radiolabelled polyI:C for use in experiments.  
During agonist loading studies, radiolabelled polyI:C can be added either stepwise or at the whole 
dose to liposomes. Percentage loading can be determined as the quantity of radioactivity retained 
within the liposome pellet following ultracentrifugation (125,000 x g, 4 °C, 45 minutes). After two 
washes (with Tris 10 mM pH 7.4), the 32P recovery in the pellet and supernatant was measured by 
standard scintillation counting procedures using a 1600TR Liquid Scintillation Counter. 
 
2.5. Methods and techniques in chemical synthesis 
2.5.1.  Design and synthesis of a novel lipid-TLR agonist conjugate 
 
It was proposed to design and synthesise a novel lipid-TLR agonist conjugate consisting of the lipid 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) and the TLR7 agonist resiquimod 
(otherwise known as R848) which possesses anti-viral and anti-tumoral activities. Both lipid and TLR 
agonist are displayed in Figures 2.8 A and B. 
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Figure 2-8. Chemical structures of (A) DSPE lipid and (B) Resiquimod. 
 
It was hypothesised these two molecules are able to form a conjugate due to the presence of a 
hydroxyl (- OH) group on resiquimod which provides an ideal linker molecule in order to bind to the 
A 
B 
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amine (- NH3 
+) group present on the lipid head group of DSPE. This chemical reaction will require a 
strong activating agent, termed diisopropyl azodicarboxylate (or DIAD) and succinic anhydride. This 
study will require two important chemical reactions; firstly DSPE and succinic anhydride will be 
reacted together (under heat and magnetic stirring) in order to form the DSPE lipid with amide bond 
and terminal carboxylate. Upon formation of this structure, we will subsequently add the TLR 
agonist resiquimod [which contains an alcohol group (-OH)] in the presence of the diisopropyl 
azodicarboxylate (DIAD) activating agent and triphenylphosphine (TPP). This will lead to the 
formation of an ester (due to the Mitsunobu reaction) made up of DSPE conjugated to the 
resiquimod TLR7 agonist. 
 
2.5.2. Step 1 Succinylation Reaction 
 
DSPE lipid and succinic anhydride (SA) were dissolved in chloroform/methanol (9:1 v/v) and 
chloroform respectively (Hermanson, 2008). These starting materials were added together (under 
magnetic stirring) at a number of different ratios (1:2 M/M, 1:5 M/M and 1:10 M/M) in separate 
reactions in order to determine optimal reaction conditions to produce the correct reaction product 
(which was determined to be 1:5 M/M). The temperature was either maintained at room 
temperature or increased to 40 °C also to determine optimal reaction conditions (which was 
determined to be at room temperature). This reaction is schematically represented in Figure 2.9. At 
various time points, aliquots (around 50 μL) of the reaction mixture were kept for future analysis by 
thin layer chromatography (TLC). Upon completion of the reaction, excess water is ‘quenched’ by the 
addition of sodium hydroxide (NaOH) at a 1M concentration before separation of the reaction 
product using a separation column. Upon separation, dried magnesium sulphate (MgSO4) was added 
before filtration. The reaction product (in chloroform) was dried using rotary evaporation and placed 
in the dessicator for future analysis by infra-red (IR) spectroscopy and nuclear magnetic resonance 
(NMR) spectroscopy. 
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Figure 2-9. Schematic Diagram of the Step 1 Succinylation Reaction. 
 
2.5.3. Step 2 Mitsunobu Esterification Reaction 
 
The product from the Step 1 reaction is added with the TLR agonist resiquimod in the presence of 
the activation (coupling) agent, diethylazodicarboxylate (DEAD) and triphenylphosphine as part of a 
Mitsunobu esterification reaction (Mitsunobu and Yamada, 1967, Mitsunobu et al., 1967). As the 
resiquimod TLR7 agonist contained a tertiary alcohol group, the –OH bond may be sterically 
hindered therefore a different activation agent may be required, therefore diisopropyl 
azodicarboxylate (DIAD) was used, in combination with TPP, as the activation agents in this reaction. 
The starting materials, Step 1 reaction product and TLR agonist resiquimod respectively, were added 
together during this reaction at a 1:1 M/M ratio as we require 1 molecule of DSPE to be attached or 
conjugated to 1 molecule of resiquimod. This reaction was taken place at room temperature over 
several hours, or overnight if required under magnetic stirring. This reaction is schematically 
represented in Figure 2.10. At various time points (every 1 hour), aliquots of the reaction mixture 
were kept for future analysis by thin layer chromatography (TLC). Upon completion of the reaction 
as described previously excess water is ‘quenched’ by the addition of sodium hydroxide (NaOH) at a 
1M concentration before separation of the reaction product using a separation column. Upon 
separation, dried magnesium sulphate (MgSO4) was added before filtration. The reaction product (in 
chloroform) was dried using rotary evaporation and placed in the dessicator for future analysis by 
infra-red (IR) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy. 
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Figure 2-10. Schematic Diagram of the Step 2 Mitsunobu Esterification Reaction. 
 
2.5.4. Thin Layer Chromatography (TLC) 
 
As described previously in Sections 2.5.2 and 2.5.3, aliquots of the reaction mixture were decanted 
at 1 hour time points ready for analysis by thin layer chromatography (TLC). Samples from these 
aliquots were taken up by capillary tubes and spotted on to TLC silica-plates (stationary phase). If 
multiple spotting for each sample was required, then the spot was allowed to dry before the next 
spot was applied in the same position. Once the plate had been spotted it was allowed to dry before 
being placed into a sample chamber containing solvent (ethyl acetate) as the mobile phase, which 
was below the line containing the samples of interest. During experiments, the mobile phase was 
differed to show if there was any observed effects on the moving of compounds in the reaction 
mixture (spotted onto the plate).  
The TLC plate was allowed to run until the solvent front had been reached. The plate was left to dry 
before being placed under UV light in order to view the movement of the various molecules (in the 
reaction mixture) along the plate. These spots were visualised by vanillin staining or taking a camera 
picture of the plate under UV light. The relative frequency (Rf) of each compound in the various 
aliquots was determined by the following calculation; 
Relative frequency (Rf) = distance travelled by sample (spot) / distance of solvent front. 
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2.5.5. Column Chromatography 
 
If a number of compounds were present in the same reaction mixture, as determined by TLC, it was 
required to separate these compounds by column chromatography. This was carried out as 
described in the methodology by W. Clark Still and colleagues in 1978. 
A glass column was set up containing silica and sand. Subsequently the mobile phase was run 
through the column (same mobile phase as used in TLC analysis). The mobile phase was allowed to 
run through until reaching just above the silica-sand column. The reaction mixture was then placed 
on the column and allowed to run through, making sure that the column was never allowed to run 
dry (constantly supplied with mobile phase). Aliquots (10 mL) were collected in test tubes every 1 
minute. These aliquots were subsequently used in TLC analysis in order to identify and isolate the 
compound of interest from the reaction mixture. Test tubes containing the sample of interest were 
pooled together and subjected to rotary evaporation and drying procedures. These samples were 
then analysed by IR and NMR spectroscopy respectively. 
 
2.5.6. Nuclear Magnetic Resonance Spectroscopy (1H-NMR) 
 
Upon overnight drying of the sample in the dessicator as described previously in Section 2.5.2, the 
sample was analysed by 1H-NMR. Each sample (around 5 mg) was dissolved in a deuteriated solvent 
[either chloroform or dimethylsulfoxide (DMSO)], however this choice of solvent was kept constant 
between samples (starting materials and reaction product). The sample vial was then placed in a 
spin magnet and then into an automated sample vial collector. The sample was run for either 16 or 
64 scans at room temperature. Upon initiation of the experiment, the sample proceeded to move 
into the vicinity of the magnet in order to be analysed. Upon completion of the experiment, a 
specific 1H-NMR spectra was collected and analysed in order to show which functional groups were 
present in the reaction product or starting materials respectively. 
 
2.5.7. Infra-Red (IR) Spectroscopy 
 
Upon overnight drying of the sample in the dessicator as described previously in Section 2.5.2, the 
sample was analysed by IR. Initially a background spectrum was run on the spectrometer 
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(ThermoScientific Nicolet; ID5 ATR). Then a small sample of powder (few milligrams) from either the 
starting material or reaction product was placed on the ID5 ATR Diamond sample window holder 
before the pressure screw was placed down upon the sample. The sample was then ran in order to 
obtain a spectra of the starting material or reaction product in order to show which functional 
groups were present in the sample mixture. 
 
2.6. In vivo studies 
2.6.1. Ethics Approvals for in vivo studies  
 
BALB/c and C57/BL6 mice were the strain of mice used for research in biodistribution and vaccine 
studies respectively and were obtained from Charles River Laboratories UK Ltd. (Margate, Kent, UK). 
Experimentation strictly adhered to the 1986 Scientific Procedures Act (UK) and all protocols were 
carried out in a designated establishment and are subject to ethical review. 
All experimentation undertaken at Statens Serum Institut, Denmark strictly adhered to the 
regulations of the Danish Ministry of Justice and animal protection committees and was in 
compliance with European Community Directive 86/609. All protocols were subject to ethical review 
and were carried out in a designated establishment. CB6/F1 mice were obtained from Harlan 
Scandinavia, Allerod, Denmark. 
During this thesis, a number of biodistribution studies were carried out. The first of which 
investigated the effect of liposome surface charge on the formation of an antigen depot (either H56 
vaccine or the cationic model protein lysozyme) at two sites (SOI and PLN). The second study 
concentrated on the effect of liposome preparation method and charge on the ensuing liposome 
and antigen depot (at these same two sites). In further studies, the biodistribution of TLR agonist as 
well as the delivery system was also measured.  
 
2.6.2. General conditions for mice 
 
BALB/c mice were used for in vivo biodistribution studies in order to study the movement of 
liposomes and antigen from the site of injection (SOI). It was decided that 4 mice/group was 
sufficient to produce quality and sufficient data. Mice were housed under conventional conditions 
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(22 °C, 55 % humidity, 12 h day/night cycle) in their experimental groups (4 mice/cage) and were 
given a standard diet ad libitum. All mice were female and purchased at 6-8 weeks of age at the start 
of the experiment. 
 
2.6.3. Preparation of radiolabelled vaccine formulations for biodistribution studies 
 
Four to seven days prior to injection with the radiolabeled vaccine (liposome) formulation, mice 
were injected subcutaneously (s.c) into the scruff of the neck with 200 μL (Figure 2.11) pontamine 
blue [Sigma Aldrich; 0.5% w/v in PBS buffer (10 mM; pH 7.4)]. Pontamine blue stain is phagocytosed 
by monocytes and therefore a suitable marker for aiding location of lymph nodes during dissection 
(Tilney, 1971). 
 
Figure 2-11. Routes of administration for injection during biodistribution studies [A: Subcutaneous injection 
(s.c) into scruff of neck; B: intramuscular (i.m) injection into left quadricep]. 
  
Biodistribution studies were conducted with 3H-labelled liposomes (radiolabelled with 3H-
Cholesterol) and 125I -labelled protein antigen. Due to the dilution of antigen during the gel filtration 
step after iodination, the concentration of the liposomes had to be increased 2-fold so that upon 
mixing of equal volumes of protein and liposome the final concentration remained 1.25 mg lipid/mL 
equivalent to 250 μg lipid:dose. Furthermore, the final concentration of the liposomes and antigen 
had to be further concentrated as whilst this dosage volume (200 μL) was suitable for subcutaneous 
(s.c.) injection, the recommended volume for intramuscular (i.m) injection was 50 μL (Figure 2.11). 
Liposomes were actually rehydrated in a volume of buffer 8-fold less than usual, followed by the 
addition of an equal volume of antigen at a concentration 2-fold higher than required so that upon 
dilution the correct in vivo concentration is achieved (0.1 mg/mL). Approximately 1 hr prior to 
injection, radiolabelled (3H-Chol) liposome and protein antigen (I125) were mixed together and 
allowed to adsorb to each other (Figure 2.12). Each dose contained 250 μg lipid, 50 μg TDB and 5 μg 
A: Subcutaneous (s.c) injection of 
pontamine blue into scruff of neck 
B: Intramuscular injection  of vaccine 
formulation(i.m) into left quadricep 
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protein antigen (lysozyme or H56). Vaccines were given by the i.m route into the left quadricep with 
a dose volume of 50 μL (Figure 2.12). In order to provide isotonicity within the vaccine formulation, 
trehalose was added at a final concentration of 10 % w/v. Upon rehydration of the lipid film, 
trehalose was added at a concentration of 20 % w/v so that upon dilution of liposomes the final 
concentration was 10 % w/v. 
 
Figure 2-12. Schematic Diagram for the preparation of radiolabelled liposome vaccine formulations 
 
In order to prepare radiolabelled dehydration-rehydration vesicle (DRV) vaccine formulations, 
trehalose was added (at a concentration of 10 % w/v) in the final controlled rehydration step in 
order to maintain isotonicity within the radiolabelled liposome vaccine formulations. Also, in order 
to prepare radiolabelled double emulsion (DE) vaccine formulations, trehalose was added at a 
concentration of 10 % (w/v) at the end of the preparation process in order to maintain isotonicity 
within these radiolabelled liposome vaccine formulations. 
 
2.6.3.1. Processing of tissues 
 
Mice were terminated at the relevant time points during this study (24 hours, 4 days and 8 or 14 
days) by cervical dislocation and a number of various tissues were collected [muscle from the site of 
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injection (left quadricep) and popliteal lymph nodes (PLN)]. All tissues were processed in the same 
manner as described in a previous study (Henriksen-Lacey et al., 2010a).  
The major steps of this tissue processing protocol were solubilisation of tissues (muscle from 
vaccination site, spleen and draining lymph nodes), quantification of 125I, bleaching with hydrogen 
peroxide (H202) followed by quantification of H
3 (Figure 2.13). Each tissue sample was weighed into a 
γ-vial and Solvable™ (1.5 mL) added to each sample before quantifying 125I presence using a Cobra™ 
CPM Auto-Gamma® counter (Packard Instruments Company inc., IL, USA). During data analysis the 
percentage dose per mg of tissue from the draining lymph nodes was quantified. 
 
Figure 2-13. Schematic diagram showing the processes involved in tissue processing to detect 
125
I and 
3
H 
presence following injection of dual-radiolabelled components (Henriksen-Lacey et al, 2010). 
 
As described by Henriksen-Lacey et al (2010); to verify that the presence of undigested tissue and 
whole organs did not affect the count rate, all samples from original experiments were counted for 
125I prior and post-tissue digestion with no difference in the results noted (results not shown). 
All tissue samples were solubilised using Solvable™, and heated at 50 °C until tissues were fully 
solubilised. These samples were then quantified for the percentage of 125I-antigen retention. 
Following which these samples were allowed to cool and then transferred into 20 mL plastic 
scintillation vials. Hydrogen peroxide (200 μL) was added to each sample and once fully bleached 
(sometimes additional heating of samples was required to ensure complete digestion), Ultima Gold™ 
scintillation fluid (10 mL) was added to each sample and 3H presence quantified using a standard 3H 
detection protocol using a 1600TR Liquid Scintillation Counter (Packard). 
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2.6.3.2. Quantification of the proportion of vaccine components in various tissues 
 
For the determination of liposome (3H) and antigen (125I) in the different tissues, the data was 
presented as a proportion of the dose (% dose) at a number of sites (vaccination site, spleen and 
draining lymph nodes). The results were presented as percentage dose per mg tissue at the draining 
lymph nodes. To calculate the % dose, triplicate samples of the original dose were processed 
simultaneously to the tissue processing. In some cases, these doses represented a fraction of the 
whole dose and relevant dilution factors were considered after obtaining the cpm values. Therefore 
the specific % dose was calculated by dividing the radioactivity counts (for antigen or liposome in a 
specific tissue) divided by the total amount of radioactivity (per dose) multiplied by 100. 
For all samples, the cpm values derived from the Cobra™ CPM Auto-Gamma® counter (relating to 125I 
presence) did not need additional processing as 3H scintillation counts cannot be detected by the 
gamma counter  (Figure 2.13) without the presence of a scintillant; solely the removal of background 
values (average of three Solvable™ samples) was undertaken.  
 
2.6.3.3. Preparation of 125I standard curve in order to factor out 125I counts measured on 
the scintillation counter 
 
For the determination of actual 3H (tritium) counts, the amount of 125I (from radiolabelled antigen) 
had to be considered as 125I counts detectable on a scintillation counter. There is no such problem 
measuring gamma (γ) counts, as this is the only radiation detected on a gamma counter. A method 
was devised whereby the 125I could be factored out by the use of a standard curve (communication 
with Malou Henriksen-Lacey). Triplicate samples of 125I starting at an activity equivalent to the dose 
administered in vivo (~ 100 kBq) were diluted 2-fold until background levels (~ 20 cpms) were 
reached (therefore about 18 dilutions). 
These samples were counted using a γ-counter and then transferred and processed as the tissue 
samples would be. The samples were then counted on a scintillation counter using the same 
detection protocol as used for the tissue samples (as described previously in Section 2.6.3.1 and 
Figure 2.13). For each sample, a plot of the cpm (counts per minute) values derived from the gamma 
counter (x-axis) was plotted against the cpm values from the scintillation counter (y-axis) was made. 
The line of best fit and equation for samples below 50,000 cpm (~ 2 % of the dose or less) and those 
above 50,000 cpm (~ 2 % of the dose or more) was carried out. The two equations (derived from 
these standard curves) were used to calculate the effective interference that the 125I would have on 
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the 3H values determined by scintillation counting. So therefore, uncorrected scintillation counts 
were put into the equation of choice (depending on the number of gamma counts) in order to 
determine the actual number of scintillation counts. 
 
2.6.4. Immunisation Studies in Mice 
 
The first and final immunisation studies were conducted at Aston University. Whereas, the second in 
vivo study was carried out in collaboration with Statens Serum Institute (Copenhagen, Denmark). 
These immunisation studies have been subject to ethical review and carried out in a designated 
establishment. The number of mice per experimental group and allocated per researcher was not 
constant between experiments – Table 2.1 outlines the experimental design for each of these in vivo 
studies. 
The aim of Study 1 was to investigate the effect of liposome surface charge on the ensuing 
immunogenicity of vaccine formulations. The H56 TB subunit vaccine was adsorbed to cationic 
DDA/TDB and anionic DSPS/TDB (at an in vivo concentration of 5 μg or 0.1 mg/mL). During Study 2, 
liposomal vaccine formulations were prepared at Statens Serum Institute by either the lipid-film 
hydration (LH) method, double emulsion (DE) solvent evaporation method or the dehydration-
rehydration vesicle (DRV) method with the liposomes adsorbing Ag85B-ESAT-6-Rv2660c (H56) 
antigen to a final concentration of 0.1 mg/mL (5 µg/vaccine dose). These formulations were 
prepared with the addition of trehalose (10 % w/v) to the hydration buffer in order to maintain 
isotonicity. During the DE preparation process the H56 antigen was added in the primary water 
phase whereas during the DRV preparation process the antigen was added to small unilamellar 
vesicles (SUVs) prior to freezing (- 70 °C), overnight freeze drying (at - 40 °C) and rehydration the 
following day. All mice were immunised intramuscularly (i.m.) into the left quadriceps with the 
proposed vaccine (50 µL/dose) three times (at days 0, 14 and 28), with two week intervals between 
each immunisation.  
The aim of the final study 3 was to show the effect of inclusion of TLR agonists within the delivery 
system on the resulting immune response. The TLR 7 agonist, resiquimod, was included within these 
formulations.  
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Table 2-1. Summary of vaccine immunisation studies carried out during this thesis 
FORMULATION STUDY 1 (ASTON) STUDY 2 (SSI) STUDY 3 (ASTON) 
1 MLV DDA/TDB:H56 (5) MLV DDA/TDB:H56 (6) H56 (5) 
2 MLV DSPS/TDB:H56 (5) MLV DSPS/TDB:H56 (6) MLV DDA/TDB/DSPE: 
Resiquimod: H56 (5) 
3 H56 (5) DRV DDA/TDB:H56 (6) MLV DDA/TDB/DSPE= 
Resiquimod:H56 (5) 
4 PBS (5) DRV DSPS/TDB:H56 (6) Resiquimod alone (5) 
5  DE DDA/TDB:H56 (6) MLV DDA/TDB: H56 (5) 
6  DE DSPS/TDB:H56 (6)  
7  H56 (6)  
8  Naive (6)  
 
2.6.4.1. Preparation of vaccine formulations for studies 
 
The liposome-based vaccine formulations were prepared as in Sections 2.2 for multilamellar vesicles 
(MLV), dehydration-rehydration vesicles (DRV) and double emulsion (DE) vesicles. The only 
difference in the liposome preparation stage was with the use of trehalose (at a final concentration 
of 10 % w/v) in the rehydration buffer in order to maintain isotonicity. When PBS buffer alone was 
used as a control in experiments there was no need to add trehalose as this buffer is already isotonic 
in nature. Mice were immunised with a dose volume of 50 μL into the left quadriceps (Figure 2.14). 
 
Figure 2-14. Routes of administration for injection during vaccine immunisation studies [A: intramuscular 
(i.m) injection into left quadricep. 
 
2.6.4.2. Antibody analysis 
 
Serum samples were collected for the detection of IgG, IgG1 and IgG2b antibodies (AbD Serotec, 
Oxford, UK). Blood (50 μL) was collected using capillary tubes dipped in 1 % heparin (Sigma Aldrich, 
UK). The blood was diluted 10-fold in PBS; 10 mM, pH 7.4 (50 µl blood + 450 µl PBS) and centrifuged 
for 5 minutes (at 10,000 x g) to obtain serum. The serum was then decanted in order to be analysed 
A: Intramuscular injection  of vaccine 
formulation (i.m) into left quadricep 
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for the presence of antibodies and cytokines. In order to achieve an initial 1/400 dilution, the blood 
sera was subsequently diluted 1/20 using PBS if the volume ratio of sera:red blood cells is 1:1. Blood 
sera was subsequently diluted down the ELISA plate in order to determine the log10 reciprocal 
endpoint dilution where the absorbance was greater than 0.2. 
Standard ELISA protocol was used to detect antibodies. Briefly, plates were coated overnight with 
H56 antigen (5 μg/mL), blocked for 1 hour (with Marvel milk; 4 % w/v in PBS) and 100 μL serially 
diluted serum added. Serum (10 μL) was added to the appropriate wells of row A and mixed well – a 
50 μl sample was removed and added to the wells in row B. Again, this was thoroughly mixed and 
the serial dilutions continued until lastly 50 μL of diluted serum was removed from the wells of row 
A and H so that the total volume of serially diluted serum in all wells was 100 μL. Each sample was 
investigated in duplicate, and were allowed to incubate for 2 hours.  Goat anti-mouse IgG (1:500), 
IgG1(1:4000) and IgG2b (1:4000) were added to wells for 1 hour followed by addition of ABTS 
substrate (in citrate buffer); samples were detected by reading the absorbance at 405 nm and the 
results expressed as the log10 of the reciprocal of the end-point dilution giving an optical density 
(O.D) of ≥ 0.2. Between each of these stages, the contents of each of the wells are aspirated before 
the plate is washed three times using PBST wash buffer (40 g NaCl, 1 g KCl, 1 g KH2PO4, 7.2 g 
Na2HPO4(2H2O), 0.4 mL Tween 20, 5 L ddH2O). 
 
2.6.4.3. Proliferation of restimulated splenocytes and lymph nodes ex vivo 
 
Spleens and popliteal lymph nodes (PLN) from individual mice were removed on day 49 of the 
vaccination study and cell suspensions obtained. Each spleen was placed in a 7 mL bijoux tube 
containing 5 mL PBS, making sure that this solution is kept ice-cold. Whereas for the PLN, these are 
pooled together for each immunisation group (also making sure that this solution is kept ice-cold). 
Spleens and PLN were mashed and strained using a cell strainer into a 50 ml centrifuge tube before 
the addition of 10 mL cold RPMI 1640 solution without L-glutamine (pH 6.9-7.2), containing 10 % FBS 
and 1 % PSG. The cell debris was allowed to settle in the 50 mL centrifuge tube for 5 minutes before 
the supernatant (13 mL) was transferred into a 15 mL centrifuge tube. This tube was further 
centrifuged at 1200 rpm for 10 minutes (15 °C) and the supernatant discarded before a further wash 
and centrifugation step using 10 mL cold RPMI solution. The final pellet was resuspended in 5 mL or 
400 μL cold RPMI (for splenocyte cells and lymph node cells respectively) before performing a cell 
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count, and the cell number was subsequently adjusted to 0.2-1 x 107 cells/ mL for splenocytes and 
LN (making sure that the same cell number was used for each mouse/organ).  
 
Determination of cell number for experiments was achieved via tryphan blue exclusion whereby 20 
μL of resuspended cells were removed and mixed with 80 μL of tryphan blue. Using a 
hemocytometer, cells excluding tryphan blue were quantified visually by microscopy (Figure 2.15) 
and the number of cells/ml was calculated using the following equation:  
 
No of cells/ml = no. cells/sq x dilution factor x 104 
 
Where: no. cells/sq is the average of 5 squares in the hemocytometer . 
Dilution factor is 5 if resuspended cells and tryphan blue are used in 1:5 v/v ratio.  
104 is the multiplication factor related to the volume of the hemocytometer grid. 
 
 
 
 
 
Figure 2-15. Visualisation of cells via microscopy. Viable cells are stained using tryphan blue exclusion. 
 
Splenocytes and PLN cells were plated in 96-well plates (0.2-1 x 107 cells/mL) and stimulated with 
either ConA (2 μg/mL) as a positive control, medium only (as a negative control) or H56 antigen 
(Ag85B-ESAT-6-Rv2660c) at a concentration of 0.05, 0.5 and 5 μg/mL in cold RPMI in order to make a 
total volume of 200 μL in each well of the plate. These splenocyte and lymph node cells were 
incubated (37 °C, 5 % CO2, 95 % humidity) for 48 hours (with 6 wells per mouse, formulation and 
restimulation condition), following which the supernatants were decanted for future analysis. If not 
being used immediately, these supernatants were frozen at – 20 °C. 
In a separate plate, splenocytes were incubated (37 °C, 5 % CO2, 95 % humidity) for 72 hrs after 
which 18.5 kBq 3H-thymidine (GE Healthcare) was added per well. Incubation occurred for a further 
24 hrs before the cells were harvested using a cell harvester (Titertek) with quartz filter mats and 3H 
detected using standard scintillation counting procedures (as described previously) with each mat 
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being placed into a plastic scintillation vial with the addition of 5 mL Ultima Gold™ scintillation fluid 
per sample. Each spleen was assayed in triplicate under each condition. 
 
2.6.4.4. Cytokine analysis from ex vivo restimulated splenocytes 
Splenocyte suspensions restimulated with ConA or Ag85B-ESAT-6 were prepared as outlined in 
Section 2.6.4.3. After incubation, supernatants were removed and pooled according to spleen and 
restimulation condition. Duoset® sandwich ELISAs were used to detect IL-2, IL-5, IL-6, IL-10 and IFN-γ 
(RnD, Abingdon, UK) in the supernatants.  
In brief, ELISA plates were coated with cytokine-specific capture antibody (IFNγ – 4 µg/mL; IL17 – 2 
µg/mL; IL2 - µg/mL; IL5 – 1 µg/mL; IL10 – 4 µg/mL; IL6 – 2 µg/mL; IL1β – 4 µg/mL; IL33 – 0.8 µg/mL; 
IL18 – 4 µg/mL), blocked with 1 % bovine serum albumin (BSA) and then samples and serially diluted 
standards added. After 2 hrs incubation, plates were washed followed by addition of cytokine-
specific detection antibody (IFNγ – 100 ng/mL; IL17 – 400 ng/mL; IL2 – 400 ng/mL; IL5 – 100 ng/mL; 
IL10 – 300 ng/mL; IL1β – 2.5 µg/mL; IL18 – 2.5 µg/mL; IL33 – 200 ng/mL) , streptavidin-HRP 
conjugate (in dark), TMB substrate solution (in dark) and stop solution. The OD at 450 nm was 
measured and a 4-parameter sigmoidal standard curve for each cytokine standard created using 
GraphPad Prism to determine cytokine concentrations in unknown samples accordingly. Between 
each of these stages, the contents of each of the wells are aspirated before the plate is washed 
three times using PBST wash buffer (40 g NaCl, 1 g KCl, 1 g KH2PO4, 7.2 g Na2HPO4(2H2O), 0.4 mL 
Tween 20, 5 L ddH2O). 
 
2.6.4.5. Cytokine analysis at the site of injection 
To determine the effect of vesicle charge and preparation method on the production of IL-1β, IL-18 
and IL-33 at the site of injection (SOI), the method described by Sharp et al was used (Sharp et al., 
2009). Muscle from the SOI was excised 3 weeks after the final injection. The quadriceps muscle was 
removed and homogenised on ice in 2.5 mL of homogenisation buffer (500 mM NaCl/50 mM Hepes, 
pH 7.4, containing 0.1 % Triton X-100, 1 % v/v Sigma protease inhibition mixture and 0.02 % NaN3). If 
not processing the tissue straight away, the legs could be flash frozen using liquid N2 and transferred 
into a labelled bijoux tube and placed in the freezer at – 70 °C. 
Samples were sonicated (2 x 15 s) and centrifuged (3600 rpm, 20 min, 4 °C) before removal of 1.4 mL 
of the supernatant layer into an eppendorf tube. These samples were then used for the detection of 
IL-1β, IL-18 and IL-33 cytokines using a standard ELISA protocol (as described previously in Section 
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2.6.4.4) and all of these experiments were carried out in duplicate. The OD at 450 nm was measured 
and a 4-parameter sigmoidal standard curve for each cytokine standard created using GraphPad 
Prism to determine cytokine concentrations in unknown samples accordingly. 
 
2.6.5. SSI Studies: The effect of liposome preparation method on vaccine immune 
response 
This study was carried out as described previously in Section 2.6.5. Mice immunised with liposome 
vaccine formulations were measured for their cytokine response (from ex vivo restimulated 
splenocytes and lymph nodes) and antibody response (in the blood sera). Blood samples were drawn 
from the cheek one day before the second immunisation in order to measure antibodies (in the 
blood sera) by ELISA assay.  Also 3 weeks after the last immunisation, blood samples were drawn 
from the cheek (50 μL) in order to measure antibodies in the blood sera. Also spleens and popliteal 
lymph nodes (PLN) were collected (3 weeks after the last immunisation) for experimental use in 
order to measure T-cell responses (by ELISA assay) as described previously (Section 2.6.3). Cells from 
these organs, following restimulation with antigen, were restimulated for 72 hours (rather than 48 
hours) in accordance to the same protocol; which also took place for vaccine studies in Chapter 7 in 
order to maintain similar protocol. 
 
2.7. Statistical analysis 
 
During analysis of data and results, statistical analysis was carried out by one-way ANOVA (analysis 
of variance) at a significance level of 0.05. This was followed by statistical analysis by the post-hoc 
Tukey’s test, in order to compare the mean differences of results between formulations. All 
statistical analyses were performed using SPSS (Statistical Package for the Social Sciences) software 
(Version 15.0 for Windows). Statistically significant differences are noted in Microsoft Excel Graphs 
(***, P < 0.001; **, P < 0.005; *, P < 0.05). Each experiment was carried out in triplicate with the 
average mean result recorded ± the standard deviation of this set of results (represented as error 
bars). 
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Chapter 3: Optimisation and Product Specification of Liposome Adjuvants 
 
 
 
 
 
 
Some of the results presented in this chapter have been published in the paper: 
Hussain, M.J., Wilkinson, A., Bramwell, V., Christensen, D., Perrie, Y. (2013) “Th1 immune responses 
can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-
phosphocholine content in liposomal adjuvants (manuscript accepted; Journal of Pharmacy and 
Pharmacology, November 2013). 
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3.1. Aims and Objectives 
 
The aim of the work reported in this chapter was in the initial characterisation and product 
specification of liposomes based on dimethyldioctadecylammonium bromide (DDA), with and 
without the addition of the immunostimulatory glycolipid trehalose 6,6’ – dibehenate (TDB). The 
physicochemical effects of the choice of hydration buffer and dilution buffer were also presented. A 
novel liposome system consisting of the anionic lipid 1,2 - distearoyl-sn-glycero-3-phospho-L-serine 
(DSPS) in combination with TDB was also formulated and observed for its measured physicochemical 
characteristics. The stability of both of these formulations was addressed following storage at two 
different temperature conditions (4 °C and 25 °C respectively). Further investigations were carried 
out with the aim of modulating various parameters of the delivery system, including vesicle size and 
surface charge, through increasing the concentration of the neutral lipid 1,2 - distearoyl-sn-glycero-
3-phosphocholine (DSPC) within the formulation. Therefore through these initial studies the aim was 
to produce a product specification for various liposome adjuvants, including cationic DDA/TDB and 
anionic DSPS/TDB liposomes. These liposomes were to be used as platforms or vehicles for the 
delivery of vaccine antigen.  
 
3.2. Introduction 
 
A key advantage of liposome-based vaccine delivery systems is their flexible and versatile nature. 
Lipid constituents can be altered or tailored in order to formulate liposomes with desired 
physicochemical parameters. Liposomes can be formulated due to the amphiphilic nature of 
phospholipids, with lipids being made up of a non-polar hydrophobic tail group and a charged, polar 
lipid head group. Therefore due to the charged nature of the lipid head groups, this will confer the 
surface charge of the delivery system itself therefore formulations can be cationic (positive), neutral 
and anionic (negative) respectively. Within our laboratory, we have used the cationic liposome 
system DDA/TDB which has been shown to have proven efficacy as a vaccine adjuvant. 
In terms of liposome formulation, various other factors are important in the formation of these 
vesicles, including the lipid transition temperature. The transition temperature can be defined as the 
temperature above which the lipid physical state is modified from the ordered gel phase to the 
disordered liquid crystalline phase. The lipid transition temperature depends on a number of criteria, 
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in which the carbon chain length and its degree of saturation can have a subsequent effect on 
liposome properties such as membrane bilayer fluidity (Perrie and Rades, 2010). 
 
3.3. Results and Discussion 
3.3.1. Investigating the effect of hydration buffer on the characteristics of cationic 
DDA/TDB and anionic DSPS/TDB liposomes 
 
During this initial investigation, DDA and DSPS were investigated due to their opposing charge, being 
cationic and anionic respectively, as well as the fact that they have tail groups which are both 
double-chained and are similar in length. Also the immunostimulatory glycolipid, TDB, was 
incorporated within these respective delivery systems at the same ratio. Therefore these initial 
experiments will serve as direct comparison to show the effect of lipid charge on the subsequent 
formulation of liposome delivery systems. 
Preliminary studies were undertaken in order to show the effect of hydration buffer on the 
subsequent characteristics and assembly of DDA/TDB and DSPS/TDB liposomes. Both distilled water 
and PBS (10 mM PBS; pH 7.4) were used as the aqueous hydration buffer in the formation of 
liposomes, as well as Tris buffer (10 mM; pH 7.4). This was carried out in order to help to gain initial 
liposome characterisation data, before model protein antigens were combined with the liposome 
delivery system (Chapter 4). The liposome characteristics (size, polydispersity and zeta potential) of 
DDA/TDB and DSPS/TDB liposomes were measured. The results are displayed in Table 3.1. 
 
Table 3-1. Liposome characteristics of DDA/TDB and DSPS/TDB liposomes prepared by the LH-method; 
either hydrated in Tris buffer (10 mM; pH 7.4), distilled water or PBS buffer (10 mM; pH 7.4). Results are the 
mean of triplicate experiments ± SD. Significance, compared to respective Tris-buffer hydrated counterparts, 
was measured by one-way ANOVA (*** p<0.001; ** p<0.01; * p<0.05).  
Formulation Hydration buffer Size (nm) PDI Zeta potential (mV) 
DDA/TDB Tris (10 mM; pH7.4) 533.8 ± 39.6 0.435 ± 0.201 80.4 ± 18.7 
DDA/TDB Distilled water 1246 ± 244.2 (***) 0.341 ± 0.043 74.1 ± 11.9 
DDA/TDB PBS (10 mM; pH 7.4) 2988 ± 337.7 (***) 0.682 ± 0.044 71.4 ± 12.1 
DSPS/TDB Tris (10 mM; pH7.4) 468.8 ± 42.2 0.730 ± 0.012 -59.7 ± 24.4 
DSPS/TDB Distilled water 369.9 ± 23.2 0.486 ± 0.060 -52.1 ± 14.5 
DSPS/TDB PBS (10 mM; pH 7.4) 659.2 ± 214.0 (**) 0.464 ± 0.063 -77.4 ± 20.0 (*) 
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These studies demonstrate that the choice of hydration buffer used in formulation of liposomes had 
a significant effect on the liposome characteristics for DDA/TDB, when compared to anionic 
DSPS/TDB liposomes. This was due to the varying interaction between the polar (charged) lipid head 
group (DDA or DSPS) with the hydration buffer in the formation and assembly of these liposomes. 
The use of either distilled water or PBS buffer in the hydration of DDA/TDB liposomes (Table 3.1) 
resulted in a significant (P < 0.01 and P < 0.001 for distilled water and PBS respectively) increase in 
the vesicle size (1246 ± 244.2 nm and 2988 ± 337.7 nm respectively) compared to hydration using 
Tris buffer (533.8 ± 39.6 nm; Table 3.1). In terms of polydispersity of cationic DDA/TDB formulations, 
PBS-buffer hydrated vesicles showed a significant increase compared to water and Tris, which may 
show that the vesicle population is more heterogenous upon using PBS as the hydration buffer 
(Table 3.1). This increase in vesicle size of the cationic DDA/TDB liposomes (in PBS buffer)  could be 
caused by salt-induced aggregation of these vesicles; the presence of neutralising counterions in 
saline buffers  has been primarily suggested to be the major cause of vesicle aggregation, due to the 
reduced repulsion between adjacent vesicles (Yan and Huang, 2009).  
In contrast there were no such pronounced changes in the vesicle characteristics of DSPS/TDB 
liposomes when hydrated using distilled water (369.9 ± 23.2 nm) or PBS buffer (659.2 ± 214.0 nm) 
compared to Tris buffer-hydrated liposomes (468.8 ± 42.2 nm) as displayed in Table 3.1. However of 
these formulations, PBS-hydrated liposomes showed significant increase in vesicle size (P < 0.05) 
compared to their distilled water and Tris buffer-hydrated counterparts.  In contrast in terms of the 
polydispersity of DSPS/TDB liposomes, Tris-hydrated vesicles showed more heterogeneity than their 
distilled water and Tris buffer hydrated counterparts (Table 3.1). 
 Overall, these results suggested that the use of hydration buffer caused an important effect in the 
assembly of MLV liposome delivery systems. The role of liposome surface charge (in relation to 
aqueous hydration buffer) has also been demonstrated in the fact that positively-charged (cationic) 
liposomes showed an increased size when hydrated using a salt-containing buffer such as PBS and to 
a lesser extent with water and Tris buffer respectively (Yan and Huang, 2009). The formation of 
liposomes was shown to be dependent on the temperature, lipid concentration, critical packing 
parameter (cpp) as well as the electrostatic interactions of the polar lipid head groups with the 
solvent and solute molecules in the hydration buffer (Perrie and Rades, 2010). During liposome 
formation, the shape of the vesicle produced during formulation can be defined by its cpp. 
Therefore, these initial studies suggested that buffer choice had a significant impact upon the 
measured characteristics of liposome delivery systems, which was due to the presence of the 
charged lipid head group and hydrophobic tail region. The effect of buffer on these vesicles was not 
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due to their charge, but was rather due to the interaction of the charged lipids with the electrolytes 
present probably causing the formation of bridges with the charged lipid head groups. This has been 
shown in the previous literature, which has shown that cationic liposomes can double in size in the 
presence of PBS; this was due to the phosphate head groups of PBS acting as ‘binders’ and 
effectively ‘bridging’ the cationic polar lipid head groups (Ciani et al., 2007). Further studies have 
also shown that cationic liposome systems can aggregate when there is a high presence of salt 
within the formulation which was due to reduced electrostatic interactions between liposome 
systems hence leading to aggregation and the formation of larger liposomes (Wasan et al., 1999). 
Flexible bilayer vesicles were increasingly likely to be formed as the hydrophobic tail region of the 
lipid (present in the formulation) increased, which occurred with double-chained lipids such as DDA, 
DSPS and DSPC which had a critical packing parameter between ½ and 1 (Perrie and Rades, 2010), 
whereas trehalose 6,6’- dibehenate (TDB) can be inserted into the bilayer in order to stabilise the 
liposome delivery system (Davidsen et al., 2005).  
 
3.3.2. Investigating the effect of buffer concentration on the characteristics of cationic and 
anionic liposomes 
 
Given that the choice of buffer used in the formulation of liposomes was shown to impact on the 
vesicle characteristics, further investigations were conducted to consider the role of buffer 
concentration. Therefore, liposomes were diluted in a set of serially diluted buffer solutions 
(concentrations of 10 mM, 1 mM, 0.1 mM and 0.01 mM, as well as distilled water) before the 
various liposome characteristics (size, polydispersity and zeta potential) were measured (Figure 3.1). 
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 Figure 3-1. Variation in liposome characteristics (A – size; B – zeta potential) for multilamellar vesicles (MLV) 
of cationic DDA/TDB and anionic DSPS/TDB liposomes (hydrated in Tris buffer; 10 mM, pH 7.4) with dilution 
in various buffer concentrations. Results are the mean of triplicate experiments ± SD.  
 
The results in figure 3.1 show that the impact of electrolytes present in the buffer occurs at low 
concentrations, with an increase in vesicle size for DDA liposomes occurring at 0.01 mM (with 
liposomes increasing from ~600 to over 700 nm in size; Figure 3.1A) but further increases in 
concentration made no impact. In contrast, the DSPS vesicles showed a drop in measured vesicle 
size when prepared in Tris buffer at 0.01mM concentration (from around 400 nm to 320 nm; Figure 
3.1A) and again, further changes in buffer concentration had no impact on size.  In both 
A 
B 
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formulations, there was no obvious trend in polydispersity with buffer concentration, which may be 
due to the more heterogeneous nature of the vesicles at all concentrations making differences 
difficult to detect (results not shown).  
The cationic nature of DDA confers the positive surface charge of these liposomes, with this charge 
being most prominent in the case of DDA/TDB liposomes diluted in Tris buffer (1 mM; pH 7.4) in 
which a zeta potential of 78.8 ± 14.8 mV (Figure 3.1B) was measured. The anionic nature of DSPS 
confers the negative charge of these liposomes, with this charge being most prominent in the case 
of DSPS/TDB liposomes diluted in 1 mM Tris buffer (pH 7.4), in which a zeta potential of – 63.9 ±  
19.8 mV was displayed (Figure 3.1B).  
These results showed that variation in Tris buffer concentration (in the dilution of liposomes at a 
range of concentrations) had no major effect on the zeta potential or vesicle size of the liposome, 
therefore this buffer did not affect the electrical double layer or the assembly of this delivery 
system.  Therefore we used Tris (10 mM; pH 7.4) as the hydration buffer for further formulations, 
whilst measuring liposomes in a weak dilution (1 mM) of the same buffer. 
The vesicle size remains unaffected by the range of concentrations of dilution buffer tested 
throughout this study during measurement of liposome characteristics (Figure 3.1A); therefore this 
suggested that the hydration buffer alone determined the molecular shape and structure of the 
liposome delivery system. During liposome formation the hydrophobic tail regions were located on 
the inner surface of the membrane bilayer, whereas around this on the outer surface of the 
liposome contained a ‘concentric shell of hydrophilic head groups’ (Florence and Attwood, 1998) 
which was termed the ‘Stern Layer’. Surrounding the charged ‘Stern Layer’ was located the diffuse, 
Gouy-Chapman electrical double layer which neutralises the charge of the ’stern layer’ (in this case, 
the liposome delivery system). Therefore during these studies, positively-charged (cationic) 
DDA/TDB liposome delivery systems were the main focus of study and these liposomes will be 
surrounded by a negatively-charged Gouy-Chapman electric double layer. The thickness of this 
double layer was known to differ depending on the ionic strength of the solution, with increased 
concentrations of electrolyte leading to the compression of this diffuse layer (Florence and Attwood, 
1998). However, during these studies, the low ionic strength buffer, Tris, was used in which even at 
high concentrations (up to 10 mM) there were no subsequent effects on vesicle characteristics 
(Figure 3.1). 
Zeta potential analysis enabled the indirect measurement of the liposome surface charge and was 
measured at the plane of closest approach of ions to the liposome surface, termed the ‘shear plane’ 
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(Delgado et al., 2005, Kaszuba et al., 2010). The zeta potential is also a key parameter that controls 
electrostatics in particle dispersions so was therefore important in understanding the stability of 
colloidal dispersions (Kaszuba et al., 2010) and also in predicting long-term stability (Shaw, 1992). 
 
3.3.3. Investigating the stability of DDA/TDB and DSPS/TDB liposomes 
 
Liposomes composed of solely dimethyldioctadecylammonium bromide (DDA) have been 
demonstrated to be physically unstable and aggregate during prolonged storage (Hilgers and Snippe, 
1992, Davidsen et al., 2005). During previous studies, the incorporation of immunostimulatory 
molecules such as trehalose 6,6’-dibehenate (TDB) and monomycolyl glycerol (MMG) were 
demonstrated to effectively stabilise these DDA-based liposomes with a consistent vesicle size being 
displayed, at temperatures of 4 ˚C and 25 ˚C (Davidsen et al., 2005, Nordly et al., 2011b). During this 
investigation, both cationic DDA/TDB and anionic DSPS/TDB liposomes (either hydrated in Tris buffer 
(10 mM; pH 7.4), distilled water or phosphate-buffered saline (PBS: 10 mM; pH 7.4) were assessed 
by their stability and liposome characteristics (size, polydispersity and zeta potential) over a 28-day 
time period. 
 
3.3.3.1. Vesicle size 
 
The effect of hydration buffer on the vesicle size of DDA/TDB and DSPS/TDB formulations was 
assessed during this investigation (Figure 3.2). Over the 28 day time period, at temperatures of 4 ˚C 
and 25 ˚C, cationic DDA/TDB liposomes (hydrated in Tris buffer) displayed a vesicle size in the region 
of 550 nm at the day 0 time point (Figure 3.2A), with these liposomes showing an increase in size 
over this 28-day study (~ 750 nm). This change in vesicle size was significant (p < 0.01). The anionic 
liposome formulation DSPS/TDB (hydrated in Tris buffer) displayed no significant increase in particle 
size, over this 28-day study, with size measurements of between 400-500 nm being displayed at 
both storage temperatures (Figure 3.2B) at all these various time points. By the day 28 time point (at 
a temperature of 25 ˚C), DSPS/TDB liposomes were measured to be in the region of 330 nm in size, 
suggesting a slight reduction in vesicle size however this was not significant. 
 
When cationic DDA/TDB liposomes were hydrated using distilled water and the size characteristics 
were measured, these delivery systems were in the region of 1-1.2 µm over the course of this 28-day 
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study (Figure 3.2C) irrespective of the storage temperature (4 °C or 25 °C). Anionic DSPS/TDB 
liposomes (hydrated in distilled water) displayed size characteristics of between 400-500 nm over 
the time course of this study, at both storage temperatures of 4 ˚C and 25 ˚C respectively (Figure 
3.2D). 
Upon hydration of cationic DDA/TDB liposomes in PBS buffer, this gave rise to a significant increase 
in vesicle size of these formulations (P < 0.001) over their Tris- and distilled water counterparts and 
also over the time course of this study. The increased particle size displayed by these liposomes was 
indicative of increased instability of PBS-hydrated liposomes over this time period (Figure 3.2E). Also, 
for anionic DSPS/TDB liposomes, hydrated in PBS buffer, these vesicles showed a slight increase in 
vesicle size, at 4˚C, with this effect being increased at 25 ˚C over the time-course of this study (P < 
0.001), from 659 nm (at day 0) to ~800 nm (at 4 ˚C at day 28) or ~ 1.3 µm (at 25 ˚C at day 28; Figure 
3.2F). 
Therefore these studies have shown that variation in aqueous buffer for the hydration of liposomes 
had a significant effect on the short-term stability of liposome formulations. Hydration of liposomes 
with salt-containing buffers, such as PBS, had a greater effect on the cationic DDA/TDB liposomes in 
comparison to the anionic DSPS/TDB formulation in terms of vesicle size. This has been discussed in 
the previous literature in which liposomes with higher transition temperatures appear to be more 
stable in PBS both at temperatures of 4 °C or 37 °C, which therefore suggested that the increased 
acyl chain length (and therefore transition temperature) was directly proportional to the stability of 
the liposome formulation (Andersen and Omri, 2004). During these studies the use of various other 
buffers in the hydration of liposomes, such as low-salt containing buffer (Tris 10 mM; pH 7.4) and 
distilled water, had a lesser effect on initial vesicle characteristics and the subsequent stability of 
these formulations when compared to PBS-hydrated liposomes. During these short term stability 
trials, the stability of these vesicles was due to their small size and highly charged nature (either 
cationic or anionic) upon hydration with Tris buffer (10 mM; pH 7.4). The high stability of these 
vesicles was due to the insertion of the double-chained glycolipid trehalose – 6,6’ dibehenate (TDB) 
within the lipid bilayer (Christensen et al., 2008). It was shown that the insertion of trehalose 
dimycolate (TDM) and TDB within the bilayer inhibits the fusion between phospholipid vesicles 
(Spargo et al., 1991, Crowe et al., 1994) thus causing a reduction in vesicle aggregation. Therefore 
during these studies the incorporation of TDB within the liposomal system will increase the 
hydration of the membrane, thereby preventing the dehydration of the quaternary ammonium ion 
head groups of the lipids present within the formulation, which would otherwise lead to reduction in 
charge repulsion and aggregation of vesicles (Christensen et al., 2008) thus leading to enhanced 
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vesicle stability (Davidsen et al., 2005). However even the insertion of the stabilising TDB is not 
enough to counteract the effect of PBS buffer on the stability of these formulations. Therefore this 
hydration buffer will not be taken forward into further studies. 
  
  
  
Figure 3-2. Time development of the average mean particle size of DDA/TDB (A, C and E) and DSPS/TDB (B, D 
and F) liposomes hydrated in Tris buffer (10 mM; pH 7.4 – A and B), distilled water (C and D) and PBS buffer 
(10 mM; pH 7.4 – E and F) at storage temperatures of 4 ˚C and 25 ˚C. Results are the mean of triplicate 
experiments ± SD. Significance between these characteristics between Day 0 and Day 28 was measured by 
one-way ANOVA (*** p<0.001; ** p<0.01). Solid and dotted lines represent storage at 4 ˚C and 25 ˚C 
respectively. 
 
0
200
400
600
800
1000
0 10 20 30
Si
ze
 (
n
m
) 
Day 
** 
0
100
200
300
400
500
600
0 10 20 30
Si
ze
 (
n
m
) 
Day 
0
200
400
600
800
1000
1200
1400
1600
0 10 20 30
Si
ze
 (
n
m
) 
Day 
0
100
200
300
400
500
600
700
0 10 20 30
Si
ze
 (
n
m
) 
Day 
0
1000
2000
3000
4000
5000
6000
0 10 20 30
Si
ze
 (
n
m
) 
Day 
*** 
0
200
400
600
800
1000
1200
1400
1600
1800
0 10 20 30
Si
ze
 (
n
m
) 
Day 
*** 
A B 
C 
E F 
  
 
D 
 
  
 
113 
 
3.3.3.2. Zeta potential 
 
During these studies it was also required to show the effect of hydration buffer on the zeta potential 
of DDA/TDB and DSPS/TDB formulations. Over the 28 day time point, at temperatures of 4 ˚C and    
25 ˚C, cationic DDA/TDB liposomes (hydrated in Tris buffer) exhibited a zeta potential in the range 
between 60-80 mV, with no dramatic change being observed over this study (Figure 3.3A). The 
maintenance of a highly positive zeta potential over this study suggested that these liposomes 
remained relatively stable. Also, the anionic liposome formulation DSPS/TDB (hydrated in Tris buffer) 
revealed no major changes in the surface characteristics of liposomes stored at both 4 ˚C and 25 ˚C 
(Figure 3.3B) with measurements of between - 60 to - 80 mV being displayed throughout this study.  
The zeta potential analysis of the cationic liposome formulation DDA/TDB (hydrated in distilled 
water) showed that no significant changes in the zeta potential were displayed at both storage 
temperatures (Figures 3.3C) with measurements of between 55-70 mV being displayed throughout 
this study at all shown time points. Likewise, for the anionic DSPS/TDB liposome formulation (when 
hydrated in distilled water) this showed that no significant changes in the liposome surface charge 
are displayed over this 28-day study, at storage temperatures of 4 ˚C and 25 ˚C respectively (Figures 
3.3D). The initial zeta potential of these anionic liposomes was shown to be in the region of - 50 mV. 
These liposomes were less stable than their Tris-hydrated counterparts (at 25 ˚C), with a reduction in 
zeta potential being measured at the day 28 time point. Whereas when these liposomes were stored 
at 4 °C, they displayed a zeta potential of ~ -65 mV (Figure 3.3D). 
When studying the zeta potential of cationic DDA/TDB liposomes (when hydrated in PBS buffer) this 
showed that over the 28-day time period of this study there was a marked reduction (P < 0.01) in the 
liposome surface charge from ~ 70 mV to ~ 40 mV by day 7 (Figure 3.3E) following storage at 25 ˚C. 
Whereas following storage at 4 ˚C, there were no significant changes over the initial 7 days, however 
there was a further reduction to around 40 mV by day 28 of the stability study. This was indicative of 
the salt-induced aggregation of these liposomes as was also indicated by the increased particle size 
at each of these time points at both storage temperatures (Figure 3.2E). However for anionic 
DSPS/TDB liposomes (hydrated in PBS buffer), these vesicles also showed a reduction in zeta 
potential of DSPS/TDB over the time period of this 28-day study, with a reduction from -77.4 mV to ~ 
-60mV (P < 0.05) being displayed (Figure 3.3F). This reduction in zeta potential was not as 
pronounced as that for DDA/TDB liposomes, therefore indicating that hydration using PBS buffer did 
not affect the stability of these negatively-charged liposomes as much as their positively-charged 
counterparts.  
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Figure 3-3. Time development of the average zeta potential of DDA/TDB (A, C and E) and DSPS/TDB (B, D 
and F) liposomes hydrated in Tris buffer (10 mM; pH 7.4 – A and B), distilled water (C and D) and PBS buffer 
(10 mM; pH 7.4 – E and F) at storage temperatures of 4 ˚C and 25 ˚C. Results are the mean of triplicate 
experiments ± SD. Significance between these characteristics between Day 0 and Day 28 was measured by 
one-way ANOVA (** p<0.01; * p<0.05). 
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As described previously for vesicle size, over this short-term stability study, PBS-hydrated liposomes 
showed relative instability in comparison to their distilled water and Tris-hydrated counterparts 
(Figure 3.2). As described previously the high presence of salt within the formulation could lead to 
vesicle aggregation due to reduced electrostatic interactions between the systems (Wasan et al., 
1999). The impact of vesicle aggregation over time, for PBS-buffer hydrated liposomes, also 
appeared to have an effect on the zeta potential of the formulation, with a noticeable reduction in 
zeta potential being shown for both DDA/TDB and DSPS/TDB liposome formulations. It has 
previously been discussed that increasing electrolyte concentration led to the condensing of the 
‘electrical double layer’ and hence resulted in reduction in the zeta potential on a charged surface 
(Florence and Attwood, 1998), which may explain the reduction in zeta potential of both cationic 
DDA/TDB and anionic DSPS/TDB liposome systems over this short term stability study. 
 
3.3.3.3. Visual stability 
 
During these studies, the visual stability of these liposome systems was observed. The physical 
instability of DDA/TDB liposomes prepared using PBS buffer was seen in Figure 3.4. These liposomes 
were stored at 4 ˚C and 25 ˚C and results (Figure 3.4) showed clear phase separation even after 3 
days, with this effect becoming more pronounced over the 28-day time period. This was in contrast 
to DDA/TDB liposomes, prepared using Tris buffer or distilled water, which remained notably more 
homogenous even after a 28-day storage period (at both storage temperatures; Figure 3.4) which 
was evident by no significant changes in both vesicle size and zeta potential (Figures 3.2 and 3.3 A 
and C). 
In contrast DSPS/TDB liposomes prepared using PBS buffer remained more stable than their cationic 
DDA/TDB counterparts hydrated in PBS buffer, with sedimentation of liposomes appearing on the 
bottom of the vial appearing after just 3 days post liposome formation (Figure 3.5). This explained 
the slight increase in vesicle size and reduction in zeta potential measured over the 28-day storage 
period of this study (Figures 3.2F and 3.3F) Therefore, the difference in charge of the lipid head 
groups of both cationic DDA/TDB and anionic DSPS/TDB liposome delivery systems and the 
hydration buffer used in the study had a direct effect on the assembly and characteristics of these 
vesicles (including the size and zeta potential). This was in contrast to vesicle characteristics of 
DSPS/TDB liposomes prepared using either distilled water or Tris buffer, which remained fairly 
homogenous even after 28 days (at 4 ˚C or 25 ˚C) as shown in Figure 3.5. 
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The difference in visual stability of the liposomes, between either phase separation or sedimentation 
for cationic DDA/TDB and anionic DSPS/TDB therefore showed that charged lipids interact differently 
with aqueous salt-containing buffers in the assembly of liposomes. Vesicle aggregation, in presence 
of PBS buffer, was therefore hypothesised to be dependent on the charge of the liposome 
formulation. As described previously, Ciani and colleagues showed that cationic liposomes can at 
least double in size in the presence of PBS, with this buffer causing a bridging effect between 
cationic lipid head groups thus causing vesicle aggregation (Ciani et al., 2007) and hence phase 
separation (Figure 3.4). However as described in these studies, anionic DSPS/TDB liposomes showed 
slightly less vesicle aggregation, especially in 4 °C temperature conditions, which suggested that the 
anionic lipid head groups interact to a lesser extent with the electrolytes present in PBS buffer. 
The stability of liposomes was a crucial issue for the use of these vesicles as vaccine delivery 
systems. The storage and handling of these liposomes is extremely important in order to maintain 
the ability to act as vaccine adjuvants, and also in being able to transport them globally for use in 
vaccination. Since most vaccines are thermally unstable, there is an important need to create stable 
vaccine formulations which can be transported to third world countries. The distribution of vaccines 
requires “cold-chains” with functional freezers, as well as reliable transport links (Christensen et al., 
2007a) therefore making vaccine stability a key criteria in the development of these delivery 
systems. 
These results have suggested that both DDA/TDB and DSPS/TDB liposomes hydrated in Tris buffer 
(10 mM; pH 7.4) displayed sub-micron vesicle size over the time-course of these studies, irrespective 
of the storage temperature. Therefore hydration of liposomes, using this aqueous buffer, was 
carried forward into further studies throughout this thesis. 
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Figure 3-4. DDA/TDB liposome samples made in either Tris buffer (10 mM; pH 7.4), distilled water or PBS 
buffer (10 mM; pH 7.4) were stored for 28 days at 4 ˚C and 25 ˚C. 
 
Figure 3-5. DSPS/TDB liposome samples made in either Tris buffer (10 mM; pH 7.4), distilled water or PBS 
buffer (10 mM; pH 7.4) were stored for 28 days at 4 ˚C and 25 ˚C. 
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However further results have suggested that the storage of formulations in an aqueous format has 
the possibility to lead to longer-term storage issues, especially using salt-containing buffers such as 
PBS. However, the stability of these liposomal-based vaccines can be improved due to the formation 
of a stable, sterile freeze-dried formulation This process of freeze-drying can be further enhanced by 
the addition of sugars, such as trehalose and sucrose, which act as cryoprotectants for 
biopharmaceuticals (Christensen et al., 2008). The addition of a cryoprotectant during the freeze-
drying of liposomes leads to the prevention of fusion of the lipid membranes from occurring. Due to 
the freezing and rehydration of these liposomes it was then possible for these liposomes to maintain 
their adjuvant effect and ability to maintain an immune response. The inclusion of TDB within 
liposomal-based vaccine delivery systems leads to an increased vesicle stability (Davidsen et al., 
2005) of DDA-based liposomes. The inclusion of TDB within liposomes leads to an enhanced 
stabilisation of the lipid membrane due to an increased hydration of the membrane surface 
(Christensen et al., 2008). 
During liposome formulation, the optimisation of the preparation process including the 
temperature, ionic strength of the buffer as well as the addition of stabilising components within the 
bilayer (including cholesterol and immunostimulatory lipids) can lead to increased stability of the 
delivery system also (Grit and Crommelin, 1993, Zuidam et al., 1995, Davidsen et al., 2005). 
 
3.3.4. Investigating the effect of additional phospholipid content in the DDA and DSPS 
liposomal systems. 
 
In a further investigation, the well characterised cationic adjuvant formulation DDA/TDB (or CAF01) 
was formulated at the optimal ratio between DDA and TDB (5:1 w/w or 8:1 M/M) which has been 
discovered to provide the optimal immune response in characterisation and vaccination studies 
(Davidsen et al., 2005). Further liposome formulations were prepared (Table 3.2) in order to 
investigate the effect of increasing DSPC lipid content on the liposome characteristics (size, zeta 
potential and polydispersity) of this liposome system, as well as the anionic liposome formulation 
DSPS/TDB. These liposome systems were formulated with and without the in vivo dose of the latent 
H56 TB antigen (0.1 mg/mL). 
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Table 3-2 - Liposome formulations including cationic or anionic lipids, with increased replacement with the 
neutral lipid DSPC. For all formulations, the molar concentration of TDB is 11 mol%, apart from where noted 
by # where the molar concentration of TDB is increased to 25 mol %. 
FORMULATION [Lipid (DDA or 
DSPS)] (mg/mL) 
[DSPC] (mg/mL) Lipid:DSPC 
ratio 
[TDB] (mg/mL) 
Lipid/DSPC/TDB 1.25 0 100%:0% 0.25 
Lipid/DSPC/TDB 0.75 0.5 60%:40% 0.25 
Lipid/DSPC/TDB 0.5 0.75 40%:60% 0.25 
Lipid/DSPC/TDB 0.5 0 40%:0% 0.25 (#) 
Lipid/DSPC/TDB 0.25 1 20%:80% 0.25 
Lipid/DSPC/TDB 0.05 1.20 5%:95% 0.25 
Lipid/DSPC/TDB 0 1.25 0%:100% 0.25 
 
The data collected during this study was summarised in Figures 3.6 to 3.8. These results showed that 
modification of the lipid molar ratio in the formulation of liposome delivery systems had a significant 
effect upon vesicle characteristics as well as their subsequent ability to load the latent TB subunit 
vaccine, H56. During these studies, liposomes were diluted with Tris buffer (1 mM; pH 7.4) as 
previous investigations have revealed that this choice of dilution buffer had no significant effect on 
vesicle characteristics (Figure 3.1). 
 
Zeta potential analysis of these liposome formulations showed a trend in which increasing DSPC 
content within the formulation led to a reduction in zeta potential, hence neutralisation of the 
surface charge. This difference becomes significant (P < 0.01) for DDA/DSPC/TDB (0.05 mg/ml: 1.2 
mg/mL : 0.25 mg/mL; Figure 3.6). Therefore the surface charge can be modulated by increased 
replacement of DDA with DSPC within the formulation. Therefore upon increasing the content of the 
DSPC lipid, as well as decreasing the DDA content within the formulation led to modulation of the 
liposome surface charge due to neutralisation of the surface charge. The main lipid constituent 
present within the formulation was therefore shown in the resultant liposome surface charge, due 
to the charged nature of polar lipid head groups present within the bilayer.  
DSPS/TDB liposomes displayed a zeta potential in the region of – 60 to -70 mV (as has been 
displayed previously in this Chapter). However, upon replacement of the anionic DSPS lipid with 
neutral DSPC within the liposome formulation this led to the neutralisation of the surface charge as 
shown by a significant reduction (P < 0.001) in the zeta potential (Figure 3.6). This again showed that 
liposome surface charge could be modulated upon anionic lipid (DSPS) replacement with DSPC. 
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Vesicle size analysis of these liposome formulations (Figure 3.7), in combination with the anionic H56 
TB antigen (at the proposed in vivo dose of 5 µg or 0.1 mg/mL) was carried out. Upon surface 
adsorption of the anionic H56 antigen, the particle size of all the cationic liposome formulations was 
measured to be in the region of 700-800 nm. The sole exception was with complete cationic 
replacement with the neutral DSPC lipid in which the vesicle size was measured to be close to 2 µm 
both with and without antigen (Figure 3.7). So upon complete DDA replacement with the neutral 
lipid DSPC within the formulation (without antigen) this resulted in a significant increase in initial 
vesicle size (P < 0.001). 
Anionic DSPS/TDB liposomes displayed a vesicle size of around 450 nm (which was similar to 
previously measured values; Table 3.1). Upon incorporation and replacement of DSPS, with neutral 
DSPC, this resulted in vesicles ranging in size from 300-400 nm. Whilst complete lipid replacement to 
form neutral DSPC-TDB liposomes, led to vesicles in the region of ~ 2 µm (Figure 3.7) which were 
significantly higher in size (P < 0.001). 
Antigen loading results showed that liposome formulations which were highly cationic (positive) in 
charge have the ability to electrostatically bind with anionic (negatively charged) antigen at the 
liposome surface, with antigen loading values in the region of 80 % being measured (Figure 3.8). The 
increasing replacement of cationic DDA with DSPC, or full replacement with DSPC or DSPS, within the 
formulation resulted in significant reduction (P < 0.001) in loading of the H56 TB antigen (Figure 3.8). 
This is due to lesser interactions between antigen and liposome components, which led to lower 
antigen loading and hence no significant change in the vesicle size and zeta potential for DSPC/TDB 
and DSPS/TDB (upon addition of H56 TB antigen). Due to the similarity in antigen loading values 
between DSPS/TDB and DSPC/TDB the loading values between these two formulations (increased 
anionic lipid replacement) were not measured. The effect of liposome charge in the loading and 
biodistribution of various antigens has been studied in the previous literature (Henriksen-Lacey et 
al., 2010a, Henriksen-Lacey et al., 2010c), with electrostatic interaction between oppositely-charged 
antigen and delivery system being important with regards to high antigen loading.  
Therefore as described previously cationic liposomes are able to highly load anionic vaccine 
antigens, such as the TB vaccine candidate H1 (Henriksen-Lacey et al., 2011a, Kaur et al., 2011, Perrie 
et al., 2013) with these studies showing that the formation of a strong ‘antigen depot’ was important 
in the potentiation of a strong Th1 immune response (Perrie et al., 2013). 
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Figure 3-6. The effect of lipid molar ratio on the zeta potential of liposome formulations. All formulations 
are prepared with the addition of the in vivo dose of H56 antigen (5 µg per dose; 0.1 mg/mL). Results are the 
mean of triplicate experiments ± SD. For all formulations, the molar concentration of TDB is 11 mol%, apart 
from where noted by # where the molar concentration of TDB is increased to 25 mol %. 
 
 
Figure 3-7. The effect of lipid molar ratio on the vesicle size of liposome formulations. All formulations are 
prepared with the addition of the in vivo dose of H56 antigen (5 µg per dose; 0.1 mg/mL). Results are the 
mean of triplicate experiments ± SD. For all formulations, the molar concentration of TDB is 11 mol%, apart 
from where noted by # where the molar concentration of TDB is increased to 25 mol %. 
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Figure 3-8. Percentage (%) antigen loading (represented by bar columns) and zeta potential (represented by 
squares) of a series of liposome formulations with increasing cationic lipid replacement with neutral DSPC 
and anionic DSPS. Results are the mean of triplicate experiments ± SD. Results are the mean of triplicate 
experiments ± SD. Significance  was measured by one-way ANOVA (*** p<0.001; * p<0.05) as compared to 
DDA-DSPC-TDB (100%:0%). For all formulations, the molar concentration of TDB is 11 mol%, apart from where 
noted by # where the molar concentration of TDB is increased to 25 mol %. 
 
3.3.4.1. Immunogenicity of liposome vaccine formulations upon cationic lipid replacement 
with DSPC 
 
The immunological capability of these liposomal adjuvants (in combination with H56 vaccine 
antigen), with increasing DDA replacement with DSPC, has been assessed during in vivo vaccine 
studies (Hussain et al., 2013). Upon immunisation, partial and complete DDA replacement with DSPC 
reduced the levels of antigen-specific IgG2b antibody production, as well as a significant reduction in 
the levels of splenocyte proliferation. This reduction in splenocyte proliferation correlated with 
lower levels of Th1 cytokine production (IFN-γ and IL-2). However DSPC-enriched liposomal 
adjuvants induced significantly higher levels of Th2 cytokines (IL-5 and IL-10), therefore this 
suggested that the Th2 immune responses obtained were independent of the surface charge of the 
adjuvant which correlated with the previous literature (Henriksen-Lacey et al., 2010c). 
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3.3.5. Product specification for liposome vaccine adjuvants 
 
As a result of these studies a product specification has been set up for both cationic DDA/TDB 
anionic DSPS/TDB liposome formulations. These are displayed in Table 3.3. These studies were 
therefore used to validate formulations prepared in Chapter 4 of this thesis, for use in further in vivo 
studies. 
Table 3-3. Production specification of cationic DDA/TDB and anionic DSPS/TDB liposome adjuvants 
Formulation              DDA/TDB             DSPS/TDB 
Hydration buffer Tris (10 mM; pH 7.4) Tris (10 mM; pH 7.4) 
Dilution buffer Tris (1 mM; pH 7.4) Tris (1 mM; pH 7.4) 
Expected vesicle size  500-700 nm 350-500 nm 
Expected zeta potential 65 to 80 mV -60 to -80 mV 
Expected PDI 0.3 to 0.5 0.4 to 0.7 
Expected H56 antigen loading 
(antigen added at 0.1 mg/mL) 
80-90 % 15-25 % 
 
3.4. Conclusions 
 
The work in this chapter showed that a range of liposomal systems can be prepared over the full 
range of charge using DDA and DSPS. The charged lipid content was shown to impact on the 
measured zeta potential and in some cases the vesicle size. The choice of buffer used in these 
liposome systems was also shown to be important, with high electrolyte buffers such as PBS shown 
to cause flocculation and aggregation of the DDA-based liposomes which resulted in phase 
separation. Similarly the DSPS-based liposome systems were shown to sediment over time, 
suggesting that for longer term storage of these systems, the process of freeze-drying may be 
required. Furthermore from these initial experiments, product specifications have been developed 
for both the DDA- and DSPS-based formulations. These will be used to validate any further 
formulations used prior to in vivo studies. 
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Chapter 4: The role of liposome surface charge in vaccine delivery and 
formulation 
 
 
 
 
Some of the results presented in this chapter have been published in the paper: 
Wilkinson A., Kaur R., Henriksen-Lacey M., Christensen D., Mohammed AR, Perrie Y. “Investigating 
the role of surface charge on the ability of liposome vaccine formulations to form an antigen depot 
and subsequently induce an immune response” (manuscript in preparation). 
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4.1. Aims and Objectives 
 
The aim of the work reported in this chapter was to further investigate the effect of liposome 
surface charge and liposome-antigen interactions, defined by electrostatic interaction, on the 
production of a liposome and vaccine antigen depot at the injection site. Cationic DDA/TDB and 
anionic DSPS/TDB liposomes with various antigens were investigated (formulated by the lipid film-
hydration method) and physicochemical characteristics measured, as well their ability to load and 
retain antigen. The issue of stability of these systems was considered. In vivo biodistribution and 
immunisation studies in mice were undertaken in order to investigate the effect of liposome surface 
charge on the subsequent immunogenicity of the formulation, in terms of immune responses such 
as cytokine analysis at the spleen, leg (site of injection) as well as antibody production in the blood 
sera. 
 
4.2. Introduction 
 
Liposomes are an ideal vaccine delivery system due to their particulate nature, versatility and 
flexibility in formulation and it is these parameters that can be used to promote a range of immune 
responses (Foged et al., 2004). This is due to the ability of liposomes as delivery systems to render 
soluble antigen into a particulate form, thereby leading to the lengthening of their in vivo half life 
(Henriksen-Lacey et al., 2011c). The importance of charge, antigen isoelectric point (pI) and buffer 
pH for liposomes offers an important platform for antigen adsorption due to electrostatic interaction 
between oppositely charged liposome and antigen components.  
 
This ‘depot effect’ has been shown to be the mechanism of action for cationic liposomes (Vangasseri 
et al., 2006, Henriksen-Lacey et al., 2010a, Henriksen-Lacey et al., 2010c, 2011a). The liposome 
composition, such as the lipid head-group structure (conferring the surface charge) and membrane 
fluidity as well as the cationic surface charge have been shown to play an important role in the 
retention of vaccine at the site of injection (SOI) in order to initiate a vaccine-specific immune 
response (Henriksen-Lacey et al., 2011a). The surface charge of liposomes has also been shown to 
have a positive effect on the immune response with cationic DDA-based liposomes having an 
advantage over their neutral and anionic counterparts (Henriksen-Lacey et al., 2010c, 2011a) due to 
their ability to electrostatically bind anionic antigen. This has been attributed to their ability to form 
a ‘depot’ at the SOI, due to their interaction with negatively-charged serum proteins following s.c 
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and i.m injection, hence leading to monocyte influx and local activation of dendritic cells (Korsholm 
et al., 2007). Through association with DCs, such as antigen presenting cells (APCs) this release of 
antigen can then drain to the lymph nodes in order to and initiate T-cells to activate a Th1 cell-
mediated immune response.  
 
A number of other research studies have investigated the variation in surface charge of liposomes 
and the subsequent effect on the generated immune response in mice. For example, Nakanishi et al 
showed that encapsulation of ovalbumin (OVA) or diphtheria toxin in cationic liposomes 
(PC:Cholesterol:SA) elicited the highest anti-OVA serum IgG1 responses (Nakanishi et al., 1999) when 
compared to anionic and neutral liposomes (PC:Cholesterol:PA and PC:Cholesterol respectively). 
Therefore these studies support the conclusion that cationic liposomes promote stronger Th1 
immunity, as well as antigen-specific serum antibody responses when compared to otherwise similar 
anionic and neutral formulations, although these responses are not always specifically correlated. 
 
However, in contrast, original studies by Allison and Gregoriadis in 1974 demonstrated the use of 
diphtheria toxoid in combination with negatively-charged liposomes which caused a significant 
elevation in the levels of antibody in comparison to positively-charged liposomes (Allison and 
Gregoriadis, 1974). The use of liposomes of varying charge has also been investigated by Yanasarn et 
al, in which some negatively-charged liposomes (including the anionic lipid DOPA) are able to 
generate strong and functional antibody responses, as well as upregulating gene expression related 
to the activation and maturation of dendritic cells (Yanasarn et al., 2011). This occurred due to the 
simple mixing of pre-formed negatively charged liposomes with antigens. However, these studies did 
not compare between cationic and neutral liposomes. The general trend during the studied 
literature is for cationic liposomes having greater potential and efficacy as vaccine adjuvants, in 
comparison to their anionic and neutral counterparts.  
Therefore, to consider these factors, it was required to directly compare between cationic and 
anionic liposomes in terms of their characterisation, antigen loading ability, biodistribution and their 
ability to act as a vaccine adjuvant. Of interest during this study is the immunostimulatory capability 
of DSPS/TDB liposomes, in comparison to the well characterised CAF01 vaccine adjuvant (DDA/TDB), 
which is currently in clinical trials for the TB subunit vaccine, H1 (NCT 00922363). 
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4.3. Results and Discussion 
4.3.1. Physicochemical characteristics including quantification of antigen loading 
 
Liposomes composed of DDA and TDB at a 5:1 weight ratio expressed physicochemical 
characteristics as described in Chapter 3; displaying a vesicle size of ~500 nm and a zeta potential of 
~63 mV (summarised in Table 4.1). DSPS/TDB liposomes were made at an 8:1 molar ratio (therefore 
mimicking the DDA/TDB formulation to serve as a direct comparison): DSPS/TDB liposomes had an 
average vesicle size of around 400 nm and polydispersity of 0.5 (Table 4.1). DSPS/TDB liposomes 
were slightly reduced in size (P < 0.05) in comparison to their counterpart DDA/TDB liposomes (Table 
4.1). This size similarity was confirmed by cryo-TEM imaging (Figure 4.1). DSPS lipid has an anionic 
(negatively charged) head group and therefore liposomes produced of DSPS with TDB express a 
strongly anionic zeta potential. Therefore, substitution of DDA with DSPS results in a decrease in zeta 
potential from approximately +63 mV to – 65 mV (Table 4.1). 
Table 4-1. Physical characterisation of cationic DDA/TDB liposomes and anionic DSPS/TDB liposomes 
formulated by the lipid-film hydration (LH) method. Results are the mean ± SD of triplicate experiments. 
  DDA/TDB liposomes DSPS/TDB liposomes 
Size (nm) 508 ± 100 419 ± 80 
Polydispersity (PDI) 0.516 ± 0.040 0.464 ± 0.150 
Zeta potential (mV) 63 ± 10 -65 ± 6 
 
 
Figure 4-1. Cryo-TEM micrograph of (A) DDA/TDB and (B) DSPS/TDB liposomes prepared by the lipid-film 
hydration method. The long dark structures are the carbon grid the sample was deposited on before analysis. 
 
 
A B 
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4.3.2. Effect of antigen charge on the physicochemical characteristics of liposomal 
adjuvants 
 
To consider the ability of these systems to deliver antigens, multilamellar vesicles (MLV) of cationic 
DDA/TDB and anionic DSPS/TDB liposomes were prepared and their characteristics considered, both 
with and without antigen (cationic lysozyme or anionic OVA). DSPS/TDB liposomes were formulated 
at the 8:1 molar ratio, thereby mimicking the DDA/TDB formulation (as described previously in 
Chapter 3). 
Prior to addition of protein, the cationic DDA/TDB and anionic DSPS/TDB liposomes had zeta 
potential values of 67.3 ± 5.8 mV and – 58.3 ± 8.9 mV, respectively (Figure 4.2A). The addition of 
lysozyme to DDA/TDB resulted in minimal to no adsorption (1.78 ± 0.5 %), which correlates with no 
significant change in the zeta potential (59.2 ± 3.3 mV). The addition of OVA (1 mg/mL) to DDA/TDB 
liposomes (post-lipid film hydration) resulted in a significant (P < 0.001) reduction in zeta potential, 
suggesting high adsorption of anionic OVA to cationic DDA/TDB by electrostatic interactions at the 
liposome surface, which thus reduced the cationic charge. In contrast, the outcome with the anionic 
DSPS/TDB formulation (Figure 4.2A) is reversed with electrostatic binding and the subsequent 
significant changes (P < 0.001) occurring only with lysozyme (-21.2 ± 3.1 mV and 79.1 ± 10.3 % 
adsorption) and not with OVA (-59.3 ± 10.3 mV and 0.35 % adsorption). 
The results in Figure 4.2B showed that DDA/TDB liposomes displayed a vesicle size in the region                  
of 700 nm and a polydispersity of 0.53 ± 0.05. Whereas DSPS/TDB liposomes (prepared at the same 
molar ratio) had similar size characteristics; being around 400 nm in size (Figure 4.2B), but slightly 
less polydisperse (0.39 ± 0.17). The addition of ovalbumin (OVA) to DDA/TDB (at a final 
concentration of 1 mg/mL) resulted in a significant (P < 0.001) increase in vesicle size and 
polydispersity (Figure 4.2B). In contrast, the addition of OVA had no significant effect on the 
liposome characteristics of DSPS/TDB. The addition of cationic lysozyme to DSPS/TDB liposomes 
resulted in a significant (P < 0.001) increase in vesicle size and polydispersity, with the addition of 
lysozyme to DDA/TDB having no significant effect on liposome characteristics. These results 
indicated that the addition of oppositely charged liposome and antigen components leads to vesicle 
aggregation (as shown by an increased vesicle size and polydispersity; Figure 4.2B) due to high 
antigen adsorption to the liposome surface by electrostatic interactions (Figure 4.2A) which caused 
subsequent neutralisation of the liposome surface charge (Figure 4.2A). 
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Figure 4-2. Liposome characteristics [A: antigen adsorption (columns) and zeta potential (squares); B: size 
(columns) and polydispersity (squares)] of cationic DDA/TDB and anionic DSPS/TDB liposomes with or 
without the addition of 1 mg/mL protein (OVA or lysozyme). Antigen adsorption is measured as total 
protein recovered in the supernatant fraction (following analysis by BCA assay). Results are the mean of 3 
experiments ± SD. Significance between liposome characteristics was measured by one-way ANOVA (*** 
p<0.001). 
Table 4-2. Summary table of proteins used during this investigation 
PROTEIN BUFFER MOLECULAR WEIGHT (kDa) ISOELECTRIC POINT (pI) 
Ovalbumin (OVA) 10 mM Tris (pH 7.4) 45.0 4.5 
Lysozyme 10 mM Tris (pH 4.0) 14.7 11.2 
H56 (Ag85B-ESAT6-Rv2660c) 10 mM Glycine (pH 9.2) 46.0 4 
 
DDA-based liposomes were shown to display a cationic (positive) surface charge, whereas DSPS/TDB 
liposomes displayed an anionic (negative) charge. OVA and lysozyme have a pI (isoelectric point) 
value of 4.5 and 11.2 units, making them either positively or negatively-charged at pH 7.4 (Table 4.2) 
respectively. Therefore, upon addition of oppositely-charged liposome and antigen components, 
electrostatic-mediated adsorption of protein antigen to the liposome surface can occur. 
The addition of protein antigen (at a concentration of 1 mg/mL) was undertaken in order to 
investigate the subsequent effects on liposome characteristics including vesicle size, zeta potential 
and antigen adsorption. Electrostatic interactions have been shown to play a role in the interaction 
between liposome and antigen, so when these components are opposing in charge this results in 
charge-related interactions at the liposome surface as described in previous studies (Shek and 
Heath, 1983, Tsuruta et al., 1997, Korsholm et al., 2007, Henriksen-Lacey et al., 2010c). Antigen 
adsorption to the liposome results in an increased shielding of the liposome surface, hence the 
observed increase in vesicle size and reduction in zeta potential. The electrostatic interactions 
between the cationic surface of the liposomes with the anionic protein structures (and vice versa, 
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with anionic liposomes and cationic protein) results in charge neutralisation and hence a reduction 
in the measured zeta potential of the vesicles 
Electrostatic interactions between liposome and antigen have been shown to occur during these 
studies, in which this interaction leads to vesicle aggregation due to the adsorption of protein at the 
liposome surface. This causes the increase in vesicle size and reduction in zeta potential, which 
increases at higher concentrations of oppositely-charged (to the liposome) protein antigen (see 
Sections 4.3.2.1 and 4.3.2.2). However, when liposome and antigen are similar in charge (cationic 
DDA/TDB and cationic protein lysozyme) no electrostatic binding will occur, as shown by the low 
levels of antigen adsorption and no notable changes in vesicles characteristics measured. Such 
interactions have previously been shown with other systems, most commonly in gene therapy 
systems where cationic liposomes are used to deliver DNA. For example, the addition of increasing 
concentration of DNA to cationic liposomes leads to vesicle aggregation with increases in vesicle size 
and reduction in zeta potential (Moghaddam et al., 2011). However addition of DNA to pre-formed 
anionic liposomes has been previously shown to lead to minimal loading and hence no measured 
changes in vesicle characteristics (Perrie and Gregoriadis, 2000). 
 
4.3.2.1. The effect of the addition of anionic protein antigen on vesicle characteristics 
  
Given the electrostatic interactions of antigen with the above liposome formulations, the effect of 
+/- and charge ratios were considered and the characteristics of both cationic and anionic liposomes 
were investigated after the addition of varying concentrations of these model antigens (Table 
4.2).The physicochemical characteristics of both cationic DDA/TDB and anionic DSPS/TDB liposomes 
were investigated after the addition of varying concentrations of OVA. The addition of increasing 
concentrations of OVA (between 0 and 10 mg/mL) resulted in no significant difference in the 
liposome characteristics of anionic DSPS/TDB liposomes, with the vesicle size and polydispersity 
remaining around 400 nm and between 0.5-0.6 respectively (Figure 4.3A). 
Zeta potential analysis also showed no significant effect on anionic DSPS/TDB upon addition of 
increasing concentrations of OVA, with measurements of between -70 to -80 mV being recorded 
(Figure 4.3B). Both antigen and delivery systems are net anionic in charge which suggests that even 
at high OVA concentrations, there is no electrostatic binding between these similarly charged 
liposome and antigen components (both anionic in charge) over a wide concentration range.  
131 
 
 
Figure 4-3. Variation in liposome characteristics of anionic DSPS/TDB liposomes, A: size (columns) and 
polydispersity (points), B: zeta potential; with the addition of increasing concentrations of OVA. Results are 
the mean of triplicate experiments ± SD. 
 
Upon addition of increasing concentrations of OVA to cationic DDA/TDB liposomes, there was a 
significant (P < 0.001) increase in vesicle size and neutralisation of the surface charge when 
compared to empty DDA/TDB liposomes. The binding of anionic OVA to these cationic liposomes 
occurred via electrostatic interactions (indicated by high OVA adsorption in Figure 4.2A); at an in vivo 
dose concentration of 5 µg (0.1 mg/mL), there are no significant changes in liposome characteristics 
for DDA/TDB. Therefore, this indicates that at low protein concentrations, liposome characteristics 
can be maintained (Figure 4.4). The vesicle size increased from 595.8 ± 41.1 nm (empty vesicle) to ~ 
2 µm (at concentrations of 1 and 10 mg/mL OVA – Figure 4.4A). Zeta potential analysis has showed 
that there was a highly significant reduction in surface charge (P < 0.001) from 76.5 ± 20.9 mV to – 
23.9 ± 4.3 mV (after addition of 10 mg/ml OVA) as displayed in Figure 4.4B. At these lower protein 
concentrations (0.1 mg/mL), the levels of antigen loading were assessed by the radioactivity method 
(Table 4.3). These studies further concluded the importance of electrostatic interactions between 
cationic DDA/TDB and negatively charged antigen (OVA), therefore resulting in high levels of antigen 
loading/adsorption occurring at the liposome surface (Table 4.3). At the in vivo antigen 
concentration (0.1 mg/mL), this level of antigen loading had no effect on the resulting liposome 
characteristics whereas at a higher antigen dose (1 and 10 mg/ml), the addition of protein resulted 
in increased binding and lowering of the cationic charge combined with an increased vesicle size as 
vesicle aggregation occurs (Figures 4.4 A and B). This correlated with previous work in the literature 
with the addition of DNA to liposomes which has shown that as the ratio between lipid and DNA 
within the formulation is modified this can lead to a reversal in zeta potential from positive to 
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negative, with subsequent increase in the vesicle size (Perrie and Gregoriadis, 2000, Perrie et al., 
2001, Moghaddam et al., 2011). 
 
 
Figure 4-4. Variation in liposome characteristics of cationic DDA/TDB liposomes, A; size (columns) and 
polydispersity (points), B; zeta potential; with the addition of increasing concentrations of OVA. Results are 
the mean of triplicate experiments ± SD. Significance was measured by one-way ANOVA (*** p<0.001; ** 
p<0.01). 
Table 4-3. Antigen Loading Characteristics for multilamellar vesicles (MLV) of DDA/TDB and DSPS/TDB 
liposomes [either empty or combined with OVA. OVA is added at an in vivo dose concentration of 5 µg (0.1 
mg/mL).  
Formulation % Antigen Loading Antigen Loading (µg) 
DDA/TDB:OVA 
93.3 ± 1.9 
4.67 ± 0.1 
DSPS/TDB:OVA 
23.1 ± 7.4 
1.16 ± 0.37 
% Antigen Loading is proportional to the total recovery of radiolabelled antigen within the liposome pellet.  
Results are the mean of 3 experiments ± SD. 
 
In subsequent studies, the tuberculosis subunit vaccine antigen H56 (Ag85B-ESAT6-Rv2660c) was 
included in combination with both cationic DDA/TDB and anionic DSPS/TDB liposomes in order to 
show the effect of this antigen addition on the liposome characteristics of MLV. Due to the OVA 
concentration range that can be produced, this protein is an ideal protein to study protein-induced 
changes on liposomal systems due to its low cost and availability. However, OVA is not a disease 
model antigen therefore we moved towards the use of the above subunit protein antigens which 
have been developed for immunisation against active and latent tuberculosis respectively (Statens 
Serum Institut, Copenhagen, Denmark).  
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H56 has a molecular weight of ~ 45-50 kDa and has a pI of around 4.0 units, making it similar in size 
and pI to OVA. The pI of H56 favours its association via electrostatic interactions with cationic 
DDA/TDB liposomes (Table 4.4). For in vivo studies, each liposome dose (250 μg lipid, 50 μg TDB) 
contained 5 μg Ag85B-ESAT6-Rv2660 (H56) antigen. The association of the H56 antigen with both 
DDA/TDB and DSPS/TDB liposome delivery systems was investigated and the vesicle characteristics 
for MLVs (size, zeta potential and polydispersity and antigen loading) are displayed in Figure 4.5 and 
Table 4.4, respectively. 
At the in vivo experimental dose of 5 µg H56/dose (0.1 mg/mL), the addition of antigen made no 
significant difference to the physico-chemical characteristics of these liposomes compared to their 
antigen-free counterparts (Figure 4.5). The adsorption of the H56 antigen (at an in vivo dose of 5 µg) 
to both DDA/TDB and DSPS/TDB has been assessed by the radioactivity method (as described 
previously) with levels of ~ 80 % and ~ 20 % being measured respectively (Table 4.4). These studies 
have indicated a high level of adsorption of this anionic (negatively charged) antigen with cationic 
DDA/TDB in comparison with low level antigen adsorption to anionic DSPS/TDB (Table 4.4). This 
again demonstrated the importance of electrostatic interactions between oppositely charged 
liposome and antigen components. 
 
Table 4-4. Antigen loading for multilamellar vesicles (MLV) of DDA/TDB and DSPS/TDB liposomes [either 
empty or combined with an in vivo dose of H56 antigen (5 µg)].  
Formulation Antigen Loading (%) 
DDA/TDB (+ H56) 77.3 ± 4.6 
DSPS/TDB (+ H56) 20.3 ± 5.2 
Results are the mean of triplicate experiments ± SD. 
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Figure 4-5. Variation in liposome characteristics [size, polydispersity (A; columns and points respectively) 
and zeta potential (B)] for DDA/TDB and DSPS/TDB with and without an in vivo experimental dose of H56 
antigen (5 µg)]. Results are the mean of 3 experiments ± SD. Significance was measured by one-way ANOVA 
(** p<0.01). 
 
These studies have demonstrated that interaction will occur by charge-related electrostatics of H56 
antigen binding to the liposome surface as is demonstrated by the high loading to the liposome 
surface of cationic DDA/TDB (Table 4.4). This will be confirmed by means of a trypsin digestion assay 
in Section 4.3.4. 
 
4.3.2.2. The effect of the addition of cationic protein on vesicle characteristics 
 
Given the electrostatic interactions of antigen with the above liposome formulations, the effect        
of -/+ and +/+ charge ratios were considered and the characteristics of both cationic and anionic 
liposomes were investigated after the addition of varying concentrations of the cationic protein 
lysozyme. 
 
The addition of increasing concentrations of lysozyme resulted in no significant changes in the 
characteristics of DDA/TDB, with liposomes displaying a vesicle size of ~500-600 nm in this study 
(Figure 4.6A). Zeta potential analysis (Figure 4.6B) of these cationic delivery systems showed a highly 
positive surface charge between 70-80 mV which remained constant (depending on lysozyme 
concentration) for all formulations. Both delivery system and protein are cationic in charge, 
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therefore upon post-LH addition of lysozyme to the formulation this results in no marked changes in 
vesicle characteristics. 
As shown previously (Figure 4.2A and B), the addition of lysozyme (at a concentration of 1 mg/mL) 
had a significant effect on the liposome characteristics of DSPS/TDB. As the concentration dose of 
protein was increased (between 0 and 10 mg/mL) there was a significant (P < 0.001) increase in 
vesicle size (from 445.7 nm to 932.7 nm) and neutralisation of the surface charge due to interaction 
between these oppositely charged liposome and antigen components (Figure 4.7). At the in vivo 
experimental dose of 5 µg (0.1 mg/mL), there were no significant differences in the size or zeta 
potential of anionic DSPS/TDB liposomes, however significant lysozyme loading occurs at this dose 
(Table 4.5). 
Zeta potential analysis shows that at lysozyme concentrations reaching up to 10 mg/mL, that a 
slightly positive surface charge is displayed (+ 16 mV) for DSPS/TDB. The addition of the cationic 
protein lysozyme will hence lead to neutralisation of the surface charge, which led to a significant (P 
< 0.001) reduction in the zeta potential of these anionic delivery systems (Figure 4.7B). These 
changes are therefore caused by high adsorption of cationic lysozyme at the negatively-charged 
surface of DSPS/TDB liposomes, causing the anionic surface charge to be masked and becoming 
weakly cationic due to neutralisation of the surface charge. 
 
 
Figure 4-6. Variation in liposome characteristics of cationic DDA/TDB liposomes, A; size (columns) and 
polydispersity (points), B; zeta potential; with the addition of increasing concentrations of lysozyme. Results 
are the mean of triplicate experiments ± SD.  
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Figure 4-7. Variation in liposome characteristics of anionic DSPS/TDB liposomes, A; size (columns) and 
polydispersity (points), B; zeta potential; with the addition of increasing concentrations of lysozyme. Results 
are the mean of triplicate experiments ± SD. Significance was measured by one-way ANOVA (*** p<0.001). 
Table 4-5. Antigen Loading Characteristics of DDA/TDB and DSPS/TDB liposomes, either empty or combined 
with lysozyme.  
Formulation % Antigen Loading Antigen Loading (µg) 
DDA/TDB: Lysozyme 27.9 ± 7.1 1.4 ± 0.36 
DSPS/TDB: Lysozyme 82.6 ± 3.5 4.1 ± 0.2 
Lysozyme is added at an in vivo dose concentration of 5 µg (0.1 mg/mL). % Antigen Loading is proportional to 
the total recovery of radiolabelled antigen within the liposome pellet. Results are the mean of 3 experiments ± 
SD. 
 
At these lower lysozyme concentrations (0.1 mg/mL), the levels of antigen loading were assessed by 
the radioactivity method. These studies further concluded the importance of electrostatic 
interactions between anionic DSPS/TDB and cationic protein (lysozyme), therefore resulting in high 
levels of antigen loading or adsorption (82.6 %) occurring at the liposome surface (Table 4.5). This 
was in comparison with DDA/TDB, which displayed low to minimal levels of lysozyme loading (27.9 
%) which is due to these components being similarly charged and therefore both liposome and 
antigen components are unable to electrostatically interact at the liposome surface (Figure 4.6). At 
this antigen dose this adsorption of antigen has no subsequent effect on liposome characteristics 
(such as size and zeta potential), whereas at higher doses of antigen this results in enhanced 
shielding of the liposome surface charge. This resulted in a significant effect on liposome 
characteristics, such as an increased vesicle size (Figure 4.7A) and reduction or neutralisation of the 
surface charge (as reflected by a reduction in zeta potential: Figure 4.7B). 
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These studies have concluded that using MLV (prepared by the LH method) for cationic DDA/TDB 
and anionic DSPS/TDB liposome delivery systems with increasing concentrations of protein (anionic 
OVA and cationic lysozyme) leads to a marked change in liposome characteristics when these 
components are opposite in charge (high antigen adsorption). Therefore, this demonstrates the 
mode of association between liposome and antigen to occur at the liposome surface and the 
mechanism of action between these oppositely charged components is by electrostatic (charge-
related) interactions (Henriksen-Lacey et al., 2010c). The high adsorption of protein (lysozyme by 
anionic DSPS/TDB, or OVA by DDA/TDB) at the liposome surface results in vesicle aggregation as 
indicated by an increased vesicle size, as well as subsequent neutralisation of the surface charge of 
the liposome delivery system. The presence of some antigen loading between similarly charged 
antigen and liposome components during this study demonstrates that electrostatic interactions 
may not be the only crucial factor in determining antigen-liposome interaction. The presence of 
hydrophobic and hydrophilic regions within the protein may demonstrate interactions between 
liposome and antigen. Also, the protein may have a net cationic charge (for example, lysozyme) but 
contain several smaller regions which are anionic in charge which therefore may favour the 
interaction with a positively charged (cationic) liposome delivery system at the surface of the vesicle. 
Also from the chemical structures of the two main lipids present in liposome formulations (DDA and 
DSPS) even though containing an overall net cationic and anionic charge respectively, these lipids 
contain areas of the opposing charge. This can be seen within the head group of the DSPS lipid which 
is overall anionic in charge, but contains an ammonium ion (-NH3) head group therefore this may 
favour the binding of a small amount of anionic protein antigen to the anionic delivery system. This 
phenomenon may be reversed with the minimal binding of lysozyme to cationic DDA/TDB 
liposomes.  
These findings in respect of protein antigen have been discussed previously with the addition of DNA 
to both cationic and anionic liposomes, in which increasing the concentration of DNA with pre-
formed cationic liposomes led to increase in vesicle size and the reduction in the zeta potential of 
vesicles (Perrie and Gregoriadis, 2000). 
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4.3.2.3. Stability of Antigen-Loaded Multilamellar Vesicles  
 
Cationic DDA/TDB and anionic DSPS/TDB (with the addition of the in vivo dose of lysozyme or H56 
antigen at a concentration of 0.1 mg/mL) liposome vaccine delivery systems were placed into 
stability trials in order to assess stability (in terms of size, zeta potential and polydispersity) over a 
28-day period. These stability studies have shown that both cationic DDA/TDB and anionic DSPS/TDB 
liposomes (in combination with an in vivo dose of H56 antigen) remain homogenous and exhibit no 
phase separation even after a 28-day storage period (at both temperatures of 4 ˚C and 25 ˚C; Figure 
4.8). Over the storage period DDA/TDB liposomes exhibited a vesicle size of ~ 550-700 nm whereas 
the zeta potential remained highly cationic throughout this study, remaining in the region of + 60-70 
mV (Figures 4.9 and 4.10). This is in correlation with previous data (Chapter 3) of DDA/TDB and 
DSPS/TDB liposomes, after hydration using Tris buffer (10 mM; pH 7.4). Similarly DSPS/TDB 
liposomes retained their zeta potential throughout the time period of this study (after the addition 
of an in vivo dose of H56 antigen), in the region of -70 to -80 mV, whilst displaying a vesicle size 
which remained constant at about 400-500 nm throughout this storage period (Figures 4.11 and 
4.12).  
 
 
Figure 4-8. Time development of the stability of DDA/TDB and DSPS/TDB liposome formulations (in 
combination with the in vivo dose of H56) following storage for 28 days at 4 ˚C or 25 ˚C. 
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Figure 4-9. Time development of liposome size characteristics for MLV DDA/TDB (with the addition of H56 at 
an in vivo dose) at a storage temperature of 4 ˚C or 25 ˚C. Results are the mean of triplicate experiments ± SD. 
 
 
Figure 4-10. Time development of liposome characteristics (zeta potential) for MLV DDA/TDB (with the 
addition of H56 at an in vivo dose) following storage at 4 and 25 ˚C. Results are the mean of triplicate 
experiments ± SD. 
 
 
 
Figure 4-11. Time development of liposome size characteristics for MLV DSPS/TDB (with the addition of H56 
at an in vivo dose) following storage at 4 and 25 ˚C. Results are the mean of triplicate experiments ± SD. 
 
  
Figure 4-12. Time development of liposome characteristics (zeta potential) for MLV DSPS/TDB (with the 
addition of H56 at an in vivo dose) following storage at 4 and 25 ˚C. Results are the mean of triplicate 
experiments ± SD. 
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These liposome systems (cationic DDA/TDB and anionic DSPS/TDB respectively), in combination with 
antigen (lysozyme), were also measured for various characteristics including size, polydispersity and 
zeta potential at a number of time points throughout this study (Figures 4.13 to 4.16). Throughout 
these studies, DDA/TDB liposomes (in combination with an in vivo dose of lysozyme; 0.1 mg/mL) 
displayed vesicles with sizes in the region of 600-650 nm (Figure 4.13). Zeta potential analysis of 
these systems showed that these systems displayed a cationic charge in the region of 70 mV (Figure 
4.14) irrespective of the storage temperature. As shown by no significant changes in characteristics 
over the 28-day period, these vesicles remained relatively stable which is a prerequisite for the use 
and development of liposomal-based vaccine formulations. 
Whereas, anionic DSPS/TDB  liposomes showed an average vesicle size of around 500 nm and a zeta 
potential between -70 to – 80 mV over the 28-day study period (Figures 4.15 and 4.16), therefore 
demonstrating these systems remained stable during this study period. These results showed that 
both of these liposome delivery systems, at both storage temperatures, remained stable in terms of 
their liposome characteristics as was confirmed by visual stability (Figure 4.17). 
 
 
 
Figure 4-13. Time development of liposome size characteristics for MLV DDA/TDB (with the addition of 
lysozyme at an in vivo dose) following storage at 4 and 25 ˚C. Results are the mean of triplicate experiments ± 
SD. 
 
 
Figure 4-14. Time development of liposome characteristics (zeta potential) for MLV DDA/TDB (with the 
addition of lysozyme at an in vivo dose) following storage at 4 and 25 ˚C. Results are the mean of triplicate 
experiments ± SD. 
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Figure 4-15. Time development of liposome size characteristics for MLV DSPS/TDB (with the addition of 
lysozyme at an in vivo dose) following storage at 4 and 25 ˚C. Results are the mean of triplicate experiments ± 
SD. 
 
 
Figure 4-16. Time development of liposome characteristics for MLV DSPS/TDB (with the addition of 
lysozyme at an in vivo dose) following storage at 4 and 25 ˚C. Results are the mean of triplicate experiments ± 
SD. 
 
  
Figure 4-17. Time development on the stability of DDA/TDB and DSPS/TDB liposome formulations (in 
combination with the in vivo dose of lysozyme) following storage for 28 days at 4 ˚C or 25 ˚C. 
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The relative stability of these vesicles over this time period is hypothesised to be due to their small 
size and highly charged nature (either cationic or anionic) upon rehydration with Tris buffer (10 mM; 
pH 7.4). The high stability of these vesicles is due to the insertion of trehalose – 6,6’ dibehenate 
within the lipid bilayer (Christensen et al., 2008). Therefore incorporation of TDB within the 
liposomal system will increase the hydration of the membrane, thereby preventing dehydration of 
the quaternary ammonium ion head groups which would otherwise lead to reduction in charge 
repulsion and aggregation of vesicles (Christensen et al., 2008) thus leading to vesicle stability 
(Davidsen et al., 2005). These vesicles, in combination with both antigens, are stable in both the 
‘cold chain’ conditions (4 °C) and at 25 °C in terms of their vesicle size and surface charge (as 
reflected by the zeta potential). This is important for the transportation and delivery of vaccines to 
third-world countries, in which the vaccines may be subjected to different temperatures upon 
storage.  
 
4.3.3. Optimisation and quantification of antigen adsorption 
4.3.3.1. Indirect quantification of antigen adsorption through use of total proteins assays 
 
During these investigations, it was possible for antigen adsorption to be quantified indirectly by 
calculating the percentage of free (un-adsorbed) protein present in the supernatant (by the BCA 
total protein assay; Figure 4.18). This was then confirmed by showing the presence of protein (OVA 
or lysozyme) in the liposome pellet or supernatant fraction, via SDS-PAGE, therefore demonstrating 
whether the protein antigen associates with the antigen delivery system. 
These results from the BCA assay showed that using multilamellar vesicles (MLV) for cationic 
DDA/TDB and anionic DSPS/TDB liposomes enabled interaction between oppositely charged 
liposome and antigen components (due to surface adsorption) resulting in high antigen adsorption, 
as measured indirectly by the presence of a reduced amount of protein antigen present in the 
supernatant (as shown by the BCA assay; Figure 4.18). These results therefore indicate high 
adsorption of anionic OVA to DDA/TDB liposomes (Figure 4.18A), with the reversed effect occurring 
with cationic lysozyme which is able to highly adsorb to anionic DSPS/TDB liposome delivery systems 
(Figure 4.18B). These results also suggested that only two wash steps [with Tris buffer (10 mM; pH 
7.4)] are required to remove all the protein (P < 0.001) from the supernatant fraction of the 
liposome formulation (Figures 4.18 A and B), so during future experiments the liposome pellet was 
only be resuspended two times in order to minimise time during the preparation process. 
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Figure 4-18. BCA assay to show the amount (%) of protein (A; OVA, B; lysozyme) in a series of supernatant 
fractions for DDA/TDB and DSPS/TDB liposomes. Results are the mean of triplicate experiments ± SD. 
Significance between the % of protein found in a series of supernatant fractions was measured by one-way 
ANOVA (*** p<0.001). 
 
A SDS-PAGE gel was carried out to show the presence of lysozyme either in the pellet (liposome) or 
supernatant fractions, for both cationic DDA/TDB and anionic DSPS/TDB liposomes (Figure 4.19A). 
The aim was to confirm whether the cationic lysozyme was being bound by DDA/TDB or DSPS/TDB 
liposomes. 
 
 
 
Figure 4-19. SDS-PAGE gel to show the presence of (A) lysozyme and (B) OVA in the supernatant or pellet 
fractions of DDA/TDB and DSPS/TDB liposomes (Lane 1: Prestained protein marker; Lane 2: DDA/TDB 
liposome pellet; Lane 3: DDA/TDB Supernatant 1; Lane 4: DDA/TDB Supernatant 2; Lane 5: DDA/TDB 
Supernatant 3; Lane 6: DSPS/TDB liposome pellet; Lane 7: DSPS/TDB Supernatant 1; Lane 8: DSPS/TDB 
Supernatant 2; Lane 9: DSPS/TDB Supernatant 3). 
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This gel (Figure 4.19A) showed that lysozyme was present in the initial supernatant fraction for the 
cationic DDA/TDB liposomes (Lane 3), and not in the pellet fraction (Lane 2). This backed up previous 
data from BCA total protein assays (Figure 4.18B) and antigen adsorption studies (Figure 4.2) which 
showed the importance of electrostatic interactions between oppositely charged liposome and 
antigen components. Also, lysozyme was present in the pellet fraction for DSPS/TDB liposomes (Lane 
6), and there was no lysozyme present in the subsequent supernatant fractions (Lanes 7-9). This 
showed that this wash step was sufficient to eliminate the majority of the protein from the 
supernatant. Lysozyme was electrostatically binding to the surface of these anionic liposomes, 
whereas this protein lacks the ability to bind to DDA/TDB liposomes to any great extent as these 
components are similar in charge. A further SDS-PAGE gel was carried out to show the presence of 
OVA either in the pellet (liposome) or supernatant fractions, for both cationic DDA/TDB and anionic 
DSPS/TDB liposomes (Figure 4.19B). 
Figure 4.19B showed that OVA was present in the pellet fraction for DDA/TDB liposomes (Lane 2), 
and no detectable protein was present in any of the subsequent supernatant fractions (Lanes 3-5). 
The opposite effect occurs for anionic DSPS/TDB liposomes with no protein being present in the 
pellet fraction (Lane 6), whilst ovalbumin (OVA) was present in the initial supernatant fraction (Lane 
7). There was also no protein present in the subsequent supernatant fractions (Lanes 8 and 9) which 
showed that all of this protein is present in the initial supernatant fraction. This again showed the 
importance of electrostatic interaction in the binding between oppositely charged liposome and 
antigen components, with high adsorption of anionic OVA to cationic DDA/TDB liposomes. Whereas, 
none to minimal of the anionic OVA protein is present in the DSPS/TDB liposome pellet fraction due 
to the similar charge of these components therefore indicating a lack of electrostatic interactions. 
These results correlated with previous data from total protein assays (Figure 4.18A) and the 
displayed liposome characteristics in order to confirm the importance of antigen-liposome 
interaction at the surface of multilamellar vesicles.  
 
4.3.3.2. Direct quantification of antigen adsorption through radiolabelling of vaccine 
antigen 
 
Following the radiolabel of protein antigen, as described previously in Section 2.4.2, it was required 
to directly quantify antigen adsorption. Verification that antigen was not displaced from liposomes 
was carried out under simulated in vivo conditions and under control conditions. This simulated in 
vivo environment was made up of a solution containing 50 % Foetal Calf Serum (FCS) thereby aiming 
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to mimic the specific protein environment that the liposomes may encounter in vivo upon injection. 
For therapeutic applications, it is crucial that vaccine or drugs are retained within the liposome 
system for an appropriate amount of time and that the release kinetics were stable. The bilayer 
composition has been shown to be a key factor in the liposomal release of drug or protein antigen 
(Devaraj et al., 2002) and therefore will be investigated in this study with the use of both cationic 
DDA/TDB and anionic DSPS/TDB formulations (prepared by the lipid-film hydration method). 
Initial antigen loading studies demonstrated that using multilamellar vesicles (MLV) there was a 
higher adsorption of radiolabelled antigen to liposomes, when these components were opposing in 
charge (Figure 4.20A). Therefore, these charged liposomes (cationic DDA/TDB and anionic 
DSPS/TDB) are ideal components for antigen adsorption, with the specific antigen isoelectric point 
(pI) determining their adsorption to either anionic or cationic liposomes. Therefore the cationic 
protein lysozyme will favour high adsorption to the outer surface of negatively charged DSPS/TDB 
liposomes (80-85 % loading), whereas the anionic H56 TB antigen will become adsorbed (~ 90 % 
loading) to the positively charged outer surface of cationic DDA/TDB (Figure 4.20). 
A short term (96 hour) study was carried out to measure the antigen loading and release kinetics of 
H56 and lysozyme when associated with DDA/TDB and DSPS/TDB liposomes placed in simulated in 
vivo conditions (FCS/Tris; 50:50 v/v). The initial levels of H56 antigen adsorption to DDA/TDB and 
DSPS/TDB liposomes were 90 % and 20 % respectively (Figure 4.20A). Upon placement of the 
liposomes in simulated in vivo conditions, there was an initial significant (p < 0.001) burst release (< 
3 hours) of antigen from liposome formulations following which there were no further significant 
losses of H56 from both cationic DDA/TDB and anionic DSPS/TDB liposomes (Figure 4.20B). In 
previous studies, exposure of cationic liposomes to FCS leads to a dramatic increase in vesicle 
aggregation and decrease in zeta potential due to interaction with negatively-charged serum 
proteins, however FCS adds cumulatively to the vaccine antigen rather than competitively displacing 
this antigen from the liposome surface (Henriksen-Lacey et al., 2010a). 
The results obtained from lysozyme release from DDA/TDB and DSPS/TDB liposomes showed a very 
similar trend; after the initial burst release within 3 to 5 hours (P < 0.001), antigen release stabilises 
with no further significant loss of lysozyme from both formulations is noted (Figure 4.20B). A similar 
trend for antigen loading and release was noted in control conditions (10 mM, pH 7.4; 37 °C) with an 
initial significant (P < 0.001) burst release of antigen being measured in the initial 5 hours of the 
study. However antigen release stabilised for the remainder of the study period (Figure 4.21B). 
146 
 
These results in Figures 4.20 and 4.21 showed that liposomes were able to efficiently retain their 
adsorbed antigen. This builds on previous knowledge (Henriksen-Lacey et al., 2010a) that has shown 
that electrostatic interaction can be exploited to load antigen onto liposomes. Liposomes composed 
of DDA/TDB and DSPS/TDB could load H56 antigen and lysozyme, respectively, therefore 
demonstrating electrostatic interaction between vaccine and delivery system. Furthermore the 
nature of the charge of liposomes is not relevant, with increasing impact coming from the ability of 
liposomes to electrostatically interact with antigen. 
 
 
Figure 4-20. Antigen loading (A) and release profile (B) after addition of tested liposome formulations to a 
simulated in vivo environment (50 % FCS in Tris buffer 10 mM pH 7.4; 37 °C). Results represent the mean ± SD 
of triplicate experiments. Significance was measured by one-way ANOVA (*** p<0.001) in terms of antigen 
retention compared to the values at 0 h. 
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Figure 4-21. Antigen loading (A) and release profile (B) after addition of tested liposome formulations to a 
control environment (10 mM Tris buffer pH 7.4; 37 °C). Results represent the mean ± SD of triplicate 
experiments. Significance was measured by one-way ANOVA (*** p<0.001) in terms of antigen retention 
compared to the values at 0 h. 
 
4.3.4. Investigating antigen protection offered by electrostatically binding antigens to 
liposomes.  
 
Whilst the above studies demonstrate that electrostatic interactions can be used to load antigens to 
liposomes, the protection these liposomal carriers afford to the antigens was not clear. Therefore, to 
investigate this, liposomal-antigen systems were exposed to enzyme digestion, via incubation of 
antigen-adsorbing liposome formulations (DDA/TDB and DSPS/TDB) with increasing concentrations 
of trypsin. These results showed a significant reduction in % antigen loading (P < 0.001) by the 
liposome systems for all formulations tested (Figure 4.22). This confirmed that addition of antigen 
post-lipid hydration to the liposome system leads to surface-associated binding of protein antigen 
which is exposed to enzyme digestion. The significant reduction in antigen loading upon increasing 
the concentration of trypsin is due to this serine protease enzyme being unable to cross the 
liposome bilayer and thus only targeting and digesting surface-adsorbed protein antigen, thereby 
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confirming that protein antigen is directly surface-adsorbed to liposomes. The effect of trypsin on 
the digestion of surface-adsorbed protein antigen has also been confirmed by means of SDS-PAGE 
assay (Figure 4.23). 
Figure 4-22. Initial antigen loading by liposome vaccine formulations and the effect of increased trypsin 
concentration on antigen loading. Results represent the mean ± SD of triplicate experiments. Significance is 
measured by one-way ANOVA, against the initial antigen loading values for each formulation. (*** p<0.001). 
 
 
Figure 4-23. Liposomes associated with antigen were exposed to various concentrations of trypsin (0, 100 
and 400 µg/mL) to free surface bound antigen. The pellets of washed formulations were analysed by SDS-
PAGE using coomasie blue to stain gels. A: DDA/TDB:H56; B: DSPS/TDB:H56; C: DDA/TDB:Lysozyme; D: 
DSPS/TDB:Lysozyme. 
 
The results in Figures 4.22 and 4.23 showed that upon exposure of antigen-adsorbing liposome 
vaccine formulations to increasing concentrations of trypsin this resulted in a significant reduction in 
antigen loading to the liposome delivery system. This correlates with previous knowledge (Kaur et 
al., 2011) for OVA-adsorbing cationic DDA/TDB liposomes which showed that increasing trypsin 
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concentration significantly reduced the amount of protein associated with the formulation. Similar 
findings were also represented in the previous literature which showed that liposome-entrapped 
human interferon-gamma (IFN-γ), which was not exposed on the liposomal surface were protected 
from enzyme digestion by trypsin (van Slooten et al, 2001) The effect of liposome preparation 
method on the localisation of antigen within the delivery system will be further addressed in Chapter 
5. 
 
4.3.5. Stability of radioactive markers within liposome formulations 
 
Liposomes (cationic DDA/TDB and anionic DSPS/TDB) were prepared by the lipid film-hydration 
method, with the incorporation of trace amounts of 3H-Cholesterol (0.17 nM). Dialysis was used to 
study the retention of 3H-Cholesterol within the liposome membrane in order to show that the 
radioactive markers used in the subsequent biodistribution study were stable and not lost from 
liposomes. At various time points (1h, 3h, 5h, 18h, 48h and 96h) over a 96 hour study period, 1 mL 
aliquots of dialysis media were removed and the amount of 3H present were measured. These 
results have demonstrated that preparation has no significant effect on the loss of the radioactive 
marker (3H-Cholesterol) from these liposome formulations. This was shown by minimal release of 3H-
labelled Cholesterol from the delivery system over the time course of this study. For LH-prepared 
formulations, there is a maximum 3H-Cholesterol release of ~ 3 % from the liposome bilayer (Figure 
4.24) over the 96 hour period of the study.  
 
Figure 4-24. Membrane stability of DDA/TDB and DSPS/TDB liposomes (prepared by the lipid film hydration 
method) was studied by the addition of a trace amount of 
3
H-Cholesterol within the liposome formulation. 
Results express the % of the original 
3
H-Cholesterol dose added to liposomes detected in the dialysis buffer 
over a 96 hr time period. The samples were stored at 37 °C in 50 % FCS in Tris buffer (10 mM; pH 7.4). Results 
denote the mean of triplicate experiments ± SD. 
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4.3.6. Biodistribution studies: the effect of liposome surface charge and antigen 
adsorption 
 
To determine the role of liposome surface charge on the antigen (and liposome) depot-effect at the 
SOI, DDA/TDB and DSPS/TDB liposomes were produced with the inclusion of 3H-Cholesterol  within 
the bilayer membrane and 125I-labelled Ag85B-ESAT6-Rv2660c (H56) antigen or lysozyme adsorbed 
to the delivery system as previously outlined. The SOI and various other tissues were collected and 
the percentage of the administered dose (% dose) quantified. 
The application of dual radiolabelled vaccines provides an ideal method for measuring the 
pharmacokinetic properties and tissue distribution of both the liposome and antigen (Henriksen-
Lacey et al., 2010b). However to overcome the problem of 125I counting using the scintillation 
counter, a standard curve can be used to factor out the presence of 125I counts. A plot of the cpm 
values derived from the γ-counter (x-axis) and the cpm values derived from the scintillation counter 
(y-axis) was made. The line of best fit and equation for samples below 50,000 cpm (2 % of the dose 
or less), and samples above 50,000 cpm (2 % of the dose or more) were derived (Figures 4.25 A and 
B). For both standard curves, the efficiency of 125I was about half of that seen by the γ-counter. 
Therefore, uncorrected values for scintillation counts for both liposome formulations were applied 
into the specific equation in order for actual scintillation counts to be measured (without 125I 
overspill) as will be required for measuring the liposome dose retention. 
 
Figure 4-25. Standard curve for 
125
I values (A) below 50,000 cpm and above 50,000 cpm (x-axis) plotted 
against their corresponding 
3
H count values. The equation and R
2
 values represent the line of best fit. Results 
are the mean of 3 measurements ± SD. 
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4.3.6.1. Vaccine retention at the injection site 
 
The biodistribution of radiolabelled liposome and antigen components was investigated at days 1, 4 
and 14 post-injection. Mice were vaccinated i.m. with 125I-labelled antigen (either H56 or lysozyme) 
with and without 3H-labelled liposomes (cationic DDA/TDB or anionic DSPS/TDB) in order to analyse 
the fate of injected antigen both at the vaccination site (left quadricep) and the draining popliteal 
lymph node (PLN). These were the only organs investigated as previous studies have shown 
negligible presence of liposome and antigen in the lung, heart, kidney, liver, brain and small intestine 
(Henriksen-Lacey et al., 2010a). 
As previously reported for DDA/TDB (Henriksen-Lacey et al., 2010a), high levels of retention at the 
injection site was noted for these liposomes with around 80, 45 and 25 % of the liposome dose 
detected on days 1, 4 and 14 p.i (post-injection) respectively (Figure 4.26A). In contrast, anionic 
DSPS/TDB liposomes drained rapidly from the SOI and by day 4 p.i only 25 % of the injected dose 
was detected, decreasing to ~ 8 % on day 14 (Figure 4.26A). Therefore the liposome dose retention 
at the SOI was significantly higher for cationic systems compared to their anionic counterparts (P < 
0.001). 
When H56 antigen was delivered in combination with cationic DDA/TDB liposomes an ‘antigen 
depot’ at the SOI was observed with similar drainage kinetics observed (80 %, 45 % and 10 % of the 
dose detected at days 1, 4 and 14 p.i respectively (Figure 4.26B)). In contrast, lysozyme delivered in 
combination with DDA/TDB drained rapidly with ~ 20 % retention at day 1 p.i and less than 1 % of 
the injected dose detected at the SOI on day 14 p.i. Delivery of lysozyme with the anionic liposome 
DSPS/TDB significantly improved the early retention of lysozyme with around 40 % dose retention at 
the SOI (p < 0.001), however by day 14 p.i the levels present were low for all formulations tested 
(Figure 4.26B). However, when anionic H56 was delivered in combination with the DSPS/TDB 
delivery system this resulted in minimal levels of antigen retention at the vaccination site with only 
18 % antigen remaining 1 day p.i with a further significant reduction (P < 0.001) at later time points 
(Figure 4.26B).  
Therefore, these studies have demonstrated the importance of cationic liposome charge for 
increased retention of the delivery system at the SOI and also that H56 antigen adsorption to the 
liposome surface (via electrostatic interactions) results in an increased antigen depot, due to charge-
related electrostatics between antigen and delivery system. Anionic DSPS/TDB liposomes have also 
been formulated which showed less retention at the SOI compared to their cationic counterparts. 
This is due to the increased ability of cationic DDA/TDB liposomes to interact with negatively 
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charged interstitial proteins at the SOI (Henriksen-Lacey et al., 2010a). Cationic liposomes, whilst 
retained at the injection site are not able to retain lysozyme due to their inability of these 
components to exploit electrostatic interaction. In contrast, whilst DSPS/TDB liposomes are lesser 
retained at the injection site they can electrostatically interact with lysozyme, and not anionic H56 
antigen. Henriksen-Lacey et al have previously shown the importance of charge-mediated 
electrostatic interactions for the efficient delivery of antigen and subsequently induce enhanced 
immune responses (Henriksen-Lacey et al., 2010c). 
  
  
Figure 4-26. Biodistribution of vaccine components, liposome (A) and antigen (B) at the site of injection (SOI) 
following intramuscular (i.m.) injection of liposome vaccine formulations. Results represent the mean ± SD of 
4 mice per group. Significance was measured by one-way ANOVA (*** p<0.001). 
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B 
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*** 
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4.3.6.2. Movement of vaccine to the draining lymph nodes 
 
The percentage dose of antigen and liposome at the draining popliteal lymph node (PLN) was also 
calculated, as this is the local lymphoid tissue to which antigen detected at the SOI (left quadricep) 
drains. These lymph nodes will therefore be the primary site at which the antigen will be presented 
to T-cells.  
Liposomal draining to the PLN followed two distinct patterns (Figure 4.27A); anionic DSPS/TDB 
liposomes were found in significantly higher amounts at the earlier time points of 1 and 4 day p.i (P < 
0.01) whilst cationic DDA/TDB liposomes were detected in low amounts (< 0.005 % dose/mg tissue 
at all 3 time points. The levels of liposome and antigen were also measured in the non-draining 
popliteal lymph node (PLN) of the non-injected leg. This gave rise to negligible levels of these vaccine 
components, which were even lower than that in the draining PLN of the injected leg (results not 
shown).  
In terms of antigen retention at the draining PLN (Figure 4.27B) an antigen depot of either H56 or 
lysozyme was present at days 1 (~ 0.015 % dose/mg tissue) and 4 p.i (~ 0.01 % dose/mg tissue) 
respectively when co-administered with DSPS/TDB rather than DDA/TDB (Figure 4.28B), with similar 
levels of antigen retention displayed for all formulations at day 14 p.i. (< 0.005 % dose/mg tissue). 
These results suggested that antigen as well as liposomes drain rapidly to the PLN when a depot of 
antigen at the injection site is not obtained (Figure 4.27B). This is due to the general trend that 
DSPS/TDB are less likely to be retained at the SOI and so are more likely to drain to the PLN. This 
pattern and the absolute values of liposome drainage are very similar to that observed previously 
(Henriksen-Lacey et al., 2010c) when DDA/TDB liposomes were compared with ‘neutral’ DSPC/TDB 
liposomes.  
The prolonged retention of antigen at the SOI mediated by DDA/TDB liposomes as compared to 
DSPS/TDB could result in a prolonged uptake of electrostatically-bound antigen by APCs, which has 
been shown previously when cationic liposomes were compared against neutral liposomes (Foged et 
al., 2004). The rapid drainage of anionic liposomal adjuvants from the injection site was shown to 
correlate with increased early presence in the draining PLN, which has previously been shown to be 
disadvantageous in the induction of Th1 immune responses (Henriksen-Lacey et al., 2010c), however 
this will be further investigated in Section 4.3.7. 
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Figure 4-27. Biodistribution of vaccine components, liposome (A) and antigen (B) at the popliteal lymph 
node (PLN) following intramuscular (i.m.) injection of liposome vaccine formulations. Results represent the 
mean ± SD of 4 mice per group. Significance was measured by one-way ANOVA (** p<0.01). 
 
4.3.6.3. Pontamine Blue as a marker for innate immune responses 
 
Similarly to previous studies, pontamine blue was used as a marker for influx of monocytes at the 
SOI (Henriksen-Lacey et al., 2010a, Henriksen-Lacey et al., 2011a). The results shown in Figure 4.28 
are in correlation with previous studies which have shown increased pontamine blue staining at the 
SOI after injection of cationic DDA/TDB liposomes. However, following i.m. immunisation with 
anionic DSPS/TDB this resulted in low or minimal staining at the SOI. These results suggest that when 
cationic liposomes are involved, regardless of the antigen associated, a higher infiltration of 
macrophages to the SOI is observed. This may provide the transport mechanism  of liposomes (and 
hence adsorbed antigen) from the vaccination site to the draining lymph nodes (Henriksen-Lacey et 
al., 2010a). This is due to slower drainage of DDA/TDB liposomes when compared to DSPS/TDB 
liposomes, which suggests that the immune response to DDA/TDB is significantly enhanced due to 
the increased induction of proinflammatory responses at this site including tissue damage which is 
A 
B 
** 
** 
** 
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due to increased toxicity of cationic liposomes (Filion and Phillips, 1997). This will lead to the 
infiltration of APCs to such areas which actively undergo endocytosis which is important for 
subsequent antigen presentation. This reported influx of innate immune cells to the SOI also 
suggests that DDA/TDB liposomes induce a “danger effect”, as originally described by Matzinger 
(Matzinger, 1994). This danger signal can be initiated upon parenteral delivery of vaccines which 
causes localised tissue damage, which may lead to the rupture of cells causing the release of 
alarmins (Bianchi et al, 2007) at the injection site, therefore leading to monocyte recruitment at this 
site.  
 
Figure 4-28. Pontamine Blue Staining at the site of injection (SOI) following i.m. injection of DDA/TDB (A and 
B) or DSPS/TDB (C and D), either adsorbing H56 (A,C) or lysozyme (B,D). These photos are taken at 1 day p.i. 
 
4.3.7. The ability of liposomal vaccines to induce immune responses 
 
In order to investigate the role of surface charge on the immunogenicity of liposome vaccine 
formulations, we will carry out a number of vaccine studies in order to show the immune response 
generated (Th1 response Vs Th2 response). The H56 TB antigen was formulated within cationic 
DDA/TDB and anionic DSPS/TDB liposomes, respectively, before intramuscular (i.m.) injection of 
these vaccine formulations into the left quadriceps. During this study, a triple homologous 
vaccination regimen was maintained in which each mouse was injected three times at two-weekly 
intervals (day 1, 15 and 29). 
4.3.7.1. Generation of antigen-specific antibody responses  
 
The ability of cationic DDA/TDB liposomes and anionic DSPS/TDB liposomes (in combination with the 
anionic H56 antigen) to induce IgG (total), IgG1 and IgG2b antibody isotypes was investigated using 
antibody ELISAs. Blood was collected on days 0, 14, 28, 36 and 49 and mice were injected with 
A C D B 
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liposome vaccine formulations on days 1, 15 and 29. These results in Figures 4.29 A to C showed that 
DDA/TDB:H56 promoted higher antibody responses than DSPS/TDB:H56 and antigen alone.  
   
 
 
 
Figure 4-29. Ag85B-ESAT6-Rv2660c (H56) specific antibody titres; IgG (A), IgG1 (B) and IgG2b (C). Groups of 
five female C57/BL6 mice, approximately six to eight weeks old, received doses of vaccine formulations 
containing 5 μg of Ag85B-ESAT6-Rv2660c (H56) in a 50 μl volume. Vaccine formulations were administered 
intramuscularly, and each mouse received three doses at intervals of two weeks at days 1, 15 and 29 (as 
represented by arrows). Serum samples were taken at days 0, 14, 28, 35 and 49. Results represent the mean of 
5 mice per group ± SD. Significance was measured by one-way ANOVA between time points and between 
formulations (*** p<0.001). 
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For IgG and IgG1 responses, for all formulations tested the antibody titres increased from 
background levels by day 28 (following 2 x immunisations) thus showing the requirement for a 
memory response. So upon reencounter of the H56 antigen (following immunisation 2) this resulted 
to the body responding by raising antibody titres in the blood sera which is important in initiating 
humoural and cell-mediated immune responses. Interestingly, in terms of the IgG2b antibody 
response, H56 coadministered with DDA/TDB liposomes was able to generate antibody responses at 
day 14 (following one immunisation) which are further boosted following further immunisation 
(Figure 4.29C). This has not been noted before in the previous literature (Henriksen-Lacey et al., 
2011b, Kaur et al., 2011) however these studies used the H1 antigen in combination with cationic 
DDA/TDB liposomes, whilst this study uses the latent TB subunit vaccine H56 in combination with 
adjuvant delivery system which has been to shown to offer significantly better protection and 
control over late stages in TB, partly due to improved T-cell responses (Aagaard et al., 2011). 
 
Results in Figure 4.29 suggested that DDA/TDB liposome induced significantly higher antibody titres 
than their anionic DSPS/TDB counterparts. This could be due to increased adsorption of H56 antigen 
to cationic DDA/TDB liposomes, as well as better retention of these liposomes at the SOI which has 
previously been shown due to interaction with anionic serum proteins (Henriksen-Lacey et al., 
2010a, Henriksen-Lacey et al., 2010c). This higher retention of H56 antigen by DDA/TDB liposomes 
allows for higher bioavailability thus allowing production of higher antigen-specific antibody titres in 
the blood sera. Previous literature has also suggested that antigen adsorbed to cationic DDA/TDB 
liposomes resulted in the eliciting of strong antibody responses and cell-mediated immunity 
(Henriksen-Lacey et al., 2010a, Henriksen-Lacey et al., 2011c). 
 
4.3.7.2. Splenocyte proliferation in response to vaccine antigen  
 
During this study, the ability of the TB antigen H56, either alone or in combination with cationic 
DDA/TDB or anionic DSPS/TDB liposomes, to be delivered to antigen presenting cells (APCs) in the 
spleen was investigated by means of a splenocyte proliferation assay. Figure 4.30 showed the 
proliferative ability of splenocytes in response to the positive control stimuli, ConA. All mice 
responded to ConA and the average 3H-thymidine uptake was between 20,000 – 60,000 counts per 
minute (CPM). Splenocytes derived from unimmunised mice or those immunised with PBS, free H56, 
anionic DSPS/TDB:H56 and cationic DDA/TDB:H56 responded to nearly equal proliferative levels (P = 
n/s). In addition to inducing splenocyte proliferation with the non-specific stimulator ConA, 
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splenocytes were also exposed to previously encountered H56 (Ag85B-ESAT6-Rv2660c) antigen. 
Figure 4.31 gives an overview of the proliferative ability for all liposomal vaccine formulations, 
assessing the proliferative ability of splenocytes following reencounter with increasing 
concentrations of H56 antigen. 
 
Figure 4–30. Splenocyte proliferation in response to stimulation or restimulation with ConA (at a 
concentration of 2 μg/mL), as measured by 
3
H-thymidine incorporation. Results are the mean of triplicate 
wells ± SD.  
The results in Figure 4.31 demonstrated a charge dependent trend in terms of splenocyte 
proliferation upon restimulation using increasing concentrations of H56 antigen (0, 0.05, 0.5 and 5 
µg/mL respectively). Upon restimulation of splenocytes with H56, those derived from mice 
immunised with DDA/TDB:H56 gave rise to the highest levels of splenocyte proliferation. Compared 
to free antigen, or antigen administered with DSPS/TDB liposomes these levels of proliferation were 
significantly higher (P < 0.001) at all H56 restimulation conditions (Figure 4.31). 
 
Figure 4-31. Splenocyte proliferation in response to stimulation or restimulation with the H56 antigen, as 
measured by 
3
H-thymidine incorporation. Results are the mean of triplicate wells ± SD. Significance was 
measured by one-way ANOVA (*** p<0.001). 
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These results suggested that liposome charge has an important role to play in terms of the ability of 
liposome vaccine formulations to deliver antigen to APCs in the spleen with DDA/TDB liposomes 
being able to induce a population of T-cells that could respond upon re-exposure to the disease 
antigen. The inability of DSPS/TDB:H56 immunised mice to mount increased levels of splenocyte 
proliferation is partly due to the lesser levels of antigen adsorption between these vaccine 
components, as described previously, therefore upon re-exposure to antigen, a smaller population 
of memory T-cells are initiated. However, these levels of proliferation are higher than mice 
immunised with H56 alone (P < 0.001; Figure 4.31). Therefore the ability of the spleen cells to 
efficiently proliferate upon response to H56 TB antigen leads to their ability to induce spleen-specific 
immune responses which will be further discussed in Section 4.3.7.3. H56-adsorbing cationic 
DDA/TDB liposomes have the ability to produce a strong cell-mediated immune responses as well as 
high levels of humoural immune response, due to their ability to form a strong antigen depot (Perrie 
et al., 2013) as well as being released from this site around the body in order to stimulate a strong 
antibody response. 
 
4.3.7.3. Cytokine response from ex vivo restimulated splenocytes  
 
The supernatants of restimulated splenocytes were assayed for the presence of cytokines IFN-γ, IL-2, 
IL-5, IL-6, IL-10. Figures 4.32 to 4.34 showed cytokine production for splenocytes derived from 
individual formulations following splenocyte restimulation with ConA, media only (negative control) 
and H56 antigen respectively. During this investigation, the presence of cytokines which were 
associated with generating a Th1-biased immune response, namely interferon-gamma (IFN-γ) and 
interleukin-2 (IL-2) were measured. Secondly, the presence of cytokines which were associated with 
generating a Th2-biased immune response namely interleukins 5, 6 and 10 (IL-5, IL-6 and IL-10) were 
measured.  
The results presented in this study showed the importance of liposome surface charge for the 
effective delivery of H56 TB antigen and, hence, the generation and production of cytokines 
associated with Th1 and Th2-immunity. In terms of splenocyte cells restimulated with the positive 
control stimuli, ConA, this led to higher production of all cytokines tested in the study with liposome 
vaccine formulations (in association with H56) initiating slightly higher levels of all these cytokines 
(Figure 4.32). In terms of our negative control, in which splenocyte cells were restimulated with 
medium only this resulted in negligible production of all cytokines tested for in this study, which was 
fully due to the fact that these restimulation conditions do not therefore allow the enhanced 
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activation of a population of memory T-cells that have previously encountered the disease antigen 
so leading to a lack of cytokine production (Figure 4.33). 
Splenocytes restimulated with H56 antigen (at a concentration of 5 μg/mL) resulted in greater 
cytokine release compared to the negative control for all cytokines tested for in this study. 
Splenocytes derived from DDA/TDB:H56 immunised mice were able to show higher levels of the Th1 
cytokines IFN-γ and IL-2 with values of ~ 2300 pg/mL and 1100 pg/mL being measured respectively 
(Figure 4.34). In contrast there was a liposome charge-dependent trend in which DSPS/TDB:H56, 
free H56 and PBS-immunised mice respectively produced significantly less (P < 0.001) amounts of 
these cytokines [IFN-γ and IL-2]. This trend was also evident in the production of interleukin-6 (IL-6) 
in which mice immunised with cationic DDA/TDB:H56 gave rise to production of this cytokine at 
levels of 500-600 pg/mL (Figure 4.34). In comparison, a two-fold decrease (P < 0.001) was noted 
upon i.m. injection of anionic DSPS/TDB:H56 with lower values being recorded for H56 alone- and 
PBS-immunised mice respectively (Figure 4.34). In contrast in terms of the production of Th2-
cytokines, interleukins 5 and 10 (upon splenocyte restimulation with H56 antigen), the opposite 
effect was observed with slightly higher production noted upon immunisation with the anionic 
DSPS/TDB:H56 liposome vaccine formulation with concentrations of ~ 300 pg/mL and ~ 700 pg/mL 
being measured respectively (Figure 4.34). This was in comparison to mice immunised with 
DDA/TDB:H56, H56-alone and PBS respectively which led to lower levels of these cytokines being 
produced. However the difference between cationic DDA/TDB:H56 and anionic DSPS/TDB:H56 
liposomes was not significant.  
Therefore these studies showed that immunisation of mice with H56 (in combination with cationic 
DDA/TDB liposomes) led to a bias towards a Th1 immune response, as characterised by high 
production of IFN-γ and IL-2. This has been shown previously following the delivery of TB subunit 
vaccine antigen (such as Ag85B-ESAT6 or H1) within cationic DDA/TDB liposomes (Davidsen et al., 
2005, Henriksen-Lacey et al., 2010a, Henriksen-Lacey et al., 2011b). Replacing the cationic lipid, with 
the anionic lipid DSPS, within the formulation led to a significant reduction in Th1 immune responses 
which are slightly higher than H56 alone-immunised mice. Also, these studies have clearly 
demonstrated that the function of TDB within the formulation is highly dependent on the 
composition of the delivery system as shown by significant reduction in the measured Th1 responses 
after replacing cationic DDA with anionic DSPS within the formulation. However, the generated Th2 
responses obtained are not dependent on the liposome surface charge. However, these liposome 
adjuvants in general induced low levels of IL-5 as compared to such adjuvants as aluminium 
hydroxide which are able to induce strong Th2 responses (Davidsen et al., 2005). 
161 
 
 
Figure 4-32. Cytokine production from splenocytes restimulated with ConA at 2 μg/mL. Results are shown for 
mice immunised with PBS (negative control) and H56 either administered alone or in combination with 
cationic DDA/TDB or anionic DSPS/TDB liposomes. Mice received 3 injections with 2-week intervals and 
splenocytes were obtained 3 weeks post the final immunisation. Cytokines were detected from splenocyte 
supernatants, following 48h restimulation, and measured using sandwich ELISAs. Results are the mean of 5 
mice per group ± SD. Significance between experimental groups was measured by one-way ANOVA (* p<0.001; 
** p<0.01; *** p < 0.05) as compared to PBS-immunised mice. 
 
Figure 4-33. Cytokine production from splenocytes restimulated with media only (negative control). Results 
are shown for mice immunised with PBS (negative control) and H56 either administered alone or in 
combination with cationic DDA/TDB or anionic DSPS/TDB liposomes using the same experimental method 
described above. 
 
Figure 4-34. Cytokine production from splenocytes restimulated with H56 at 5 μg/mL. Results are shown for 
mice immunised with PBS (negative control) and H56 either administered alone or in combination with 
cationic DDA/TDB or anionic DSPS/TDB liposomes using the same experimental method described above. 
Significance was measured by one-way ANOVA (*** p<0.001) in comparison to anionic DSPS/TDB:H56. 
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4.3.7.4. Cytokine analysis at the injection site 
 
During this investigation there was a need to monitor and study ‘leg immune responses’ at the site 
of injection (SOI). This was in order to monitor the immune response in regards to cytokines 
associated with the inflammasome complex such as interleukin1-beta (IL-1β) as well as interleukin-
18 (IL-18) and interleukin-33 (IL-33). Results from this study demonstrated a significant (P < 0.001) 
liposome charge-dependent relationship in the cytokine response at the vaccination site. IL-1β and 
IL-18 levels from mice immunised with DDA/TDB:H56 were in the region of 16 ng/g tissue and 7 ng/g 
tissue respectively (Figure 4.35 ). However, for mice immunised with DSPS/TDB:H56, free H56 and 
PBS these gave IL-1β levels of 4, 2 and 0.2 ng/g tissue respectively. There was also a similar 
correlation in terms of IL-18 levels at the vaccination site with concentration of 1.8, 1 and 0.4 ng/g 
tissue determined for DSPS/TDB:H56, free H56 and PBS control immunised mice respectively (Figure 
4.35). For DDA/TDB:H56 immunised mice, these IL-18 and IL-1β levels (at the vaccination site) are in 
correlation with increased production of IFN-γ and IL-2 (from H56 restimulated splenocytes) 
therefore this showed a Th1-bias in cytokine production for this cationic liposome formulation 
(DDA/TDB:H56) at both the injection site and from restimulated splenocytes. 
The production of IL-33 (Figure 4.35) was also monitored at the vaccination site following this 7-
week immunisation study (mice terminated at day 49). DSPS/TDB:H56 immunised mice are able to 
produce slightly higher levels of IL-33 (12 ng/g tissue) in comparison to DDA/TDB:H56, free H56 and 
PBS-control immunised mice which gave levels of 10, 1.8 and 0.5 ng/g tissue respectively (Figure 
4.35). The levels of IL-33 at the vaccination site correlated with IL-5 and IL-10 production from H56 
restimulated splenocytes, thus representing a slight change in bias from Th1 to Th2 immunity upon 
immunisation with anionic DSPS/TDB:H56 liposome vaccine formulation. Upon intramuscular 
injection of DDA/TDB:H56, a moderate amount of Th2 cytokines (IL-5, IL-10 and IL-33) are still 
produced, which suggests that a balanced Th1/Th2 immune response is generated, however this 
balanced response is strongly skewed towards Th1 cell-mediated immunity.  
 
The presence of the pro-inflammatory cytokines IL-1β, IL-18 and IL-33 suggested a role for the NALP3 
inflammasome complex in the generation of the desired immune response (Dinarello, 1999, Gracie 
et al., 2003, Schmitz et al., 2005, Sharp et al., 2009). This multi-molecular complex controls the 
activity of the interleukin (IL) converting enzyme, caspase-1. The presence of endogenous signals 
such as pathogen-associated stimuli (by Toll-like receptors) and high energy (in the form of ATP), 
have been hypothesised to lead to the activation of the NALP3 inflammasome which results in the 
conversion of inactive pro-caspase1 to form the active caspase1 (Sutterwala et al., 2006a, Sutterwala 
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et al., 2006b, Petrilli et al., 2007, Muruve et al., 2008, Stutz et al., 2009). This enzyme is able to 
proteolytically cleave pro-forms of IL1β, IL-18 and IL-33 in order to form these bio-active cytokines. 
Both IL-1β and IL-18 are highly potent proinflammatory cytokines (Dinarello, 1999, 2000) which are 
involved in the induction of interferon-gamma (IFN-γ) expression in order to promote the 
differentiation of type 1 T-helper cells (Th1). However, a classical Th2 cytokine IL-33, which is a 
member of the same family of cytokines as IL-1β and IL-18, is able to promote immune responses by 
type 2 helper T-cells (Th2) as shown by Schmitz and colleagues in 2005 (Schmitz et al., 2005). This 
evidence and results from these studies therefore suggested that caspase-1 and the NALP3 
inflammasome is critical as part of the immune response generated by these liposome vaccine 
formulations.  
 
 
Figure 4-35. IL-1β (A), IL18 (B) and IL33 (C) production from excised leg muscle from the SOI derived from 
mice immunised with Ag85B-ESAT6-Rv2660c (H56) in combination with either DDA/TDB or DSPS/TDB, as 
well as negative control groups (H56 and PBS respectively). Mice received 3 injections with 2-week intervals; 
muscle from the SOI was collected at day 49 upon termination of the study. Leg muscle was excised, digested 
and homogenised. Cytokines were measured from muscle supernatants using sandwich ELISAs. Results 
represent the mean of 5 mice per group ± SD. Significance between experimental groups was measured by 
one-way ANOVA (*** p<0.001) as compared to DSPS/TDB:H56 immunised mice.  
 
4.4. Conclusions 
 
The results in this chapter show that by changing the main lipid constituent within the formulation 
to DSPS instead of DDA this led to liposomes with slight reduction in vesicle size and reversal in 
surface charge to highly negative (anionic) respectively. Upon addition of protein antigen, post lipid-
film hydration (LH), to cationic DDA/TDB and anionic DSPS/TDB liposomes, this resulted in antigen 
loading when both vaccine components are opposing in charge, which suggests electrostatic binding. 
This antigen loading was reflected by subsequent changes in vesicle characteristics, with increasing 
vesicle size and neutralisation of the surface charge being measured. This binding at the liposome 
0
5
10
15
20
DDA/TDB:H56 DSPS/TDB:H56 H56 PBS
C
yt
o
ki
n
e
 c
o
n
ce
n
tr
at
io
n
  
(n
g/
g 
ti
ss
u
e
) 
IL1β IL18 IL33*** 
*** 
164 
 
surface was confirmed by means of trypsin digestion, with increasing trypsin concentration leading 
to significant reduction in antigen loading. In simulated in vivo conditions these formulations were 
able to efficiently retain antigen therefore confirming that these formulations remain stable. Further 
short term stability studies have also confirmed that these liposomes maintain constant vesicle size 
and surface charge characteristics over a 28-day period at storage temperatures of 4 °C and 25 °C. 
The biodistribution profile of these vaccine formulations was investigated with cationic liposome 
surface charge resulting in greater retention at the SOI, and hence controlled drainage to the local 
popliteal lymph node (PLN). Whereas anionic liposomes are non-depot forming and hence drain 
more rapidly to the PLN; which was disadvantageous in the induction of Th1 immune responses. 
Antigen, when opposing in charge to the delivery system, was efficiently retained by liposomes 
therefore causing deposition of antigen at the SOI and, hence, subsequent drainage to the PLN. 
Liposome retention was confirmed by increased pontamine blue staining at the SOI, which is a 
measure for influx of macrophages and monocytes to this site. Therefore upon the formation of a 
liposome ‘depot at the SOI this subsequently resulted in the influx of monocytes and innate immune 
cells to this site. 
These results correlated with immunisation studies in which depot-forming cationic DDA/TDB:H56 
induce strong cell-mediated Th1 responses (Perrie et al., 2013) both at the spleen and SOI, as well as 
inducing low levels of humoural immunity. However, non- depot forming anionic DSPS/TDB:H56 
liposomes resulted in a reduction in Th1 cytokine production as well as a slight increase in Th2 
immune responses. Overall these studies have demonstrated a lack of interaction between delivery 
system and antigen, in combination with a reduction in the ‘depot effect’ (for DSPS/TDB liposomes) 
leads to less efficient antigen delivery and consequently a reduced T-cell response with these levels 
representing very low T-cell activation in general. As a result, DSPS/TDB is not able to induce the pro-
inflammatory signals, which therefore supported TDB in modulating the antigen presenting cells to 
induce T-cell responses. 
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Chapter 5: The role of liposome preparation method in vaccine delivery and 
formulation 
 
 
 
Some of the results presented in this chapter have been published in the paper: 
Wilkinson A., Kaur R., Korsholm K.S., Christensen D., Mohammed A.R., Perrie Y. “Investigating the 
role of liposome preparation method on ability of vaccine formulations to form an antigen ‘depot’ at 
the site of injection and the subsequent effect on the generated immune response” (Manuscript in 
preparation). 
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5.1. Introduction 
 
Since the initial discovery of liposomes by Bangham and co-workers in 1965 (Bangham et al., 1965), 
a variety of different methods have been developed for the preparation and formulation of 
liposomes. Due to the flexibility and versatility of liposomes, drug or vaccine can become adsorbed 
to the liposome surface, reconstituted within the membrane bilayer, encapsulated in the aqueous 
interior of the vesicle or covalently conjugated to the liposome surface (Watson et al., 2012). This 
apparent versatility of these vesicles allows proteins, nucleic acid and antigens of all types to be 
incorporated within liposome formulations; however, the ability to deliver these moieties can be 
dictated by a number of factors including antigen size and liposome surface charge (as studied 
during Chapter 4). In relation to this investigation, the literature is very mixed in terms of whether 
localisation of a vaccine within the liposomal system impacts on the subsequent immune response. 
Many initial studies in this field have shown that both antigen surface adsorption to, and 
encapsulation within liposomes induce T-cell and antibody responses to associated protein antigens 
(Gregoriadis et al., 1987, Shahum and Therien, 1995, Fortin et al., 1996). More recent studies have 
shown that protein antigens adsorbed to the surface of cationic DDA/TDB liposomes led to the 
induction of strong cell-mediated and enhanced antibody responses (Henriksen-Lacey et al., 2010a, 
Henriksen-Lacey et al., 2011b). Initial studies have been carried out to investigate the role of antigen 
entrapment, compared to surface adsorption, in association with cationic DDA/TDB liposomes (Kaur 
et al., 2011). However, in order to further understand the effect of antigen localisation more further 
investigations need to be carried out. 
Therefore to study the impact of antigen entrapment within liposomes, a modified double emulsion 
solvent evaporation method was investigated for the formulation of liposomes with protein antigen 
added to the inner water phase during the preparation process (Nordly et al., 2011c). The premise of 
this present study was to formulate a stable adjuvant composed of protein antigen (H56 and 
lysozyme) and the promising adjuvant system termed DDA/TDB (or CAF01) as well as the anionic 
liposome system, DSPS/TDB. This method is advantageous as heating above the phase transition 
temperature (for the main lipid in the formulation) is avoided (Nordly et al., 2011c). The use of 
ethanol in the outer water phase of the preparation process has been hypothesised to destabilise 
the lipid membrane and help in the formation of liposomes (Maurer et al., 2001) with associated 
antigen or immunostimulatory Toll-like Receptor (TLR) agonists, such as polyI:C (Nordly et al., 
2011c). Therefore, the aim was to formulate antigen within liposome adjuvants, prepared as double 
emulsion (DE) vesicles. 
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In comparison, the previously established dehydration-rehydration vesicle (DRV) method 
(Gregoriadis et al., 1987) was investigated for the same liposomal adjuvants with the aim of 
entrapping protein antigen within the delivery system. The advantage of this method is its relative 
simplicity combined with the fact that a range of moieties (protein, nucleic acid and antigens) can 
become efficiently incorporated within the delivery system (Gregoriadis et al., 1987, Perrie and 
Gregoriadis, 2000, Kaur et al., 2011). 
 
5.2. Aim and Objectives 
 
The aims of the work reported within this chapter was to compare liposomal adjuvants prepared by 
different preparation methods which can impact on the location of antigen within the liposomal 
system, and thus potentially influencing their ability to co-deliver the antigen and liposomes to 
appropriate antigen presenting cells. Therefore the objectives of this work were to: 
 physicochemically characterise cationic DDA/TDB and anionic DSPS/TDB liposomes prepared 
by DRV and DE methods, 
 compare their antigen release kinetics in simulated in vivo conditions and their shelf-life 
stability at 4 °C and 25 °C temperature conditions, 
 measure the ability of these liposome formulations in combination with various antigens 
(cationic lysozyme or anionic H56 TB antigen (Ag85B-ESAT6-Rv2660c)) to form an antigen 
depot during in vivo biodistribution studies, 
 compare the immunological activity of these adjuvant systems and thus consider the impact 
of antigen location in their efficacy. 
 
5.3. Results and Discussion 
 
In this chapter, both cationic DDA/TDB and anionic DSPS/TDB liposome delivery systems were 
prepared using two different methods: the dehydration-rehydration vesicle method and the double 
emulsion solvent evaporation method, in order to understand how antigen-liposome interactions 
and localisation of antigen with the delivery system (surface adsorption against entrapment) 
contributed to the measured liposome characteristics, antigen loading and antigen release kinetics. 
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5.3.1. Investigating the effect of liposome preparation method on the physicochemical 
characteristics of liposomal adjuvants 
 
As described in Chapter 4, the lipids DDA and DSPS were combined in an 8:1 molar ratio with TDB in 
order to formulate DDA/TDB and DSPS/TDB liposomes respectively.  
Dehydration-rehydration vesicles for both cationic DDA/TDB and anionic DSPS/TDB liposomes were 
prepared and various liposome characteristics were obtained, both without antigen and with the 
anionic H56 or cationic lysozyme antigen (at the in vivo dose of 0.1 mg/mL). The addition of H56 or 
lysozyme to cationic DDA/TDB liposomes at the concentration used, resulted in no significant 
difference in vesicle size, polydispersity or zeta potential (Figure 5.1). For DSPS/TDB liposomes, again 
there was no significant increase in vesicle size upon addition of protein to these delivery systems; 
however, there was a significant (P < .0.05) reduction in zeta potential (from ~ -60 mV to -44 mV; 
Figure 5.1). When comparing these DRV systems with the previously formulated MLV liposomes 
(prepared by the lipid-film hydration method, where the antigen was adsorbed to the liposomal 
surface), at equivalent concentrations, these MLV were also shown to be similar in size (Chapter 4; 
Section 4.3.2.1).  
DDA/TDB and DSPS/TDB liposomes prepared by the double emulsion method were also 
characterised, both as ‘empty’ liposomes and with the addition of H56 antigen or lysozyme (at an in 
vivo dose of 5 µg or 0.1 mg/mL respectively; Figure 5.1). For cationic DDA/TDB, upon addition of 
anionic H56 antigen there was a significant effect (P < 0.05) on liposome characteristics between 
empty vesicles and antigen-loaded vesicles with an increase vesicle size from 300-350 nm to around 
490 nm and a reduction in zeta potential from 40-50 mV to around 30 mV (Figure 5.1). However 
DSPS/TDB liposomes formulated by the double emulsion method displayed no significant change in 
size on addition of H56; ‘empty’ vesicles were in the region of 240 nm and a zeta potential of around 
– 50 mV (Figure 5.1) and upon addition of H56 antigen at an in vivo dose of 5 µg), there was no 
significant change. Whereas upon addition of a lysozyme to anionic DSPS/TDB double emulsion 
liposomes there was a significant increase (P < 0.05) in the size of these vesicles (compared to empty 
liposomes) with their sizes increasing from ~ 240 nm to ~ 440 nm (Figure 5.1A). Considering, the zeta 
potential of these anionic DSPS/TDB double emulsion liposomes, the anionic zeta potential of these 
systems was masked by the addition of antigen and increased to -25.4 ± 0.9 mV (Figure 5.1B).  
When comparing empty DDA/TDB and DSPS/TDB liposomes formulated by the DE method (~350 nm 
and 240 nm respectively), these vesicles were significantly smaller in size (P < 0.001) compared to 
their DRV counterparts and previously characterised MLVs (Chapter 4). This suggested that liposome 
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preparation method played a significant role in the assembly of these liposomal adjuvants as all 
vesicles were prepared at the same lipid/TDB ratio. 
During the DRV preparation method, the rehydration of the freeze-dried lipid/protein cake resulted 
in the protein antigen becoming part-associated within the liposome delivery system (within the 
membrane bilayer) rather than just adsorbing at the liposome surface. Therefore, charge-related 
electrostatics can still play a role in the association between antigen and liposome. This method 
began with the preparation of empty small unilamellar vesicles (SUV) before mixing of the protein 
antigen which was required to be entrapped. Post freeze-drying of the vesicles, they were 
rehydrated using water. As the vesicles become increasingly concentrated during the dehydration 
(freeze-drying) procedure, this leads to their flattening and fusion leading to the formation of 
multilamellar planes (Gregoriadis et al., 1987) in which protein antigen can become bound or 
attached (Kaur et al., 2011). Therefore upon hydration this results in the formation of larger vesicles, 
with entrapped and bound antigen. The results in Figure 5.1 suggested that as the liposomes were 
able to retain their size, following addition of protein antigen at the same concentration, this may be 
reflected with entrapment of antigen within the delivery system. There were also no resulting 
changes in vesicle characteristics following surface adsorption of antigen to the delivery system (at 
these low protein concentrations). However upon addition of higher concentrations of protein, 
measured changes in vesicle characteristics were observed such as the increase in vesicle size which 
was due to higher antigen association at the liposome surface (as described previously in Chapter 4) 
which could also cause ‘masking’ of the cationic surface charge as described in the previous 
literature following association of nucleic acids with the liposome delivery system (Moghaddam et 
al., 2011). However at these low concentrations used in Figure 5.1, there were no significant changes 
in vesicle characteristics possibly due to the high cationic lipid/protein ratios used, therefore no 
significant highlighted differences were noted for these formulations.  
It was hypothesised that the changes in vesicle characteristics were more notable for DE 
formulations, upon addition of oppositely-charged antigen, (at this lower protein concentration) due 
to the initial smaller size of these vesicles noted (Figure 5.1A) as has been shown also in the previous 
literature (Milicic et al., 2012). So upon addition of antigen to the formulation there was a smaller 
surface area of the delivery system to associate onto, therefore resultant changes in vesicle 
characteristics were measured. Therefore, these smaller vesicles were less able to incorporate 
antigens of the opposite charge to the vesicles without some aggregation effects being noted. 
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Figure 5-1. Vesicle size (A) and zeta potential (B) for cationic DDA/TDB and anionic DSPS/TDB liposomes with 
or without the addition of protein antigen at a concentration of 0.1 mg/ml (H56 or lysozyme). Results are the 
mean of triplicate experiments ± SD. Significance between various liposome characteristics was measured by 
one-way ANOVA (*** p<0.001; * p<0.05). 
 
To consider the ability of these systems to carry and deliver antigen, their loading capacity was 
compared using the above outlined antigen doses. These results showed that the antigen loading 
was relatively low for all DE formulations tested (Table 5.1), with oppositely charged liposome and 
antigen displaying higher levels of initial antigen association (DDA/TDB:H56 and 
DSPS/TDB:Lysozyme: ~ 50 %; DDA/TDB:Lysozyme and DSPS/TDB:H56: ~ 18 %). In contrast, all DRV 
formulations showed enhanced loading in comparison to their DE-counterparts (Table 5.1) with 
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oppositely charged systems showing around 90 % antigen loading and similarly charged systems 
showing loading levels of ~ 50 %.  
The results in Table 5.1 suggest that the choice of liposome preparation method has a notable effect 
on the subsequent ability to load protein antigen and is not only controlled by electrostatic 
interactions. Also, the higher levels of loading (~ 50 %) of antigen (which was similar in charge to 
delivery system) suggested that antigen may become entrapped within the delivery system as has 
been described previously for the delivery of DNA within liposomes of varying composition (Perrie 
and Gregoriadis, 2000, Perrie et al., 2001). The DE method was suggested to give lower levels of 
antigen loading for all formulations tested as a result of this method of preparation, in which 
sonication was used during liposome formulation therefore this may have affected antigen which 
was not entrapped within the delivery system (Nordly et al., 2011c). During previous studies using 
DE-formulated liposomes the antigen was merely surface-associated to preformed liposomes which 
simplified the preparation process as otherwise care needs to be taken to circumvent denaturation 
and degradation of the antigen during the liposome preparation process (Nordly et al., 2011c). 
Table 5-1. Antigen loading values for double emulsion and dehydration-rehydration vesicles for DDA/TDB 
and DSPS/TDB liposomes. Antigen (H56 or lysozyme) was added at a concentration of 0.1 mg/mL (or 5 µg per 
dose) during the preparation process. Significance, in comparison to LH-prepared counterparts, was measured 
by one-way ANOVA (*** p<0.001). 
 Antigen loading (% of initial amount used) 
Formulation DE DRV LH 
DDA/TDB:H56 49.7 ± 10.6 (***) 88.7 ± 1.6 77.3 ± 4.6 
DDA/TDB:Lysozyme 18.2 ± 7.9 44.8 ± 0.7 (***) 20.3 ± 5.2 
DSPS/TDB:H56 17.0 ± 10.7 47.8 ± 6.1 (***) 27.9 ± 7.1 
DSPS/TDB:Lysozyme 55.6 ± 3.6 (***) 90.3 ± 0.5 82.6 ± 3.5 
 
To consider if the antigen loading recorded in Table 5.1 represented intact protein, or if degradation 
was occurring, the stability of protein associated with vesicles produced by the double emulsion 
solvent evaporation method and the dehydration-rehydration vesicle method was assessed by SDS-
PAGE (Figure 5.2). These results suggest potentially lower levels of protein noted for the DE 
liposomal system (Table 5.1) which may be a result of sonication used during this procedure, indeed 
subjecting ‘free’ antigen to sonication resulted in complete destruction of the protein (Figure 5.2; 
Lane 5) and this may be the reason for the reduced antigen loading noted for the DE formulations 
compared to their DRV counterparts. However at these protein concentrations used in this study, 
the intensity of protein bands were similar upon detection using SDS-PAGE (Figure 5.2). 
 
172 
 
 
Figure 5-2. SDS-PAGE gel to represent the stability of liposome-associated protein for vesicles produced by 
the double emulsion method and DRV method. Lane 1; Pre-stained protein marker; Lane 2 - DE DDA/TDB:H56 
post-formulation; Lane 3 – DRV DDA/TDB: H56 Liposome post-formulation; Lane 4 – Free H56; Lane 5 – H56 
after sonication. 
 
5.3.2. Stability of DRV and DE-prepared formulations, with and without entrapped antigen 
 
The stability of liposomes is a crucial factor in the development and formulation of novel vaccine 
delivery systems. With this in mind, both cationic DDA/TDB and anionic DSPS/TDB liposome vaccine 
delivery systems were placed into stability trials in order to assess the time development of 
characteristics (size and zeta potential) over a 28-day period. These liposome delivery systems were 
prepared by either the DRV or the DE method, and were stored at 4 °C or 25 °C temperature storage 
conditions in an aqueous format.  
 
Cationic DDA/TDB liposomes prepared by the DRV method displayed an initial vesicle size of ~ 550-
600 nm and a zeta potential of between 50-60 mV, both with and without H56 antigen (Figure 5.3A). 
Throughout the time period of this study there was a general trend of increasing size over time 
noted for all formulations, however these changes were not deemed significant. For the vesicle 
surface charge (as represented by the zeta potential) there was no obvious trend between 
formulations, but fluctuations were noted (Figure 5.3B). DSPS/TDB liposomes prepared by the DRV 
method, vesicles had an initial size of ~ 500 nm (with and without H56 antigen; Figure 5.3C) a zeta 
potential of -70 mV and -50 mV with and without H56 antigen respectively (Figure 5.3D). There were 
no significant increases in vesicle size (over the 28 day period) with empty DRV DSPS/TDB vesicles 
showing a vesicle size of ~ 600 nm and 700 nm (at storage temperatures of 4 °C and 25 °C 
respectively) by day 28. However, antigen-loaded DRV vesicles maintained a fairly constant size 
throughout this study. The vesicle charge (as represented by zeta potential) also remained constant 
up until day 28, with no significant differences between the initial vesicle characteristics for all 
formulations tested. 
   1         2          3         4         5       
H56 antigen 
10 kDa 
20 kDa 
30 kDa 
50 kDa 
40 kDa 
15 kDa 
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Cationic DDA/TDB liposomes prepared by the DE method were similarly studied. At the initial time 
point (day 0), these vesicles were either 230 nm or 480 nm in size, with and without H56 antigen 
respectively (Figure 5.3E). Antigen-loaded DE vesicles were significantly larger in size than their 
‘empty’ counterparts (P < 0.001), which was primarily due to antigen association with the liposome 
delivery system (as described in previous characterisation studies in Section 5.3.1). During the time 
period of this study, antigen-loaded DE vesicles did not show a significant change in size; however, 
empty DE vesicles significantly increased (P < 0.01) in vesicle size to ~ 400 nm (by day 28; Figure 
5.3E). Considering their zeta potential, cationic DDA/TDB DE vesicles gave initial values 50-60 mV 
with no significant difference noted if antigen was present or not within the formulation. 
Throughout the time period of this study, antigen-loaded cationic DE vesicles showed a significant (p 
< 0.001) reduction in zeta potential with values of ~ 30 mV being measured after day 28 (Figure 
5.3F). So these liposome adjuvants showed reduced zeta potential following storage. The zeta 
potential for empty DE vesicles did not significantly change following storage at 4 °C or 25 °C over 
this time period (Figure 5.3F). Anionic DSPS/TDB liposomes prepared by the DE method displayed an 
initial vesicle size of ~ 250 nm, both with and without H56 antigen and did not significantly change 
over the period of the study (Figure 5.3G). At the initial time point (day 0) in terms of zeta potential, 
the anionic DE DSPS/TDB liposomes displayed values of -40 mV and -50 mV (with and without H56 
antigen respectively) with no significant difference noted if antigen was present or not within the 
formulation and throughout the time period of this study (between day 0 and day 28), antigen-
loaded DSPS/TDB vesicles showed no significant changes with a zeta potential of around – 40 mV 
being measured both at storage temperatures of 4 °C and 25 °C. However empty DSPS/TDB vesicles 
showed a reduction in zeta potential, following storage at 25 °C and 4 °C, with values of -26 mV (P < 
0.01; compared to day 0) and -35 mV being measured respectively (Figure 5.3H). 
The stability of TDB-containing liposomal adjuvants was previously shown in Chapters 3 and 4. 
However during this section the effect of preparation method on the stability of liposome 
formulations was further investigated. These stability studies have showed that DRV formulations 
were more suitable, in comparison to their DE-counterparts, for storage in an aqueous format over 
an initial 28 day time period both at 4 °C and 25 °C temperature conditions. This was further 
demonstrated in Figure 5.4, as DRV formulations remained homogenous and exhibited minimal 
phase separation even after a 28-day storage period (Figure 5.4). Following storage over a 28-day 
period, DE-formulations are more prone to changes in vesicle characteristics therefore long term 
storage in the aqueous phase would not be suitable for these formulations. Liposome storage in the 
aqueous format may thus have an effect on the inherent instability of these formulations as has 
been suggested previously (Davidsen et al., 2005). Therefore a number of liposome vaccine 
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formulations used in the clinic are in a freeze-dried format (Mohammed et al., 2006). In order to 
enhance vesicle stability during the freeze-drying process a number of cryoprotectants including 
saccharides (such as sucrose, trehalose, and lactose) and their derivatives can be employed 
(Mohammed et al., 2006, Christensen et al., 2008, Mohammed et al., 2010). 
 
  
  
  
Figure 5-3. Time development of the average size (A, C, E and G) and zeta potential (B, D, F and G) of 
DDA/TDB and DSPS/TDB liposomes prepared by either the DRV or DE methods (both with and without H56 
antigen at in vivo dose of 5 μg) following storage at 4 ˚C and 25 ˚C. Results are the mean of triplicate 
experiments ± SD. Significance was measured by one-way ANOVA (** p<0.01). 
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Figure 5-4. DDA/TDB and DSPS/TDB liposome samples stored into glass vials were prepared by the (A) 
double emulsion (DE) solvent evaporation method or the (B) dehydration-rehydration vesicle (DRV) method 
and were stored for 28 days at 4 ˚C and 25 ˚C. 
 
5.3.3. Antigen release from liposomal formulations in simulated in vivo conditions 
 
During initial experiments, the antigen loading and release of both H56 and lysozyme from double 
emulsion vesicles for DDA/TDB and DSPS/TDB liposomes was quantified directly both in simulated in 
vivo conditions (FCS/Tris; 50/50 v/v) and control conditions (Tris buffer; 10 mM, pH 7.4). In order to 
quantify loading, antigen (H56 or lysozyme) was radiolabelled with 125I before being formulated with 
or within the delivery system. At a number of time points, following centrifugation, the antigen 
loading was determined by calculating the percentage of radiolabelled antigen found within the 
liposome pellet fraction. 
These results showed that the antigen loading was low for all DE formulations tested (as described 
previously in Table 5.1), with oppositely charged liposome and antigen displaying significantly higher 
levels (P < 0.001) of initial antigen association (Figure 5.5). As shown previously for MLV formulations 
(Chapter 4) there was an initial release of antigen from all liposome formulations (irrespective of 
antigen charge), before the stabilisation of antigen release after around 5 hours (Figure 5.5).  
During further studies, the antigen loading and release kinetics of the anionic H56 TB antigen and 
the cationic protein lysozyme from dehydration-rehydration vesicles for cationic DDA/TDB and 
B A 
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anionic DSPS/TDB liposomes were quantified directly both in simulated in vivo conditions (FCS/Tris: 
50/50 v/v; 37 °C) and control conditions respectively (Tris 10 mM; pH 7.4; 37 °C). These initial results 
showed that the levels of antigen loading were increased upon binding between oppositely charged 
liposome and antigen components [DSPS/TDB:Lysozyme and DDA/TDB:H56 respectively) with levels 
of antigen loading measured between 85-90 % (Figure 5.6). So, antigen becomes bound with the 
liposome delivery system upon the rehydration of the freeze-dried lipid/protein mixture. These 
results showed similar levels of antigen release from all formulations tested in simulated in vivo 
conditions compared to control conditions.  
However a general trend showed that antigen release for DRV formulations was significantly lower 
compared to their DE-prepared counterparts (P < 0.01), which may be ascribed to more efficient 
entrapment of antigen within DRV-formulations, compared to lower levels of loading by DE-
formulations. However as described previously, following the initial burst release of antigen from the 
formulation this H56 antigen release stabilised over time with the remaining antigen staying with the 
delivery system. 
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Figure 5-5. Antigen loading (A, C) and release profile (B, D) from double emulsion vesicles (DEs) for DDA/TDB 
and DSPS/TDB liposomes when stored under simulated in vivo conditions (A and B - 50 % FCS in Tris Buffer, 
10 mM pH 7.4; 37 ˚C) and control conditions (C and D - 10 mM Tris buffer pH 7.4; 37 ˚C). Results are the mean 
of triplicate experiments ± SD. Significance was measured by one-way ANOVA (*** p<0.001; ** p<0.01) 
compared to the initial antigen loading values at 0 h 
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Figure 5-6. Antigen loading (A, C) and release profile (B, D) from dehydration-rehydration vesicles (DRV) for 
DDA/TDB and DSPS/TDB liposomes when stored under simulated in vivo conditions (A and B - 50 % FCS in 
Tris Buffer, 10 mM pH 7.4; 37 ˚C) and control conditions (C and D - 10 mM Tris buffer pH 7.4; 37 ˚C). Results 
are the mean of 3 experiments ± SD. Significance was measured by one-way ANOVA (*** p<0.001) compared 
to the initial antigen loading values at 0 h.  
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The antigen release from liposome formulations was studied in order to consider if antigen 
remained associated with the liposome delivery system, especially under simulated in vivo 
conditions. For the use of liposomes as effective vaccine delivery systems it is a prerequisite for 
antigen to remain associated or bound to these vesicles. With this in mind, Foetal Calf Serum (FCS) 
was used to simulate the in vivo environment (Henriksen-Lacey et al., 2010a), in order to promote to 
conditions more similar to what liposomes may encounter upon administration in vivo. In general 
terms, an initial burst release of antigen was observed under this simulated environment before 
antigen release stabilised over the time period of these studies (Figures 5.5 and 5.6).  
For both DRV and DE vesicles; when opposing in charge with protein antigen this led to higher levels 
of initial antigen association to the liposome delivery system. However when opposing in charge, 
MLV (Chapter 4) and DRV liposomes (for cationic DDA/TDB and anionic DSPS/TDB) have been shown 
to display higher levels of antigen adsorption compared to their double emulsion (DE) vesicle 
counterparts. The mechanism of action for antigen association with liposome delivery systems 
therefore varied depending on the method of liposome preparation. During this chapter and 
previous studies for multilamellar vesicles (Chapter 4), adsorption of antigen to the liposome surface 
has been proposed to be the mechanism of action for this antigen association (Henriksen-Lacey et 
al., 2010c, McNeil et al., 2011). For DRV, antigen can associate both at the liposome surface and can 
bind the cationic charges within the membrane bilayer itself as discussed previously (Perrie and 
Gregoriadis, 2000), rather than solely at the liposome surface for LH-prepared formulations 
(Henriksen-Lacey et al., 2010c). 
The use of the DE method (Nordly et al., 2011c) has proven to be the least effective in terms of 
antigen-liposome association. For this preparation method, electrostatic interactions between 
oppositely charged liposome and antigen still played a role (Henriksen-Lacey et al., 2010c) in this 
association with higher entrapment values being associated with oppositely charged liposome and 
antigen (DDA/TDB:H56 and DSPS/TDB:Lysozyme).  
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5.3.4. Investigating antigen localisation within the liposomal adjuvants 
 
In terms of DDA/TDB and DSPS/TDB, given the respective cationic and anionic nature of these 
vesicles it is likely that antigen may become attached at the liposome surface as well as incorporated 
within the delivery system. In order to establish the localisation of antigen in regards to the delivery 
system both DE and DRV liposome vaccine formulations (in combination with either anionic H56 or 
cationic lysozyme) were subjected to increasing concentrations of trypsin and subsequently the 
antigen retention was measured.  
Using the anionic H56 antigen, for cationic DRV vesicles this resulted in similar antigen loading values 
irrespective of the concentration of trypsin (Figure 5.7) as has been shown by SDS-PAGE (Figure 5.8) 
and loading of radiolabelled antigen which demonstrated that antigen was becoming entrapped 
within the delivery system due to this preparation method. A similar trend was also noted for all 
other formulations in this study. However for cationic DE liposome formulations, SDS-PAGE and 
antigen retention data has shown that increasing the concentration of trypsin resulted in a 
significant reduction in antigen loading (P < 0.01) therefore this showed that antigen was localised at 
the surface of the liposome delivery system (Figure 5.7) as well as entrapped within the 
formulations, albeit at lower levels. 
Whilst using the cationic protein, lysozyme in combination with anionic DSPS/TDB this led to the 
same findings in which increasing the concentration of trypsin had a greater effect on DE-liposome 
vaccine formulations (P < 0.001) when compared to their DRV counterparts as again was confirmed 
by SDS-PAGE (Figure 5.8) and tracking of radiolabelled antigen with the formulation (Figure 5.7). This 
showed that antigen was located at the liposome surface, as well as entrapped within the delivery 
system depending on the method of liposome preparation.  
When analysing the data for DDA/TDB:Lysozyme (+/+) and DSPS/TDB:H56 (-/-), these formulations 
offered lower levels of initial antigen loading when prepared by both DRV and DE methods (Figures 
5.7). However, the same trend was present as described previously, in the fact that upon exposure 
to increasing concentrations of trypsin, DRV formulations retained more antigen than their 
respective DE counterparts. 
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Figure 5-7 Trypsinisation Studies showing antigen loading (A and C) and retention (B and D) for cationic 
DDA/TDB (A and B) and anionic DSPS/TDB formulations. Antigen (H56 or lysozyme) is radiolabelled and 
added at a dose concentration of 5 μg (0.1 mg/mL). Vaccine formulations were subjected to increasing 
concentrations of trypsin (0, 100, 200 and 400 µg/mL) and % antigen loading was determined. Results are 
the mean of triplicate experiments ± SD. Significance was measured by one-way ANOVA (*** p<0.001; ** 
p<0.01) compared to the initial antigen loading values at 0 h. 
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Figure 5-8. SDS-PAGE analysis in order to investigate the effect of trypsinisation on antigen loading and 
localisation in regards to the delivery system. Blue arrows indicate increasing concentrations of trypsin (0, 100 
and 400 µg/mL). 
 
5.3.5. Stability of radioactive markers within liposome formulations in order to investigate 
membrane stability 
 
Liposomes (cationic DDA/TDB and anionic DSPS/TDB) were prepared by either the dehydration-
rehydration vesicle method or the double emulsion solvent evaporation method, with the 
incorporation of trace amounts of 3H-Cholesterol (0.17 nM). Dialysis was used to study the retention 
of 3H-Cholesterol within the liposome membrane. At various time points (1h, 3h, 5h, 18h, 48h and 
96h) over a 96 hour study period, 1 mL aliquots of dialysis media were removed and the amount of 
3H present were measured. As described previously with the lipid-film hydration method, only very 
low levels of loss of 3H-Cholesterol were noted (Figure 5.9). These results suggested that liposomes 
prepared by the DRV and DE methods respectively were stable and these radiolabelled liposome 
formulations were taken forward into in vivo biodistribution studies. 
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Figure 5-9. Membrane stability of DDA/TDB and DSPS/TDB liposomes prepared by the dehydration-
rehydration vesicle method (A) and double emulsion method (B) were studied using a trace amount of 
3
H-
Cholesterol. Results express the % of the original 
3
H-Cholesterol dose added to liposomes that was detected 
in the dialysis buffer over a 96 hr time period. The samples were stored at 37 °C in 50 % FCS. Results denote 
the mean of triplicate experiments ± SD. 
 
5.3.6. Biodistribution studies: the effect of preparation method  
5.3.6.1. Determination and quantification of vaccine retention at the injection site 
 
To determine the role of liposome preparation method on the antigen (and liposome) depot-effect 
at the SOI, DDA/TDB liposomes were produced with the inclusion of 3H-Cholesterol in the bilayer 
membrane and 125I-labelled antigen (H56 or lysozyme) as previously outlined (Chapter 4). The SOI 
and various other tissues were collected and the percentage of the administered dose (% dose) 
quantified.  
These results (Figure 5.10) showed that irrespective of preparation method (DE or DRV), cationic 
liposomes have a notable advantage in terms of liposome retention at the vaccination site with 
around 85 % (at day 1 p.i) of the liposome dose recovered at the SOI (when combined with anionic 
H56) or 55-60 % (when combined with cationic lysozyme) at day 1. This difference may be attributed 
to the antigen which is associated with the delivery system. At subsequent time points, days 4 and 
14 p.i, there was a decrease in recovery of the injected dose; however, around 20 % of the injected 
dose was still recovered at day 14 p.i. This strong retention of cationic liposomes at the SOI is 
primarily due to interactions between cationic liposomes with negatively-charged serum proteins at 
the SOI through electrostatic-mediated interactions, therefore cationic DDA/TDB form a ‘depot’ at 
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the vaccination site (Henriksen-Lacey et al., 2010a). In comparison, irrespective of the preparation 
method, there was significantly lower retention (P < 0.01) of anionic DSPS/TDB liposome vaccine 
formulations (around 40 %, 15 % and 5 % at days 1, 4 and 14 p.i respectively) which showed that 
these liposomes are removed/drain faster from the vaccination site which is due to their anionic 
nature meaning they do not interact with interstitial proteins present at the injection site. Therefore, 
this will lead to reduced retention at the SOI, therefore a liposome ‘depot’ was not formed. These 
results suggested that for liposome formulations, the method of preparation had no significant 
effect on the subsequent ability to form a depot at the injection site. 
When considering the retention of antigen at the SOI this was not significantly changed due to the 
method of liposome preparation (Figure 5.10). However electrostatic interactions between 
oppositely-charged liposome and vaccine antigen components resulted in increased antigen dose 
retention at the SOI as has been shown in previous studies (Henriksen-Lacey et al. 2010a) and in 
Chapter 4 of this thesis. Delivery of H56 antigen in combination with cationic DDA/TDB liposomes 
(either prepared as DRV or DE) resulted in 60 %, 20% and 4 % recovery of the antigen dose at days 1, 
4 and 14 post-injection (p.i) respectively. Whilst delivery of lysozyme in combination with anionic 
DSPS/TDB liposomes (DE or DRV) gave antigen recovery of 35 % and around 10 % at days 1 and 4 p.i 
respectively, with minimal recovery by day 14 p.i.  
Irrespective of the method of liposome preparation, the co-administration of similarly charged 
liposome and antigen as is the case with DSPS/TDB liposomes in combination with H56, and 
DDA/TDB liposomes in combination with lysozyme, resulted in a significant reduction (P < 0.001) in 
initial antigen retention with around 10-15 % antigen remaining with the delivery system at day 1 p.i 
(Figure 5.10). At days 4 and 14 p.i there was subsequent reduction (P < 0.001) in antigen dose 
retention due to drainage of the dose from the SOI.  
As a negative control, free H56 antigen was delivered i.m into the left quadricep (as for the other 
formulations). Upon recovery, very low levels of antigen retention were measured at the injection 
site at all time points, which therefore indicated the rapid drainage of free antigen from the SOI. This 
data also indicated the importance for a liposome delivery system in order to deliver antigen, as 
antigen can be strongly retained at the SOI when delivered within liposomes.  
Therefore in terms of liposome preparation method, there was no significant effect noted between 
formulations thereby suggesting that antigen localisation does not significantly enhance antigen 
retention at this injection site. 
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Figure 5-10. Biodistribution of vaccine components, liposome and antigen, at the SOI following intramuscular (i.m.) injection of liposome vaccine formulations. Results 
are shown as % dose recovered at the SOI and represent the mean ± SD of 4 mice per group.  
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5.3.6.2. Determination of vaccine drainage to the popliteal lymph node (PLN) 
 
In addition to investigating the ability of cationic DDA/TDB and anionic DSPS/TDB liposomes to retain 
antigen at the SOI, various tissues were assayed and the percentage dose of both liposome and 
antigen components determined. The left popliteal lymph node (PLN) is the local lymph tissue to 
which liposome (and associated antigen) drained to following intramuscular injection into the left 
quadricep. Therefore, this was the primary site at which antigen will be presented to members of 
the T-cell family in order to initiate the immune response.  
The results showed that vesicle charge plays a role in the clearance of liposomes to the local 
popliteal lymph node (PLN) with anionic DSPS/TDB appearing in the PLN faster than cationic 
DDA/TDB liposomes (as described previously in Chapter 4). However by days 4 and 14 p.i, the 
presence of anionic DSPS/TDB liposomes was significantly reduced (P < 0.001) at the PLN. In 
contrast, cationic DDA/TDB liposomes were slowly drained to the PLN at day 1 p.i (which 
corresponds to high liposome retention at the SOI), however by days 4 and 14 p.i the levels of these 
cationic liposomes were increased therefore indicating controlled release and drainage of these 
formulations to the draining lymph node (Figure 5.11) which was significant over the time period of 
this study (P < 0.05). In terms of liposome preparation method (DE vs DRV), there was no significant 
effect on the drainage of either cationic or anionic liposomal adjuvants to the draining PLN over this 
study 
When observing the drainage of antigen to the popliteal lymph node (PLN), in regards to the effect 
of liposome preparation method, there were no significant differences between tested liposome 
vaccine formulations (Figure 5.11). Antigen, when associated with anionic DSPS/TDB, was rapidly 
drained and present in the PLN at day 1 p.i. However, as with liposome dose drainage, this antigen 
was present in significantly lower amounts (P < 0.001) by days 4 and 14 p.i. In contrast, antigen when 
associated with cationic DDA/TDB liposomes was lowly retained at at all three time points however 
H56-adsorbing cationic DDA/TDB liposomes (DRV- and DE-formulated) exhibited controlled release 
with higher amounts of antigen present at day 14 p.i when compared to day 1 p.i. As a control, 
liposome and antigen drainage to the distally located popliteal lymph node (of the uninjected leg) 
were measured, with even lower drainage observed than the PLN, therefore showing that upon i.m. 
injection vaccine is drained to the associated lymph nodes (results  not shown). 
Therefore these studies have suggested that antigen entrapment with the delivery system (as for 
DRV formulations) had no significant effect on the delivery of these liposomal vaccines to the 
draining lymph node. 
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Figure 5-11. Biodistribution of vaccine components, liposome and antigen, at the PLN following intramuscular (i.m.) injection of liposome vaccine formulations. Results 
are shown as % dose per mg tissue from the PLN and represent the mean ± SD of 4 mice per group. Significance was measured by one-way ANOVA (*** p<0.001; * p<0.05) 
compared drainage levels at day 1 p.i 
* 
* 
* 
* 
*** *** *** 
*** 
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This data demonstrated the movement and drainage of liposome (and associated antigen) from the 
SOI to the draining PLN. However antigen entrapment (as for DRV) did not significantly enhance 
vaccine retention at the SOI, as well as delivery to the PLN. The formation of a strong ‘depot’ at the 
injection site (as shown for cationic DDA/TDB formulations), coupled with controlled release of both 
liposome and associated antigen was previously shown to be advantageous in the induction of Th1 
immune responses, as characterised by IFN-γ production and the promotion of strong antibody 
responses (Henriksen-Lacey et al., 2010a, Christensen et al., 2012, Perrie et al., 2013). 
 
5.3.6.3. Monocyte influx at the injection site 
 
Similarly to previous studies carried out within our laboratory, pontamine blue was used as a marker 
for influx of monocytes at the SOI (Henriksen-Lacey et al., 2010a). All liposome vaccine formulations 
induced monocyte infiltration to the vaccination site; however, the kinetics and intensity were 
varied depending on the liposome surface charge and preparation method (Figure 5.12). 
Irrespective of the method of liposome preparation (DE or DRV), post-i.m. injection of H56 antigen 
or lysozyme in combination with cationic liposome formulation DDA/TDB resulted in monocyte 
influx (as shown by blue staining) at the vaccination site (Figure 5.12), which was due to higher 
deposition of the cationic liposomes at the injection site (Figure 5.10). However, irrespective of 
preparation method there was a reduction in infiltration of monocytes, at the SOI after injection of 
lysozyme or H56 antigen co-administered with the anionic DSPS/TDB formulation (Figure 5.12). 
Also irrespective of the method of liposome preparation and antigen location within the vesicles, the 
charge of the liposomes is the key driver for monocyte influx which was shown to play a role in the 
transport mechanism of liposomes (and hence adsorbed antigen) from the vaccination site to the 
draining popliteal lymph node (PLN) due to increased antigen presentation on MHC, thus making 
antigen available to interact with T-cells in order to initiate the immune response (Henriksen-Lacey 
et al., 2010a). 
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Figure 5-12. Liposome preparation method has no dramatic effect of the intensity of blue staining seen at 
the site of injection. However as described previously, following administration of cationic liposomes this 
leads to enhanced staining at this site compared to their anionic counterparts which is due to enhanced 
monocyte influx. Pictures are representative of 4 mice/group and show the quadriceps muscle from the 
vaccine injected leg at day 1 post-injection (p.i). 
 
5.3.7. Immunogenicity of liposomal vaccines-adsorbing H56 antigen 
 
In order to investigate the role of liposome preparation method on the immunogenicity of liposome 
vaccine formulations, a number of vaccine studies were carried out (at Statens Serum Institute) in 
order to show the immune response generated (Th1 response Vs Th2 response). The H56 TB antigen 
was formulated within cationic DDA/TDB and anionic DSPS/TDB liposomes respectively (formulated 
by LH, DRV and DE methods) before intramuscular (i.m.) injection of these vaccine formulations into 
the left quadriceps. During this study a triple homologous vaccination regimen was maintained in 
which each mouse was injected three times at two-weekly intervals (day 1, 15 and 29). 
5.3.7.1. Generation of H56-specific antibody responses 
 
In terms of all antibody responses (IgG1, Ig2a and IgG2b), naive (unimmunised) mice gave no 
responses as would be expected, both at days 13 and 46 (Figures 5.13 to 5.18). Also for H56-
immunised mice, only minimal responses to all antibody isotypes were measured with the general 
trend that liposome-formulated H56 vaccines gave enhanced responses compared to H56 antigen 
alone (Figures 5.13 to 5.18).  
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In terms of liposome preparation method, there was no significant difference in IgG1 antibody 
production between the different preparation types. However, in terms of the production of IgG2a 
and IgG2b antibody isotypes (associated with the Th1 immune response (Mosmann et al., 1986, 
Martin and Lew, 1998)), the antigen location within the vesicles had an impact; either entrapped or 
surface-adsorbed, had an effect on the generated IgG2a and IgG2b antibody responses in the blood 
sera at day 46 p.i (Figures 5.16 and 5.18), with higher initial levels of H56 antigen loading by these 
liposome formulations leading to increased production of these antibodies as has been noted for 
DRV (antigen-entrapped) and LH-prepared (surface-adsorbed antigen) formulations.  
These results also demonstrated a general ‘liposome-charge dependent’ trend in the production of 
all antibody isotypes (IgG1, IgG2a and IgG2b) with cationic DDA/TDB:H56 vaccine formulations 
displaying enhanced antibody titres compared to their anionic DSPS/TDB:H56 counterparts at day 46 
(p < 0.001). This was described previously in Chapter 4 as well as the previous literature that cationic 
formulations showed an advantage in terms of generating increased antibody responses in the blood 
sera (Henriksen-Lacey et al., 2010c) which was ascribed to the higher bioavailability of antigen, thus 
allowing higher antigen-specific antibody titres. Also as would be expected, all antibody titres 
displayed at day 46 were significantly higher (P < 0.001) than at day 13, upon delivery of liposome-
formulated antigen. This was due to these mice having received their three immunisations of the 
liposomal vaccine formulations, therefore they are able to recognise antigen and boost the immune 
response in terms of antibody production. 
Therefore the method of antigen association within the liposomal adjuvant can be a critical 
parameter influencing the immunogenicity of liposomal vaccines as has been reviewed previously by 
Watson and colleagues (Watson et al., 2012) who noted mixed responses noted in terms of whether 
liposome surface-adsorbed antigen or liposome-entrapped antigen displayed higher levels of 
immune responses. The results presented within this section have showed that for H56-adsorbing 
DDA/TDB formulations, DRV and LH-prepared formulations gave higher IgG2a and IgG2b responses 
than their respective DE-counterparts. However, for H56-mixed with DSPS/TDB formulations, 
preparation method seemed to have no impact on the generation of increased antibody responses, 
which was hypothesised to be due to the low antigen-loading ability coupled with the fact that these 
liposomes are unable to form a depot at the SOI (as described previously within this chapter; Section 
5.3.6). In contrast for DE-formulations, there was a general trend for the delivery of H56 vaccine 
antigen with cationic DDA/TDB and anionic DSPS/TDB to have no significant effect on the production 
of all antibody isotypes studied at the day 46 time point (following 3 x i.m. injections). 
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Figure 5-13. Antibody response curves. Blood sera was collected at day 13 and tested for the presence of IgG1 antibodies. (A) shows the effect of preparation method 
for cationic DDA/TDB formulations. (B) shows the effect of preparation method for anionic DSPS/TDB formulations. (C) and (D) show the effect of liposome surface 
charge for DRV and DE formulations respectively. Results are the mean ± SD of 6 mice per experimental group. 
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Figure 5-14. Antibody response curves. Blood sera was collected at day 46 and tested for the presence of IgG1 antibodies. (A) shows the effect of preparation method 
for cationic DDA/TDB formulations. (B) shows the effect of preparation method for anionic DSPS/TDB formulations. (C) and (D) show the effect of liposome surface 
charge for DRV and DE formulations respectively. Results are the mean ± SD of 6 mice per experimental group. 
0
0.5
1
1.5
2
2.5
3
3.5
4
100 10000 1000000 100000000
A
b
so
rb
an
ce
 
Dilution of Blood Sera (Log10) 
Naive
H56
H56 + LH-DDA/TDB
H56 + DRV DDA/TDB
H56 + DE DDA/TDB
0
0.5
1
1.5
2
2.5
3
3.5
4
100 10000 1000000 100000000
A
b
so
rb
an
ce
 
Dilution of Blood Sera (Log10) 
Naive
H56
H56 + LH-DSPS/TDB
H56 + DRV-DSPS/TDB
H56 + DE-DSPS/TDB
0
0.5
1
1.5
2
2.5
3
3.5
4
100 10000 1000000 100000000
A
b
so
rb
an
ce
 
Dilution of Blood Sera (Log10) 
Naive
H56
H56 + DRV DDA/TDB
H56 + DRV-DSPS/TDB
0
0.5
1
1.5
2
2.5
3
3.5
4
100 10000 1000000 100000000
A
b
so
rb
an
ce
 
Dilution of Blood Sera (Log10) 
Naive
H56
H56 + DE DDA/TDB
H56 + DE-DSPS/TDB
A B 
C D 
193 
 
 
 
Figure 5-15. Antibody response curves. Blood sera was collected at day 13 and tested for the presence of IgG2a antibodies. (A) shows the effect of preparation method 
for cationic DDA/TDB formulations. (B) shows the effect of preparation method for anionic DSPS/TDB formulations. (C) and (D) show the effect of liposome surface 
charge for DRV and DE formulations respectively. Results are the mean ± SD of 6 mice per experimental group. 
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Figure 5.16. Antibody response curves. Blood sera was collected at day 46 and tested for the presence of IgG2a antibodies. (A) shows the effect of preparation method 
for cationic DDA/TDB formulations. (B) shows the effect of preparation method for anionic DSPS/TDB formulations. (C) and (D) show the effect of liposome surface 
charge for DRV and DE formulations respectively. Results are the mean ± SD of 6 mice per experimental group. 
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Figure 5-17. Antibody response curves. Blood sera was collected at day 13 and tested for the presence of IgG2b antibodies. (A) shows the effect of preparation method 
for cationic DDA/TDB formulations. (B) shows the effect of preparation method for anionic DSPS/TDB formulations. (C) and (D) show the effect of liposome surface 
charge for DRV and DE formulations respectively. Results are the mean ± SD of 6 mice per experimental group. 
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Figure 5.18. Antibody response curves. Blood sera was collected at day 46 and tested for the presence of IgG2b antibodies. (A) shows the effect of preparation method 
for cationic DDA/TDB formulations. (B) shows the effect of preparation method for anionic DSPS/TDB formulations. (C) and (D) show the effect of liposome surface 
charge for DRV and DE formulations respectively. Results are the mean ± SD of 6 mice per experimental group
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5.3.7.2. Cytokine analysis from ex vivo restimulated splenocytes and lymph nodes 
 
Following the determination of the ability of H56 vaccine antigen, when formulated with cationic 
DDA/TDB and anionic DSPS/TDB liposomes, to induce antibody responses in the blood sera it was 
required to analyse the production of Th1 and Th2-related cytokines from restimulated splenocytes 
and popliteal lymph node cell upon restimulation with previously re-encountered H56 vaccine 
antigen. Upon termination of the experiment, spleens and popliteal lymph nodes (PLN) were 
dissected and collected according to formulation. Following the mashing of these organs, 
splenocytes and lymph node cells were restimulated with PMA/Ionomycin (positive control), media 
only (negative control) or H56 antigen (at concentrations of 0.05, 0.5 and 5 μg/mL respectively). 
Following 72 h incubation at 37 °C, the supernatant was then decanted for use in cytokine ELISA 
assays.  
In order to serve as a positive control, splenocytes and lymph node cells were restimulated with 
PMA/Ionomycin and the cytokine release from the cells was measured using ELISA. These results are 
displayed in Figures 5.19 to 5.21 in terms of cytokine release for IFN-γ, IL-17 and IL-5 respectively. 
Ionomycin is an ionophore produced by the bacterium Streptomyces conglobatus. In research, 
ionomycin was used to raise the intracellular level of calcium (Ca2+) therefore upon cell restimulation 
these enhanced levels of calcium can stimulate T-cell activation, proliferation and the intracellular 
production of cytokines, usually in conjunction with phorbol 12-myristate 13-acetate (PMA).  
These results showed that upon restimulation of splenocytes and PLN with the positive control 
stimuli, PMA/Ionomycin, this resulted in high cytokine production with no significant trends 
observed between the cells derived from tested formulations. This shows that our positive control 
worked successfully in that these cells, upon restimulation, respond with observed cytokine 
production. 
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Figure 5-19. IFN-γ cytokine analysis from PMA/Ionomycin restimulated splenocytes (A) and popliteal lymph 
nodes (B). Results are the mean of 6 mice per experimental group ± SD. 
 
Figure 5-20. IL-17 cytokine analysis from PMA/Ionomycin restimulated splenocytes (A) and popliteal lymph 
nodes (B). Results are the mean of 6 mice per experimental group ± SD. 
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Figure 5-21. IL-5 cytokine analysis from PMA/Ionomycin restimulated splenocytes (A) and popliteal lymph 
nodes (B). Results are the mean of 6 mice per experimental group ± SD. 
 
During this study, general trends were found in that in terms of the negative control (cell 
restimulated with media only), only background levels of cytokine production were measured which 
were significantly lower (P < 0.001) than the corresponding cells restimulated with H56 vaccine 
antigen, Therefore this demonstrated that these cells require stimulation with previously 
encountered antigen in order for the immune response to be initiated as characterised by cytokine 
production at the spleen and lymph nodes (Figures 5.22 to 5.24). Also as a control experimental 
group, splenocytes and PLN were derived from naive unimmunised mice. Upon restimulation, these 
cells did not respond and therefore only background levels of all cytokines were produced (Figures 
5.22 to 5.24).  
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of tuberculosis vaccines (Agger and Andersen, 2001). In terms of the generated IFN-γ responses at 
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terms of the IFN-γ immune response generated by anionic DSPS/TDB formulations, similarly low 
levels of production were noted irrespective of the liposome preparation method (Figure 5.22). This 
may be due to lesser loading of H56 antigen by these formulations, and also anionic formulations 
have previously been shown to reduce and inhibit Th1 immune responses as has been described in 
Chapter 4 and in the previous literature (Foged et al., 2004, Parker et al., 2008). Also this correlation 
between IFN-γ production, both at the splenocytes and PLN (Figure 5.22), showed that cationic 
liposomes are promoting immune responses at both of these sites. 
 
 
Figure 5-22. IFN-γ cytokine analysis from H56 antigen restimulated splenocytes (A) and popliteal lymph 
nodes (B). Results are the mean of 6 mice per experimental group ± SD. Significance was measured between 
experimental groups by one-way ANOVA (*** p<0.001). 
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express the cytokine interleukin-17 (IL-17) and be completely separate to Th1 and Th2 polarising 
signals ex vivo (Lexberg et al., 2008). The results for IL-17 cytokine release at both the splenocytes 
and PLN were shown in Figure 5.23.  
In terms of the effect of antigen location with cationic DDA/TDB liposome formulations on the 
generated immune response, antigen entrapment (for DRV formulations) gave rise to no significant 
effect on the production of IL-17 (following splenocyte and PLN restimulation with previously re-
encountered H56 antigen), when compared to DE and LH-formulations (increased bias towards 
surface adsorbing antigen) with similarly high levels of IL-17 production noted. Also a similar trend 
was noted for anionic DSPS/TDB formulations, with similarly low levels of IL-17 being produced 
(irrespective of the liposome preparation method). This demonstrated that antigen, whether 
surface-adsorbed or entrapped within the formulation has the ability to be taken up by 
macrophages at the injection site, and lead to similar subsequent generated immune responses. 
These results also demonstrated a general liposome charge-dependent trend, in that immunisation 
of mice with H56 (in combination with cationic DDA/TDB) gave rise to the higher levels of IL-17 
production (P < 0.001), both for restimulated splenocyte and PLN (Figure 5.23). However 
immunisation of the H56 vaccine (in combination with DSPS/TDB) gave rise to lower IL-17 cytokine 
production for both sets of restimulated cells. This may be due to lesser initial loading of H56 antigen 
by these formulations therefore less antigen will be available for antigen presentation upon drainage 
of the vaccines to T-cell rich sites such as the spleen and lymph node.  
These results correlated with the previous literature in which DDA/TDB have been reported to drive 
IL-17 responses, through the interaction of TDB with its C-Lectin type receptor Mincle leading to 
downstream activation of the innate immune response through polarisation of Th17 cells through 
proinflammatory cytokine production (Werninghaus et al., 2009, Schoenen et al., 2010).  
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Figure 5-23. IL-17 cytokine analysis from H56 antigen restimulated splenocytes (A) and popliteal lymph 
nodes (B). Results are the mean of 6 mice per experimental group ± SD. Significance was measured between 
experimental groups by one-way ANOVA (** p<0.001). 
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anionic DSPS/TDB:H56 vaccine formulations, with LH-  and DRV-prepared formulations giving rise to 
significantly higher (P < 0.001) IL-5 responses in comparison to their DE-counterparts from 
restimulated splenocytes and PLN (Figure 5.24). However liposomal vaccines prepared by the double 
emulsion (DE) method, irrespective of surface charge, gave rise to low levels of IL-5 responses which 
was possibly due to the lower level of antigen adsorption by both of these liposomal adjuvants 
(cationic DDA/TDB and anionic DSPS/TDB). 
 
 
Figure 5-24. IL-5 cytokine analysis from H56 antigen restimulated splenocytes (A) and popliteal lymph nodes 
(B). Results are the mean of 6 mice per experimental group ± SD. Significance was measured between 
experimental groups by one-way ANOVA (*** p<0.001; ** p<0.01). 
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5.4. Conclusions 
 
The results presented within this chapter showed that by varying the method of liposome 
preparation that antigen can become associated with the delivery system, either by adsorption to 
the liposome surface or encapsulation within the aqueous interior. Formulation of liposomal 
adjuvants by the DRV method led to entrapment of antigen within the delivery system, whereas 
double emulsion (DE)-prepared formulations have antigen associated at the liposome surface as well 
within the delivery system. The charged nature of the lipid head group conferred the surface charge 
of the delivery system with cationic DDA/TDB and anionic DSPS/TDB being cationic and anionic in 
charge respectively. In general DE-formulated liposomes displayed a reduced vesicle size in 
comparison to their DRV counterparts, with these differences being attributed to the variation in 
preparation method.  
In terms of loading, DRV-prepared formulations showed enhanced loading and protection of antigen 
in comparison to their respective DE-formulations. Upon i.m. injection of these vaccines, cationic 
liposomes showed a higher retention profile at the injection site, whilst anionic liposomes drained 
significantly faster to the popliteal lymph node (PLN) irrespective of liposome preparation method. 
In term of the effect of antigen localisation on the observed biodistribution profile of liposomal 
vaccines, antigen entrapment offered no significant improvement on the retention of liposome (and 
associated antigen) at the injection site and the subsequent delivery to the draining lymph node. 
However, as described previously depot-forming cationic DDA/TDB liposome adjuvants showed a 
pattern of controlled release from the SOI to the PLN which was important in the generation of 
enhanced Th1 responses. During these studies, liposome retention at the SOI correlated with 
enhanced IFN-γ and IL-17 responses at both the spleen and PLN. However in terms of the effect of 
liposome preparation method on IL-5 production, anionic DSPS/TDB formulations (formulated by the 
LH- and DRV methods) gave rise to increased Th2 responses in comparison to their DE-counterparts 
For all cytokines tested, mice injected with liposome-adjuvanted vaccines gave rise to significantly 
increased immune responses. Therefore whilst DRV formulations were shown to offer better antigen 
protection and higher antigen retention (compared to LH- and DE-prepared formulations) this did 
not translate into differences in the measured biodistribution or generated immune responses for 
cationic DDA/TDB formulations. However, H56 antigen entrapment within anionic DRV DSPS/TDB 
gave rise to higher levels of Th2 immunity as characterised by enhanced IL-5 production. 
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Chapter 6: The inclusion of TLR agonists within liposome adjuvants and the 
synergy between TLR and non-TLR agonists 
 
 
 
 
206 
 
6.1. Introduction 
 
The flexible and versatile nature of liposomes allows for the potential of protein antigen and 
immunomodulatory components, including Toll-like receptor (TLR) and non-TLR agonists to be 
incorporated within the system. This chapter shall present data regarding the endosome-located TLR 
agonist, polyI:C and compare liposome systems comprising the mycobacterial- derived glycolipid 
non-TLR agonists, trehalose 6,6’ – dibehenate and monomycoloyl glycerol. 
 
6.1.1. Polyinosinic:polycytidylic acid (polyI:C) 
 
PolyI:C is an immunostimulatory molecule consisting of a double stranded RNA (dsRNA), with one of 
the strands being a polymer of inosinic acid and the other strand being a polymer of cytidylic acid,  
which is known to interact with Toll-like Receptor 3 (TLR3). PolyI:C is located within the endosome in 
cells, most preferentially in the membrane of B-cells, macrophages and dendritic cells. 
Recent studies have demonstrated the immunostimulatory ability of polyI:C following incorporation 
within cationic liposome vaccine adjuvants (Milicic et al., 2012). Addition of polyI:C significantly 
increased the adjuvant capabilities of DDA/TDB liposomes formed as MLV and antigen-entrapping 
DRV. However, DDA/TDB formed as SUV offered enhanced adjuvant capacity without the addition of 
TLR agonists to the system. 
 
6.1.2. Trehalose 6,6’ – Dibehenate (TDB) 
 
TDB is a synthetic analogue of the mycobacterial ‘cord factor’, otherwise termed as trehalose 
dimycolate (TDM) and shows less toxicity in vivo (than TDM) whilst retaining its immunogenic 
properties. This is due to the reduced number of mycolate chains which results in a shorter chain 
length (Matsunaga and Moody, 2009). These properties allow for the successful inclusion of TDB into 
cationic liposome delivery systems, with an optimal ratio of 11 mol % (8:1 M/M) shown to display 
the highest titres of antibodies (Davidsen et al., 2005) in order to generate the optimal immune 
response. This inclusion of TDB into DDA-based liposomes leads to an increasingly stable 
(Christensen et al., 2007a, Christensen et al., 2009) and efficient adjuvant delivery system which has 
the advantage of greatly improving the Th1-mediated cell immune response and the antibody 
response (Davidsen et al., 2005). The enhanced stability of this cationic adjuvant formulation is 
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caused by the interaction of the glucose headgroups of TDB with the surrounding aqueous buffer 
which is used to hydrate the liposomes (Christensen et al., 2007a, Christensen et al., 2008). The 
incorporation of TDB into DDA-based liposomes confers an increased immune response against 
various subunit vaccine antigens due to the binding of TDB to a C-type Lectin Mincle Receptor 
(Ishikawa et al., 2009, Werninghaus et al., 2009, Schoenen et al., 2010) which can activate the TLR-
independent FcR-Syk-Card9 pathway in APCs in order to cause a sufficient innate immune response, 
characterised by protective Th1- and Th17-immunity. 
 
6.1.3. Monomycoloyl Glycerol 
 
Studies (Andersen et al., 2009a, Andersen et al., 2009b) have also indicated monomycoloyl glycerol 
(MMG) as a prominent glycolipid from the mycobacterial cell wall which has an enhanced effect on 
the immune response. As described previously with trehalose 6,6’ – dibehenate, MMG can also be 
incorporated into DDA-based liposomes. 
This delivery system (DDA/MMG), in combination with the Ag85B-ESAT6 (H1) fusion protein was 
found to be highly efficient in the activation of APCs (by MMG) and the production of a Th1-biased 
immune response as characterised by high levels of interferon-gamma (IFN-γ) and IL2 as well as 
negligible levels of Th2 cytokines IL-4 and IL-5 (Rosenkrands et al., 2005). Also in more recent 
studies, synthetic analogues of MMG have been incorporated into DDA-based liposomes. These 
delivery systems in combination with vaccine antigen also lead to enhanced immune response as 
characterised by increased cytokine release including IFN-γ and IL-2, as well as Th17 responses as 
characterised by IL-17 production (Andersen et al., 2009a, Andersen et al., 2009b, Bhowruth et al., 
2009, Nordly et al., 2011b).  
 
6.1.4. Liposome formulations with and without inclusion of polyI:C TLR agonist 
 
Within this chapter, both DDA/TDB and DDA/MMG liposome formulations (termed CAF01 and 
CAF04) can also be further enhanced following the addition of the TLR3 agonist, polyI:C. The addition 
of polyI:C to CAF01 leads to the formulation of CAF05 liposomes. Whereas the incorporation of 
polyI:C to CAF04 leads to the formulation of CAF09 liposomes (Figure 6.1). 
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Figure 6-1. Nomenclature of the cationic adjuvant formulations used within this chapter of the thesis. This 
figure was originally produced by Dennis Christensen from the Statens Serum Institute. 
 
6.2. Aims and Objectives 
 
The aim of the work reported within this chapter was to successfully incorporate Toll-like Receptor 
(TLR) and non-TLR immunostimulatory components within cationic DDA-based liposome 
formulations. In order to achieve this, the effect of the following will be investigated: 
 the addition of immunostimulatory Toll-like Receptor (TLR) agonists on the physicochemical 
characteristics of cationic liposomal adjuvants, 
 the long term stability of these systems in terms of shelf life storage under standard and 
accelerated conditions, 
 varying the liposome preparation method for cationic liposomes associated with TLR3 
agonist (with or without protein antigen) with antigen loading, agonist loading and 
physicochemical characteristics being measured, 
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 preparation of liposomes by high shear mixing (HSM) homogenisation with the aim of 
reducing vesicle size and retaining TLR agonist with the delivery system, 
 stepwise incorporation of TLR agonist to DDA-based liposome formulations, in comparison 
to addition at the whole dose, in order to obtain desired physicochemical characteristics of 
liposomal adjuvants.  
 
6.3. Results and Discussion 
6.3.1. Incorporation of immunostimulatory compounds and the subsequent effect on 
vesicle characteristics 
6.3.1.1. Multilamellar vesicles formulated by the lipid hydration method 
 
Liposome vaccine formulations were prepared by LH method, with the addition of a range of 
increasing concentrations of the whole desired dose of polyI:C (between 0 and 50 µg) within the 
formulation to consider if the physicochemical characteristics of the liposome formulation was 
polyI:C concentration dependent. These liposomes were also formulated with or without the 
addition of the in vivo dose of H56 antigen (5 µg) and characterised for their size, polydispersity and 
zeta potential. During these studies, cationic DDA/TDB formulations with the inclusion of polyI:C are 
termed cationic adjuvant formulation 05 (or CAF05). 
Upon increase in the concentration of polyI:C within these cationic formulations this resulted in a 
significant concentration dependent increase in vesicle size from ~600 nm to around 2.3 μm (p < 
0.001) with a corresponding increase in polydispersity (Figure 6.2A). In general, antigen-loaded 
systems were larger in vesicle size than their empty counterparts; this could be due to loading of 
antigen at the surface of the delivery system. Antigen loading is mediated by electrostatic 
interactions between the cationic liposome and the anionic antigen at the surface of the delivery 
system (Henriksen-Lacey et al., 2010c). 
Also upon increase in the polyI:C dose concentration within the formulation, a concentration 
dependent reduction in the zeta potential (P < 0.001) of the formulation was noted (Figure 6.2B). In 
combination with this decrease in zeta potential a reduction in antigen loading was seen (Figure 
6.2B). These changes in vesicle characteristics were due to addition of anionic polyI:C, which will 
electrostatically bind (due to the opposing charge of these components) to the delivery system thus 
causing aggregation and neutralisation of the surface charge, and a reduced loading due to 
saturation of the ability to electrostatically bind polyI:C (Figure 6.2B).  
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Figure 6.2. Vesicle size and polydispersity (A), zeta potential and antigen loading (B) of liposome vaccine 
formulations prepared by the lipid-film hydration method with addition of increasing concentrations of 
polyI:C (with or without H56 antigen). Results are the mean of triplicate experiments ± SD. Significance was 
measured by one-way ANOVA (*** p<0.001; * p<0.05) as compared to the same formulation with no polyI:C (0 
µg) included. 
 
6.3.1.2. Alternative options for MLV; consideration of DRV and SUV systems  
 
Liposome vaccine formulations were also prepared as DRV and SUV, with addition of increasing 
concentrations of the whole desired dose of polyI:C within the formulation. These liposomes were 
also formulated with or without the addition of the in vivo dose of H56 antigen and characterised for 
their size, polydispersity and zeta potential (Figure 6.3). 
Upon increase in the concentration of polyI:C within these cationic formulations this resulted in a 
concentration dependent increase in vesicle size (P < 0.05; Figure 6.3A). This may be due to 
entrapment of polyI:C within the delivery system or association within the bilayer during the 
liposome preparation process. Also upon increase of the polyI:C concentration within the 
formulation this resulted in a dose-dependent reduction in the zeta potential of the formulation 
which occurred due to addition of the anionic TLR3 agonist polyI:C which was suggested to bind 
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electrostatically to the delivery system thus causing neutralisation of the surface charge (Figure 
6.3B) however these changes were not as significant as for LH-formulations (P < 0.05; upon addition 
of 50 µg polyI:C per dose) which also suggested that agonist may become entrapped within the 
liposome itself. As described previously for MLVs (Section 6.3.1.1), a general trend existed that 
antigen-loaded DRVs were larger in size (P < 0.05) compared to their ‘empty’ counterparts 
suggesting antigen can become associated with these systems. Upon increasing the dose of polyI:C 
within the formulation, up to the in vivo dose of 50 μg, there was also a minimal reduction in initial 
antigen loading (Figure 6.3B). This minimal reduction in antigen loading was due to the reduction in 
zeta potential, due to increasing polyI:C concentration within the system, therefore the formulations 
had slightly less ability to electrostatically bind and entrap anionic H56 antigen (Figure 6.3B). 
 
 
Figure 6-3. Vesicle size and polydispersity (A), zeta potential and antigen loading (B) of liposome vaccine 
formulations prepared by the dehydration-rehydration vesicle (DRV) method with addition of increasing 
concentrations of polyI:C (with or without H56 antigen) within the formulation. Results are the mean of 
triplicate experiments ± SD. Significance was measured by one-way ANOVA (* p<0.05) as compared to the 
same formulation with no polyI:C (0 µg) included. 
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Liposome vaccine formulations were prepared as small unilamellar vesicles, with the addition of 
increasing concentrations of the whole desired dose of polyI:C within the formulation. These 
liposomes were also formulated with or without the addition of the in vivo dose of H56 antigen and 
characterised for their size, polydispersity and zeta potential (Figure 6.4). 
Upon increase in the dose concentration of polyI:C, from 0 μg to 50 μg, within these cationic 
formulations this resulted in a significant dose-dependent increase in vesicle size and polydispersity 
(Figures 6.4A) from 150 nm to around 1.8 μm (P <  0.001). This was hypothesised to be due to 
electrostatic binding of the agonist at the surface of the delivery system. Also upon increase of the 
polyI:C concentration within the formulation, this resulted in a significant dose-dependent reduction 
in the zeta potential (P < 0.001) of the formulation which occurred due to addition of the anionic 
polyI:C electrostatically binding to the delivery system, thus causing neutralisation of the surface 
charge (Figure 6.4B) which became significantly different following addition of polyI:C at a 
concentration of 50 µg per dose. Upon increasing the dose of polyI:C within the formulation, up to 
the in vivo dose of 50 μg, there was also a reduction in initial antigen loading and enhanced antigen 
release kinetics from the formulation (results not shown). 
 
 
Figure 6-4. Vesicle size and polydispersity (A) and zeta potential (B) of liposome vaccine formulations 
prepared as small unilamellar vesicles (SUV) with addition of increasing concentrations of polyI:C (with or 
without H56 antigen) within the formulation. Results are the mean of triplicate experiments ± SD. Significance 
was measured by one-way ANOVA (*** p<0.001) as compared to the same formulation with no polyI:C (0 µg) 
included. 
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These studies have therefore reported the binding and association of the anionic dsRNA polyI:C TLR3 
agonist with cationic DDA/TDB liposomes which caused a concentration dependent effect on vesicle 
characteristics when these systems were formulated as MLV and SUV. The association of higher 
concentrations of polyI:C within the system led to higher levels of polyI:C loading, which thus caused 
an increase in vesicle size and ‘masking’ of the cationic surface charge of the delivery system. 
 Similar interactions have also previously been reported for the delivery of DNA (Perrie and 
Gregoriadis, 2000, Moghaddam et al., 2011) as well as protein antigen to cationic liposome systems 
(Chapter 4). Upon addition of increasing concentrations of DNA or protein antigen to cationic 
liposomes this resulted in subsequent increases in vesicle size, thus causing vesicle aggregation and 
also reduction in zeta potential of the delivery system. These studies have also demonstrated that 
variation in preparation method in order to entrap polyI:C within the delivery system (by the DRV 
method) leads to lesser changes in vesicle characteristics, albeit with similar levels of loading of 
polyI:C. 
 
6.3.1.3. The effect of liposome preparation method on polyI:C agonist loading 
 
In order to further investigate the effect of TLR agonist upon vesicle characteristics it was required to 
be able to quantify whether indeed agonist was loading within the formulation, as has been shown 
that using varying methods of preparation and addition of agonist this has a significant effect upon 
vesicle characteristics (Sections 6.3.1.1 and 6.3.1.2). Hence, polyI:C was radiolabelled with 32P before 
addition to liposome vaccine formulations. Subsequent centrifugation will allow quantification of 
agonist loading, as was determined by percentage recovery of 32P-labelled polyI:C within the 
liposome pellet. Addition of the whole dose of polyI:C to cationic liposomal adjuvants (prepared as 
MLV, DRV and SUV) resulted in high levels of agonist loading in the region of 70-80 % (Figure 6.5). 
This polyI:C agonist loading led to resultant changes in MLV and SUV vesicle characteristics as has 
been described previously in Section 6.3.1, thus implicating charge-mediated electrostatic 
interaction between agonist and delivery system resulting in vesicle aggregation. However, for DRV-
formulations, similarly high levels of polyI:C loading were noted, with lesser changes in vesicles 
characteristics measured (Figure 6.3) which suggested that TLR agonist may become entrapped 
within the delivery system as has been suggested in the previous literature for DNA delivery within 
DRV liposomes (Perrie and Gregoriadis, 2000). 
The combination of nucleic acid-based TLR3 receptors and cationic liposomes constitutes an 
effective vaccine adjuvant approach for eliciting CD8+ T-cell responses. However, the relative 
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instability of these vesicles (with the addition of polyI:C at the in vivo dose) will limit their use in 
clinical applications (Nordly et al., 2011c) due to their rapid vesicle aggregation. Therefore even 
though polyI:C was efficiently loaded by these formulations, vesicle aggregation along with greater 
antigen release may limit the use of these vaccine adjuvants in further applications. Therefore the 
next set of studies will aim to formulate stable CD8-inducing adjuvants composed of high amounts of 
polyI:C associated with cationic DDA/TDB liposomes. 
 
Figure 6-5. PolyI:C agonist loading to cationic liposome vaccine formulations, following whole dose addition. 
Results are the mean of triplicate experiments ± SD. 
 
6.3.2. Optimisation of liposome adjuvants incorporating immunostimulatory compounds 
in order to control vesicle size 
 
The next section of studies will aim to investigate the optimisation of liposomal adjuvants, including 
the TLR3 agonist polyI:C, in order to control and modulate the size of the delivery system. 
6.3.2.1. Stepwise incorporation of TLR agonist within liposome formulations: effect of 
preparation method on vesicle characteristics and initial antigen loading 
 
In order to control and modulate vesicle size, liposome vaccine formulations were initially prepared 
by the lipid-film hydration (LH) method, with the stepwise addition of polyI:C followed by vortexing 
every minute until the desired agonist concentration was reached. The aim of stepwise 
incorporation of polyI:C within the liposomal adjuvants was in order to prevent aggregation of the 
delivery system as described previously (Hansen et al., 2012). During this set of studies, DDA/TDB 
and DDA/MMG, without or with polyI:C (CAF01 and CAF05 & CAF04 and CAF09) were measured for 
their vesicle characteristics.  
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Monomycoloyl glycerol (MMG) is derived from the cell wall of mycobacteria. Through activation of 
antigen presenting cells (APCs), this non-TLR agonist has been shown to have an enhanced effect on 
the immune response (Andersen et al., 2009a). As described previously with TDB, MMG can also be 
incorporated into liposomes consisting of the cationic surfactant DDA. These liposomes were 
prepared at the same molar concentration as DDA/TDB (8:1 M/M) in order to serve as a direct 
comparison. 
Upon stepwise addition of increasing concentrations of polyI:C within these cationic formulations, 
this resulted in a concentration dependent increase in vesicle size (Figure 6.6A) from around 400-500 
nm to around 500-600 nm (following the addition of the in vivo dose of polyI:C), however these 
differences were not deemed significant as compared to whole dose addition of TLR agonist to MLV 
(Figure 6.2). Stepwise incorporation of polyI:C within the formulation also led to no significant 
changes in the zeta potential of the delivery system (Figure 6.6C) with the zeta potential being in the 
region of 60 mV and 40 mV (without and with antigen respectively) irrespective of the polyI:C 
concentration within the formulation. This was interesting as the same concentration of agonist was 
incorporated within the formulation with no such effects on vesicle characteristics. As expected and 
discussed previously, antigen loaded systems displayed a slight increase in vesicle size (from around 
400 nm to around 500-550 nm) and reduction in zeta potential (P < 0.05) compared to their empty 
counterparts (Figure 6.6) which was due to electrostatic binding of anionic H56 antigen to the 
cationic surface of the delivery system as has been confirmed by antigen loading studies (Figure 
6.6D). This has been described previously for the electrostatic interaction of anionic H1 TB antigen to 
the cationic surface of DDA/TDB liposomes (Henriksen-Lacey et al., 2010a). 
These same liposome vaccine formulations were also prepared by the dehydration-rehydration 
vesicle method, with the addition of antigen and the stepwise addition of polyI:C to the SUV 
followed by vortexing every minute until the desired agonist concentration was reached. These SUV 
were then frozen at -70 ° C, before overnight freeze-drying at – 40 ° C. The freeze-dried lipid cake 
was then rehydrated with deionised water (above the transition temperature of the main lipid in the 
formulation) as described in Chapter 2 (Section 2.2.3).  
Upon stepwise increase in the concentration of polyI:C within these cationic DRV formulations, this 
resulted in no significant effects on vesicle size, with vesicles measuring in the size range of 600 nm 
and 700 nm following addition of the in vivo dose of polyI:C (50 μg) within the formulation (Figure 
6.7A) as compared to whole dose addition of TLR agonist (Figure 6.3A), which resulted in a dose-
dependent increase in vesicle size. Stepwise incorporation of polyI:C within the formulation also 
resulted in no significant changes to the surface charge of the formulation (Figure 6.7C) as analysed 
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by the measured zeta potential which remained in the region of 60 mV for all formulations studied. 
These results suggested slow incorporation and entrapment of the TLR agonist within the 
formulation. This was interesting as the same concentration of agonist was incorporated within the 
formulation, as described previously (Section 6.3.1.2) with no such significant effects on vesicle 
characteristics. As expected and discussed previously, antigen loaded systems displayed an increase 
in vesicle size from around 450 nm to ~700 nm compared to their empty counterparts (Figure 6.7A). 
This was more significant at lower concentrations of polyI:C (P < 0.05) within the formulation (0, 5 
and 10 µg polyI:C). Irrespective of the polyI:C concentration dose added within the formulation, 
anionic H56 antigen can be efficiently loaded with the delivery system, in the region of ~ 80 %,  as 
was confirmed by antigen loading studies (Figure 6.7D). 
These liposome vaccine formulations were also prepared as small unilamellar vesicles, with the 
stepwise addition of polyI:C followed by vortexing every minute until the desired agonist 
concentration was reached. Upon stepwise addition of increasing concentrations of polyI:C within 
these SUV cationic formulations this resulted in no significant changes in vesicle characteristics with 
vesicle size ranging in the region of 200 nm to 400 nm without and with antigen respectively (Figure 
6.8), as compared to whole dose addition of TLR agonist to SUVs (Figure 6.4).  
H56 antigen-loaded systems displayed a significant (P < 0.05) increase in vesicle size and reduction in 
zeta potential compared to their empty counterparts (Figure 6.8) which was due to electrostatic 
binding of anionic H56 antigen to the cationic surface of the delivery system as was confirmed by 
antigen loading studies (Figure 6.8D) and has been described in the previous literature for anionic H1 
TB antigen (Henriksen-Lacey et al., 2010a). This was significant (P < 0.01; compared to LH- and DRV-
prepared formulations) due to the fact that antigen interacted with a higher amount of the surface 
of these systems (due to their smaller initial vesicle size) so antigen loading led to increased vesicle 
size, however during this study this had no significant impact on the surface charge of the 
formulation. 
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Figure 6-6. Vesicle size (A), polydispersity (B), zeta potential (C) and antigen loading (D) of liposome vaccine 
formulations prepared by the LH method with stepwise incorporation of polyI:C (with or without H56 
antigen). Results are the mean of triplicate experiments ± SD. Significance was measured by one-way ANOVA 
(* p<0.05). 
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Figure 6-7. Vesicle size (A), polydispersity (B), zeta potential (C) and antigen loading (D) of liposome vaccine 
formulations prepared by the DRV method with stepwise incorporation of polyI:C (with or without H56 
antigen). Results are the mean of triplicate experiments ± SD. Significance was measured by one-way ANOVA 
(* p<0.05). 
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Figure 6-8. Vesicle size (A), polydispersity (B), zeta potential (C) and antigen loading (D)of liposome vaccine 
formulations prepared as SUV with stepwise incorporation of polyI:C (with or without H56 antigen). Results 
are the mean of triplicate experiments ± SD. Significance was measured by one-way ANOVA (** p<0.01). 
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6.3.2.2. The use of high shear mixing (HSM) homogenisation in order to control vesicle 
characteristics of polyI:C containing liposomal adjuvants 
 
During initial studies at Statens Serum Institute, DDA/TDB (CAF01) liposomes were prepared by 
either the lipid-film hydration (LH) or high shear mixing (HSM) homogenisation methods, which gave 
rise to vesicles with sizes of 400 nm and 280 nm respectively (Figure 6.9A). Addition of the TLR3 
agonist polyI:C led to the formulation of CAF05 (DDA/TDB/PolyI:C) liposomes. Upon stepwise 
addition of polyI:C (at the in vivo dose; 50 µg) to pre-formed CAF01, this resulted in a minimal 
increase in vesicle size to 440 nm and 310 nm (for LH method and HSM methods respectively). This 
small increase in vesicle size was partly ascribed to the step-wise addition of polyI:C (Hansen et al., 
2012), rather than addition of the whole dose which resulted in significant changes in vesicle 
characteristics and neutralisation of the surface charge (as measured by zeta potential) especially at 
the in vivo dose of 50 μg (Section 6.3.1.1). 
CAF01 and CAF05 prepared by the high shear mixing (HSM) method were of a reduced vesicle size 
compared to their LH-prepared formulation counterparts (P < 0.05). This was due to the introduction 
of energy and larger disruptive forces (compared to vortexing) to the liposome system which led to 
smaller vesicles being produced. Therefore these results demonstrated that the high shear mixing 
method was suitable for reducing the particle size of cationic liposome formulations, CAF01 and 
CAF05. This will be further tested with CAF04 and CAF09 formulations, which will be described in 
more detail below. 
In terms of the vesicle surface charge of CAF01 (as was indicated by zeta potential), these 
formulations had measurements of 75 mV and 58 mV when formulated by the LH and HSM 
methods, respectively (Figure 6.9B). Upon addition of polyI:C to pre-formed CAF01 this led to 
formulation of CAF05 liposomes. This led to no significant reduction in the measured zeta potential 
of these liposomes (Figure 6.9B). This was in contrast to when the whole in vivo dose of polyI:C was 
added to the formulation post lipid-film hydration (LH) in section 6.3.1.1, which resulted in 
subsequent neutralisation of the surface charge. This showed that stepwise addition of polyI:C 
resulted in formulations, with or without HSM, which maintained their vesicle size as well as their 
cationic nature (as indicated by zeta potential). 
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Figure 6-9. Vesicle size and polydispersity (A) and zeta potential (B) of CAF01 and CAF05 formulations 
prepared by either the lipid-film hydration (LH) or high shear mixing (HSM) method. PDI values are placed 
above their respective column bars. Results are the mean of triplicate experiments ± SD. Significance was 
measured by one-way ANOVA (* p<0.05). 
 
DDA/MMG (CAF04) liposomes were formulated by either the LH method or by high shear mixing 
(HSM). CAF04 gave rise to vesicles with a size of 550 nm (LH) and 320 nm (HSM) respectively. Upon 
addition of the TLR3 agonist polyI:C, this resulted in the production of CAF09 liposomes. These 
CAF09 liposome formulations displayed vesicle sizes of 560 nm and 370 nm for LH- and HSM 
methods respectively (Figure 6.10A). The addition of polyI:C within the formulation led to no 
significant changes to vesicle characteristics, including the vesicle size (Figure 6.10A). As described 
previously, formulations which were produced by HSM gave rise to vesicles with a significant 
reduction in size (P < 0.01), which was due to the introduction of larger disruptive forces to the 
liposome system. Therefore these results demonstrated that the HSM method was suitable for 
reducing the particle size of CAF04 and CAF09 formulations. The vesicle size distribution of CAF04 
liposomes has been confirmed via cryo-TEM microscopy as displayed in Figure 6.11. 
In terms of the zeta potential of DDA/MMG (CAF04), these formulations showed initial 
measurements of 64 mV and 61 mV, when formulated by the LH- and HSM methods respectively. 
For CAF09 liposomes, these had a zeta potential of 61 mV and 56 mV when prepared by either the 
LH-method or HSM respectively (Figure 6.10B). These results demonstrated that high shear mixing 
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led to only a slight decrease in the measured zeta potential of these formulations, however these 
differences were not significant. This showed that controlled, stepwise addition of polyI:C (with or 
without high shear mixing) resulted in formulations which maintain their vesicle size as well as their 
cationic nature (as indicated by zeta potential).  
 
 
Figure 6-10. Vesicle size and polydispersity (A) and zeta potential (B) of CAF04 and CAF09 formulations 
prepared by either the lipid-film hydration (LH) or high shear mixing (HSM) method. Results are the mean of 
triplicate experiments ± SD. Significance was measured by one-way ANOVA (** p<0.01; * p<0.05). 
 
Figure 6-11. Cryo-TEM micrograph of DDA/MMG liposomes (or CAF04) formulated by the lipid-film 
hydration (LH) method. The long dark structures are the carbon grid onto which the sample was deposited 
before analysis. 
These initial studies showed high promise with the inclusion of high amounts of polyI:C within the 
formulation which led to no significant effects on vesicle characteristics therefore will be further 
investigated in Section 6.3.2.3. 
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6.3.2.3. Liposome formulation by HSM: effect on vesicle characteristics and antigen 
loading 
 
Through further optimisation of this method, upon stepwise addition of increasing concentrations of 
polyI:C (at varying dose concentrations between 0 and 50 µg) within these HSM-prepared cationic 
formulations this resulted in no significant measured differences in vesicle size and polydispersity 
(Figures 6.13 A and B) as compared to whole dose addition of TLR agonist which resulted in vesicle 
aggregation (as described previously in Section 6.3.1). Empty vesicles were measured in the region of 
200 nm, as confirmed by cryo-TEM, (Figure 6.12) with vesicle size increasing to ~ 250 nm upon 
stepwise addition of the complete dose of polyI:C. Stepwise incorporation of polyI:C within the 
formulation also led to no significant changes in the zeta potential of the delivery system with 
measured values between 55-60 mV (Figure 6.13C). Upon high shear mixing (HSM), there was a 
reduction in vesicle size as compared to multilamellar vesicles formulated by the lipid-film hydration 
method. However, TLR agonist was still able to be retained and loaded by the cationic delivery 
system, as reflected by no such changes in vesicle characteristics. As expected and discussed 
previously, antigen loaded systems displayed slight increases (P < 0.05) in vesicle size (from around 
200 nm to 300 nm) compared to their empty counterparts (Figure 6.13A) which was due to strong 
electrostatic binding of anionic H56 antigen to the cationic surface of the delivery system as was 
confirmed by antigen loading studies (Figure 6.13D). 
 
Figure 6-12. Cryo-TEM micrograph of DDA/TDB liposomes, formulated by the high shear mixing 
homogenisation (HSM) method. The long structures are the carbon grid the sample was loaded onto before 
analysis. 
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Figure 6-13. Vesicle size (A), polydispersity (B), zeta potential (C) and antigen loading (D) of liposome vaccine 
formulations prepared by the high shear mixing homogenisation method with stepwise incorporation of 
polyI:C (with or without H56 antigen). Results are the mean of triplicate experiments ± SD. Significance was 
measured by one-way ANOVA (* p<0.05). 
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6.3.2.4. Investigating the effect of stepwise incorporation of polyI:C on agonist loading 
within the formulation 
 
Following the investigation into the stepwise incorporation of polyI:C on the measured vesicle 
characteristics (Sections 6.3.2.2 and 6.3.2.3) it was required to study whether the polyI:C agonist was 
in fact associated with the liposome formulation. These results were then to be compared to 
previous data in which whole dose addition of polyI:C was added within the formulation (Section 
6.3.1.3). These results have suggested that stepwise incorporation of the in vivo dose of polyI:C (50 
μg), followed by vortexing or high shear mixing, led to high levels of agonist loading in the region of 
70-80 % (Figures 6.14A and B); however, this loading led to no observed changes in vesicle 
characteristics as was described previously (Section 6.3.2). The maintenance of reduced vesicle size, 
in combination with association of the TLR3 agonist polyI:C, has been suggested previously to lead to 
the enhanced immunogenicity of liposomal vaccines (Nordly et al., 2011c), which was due to the 
induction of CD8+ T-cell responses and the ability to cross-present antigen (Zaks et al., 2006, Milicic 
et al., 2012). The formulations summarised in Sections 6.3.2 thus showed high promise for the use as 
vaccine adjuvants. These formulations were able to efficiently load high levels of TLR3 agonist 
(Figure 6.14), as well as highly load vaccine antigen within the formulation causing no significant 
changes in vesicle characteristics. Therefore, these formulations have the ability to act as CD8-
inducing adjuvants containing high amounts of the TLR agonist polyI:C. 
 
 
Figure 6-14. PolyI:C agonist loading to cationic liposome vaccine formulations, following (A) stepwise 
addition of agonist and (B) high shear mixing. Results are the mean of triplicate experiments ± SD. 
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6.3.3. Long term trials to investigate the stability of liposome systems 
 
The long term stability of liposome formulations has been shown to be critically important in the 
successful development of these vaccines. During this investigation, liposomes were formulated by 
two separate methods and kept at 4 °C, 25 °C or 40 °C in order to show the effect of storage 
temperature on the vesicle characteristics of tested liposome adjuvants. 
Cationic liposomal vaccine formulations were prepared by the lipid-film hydration method with the 
addition of the in vivo dose of H56 antigen, and with or without the in vivo dose of the TLR3 agonist 
polyI:C. These formulations were stored at 4 °C, 25 °C and 40 °C over a 6-month period and were 
assessed for their vesicle characteristics at a number of time points. These vesicles, without polyI:C, 
had an initial size, zeta potential and polydispersity of 650 nm, 65 mV and 0.41 respectively. 
Whereas inclusion of polyI:C within the formulation gave vesicle characteristics of 670 nm, 64 mV 
and 0.42 respectively. Therefore stepwise inclusion of polyI:C within the formulation led to no 
significant changes in initial vesicle characteristics (Figure 6.15).  
Over the initial 28 days of this stability study, there were no significant changes measured in vesicle 
characteristics at all storage temperatures tested both for vesicle size and liposome surface charge 
(as measured by zeta potential). However storage at 40 ˚C had more impact on the vesicle size (P < 
0.01) characteristics for both formulations tested, with and without the inclusion of polyI:C, with 
vesicles increasing in size to ~ 1.2 μm (Figure 6.15A). Therefore the storage of liposomes at higher 
temperatures, can lead to vesicle aggregation, which was not a desired property for liposomal 
vaccines as this may affect their properties and subsequent ability to generate immune responses.  
Storage of liposomal formulations at 4 ˚C and 25 ˚C had no significant effect on vesicle characteristics 
up until the month 6 time point, with no significant differences in vesicle size and zeta potential 
measurements being measured. For zeta potential, up until the month 6 time point, the surface 
charge remained strongly cationic with storage temperature having no significant effect on the 
physicochemical parameter of liposomes. In terms of visual stability over the initial time points of 
this study, all samples remained homogenous which showed that vesicles had not significantly 
aggregated (Figure 6.16) during this study.  
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Figure 6-15. Vesicle size (A) and zeta potential (B) analysis of cationic liposomal vaccine formulations 
prepared by the lipid-film hydration method, with the addition of the in vivo dose of H56 antigen and also 
with and without stepwise addition of polyI:C at the in vivo dose. Results are the mean of triplicate 
experiments ± SD. Significance was measured by one-way ANOVA (*** p<0.001; ** p<0.01) as compared to 
initial characteristics at day 0. 
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Figure 6-16. Visual stability of DDA/TDB liposome samples formulated by the lipid-film hydration (LH) 
method with the addition of the in vivo dose of H56 antigen, and also with and without the stepwise 
addition of the in vivo dose of poly(I:C). These liposomes were made in Tris buffer (10 mM; pH 7.4), and were 
stored at 4 ˚C, 25 ˚C and 40 ˚C. 
 
Cationic DDA/TDB were also prepared by the high shear mixing (HSM) homogenisation method with 
the addition of the in vivo dose of H56 antigen, and with or without the in vivo dose of the TLR3 
agonist poly(I:C). These formulations were stored at 4 °C, 25 °C and 40 °C over a 6-month period and 
were assessed for their vesicle characteristics at a number of time points.  
At the initial time point, these formulations displayed an vesicle size of 324 ± 60 nm and 317 ± 78 nm 
(Figure 6.17A) for DDA/TDB:H56 and DDA/TDB/polyIC:H56 formulations respectively. In terms of the 
zeta potential, these formulations displayed initial surface charges of 54.6 ± 6.4 and 55.7 ± 3.5 mV, 
respectively (Figure 6.17B). These vesicle characteristics were in line with previously characterised 
HSM formulations prepared during this chapter (Section 6.3.2.3). Upon storage of these 
formulations at 4 °C, 25 °C and 40 °C, this led to measured differences in the characteristics of these 
formulations (Figure 6.17).  
Up until the month 2 time point, liposome formulations displayed similar size (400-500 nm) and 
surface charge characteristics (50 to 60 mV) irrespective of the storage temperature. However, by 
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month 3, liposome formulations stored at 40 °C tended to aggregate with vesicle size significantly 
increasing (P < 0.001) to between 1 and 1.2 μm (without and with polyI:C respectively), with zeta 
potential showing no further significant changes (Figure 6.17). These stability trials are currently 
ongoing up until the month 6 time point.  
 
 
Figure 6-17. Vesicle size (A) and zeta potential (B) analysis of cationic liposomal vaccine formulations 
prepared by the high shear mixing (HSM) homogenisation method, with the addition of the in vivo dose of 
H56 antigen and also with and without stepwise addition of polyI:C at the in vivo dose. Results are the mean 
of triplicate experiments ± SD. Significance was measured by one-way ANOVA (*** p<0.001) as compared to 
initial characteristics at day 0. 
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vaccine formulations 
 
In order to investigate the effect of long term stability on the integrity of antigen within the 
liposome formulation it was required to run SDS-PAGE (Figure 6.18). These results showed that 
antigen integrity was mainly dependent on the formulation storage temperature as the same 
concentration of antigen was present within each formulation. H56 antigen (within these liposome 
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following formulation storage at 4 °C, 25 °C or 40 °C, respectively, as shown by SDS-PAGE (Figure 
6.18) irrespective of whether polyI:C was present within the formulation or not. Inclusion of the 
polyI:C had no further effect on antigen integrity within the formulation (Figure 6.18). The high 
stability of these vaccines, with or without the inclusion of high amounts of polyI:C suggested that 
these formulations may have increased potential for use as vaccine adjuvants. The presence of 
polyI:C within the formulation results in the ability to ‘cross-present’ antigen through interaction 
with MHC I complexes therefore leading to the activation of CD8+ T-cells (Chikh and Schutze-
Redelmeier, 2002, O'Hagan and Valiante, 2003, Zaks et al., 2006) which leads to enhanced T-cell 
responses. 
 
Figure 6-18. SDS-PAGE to show the effect of liposome preparation method and storage temperature upon 
H56 antigen integrity for LH-prepared liposome vaccine formulations. 
 
6.3.4. Generation of an immune response from cationic liposomes with complexed-TLR 
agonists 
 
The immunostimulatory ability of cationic liposomes complexed with TLR3 agonists has previously 
been investigated in detail therefore this was not further explored during this chapter. The 
association of these agonists within cationic liposomes was able to promote the entry of antigens 
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into the MHC class I pathway in order to be presented to CD8+ T-cells (O'Hagan and Valiante, 2003). 
Further it has been shown that cationic liposomes can facilitate the interaction of TLR3 and TLR9 
agonists with their endosomal receptors and therefore promote immune activation (Gursel et al., 
2001, Suzuki et al., 2004, Zaks et al., 2006, Nordly et al., 2011c). Further studies within our 
laboratory have demonstrated the ability of cationic DDA/TDB liposomes (formulated as MLV, DRV 
and SUV) in combination with polyI:C and/or CpG DNA with the aim of eliciting CD8 responses 
(Milicic et al., 2012) as has been discussed by Christensen and colleagues (Christensen et al., 2011). 
These complexed TLR agonists were able to enhance immune responses with MLV and DRV cationic 
DDA/TDB liposomes, however SUV liposomes were able to induce stronger immune responses 
without the need for addition of these TLR agonists (Milicic et al., 2012). 
 
6.4. Conclusions 
 
The flexible and versatile nature of liposomes allowed the incorporation of immunostimulatory lipids 
and TLR-agonists with or within the delivery system, which has the potential to further enhance the 
generated immune response.  
Controlling the size of liposomal adjuvants can be achieved using high shear mixing (HSM) in which 
the immunostimulatory TLR3 agonist, polyI:C, can be incorporated with cationic liposome delivery 
systems (DDA/TDB and DDA/MMG) with no further significant changes in vesicle characteristics 
being measured. Immunostimulatory TLR agonists can also be added stepwise (at higher doses) to 
vesicles prepared by the lipid-hydration method, without vesicle characteristics being significantly 
altered. This was important as reduction in vesicle size in combination with TLR agonist association 
within the formulation is important in vaccine design in order to further stimulate CD8+ T-cell 
responses (Nordly et al., 2011c). 
This was in contrast to whole dose addition of these TLR agonists to pre-formed vesicles (MLV and 
SUV), which at the higher doses (in vivo dose; 50 µg polyI:C) resulted in vesicle aggregation as was 
noted through increases in vesicle size and neutralisation of the surface charge. Through variation in 
liposome preparation method, the localisation of TLR agonist in regards to the delivery system can 
be modified, similar to that of antigen (as discussed in Chapter 5). However through preparation of 
liposomes by the DRV method, this was suggested to lead to the entrapment of TLR agonist with the 
delivery system as shown by lesser effects on vesicle characteristics.  
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Antigen loading studies, using the anionic H56 subunit vaccine antigen, have been carried out which 
have demonstrated high loading due to the general trend of retention of the cationic surface charge 
of the liposome delivery system (especially after stepwise TLR agonist addition and HSM). A slight 
reduction in antigen loading was observed following whole dose addition of TLR agonist within the 
liposome formulation, which was attributed to measured changes in the physicochemical 
characteristics due to slight vesicle aggregation through interaction with agonist at the liposome 
surface.  
A number of formulations were entered into long term stability trials over a 6 month time period in 
which cationic DDA/TDB liposomes were formulated, through either the lipid hydration (LH) or high 
shear mixing (HSM) method, in combination with the in vivo dose of H56 TB vaccine antigen and 
with or without polyI:C. These studies have demonstrated that storage of liposome-based vaccines 
at 4 °C and 25 °C resulted in lesser changes compared to storage in accelerated conditions (40 °C), 
for LH-formulated vaccines. Initial studies for HSM liposomal vaccine formulations have shown no 
significant changes in vesicle characteristics, irrespective of the storage temperature, up to the 
month 2 time point of the study. However following month 3 of storage, vesicles stored at 40 °C 
tended to aggregate as shown by significant increase in vesicle size. 
To conclude, through modification in liposome preparation method, as well as the incorporation of 
TLR agonists, it was suggested that electrostatics were the main source of interaction between 
anionic systems combined with cationic liposomes. However, electrostatic interactions had the 
potential to lead to issues with regards to vesicle aggregation. This has been solved through the 
stepwise incorporation of TLR agonist within liposomal adjuvants, with or without high shear mixing 
homogenisation in order to control and modulate vesicle size and surface charge characteristics. 
However as an alternative, another method in which to incorporate TLR agonists and control vesicle 
size could be to conjugate lipid to TLR agonist and incorporate within the membrane bilayer of 
cationic liposomes, as will be discussed in further detail within Chapter 7. 
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Chapter 7: The inclusion of immunomodulatory resiquimod within liposome 
vaccine adjuvants 
 
 
 
Some of the results presented in this chapter have been published in the paper: 
Wilkinson A., Lattmann E., Perrie Y. “The development of a novel cationic liposome vaccine adjuvant 
using DDA/TDB as a platform with bilayer conjugation of a lipid=TLR7 agonist conjugate within the 
formulation” (Manuscript in preparation). 
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7.1. Introduction 
 
Imidazoquinoline molecules are able to activate B-cells to proliferate and differentiate into antibody-
secreting cells therefore leading to enhanced antibody production (Bishop et al., 2000, Tomai et al., 
2000). This family of molecules are able to activate both Toll-like receptor (TLR) 7 and 8 agonists 
leading the skewing of immunity towards a Th1 immune response (Jurk et al., 2002). These 
molecules present in the imidazoquinolines are termed synthetic immune response modifiers (IRM) 
due to their ability to selectively activate these specific TLRs. These TLRs are located within the 
endosomal compartment of the cell and are able to recognise guanosine- and uridine-rich single 
stranded (ss)RNA (Diebold et al., 2004, Heil et al., 2004, Gorden et al., 2006) as well as IRM such as 
imidazoquinolines. Therefore activation of these TLRs occurs at the endosome, which has been 
shown to be due to activation of these TLRs (by imiquimod and resiquimod) leading to endosomal 
acidification and downstream events leading to the activation of the specific immune response 
(Tomai et al., 2007). This has been further demonstrated by agents that block acidification of 
endosomes and hence block the subsequent activation of the immune response (Hart et al., 2005). 
Although resiquimod and other analogues (which activate through TLR7 and/or TLR8) have been 
demonstrated as effective vaccine adjuvants in a number of model systems, several other studies 
have given mixed success in their ability to act as vaccine adjuvants (Wille-Reece et al., 2005). The 
short half life, in combination with small size (Mw = 314.38) and high aqueous solubility, may lead to 
the rapid distribution throughout the body rather than staying at the injection site which is not ideal 
for the local activation of dendritic cells at the injection site. Therefore, these TLR7/8 agonists may 
need to be co-localised with other stimuli (e.g. antigen and adjuvants) at the injection site in order to 
offer enhanced immunity (Ahonen et al., 2004). Therefore, for optimal vaccine adjuvant formulation 
it may be required to retain the TLR agonist at the site of injection in order to induce local adjuvant 
effects without inducing systemic cytokines, which may give side effects. This could be achieved by 
formulating the agonist within a delivery system such as liposomes. 
During this investigation, DSPE was selected as a lipid which could be conjugated to the TLR7 agonist 
resiquimod; this was due to this lipid containing a primary amine group (-NH3
+) which could initially 
react with succinic anhydride to form a carboxylate, which could subsequently form an ester upon 
reaction with resiquimod. 
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7.2. Aims and Objectives 
 
The aim of the work reported in this final chapter addressed the inclusion of the TLR7 agonist 
resiquimod within the cationic DDA/TDB liposome formulation. In order to achieve this it was 
required to; 
 chemically synthesise a conjugate between lipid and TLR agonist, which will be confirmed by 
chemical analysis, 
 formulate cationic DDA/TDB liposomes with the inclusion of the lipid-TLR agonist conjugate, 
with the physicochemical characteristics and stability of these systems being measured, 
 determine TLR agonist and antigen loading and retention within the formulation, 
 carry out in vivo biodistribution studies to investigate the presence of liposome and TLR 
agonist at the injection site, draining lymph nodes and other organs, 
 investigate these formulations as vaccine adjuvants for the induction of cell mediated 
immune (CMI) and humoural responses after immunisation with the tuberculosis subunit 
vaccine antigen Ag85B-ESAT6-Rv2660c (H56). 
 
7.3. Results and Discussion 
7.3.1. Chemical Synthesis of Lipid-TLR conjugate 
 
It was proposed to design and synthesise a novel lipid-TLR agonist conjugate consisting of the lipid 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) and the TLR7 agonist resiquimod. Both 
lipid and TLR agonist are displayed in Figures 7.1 A and B. 
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Figure 7-1. Chemical structures of (A) DSPE lipid and (B) Resiquimod. 
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B 
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This study will require two important chemical reactions (Figure 7.2); firstly DSPE and succinic 
anhydride will be reacted together (under heat and magnetic stirring) in order to form the DSPE lipid 
with amide bond and terminal carboxylate. Upon formation of this structure, subsequently the TLR 
agonist resiquimod was added (which contains an alcohol group (-OH)) in the presence of the 
diisopropyl azodicarboxylate (DIAD) activating agent and triphenylphosphine (TPP). This will lead to 
the formation of an ester (due to the Mitsunobu reaction) made up of DSPE conjugated to the 
resiquimod TLR7 agonist. 
 
 
Figure 7-2. Overview of chemical synthesis reactions. 
 
7.3.1.1. Initial Optimisation of Step 1 Reaction 
 
To synthesise the lipid-TLR conjugate, DSPE and succinic anhydride (SA) were initially reacted 
together at various molar ratios (either at 1:2, 1:5 or 1:10 M/M ratio) at either room temperature or 
40 °C.  These variables were tested to show which concentration of succinic anhydride was required 
Succinic anhydride (SA) 
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to synthesise the correct product, as it was previously suggested that this may have an effect on the 
reaction (Hermanson, 2008). Variation in reaction temperature was also tested in order to 
investigate whether this variable had an effect on the kinetics of this reaction. In general, increasing 
the temperature of a substance increases the average speed (or energy) of the particles and 
consequently the number of particles colliding with sufficient energy to react. So, at higher 
temperatures there are more successful collisions (between reaction materials) and therefore a 
faster reaction.  
The aim of this reaction was to produce a reaction product, with the DSPE lipid containing an amide 
bond and terminal carboxylate (Figure 7.2). This reaction product should form due to a ring-opening 
process (Klotz, 1967), using succinic anhydride (SA) in order to react with the amine group of the 
DSPE lipid. 
Both at 1:2 and 1:10 M/M ratios of DSPE to SA this reaction did not prove efficient with incorrect 
product formed, as per analysis by TLC, NMR and IR (results not shown). However, the kinetics of the 
reaction can be altered upon altering the temperature in which the reaction takes place or by 
altering the molar ratio between starting materials. Therefore, upon 1:5 M/M ratio reaction 
between DSPE and SA (at 40 °C) this led to the formation of two products as shown by TLC, showing 
the reaction product was not pure; however, these products can be separated by column 
chromatography. During this investigation, the effect of the choice of solvent as the mobile phase 
was investigated. Upon optimisation, ethyl acetate was determined to be the chosen mobile phase 
for all subsequent analyses by TLC due to this solvent providing good separation between reaction 
products (data and results not shown). 
 
7.3.1.2. Optimised Step 1 Reaction 
 
In an optimised reaction, DSPE lipid and succinic anhydride were reacted together at a 1:5 M/M ratio 
at room temperature under magnetic stirring. As the initial reaction product (following reaction at 
40 °C) was not completely pure and required an additional separation stage (which was not ideal), it 
was chosen to carry out the reaction now at room temperature with the aim of synthesising the 
pure correct reaction product. This reaction was allowed to take place for several hours with 
aliquots (50 μL) of the reaction mixture taken at various time points for analysis by thin layer 
chromatography (TLC). Products from this reaction (and the initial starting materials) were visualised 
under UV light (Figure 7.3). These results showed that a reaction product was formed with an Rf 
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value of ~ 0.75. This reaction product, following 24 hours, was shown to be different from the 
starting materials by simultaneously spotting these materials onto the TLC plate. The starting 
materials were shown not to leave a spot on the TLC plate, which was suggested due to the highly 
lipophilic and hydrophilic nature of DSPE lipid and SA respectively. This was shown in all analyses by 
TLC during this investigation. However the reaction product left a spot on the plate thereby showing 
the DSPE lipid has been modified during this reaction (Figure 7.3). Based on this, the reaction 
mixture was dried under vacuum and dessication in order to form a powder residue. This powder, as 
well as the starting materials (DSPE and SA), were subsequently analysed by infrared spectroscopy 
(IR) and nuclear magnetic resonance (NMR) spectroscopy, with the resulting spectra being displayed 
in Figures 7.4 and 7.5 respectively. 
 
 
Figure 7-3. TLC plate analysis of starting materials and various aliquots of reaction product (RP) from the 
succinylation reaction between DSPE and SA (1:5 M/M ratio at room temperature under magnetic stirring). 
 
Reaction Product; Rf = 0.75 
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Figure 7-4. Infra-Red (IR) Spectra of (A) DSPE lipid, (B) succinic anhydride and (C) the reaction product 
formed during the succinylation reaction between DSPE and SA (at a 1:5 M/M ratio at room temperature 
under magnetic stirring). 
C 
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Figure 7-5. NMR Spectra of the Reaction Product formed during the succinylation reaction between DSPE 
and SA (at a 1:5 M/M ratio at room temperature under magnetic stirring). 
 
For the IR spectra of the step 1 reaction product there was a triplet peak at around 3000 cm-1 with 
these peaks also occurring in the spectra for the DSPE lipid (Figure 7.4A) thus showing the retention 
of the lipid tail group (C-H stretch for alkanes) within this reaction product. There was also the 
presence of a new peak present at 3300 cm-1 which represented the presence of an amide (N-H) 
bond within the reaction product. There was also a peak at around 1700 cm-1 which represents the 
C=0 bonds present within the structure of the newly formed amide and carboxylate (Figure 7.4C). 
This showed that the lipid head group was modified upon successful completion of this reaction. 
Furthermore, for the NMR spectra of this Step 1 reaction product there was the presence of multiple 
peaks between 0.9 and 1.7 ppm. These peaks represented the C-H bonds in the tail group of the 
DSPE lipid therefore this suggested that the DSPE lipid tail was retained within this reaction product. 
There were also small peaks at 3.5 and 4.8 ppm which represented the presence of additional 
functional groups within the reaction product, such as amide bond (N-H) and carboxylate (C=O), 
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which were not present in the DSPE lipid itself (Figure 7.5). These peaks were small due to the large 
major presence of the DSPE lipid within the reaction product. The peaks at 7.2 ppm and 0 ppm 
represented chloroform (solvent) and tetramethylsaline (TMS) respectively (Figure 7.5). 
 
7.3.1.2. Step 2 Reaction 
 
Upon formation of the correct structure in step 1 of the reaction, the TLR agonist resiquimod (which 
contains an alcohol group (-OH)) was added to the reaction mixture in the presence of the 
diisopropyl azodicarboxylate (DIAD) activating agent and triphenylphosphine (TPP) with the aim to 
form a conjugate structure between DSPE and resiquimod TLR agonist. Therefore we hypothesised 
that under the optimal conditions (1:1 M/M ratio at room temperature under magnetic stirring) this 
would lead to the formation of an ‘ester’ bond, due to the Mitsunobu reaction (But and Toy, 2007, 
Swamy et al., 2009, Otera and Nishikido, 2010), conjugating the DSPE lipid to the resiquimod TLR7 
agonist (Figures 7.1 and 7.2). As described previously (Section 7.3.1.1) in an initial reaction the 
DSPE:SA conjugate (formed in the step 1 reaction) was reacted with TLR7 agonist resiquimod in the 
presence of the activating agent diisopropyl azodicarboxylate (DIAD) and triphenylphosphine (TPP) 
in order to form the correct reaction product. In an initial reaction, DIAD and TPP were reacted 
together at room temperature at a 1:1 M/M ratio in order to form the betaine 1 (Morrison-Bruns-
Huisgen) intermediate, which was zwitterionic and required for the subsequent activation step in 
the reaction (Otera and Nishikido, 2010). The formation of this intermediate was determined by TLC 
analysis (Figure 7.6A). Following the production of this intermediate, subsequently the step 1 
reaction product (DSPE:SA conjugate containing amide bond and terminal carboxylate) followed by 
resiquimod were added to the reaction mixture (at a 1:1 M/M ratio) at room temperature under 
magnetic stirring.  
Subsequently, upon the addition of the DSPE lipid bearing a terminal carboxylate (step 1 reaction 
product) this led to the formation of a separate reaction product (Figure 7.6B) which had an Rf value 
of 0.4. Subsequently upon addition of the TLR7 agonist resiquimod to the reaction mixture, this 
resulted in a further shift in the Rf value of the reaction product, from 0.4 to 0.15 (Figure 7.6C), with 
a small by-product present at Rf(0.4). This suggested that a new product was formed, however there 
was a by-product from this reaction which was suggested to be triphenyloxide or TPhP=O (Otera and 
Nishikido, 2010).  
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Figure 7-6. TLC plate analysis of various aliquots (taken at 1 hour time points) taken from the Mitsunobu 
esterification reaction between step 1 reaction product and resiquimod, in the presence of diisopropyl 
azodicarboxylate (DIAD) and triphenylphosphine (TPP) as activating agents. 
 
Following this analysis, the reaction mixture was initially subjected to silica-sand column 
chromatography in order to extract, isolate and separate the correct reaction product which was 
present at Rf(0.15). This reaction product was dried under vacuum and dessication in order to form a 
powder residue. This product was subsequently analysed by Infrared spectroscopy (IR) and nuclear 
magnetic resonance (NMR) spectroscopy with the resulting spectra being displayed in Figures 7.7 
and 7.8 respectively. Analysis of the IR spectra from this newly formed product suggested the 
retention of the major functional groups of the step 1 reaction product (DSPE:SA conjugate) in the 
final product including the amide (N-H) bonds at 3300 cm-1 and 1700 cm-1 (C=O) as well as the C-H 
stretch triplet peak at 2800-3000 cm-1 (Figure 7.7). However, there were additional peaks in this 
Rf = 0.25-0.3 
Rf = 0.4 
Rf = 0.15 
A 
B 
C 
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spectra suggesting the presence of an ester group, which was required as the ‘linker’ in this product 
as represented by peaks at 1100 and 1700 cm-1 (C=O and C-O peaks respectively). There were also 
additional peaks at 3600-3700 cm-1 and ~ 1500 cm-1 which represented C-H and C-C bonds present 
in the aromatics of resiquimod, respectively (Figure 7.7). This showed that resiquimod was able to be 
conjugated to DSPE lipid, which can then be subsequently used in liposome formulation. 
 
Figure 7-7. IR Spectra of the Reaction Product formed during the Mitsunobu esterification reaction between 
DSPE:SA conjugate (Step 1 reaction product) and Resiquimod (at a 1:1 M/M ratio at room temperature 
under magnetic stirring). 
 
The NMR spectrum of this Step 2 reaction product displayed the retention of peaks between 0.9         
and 1.7 ppm, which indicated the retention of the DSPE lipid component. There were also more 
pronounced peaks at 3.5 and 4.8-5.0 ppm (Figure 7.8), which represented newly attached bonds in 
the attached resiquimod molecule. The additional peaks between 7.5 and 8.0 ppm suggested the 
presence of an aromatic molecule or residues, which was shown due to the presence of resiquimod 
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in the conjugate structure. The peaks at 7.2 ppm and 0 ppm represented chloroform and 
tetramethylsilane (TMS) respectively (Figure 7.8). 
 
Figure 7-8. NMR Spectra of the Reaction Product formed during the Mitsunobu esterification reaction 
between DSPE:SA conjugate and Resiquimod (at a 1:1 M/M ratio at room temperature under magnetic 
stirring). 
 
7.3.2. Incorporation of immunostimulatory resiquimod within multilamellar vesicles 
 
During these studies, DDA/TDB MLVs were formulated with DSPE-conjugated resiquimod 
(DSPE=Resiquimod; Figure 7.9A) and also with inclusion of DSPE (within the bilayer) and addition of 
resiquimod post-LH (Figure 7.9B). 
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Figure 7-9. Multilamellar vesicles; with bilayer incorporation of DSPE=Resiquimod conjugate to DDA/TDB (A) 
or incorporation of DSPE and post-LH addition of resiquimod to DDA/TDB (B). 
 
7.3.2.1. Characterisation and stability of resiquimod/MLV formulations 
 
All liposome-adjuvanted formulations displayed vesicle sizes in the region of 500-600 nm. There 
were also no significant changes in the polydispersity (PDI) of these tested formulations (Figures 7.10 
A and B). This showed that association of DSPE within the bilayer of the formulation, with either 
conjugated resiquimod or the addition of resiquimod post lipid film-hydration, had no significant 
impact on the vesicle characteristics of these liposome systems. 
Zeta potential analysis of all-tested liposome formulations gave rise to surface charges in the region 
of 60 to 65 mV, which were strongly cationic, as would be expected by the positively-charged head 
group of DDA present within the formulation (Figure 7.10C). Therefore association of DSPE and 
resiquimod within cationic liposome vaccine formulations resulted in no significant changes in the 
zeta potential of these formulations. This was suggested to be due to the fact that resiquimod, due 
to its small size and high aqueous solubility (Tomai et al., 2007) was unable to remain with the 
formulation (when added post lipid film-hydration). However, conjugating resiquimod to the bilayer 
of vesicles led to efficient incorporation of this TLR agonist without further significant effects on 
vesicle characteristics, which has been hypothesised to be optimal for the adjuvant action of these 
formulations (Tomai et al., 2007). 
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Figure 7-10. Characterisation of liposome vaccine formulations (A: Size; B: Polydispersity; C: Zeta potential) 
with addition of the in vivo dose of H56 antigen (5 μg per dose). Results are the mean of triplicate 
experiments ± SD. 
 
The stability of liposomes is a crucial factor in the development and formulation of novel liposome 
vaccine delivery systems. Cationic DDA/TDB liposomes were incorporated with DSPE lipid within the 
bilayer and resiquimod post-LH (DDA/TDB/DSPE/Resiquimod), or were incorporated with the 
addition of the DSPE=Resiquimod (lipid=TLR) conjugate within the bilayer 
(DDA/TDB/DSPE=Resiquimod). Both of these liposome formulations contained the same molar ratio 
of all lipids and TLR agonist. These liposomes were also combined with and without the addition of 
the in vivo concentration of H56 antigen (5 μg). The stability of vesicles was tested over a 28 day 
period following storage at 4 °C and 25 °C respectively.  
Cationic DDA/TDB/DSPE liposomes (mixed post lipid film-hydration with resiquimod) displayed an 
initial vesicle size of either 500 or 550 nm (without and with H56 antigen respectively; Figure 7.11A). 
In terms of storage conditions, liposome systems (both with and without antigen) stored at 25 °C 
displayed a slight increase in vesicle size (over time) compared to when stored in 4 °C  standard 
conditions however these changes were not significant over a 28-day study period. Polydispersity 
analysis (Figure 7.11B) showed that cationic DDA/TDB/DSPE/Resiquimod, both with and without 
antigen, gave rise to vesicles which had a fairly narrow size distribution and a uniform and 
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homogenous population. In terms of zeta potential these liposome vaccine formulations displayed 
initial zeta potential values of 65 mV and 60 mV, both without and with antigen respectively (Figure 
7.11C). Over the time period of this study both empty and antigen-loaded liposome systems showed 
no significant changes in zeta potential. This showed that the vesicle characteristics of these 
liposomes remained stable over this study period, both following storage at 4 °C and 25 °C. These 
stability studies have shown that cationic DDA/TDB/DSPE/Resiquimod liposomes (both with and 
without H56 antigen) remained homogenous and exhibited minimal phase separation even after a 
28-day storage period (at both temperatures of 4 ˚C and 25 ˚C; Figures 7.12 A and B). The 
homogenous nature of these liposome samples when stored at 4 ˚C at 25 ˚C conditions was reflected 
by no hugely significant changes in the vesicle size, polydispersity and zeta potential over the time 
period (Figure 7.11) therefore these formulations are recommended for storage at both of these 
temperature conditions in an aqueous format. 
Cationic DDA/TDB/DSPE=Resiquimod liposome formulations (incorporating the TLR agonist 
conjugate within the bilayer) were measured for their vesicle size, polydispersity and zeta potential. 
This liposome formulation displayed an initial vesicle size of either 420 or 500 nm (without and with 
H56 antigen respectively; Figure 7.13A). Empty and antigen-loaded liposome systems displayed 
similar vesicle sizes following storage at 4 °C and 25 °C. By day 28 both empty and antigen-loaded 
systems displayed vesicle sizes in the region of 600 and 730 nm respectively (Figure 7.13A). 
Polydispersity analysis (Figure 7.13 B) showed that cationic DDA/TDB/DSPE=Resiquimod, both with 
and without antigen displayed vesicles which have a fairly narrow size distribution. In terms of zeta 
potential these liposome vaccine formulation displayed initial zeta potential values of around 65 mV 
and 61 mV, both without and with antigen respectively (Figure 7.13C). Over the time period of this 
study both empty and antigen–loaded liposome systems showed no significant changes in zeta 
potential. This showed that these systems remained stable over this study period, following storage 
at 4 °C and 25 °C respectively. Also antigen and agonist incorporation within the liposome system 
resulted in no significant changes in measured vesicle characteristics for either of these liposome 
systems (Figures 7.11 and 7.13). These stability studies have shown that cationic 
DDA/TDB/DSPE=Resiquimod liposomes (both with and without H56 antigen) remained homogenous 
and also exhibited minimal phase separation even after a 28-day storage period (at both 
temperatures of 4 ˚C and 25 ˚C; Figures 7.14 A and B). The homogenous nature of these liposome 
samples when stored in both standard (4 ˚C) and accelerated (25 ˚C) conditions was reflected by no 
hugely significant changes in the vesicle size and zeta potential respectively over the time period of 
this study (Figures 7.13), therefore suggesting these liposome systems are able to stored in an 
aqueous format, over a 28-day storage period with no significant effects on vesicle characteristics.  
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Therefore resiquimod, whether bilayer-incorporated or surface-attached within DDA/TDB liposomes, 
had no further subsequent effect on the vesicle characteristics and stability of these formulations. 
 
 
 
Figure 7-11. Vesicle size (A) analysis, polydispersity (B), zeta potential (C) and stability (over a 28-day period) 
of DDA/TDB incorporating DSPE lipid and resiquimod (mixed post-LH) with and without H56 antigen 
following storage at 4 °C and 25 °C. Results are the mean of triplicate experiments ± SD. 
  
Figure 7-12. DDA/TDB/DSPE/Resiquimod (A) and DDA/TDB/DSPE/Resiquimod:H56 (B) liposome samples 
stored in glass vials were prepared by the lipid-film hydration (LH) method and were stored for 28 days at 4 
˚C and 25 ˚C. 
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Figure 7-13. Vesicle size (A), polydispersity (B) and zeta potential (C) analysis and stability (over a 28-day 
period) of DDA/TDB incorporating DSPE=Resiquimod TLR conjugate, with and without H56 antigen following 
storage at 4 °C and 25 °C. Results are the mean of triplicate experiments ± SD. 
 
Figure 7-14. DDA/TDB/DSPE=Resiquimod (A) and DDA/TDB/DSPE=Resiquimod: H56 (B) liposome samples 
stored in glass vials were prepared by the lipid-film hydration (LH) method and were stored for 28 days at 4 
˚C and 25 ˚C. 
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7.3.3. Quantification of antigen loading and retention 
 
These liposome vaccine formulations were further tested for their ability to associate and retain 
antigen within the delivery system. These parameters were quantified by determining the amount 
(percentage) of radiolabelled antigen (H56) with the delivery system. These results showed that both 
conjugate and control formulations, DDA/TDB/DSPE=Resiquimod and DDA/TDB/DSPE/Resiquimod 
respectively, were able to associate high levels of the anionic H56 TB antigen with antigen loading 
levels of 80-90 % being determined (Figure 7.15).  
Both of these formulations showed high levels of antigen loading (Figures 7.15) and low levels of 
antigen release over this study period therefore this showed that these systems were stable (Figures 
7.16 A and B) and were able to efficiently retain the vaccine antigen associated to the surface of the 
liposome delivery system. There was an initial burst release of antigen (P < 0.001) from the 
formulation over the initial 3 to 5 hours of the study, however this release stabilised throughout the 
rest of the 96-hour study period (Figures 7.16 A and B). Therefore the presence of resiquimod within 
the formulation (either bilayer-conjugated or surface-adsorbed) had no subsequent effect on the 
ability to load and retain vaccine antigen.  
 
 
Figure 7-15. Initial loading of H56 Antigen by cationic liposome-TLR formulations. Results are the mean of 
triplicate experiments ± SD. 
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Figure 7-16. Antigen Release Kinetics from Cationic Liposome-TLR formulations in (A) simulated in vivo 
conditions (FCS/Tris; 50:50 v/v; 37 °C) and (B) control conditions (Tris 10 mM pH 7.4; 37 °C). Results are the 
mean of triplicate experiments ± SD. Significance was measured by one-way ANOVA (*** p<0.001) as 
compared to initial antigen retention at 0 h. 
 
7.3.4. Quantification of resiquimod loading and retention 
7.3.4.1. Proof of radiolabelling 
 
During these studies, the radiolabelling of resiquimod was proven by agonist loading and dialysis 
studies as well as biodistribution studies (Section 7.3.6). Following radiolabelling of this TLR agonist 
with 125I, this process was shown not to be completely efficient by dialysis (Figure 7.17). 
Radiolabelled resiquimod or DSPE-conjugated resiquimod, following association with cationic 
DDA/TDB/DSPE or DDA/TDB respectively, were placed in separate dialysis tubing in Falcon tubes 
containing Tris buffer (10 mM, pH 7.4). Gamma counts were subsequently measured in the dialysis 
tubing (total counts) and release media following dialysis, in which by the 24-hour time point         
only 30 % of the total counts (Figure 7.17A) were found in the release media (which were released in 
the first hour of dialysis; P < 0.001). Therefore free 125I was released through the dialysis tubing with 
retention of liposomes with radiolabelled resiquimod or DSPE-conjugated resiquimod within the 
tubing (Figure 7.17A). Removal of free 125I following the radiolabelling of resiquimod or DSPE-
conjugated resiquimod was by the use of sodium thiosulphate, which had the ability to convert free 
iodine to iodide (see equation 7.1). Subsequently, free iodide and tetrathionate were removed using 
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dialysis in order to obtain an efficiently radiolabelled TLR agonist free from contaminants (Figure 
7.17B). 
I2 + 2 S2O3
2-  2 I- + S4O6
2-   
Equation 7.1 
 
  
 
Figure 7-17. Radiolabelling of resiquimod-containing liposome formulations and subsequent removal of free 
radiolabel following extended dialysis, (A) or treatment with sodium thiosulphate and extended dialysis (B). 
Results are the mean of triplicate experiments ± SD. Significance between experimental groups was measured 
by one-way ANOVA (*** p<0.001). 
 
Following radiolabelling and dialysis (in order to remove free radiolabel) of resiquimod-containing 
liposome vaccine formulations, the loading of resiquimod within these formulations was 
determined. Incorporation of the DSPE=Resiquimod conjugate within the cationic DDA/TDB 
formulation resulted in high agonist retention (87 %) within the liposome pellet, therefore this 
showed that this agonist had been successfully incorporated within the liposome delivery system 
(Figure 7.18). In contrast the addition of radiolabelled resiquimod, post lipid film-hydration to the 
DDA/TDB/DSPE liposome delivery system resulted in significantly (P < 0.001) lower levels of agonist 
loading in the region of 18-20 % (Figure 7.18). This was due to the fact that resiquimod became less 
associated with the delivery system due to the lack of charge-related electrostatic interaction (Zaks 
et al., 2006, Tomai et al., 2007) and, therefore, this agonist required either entrapment by the 
delivery system or incorporation within the liposome bilayer through chemical conjugation with the 
DSPE lipid as has been displayed through these studies (Section 7.3.1). 
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Figure 7-18. Resiquimod loading ability of cationic liposome vaccine formulations, either added post-LH and 
incorporated within DDA/TDB/DSPE delivery system or conjugated to DSPE and incorporated within 
DDA/TDB delivery system. Results are the mean of triplicate experiments ± SD. Significance between 
experimental groups was measured by one-way ANOVA (*** p<0.001). 
 
7.3.4.2. Resiquimod release profile from multilamellar vesicles in simulated in vivo 
conditions 
 
Following radiolabelling, the loading and release kinetics of the TLR agonist resiquimod (either when 
conjugated to DSPE and incorporated into DDA/TDB, or added post lipid film-hydration to the 
DDA/TDB/DSPE delivery system) were also determined (Figure 7.19). Unlabelled H56 antigen was 
also added at the in vivo (0.1 mg/mL) dose to these formulations as this antigen was added during in 
vivo studies. For both formulations, there was an initial significant release of agonist from the 
delivery system (P < 0.001) within the first hour of the study. However following this initial burst 
release, both formulations displayed high levels of agonist retention (Figure 7.19 B). In terms of 
agonist retention, both formulations shared similar release profiles, whether resiquimod was 
conjugated within the bilayer or added post lipid film-hydration to the delivery system (Figure 7.19 
B). However, the DDA/TDB formulation (with bilayer-conjugated resiquimod) was able to initially 
load a higher amount of resiquimod (Figure 7.18), therefore this formulation was hypothesised to be 
advantageous in terms of its ability to exert downstream immune responses (Tomai et al., 2007) 
which will be investigated in Section 7.3.7. 
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Figure 7-19. Resiquimod TLR Agonist Loading (A) and Release Kinetics (B) from cationic Liposome-TLR 
formulations in simulated in vivo conditions (FCS/Tris; 50:50 v/v; 37 °C). Results are the mean of triplicate 
experiments ± SD. Significance was measured by one-way ANOVA (*** p<0.001) as compared to initial agonist 
retention at 0 h. 
 
7.3.5. Stability of radioactive markers within resiquimod-containing liposome 
formulations in order to investigate membrane stability  
 
As discussed previously in Chapters 4 and 5, the membrane stability of liposomes can be determined 
upon the introduction of trace amounts of 3H-Cholesterol within the bilayer membrane. Liposomes 
(DDA/TDB/DSPE/Resiquimod and DDA/TDB/DSPE=Resiquimod) were prepared by the lipid film-
hydration method, with the incorporation of trace amounts of 3H-Cholesterol (0.17 nM). Dialysis was 
used to study the retention of 3H-Cholesterol within the liposome membrane. At various time points 
(1h, 3h, 5h, 18h, 48h and 96h) over a 96 hour study period, 1 mL aliquots of dialysis media were 
removed and the amount of 3H present were measured. These results showed that incorporation of 
DSPE and either bilayer-conjugated or surface-attached resiquimod had no effect on the membrane 
stability of these liposome formulations or release of 3H-Cholesterol from the membrane with these 
formulations shown to display a maximum 3H-Cholesterol release of ~ 4.5 % from the liposome 
bilayer (Figure 7.20) over the 96 hour period of the study. These formulations were then taken 
forward into in vivo biodistribution studies. 
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Figure 7-20. Membrane stability of DDA/TDB/DSPE/Resiquimod and DDA/TDB/DSPE=Resiquimod liposomes 
(prepared by the lipid film hydration method) was studied by the addition of a trace amount of 
3
H-
Cholesterol within the liposome formulation. Results express the % of the original 
3
H-Cholesterol dose added 
to liposomes that is detected in the dialysis buffer over a 96 hr time period. The samples were stored at 37 °C 
in 50 % FCS in Tris buffer (10 mM; pH 7.4). Results denote the mean of triplicate experiments ± SD. 
 
7.3.6. Tracking the in vivo biodistribution profile of liposome and TLR agonist 
 
The biodistribution of radiolabelled liposomes and agonist was studied at day one, four and eight 
post-injection. The day 8 time point was studied (instead of day 14 p.i), as generally very low doses 
of liposome and antigen were detected at day 14 p.i in previous studies. The percentage liposome 
and agonist dose retention was examined at these time points in a number of organs including the 
vaccination site (left quadricep), draining lymph nodes, spleen, muscle, liver, lung, kidney, heart, 
blood, small intestine and brain. 
Previous studies have suggested that the ability to form a depot is important for the function of 
many adjuvants (Henriksen-Lacey et al., 2010a, Henriksen-Lacey et al., 2011a, Kaur et al., 2011, 
Christensen et al., 2012). Incorporation of DSPE (either just lipid or lipid=TLR conjugate, however 
was present at the same molar ratio) was shown to have no significant effect on the liposome dose 
retention at all time points, with all formulations studied showing a similar liposome ‘depot’ effect. 
At day 1 p.i, DDA/TDB:H56 displayed high liposome dose retention of ~ 85 % (which was similar to 
previous studies (Henriksen-Lacey et al., 2010a, Henriksen-Lacey et al., 2010c)) with still around      
30 % of the dose remaining at day 8 p.i. For both novel vaccine formulations incorporating 
resiquimod, a significant liposome ‘depot’ was observed with around 70-75 % remaining at day 1 p.i. 
whereas still 40 % and 25 % of the dose remained at days 4 and 8 p.i, respectively (Figure 7.21A). 
These results suggested that liposome was retained at a high percentage at day 1 p.i before 
controlled drainage of liposomal adjuvants by day 8 p.i (P < 0.001), as was discussed previously in 
Chapters 4 and 5 as well as in the previous literature (Henriksen-Lacey et al., 2010a). In terms of 
resiquimod retention at the SOI, when conjugated to DSPE and incorporated within the DDA/TDB 
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vaccine delivery system, resiquimod was well retained at the site of injection with around 70 % of 
the dose remaining at day 1 p.i, 40 % at day 4 p.i and 24 % at day 8 p.i. However, resiquimod agonist 
adsorbed to the delivery system gave rise to only minimal retention with 6 %, 1 % and 0.5 % of the 
dose remaining at the injection site at days 1, 4 and 8 p.i respectively (Figure 7.21B). Also resiquimod 
TLR agonist injected alone was shown to rapidly drain from the injection site. These results showed 
that resiquimod was unable to adsorb to the delivery system due to the lack of electrostatic 
interactions. However, when resiquimod was conjugated to lipid and incorporated within the 
DDA/TDB delivery system this led to the formation of significant ‘depot’ of agonist (P < 0.001) at this 
site, compared to surface-associated resiquimod (Figure 7.21B). For this formulation, the retention 
of both delivery system and TLR agonist (as well as antigen, as discussed previously in Chapters 4 
and 5) was important in the mechanism of action of  liposome vaccines termed the ‘depot effect’ 
(Storni et al., 2005, Henriksen-Lacey et al., 2010a). 
In terms of liposome drainage to the PLN (Figure 7.21C), all formulations tested showed similar 
drainage profiles. At day 1 p.i, there was ~ 0.01 % of the dose drained to the PLN (for all formulations 
tested). However by day 8 p.i, there was a significant increase (P < 0.001) of these liposome vaccines 
draining to the PLN. These results therefore suggested that these cationic liposome vaccines formed 
a superior depot at the injection site which resulted in a more delayed controlled release of the 
adjuvant to the draining lymph nodes which was important for the mechanism of action of these 
vaccine formulations. Also incorporation of the DSPE lipid (either alone, or conjugated to 
resiquimod) within the DDA/TDB formulation was shown to have no significant effect on the 
drainage of the liposome delivery system to the PLN (Figure 7.21C). In terms of agonist drainage to 
the PLN, the levels of resiquimod were very low (< 0.05 %). At day 1 p.i, resiquimod alone was 
present in higher levels however the levels of this agonist were significantly decreased by day 8 p.i (P 
< 0.01), thereby suggesting rapid drainage of agonist from the injection site (Figure 7.21D). 
Conjugation of resiquimod to DSPE and incorporation within the bilayer of the delivery system 
resulted in enhanced drainage to the popliteal lymph node (PLN) by day 8 p.i, compared to when 
just adsorbed to the delivery system (P < 0.05). Therefore the controlled release of delivery system 
in combination with resiquimod retention by the delivery system resulted in a significant increase in 
drainage from the injection site to the PLN by day 8 p.i. Pontamine blue was used a marker for the 
staining of infiltrating monocytes at the left quadricep (site of injection) as described in previous 
research studies (Tilney, 1971, Henriksen-Lacey et al., 2010a) and in Chapters 4 and 5. The injection 
of DDA and DDA/TDB liposomes had been shown in earlier studies (Korsholm et al., 2007) to result in 
the significant recruitment of circulating monocytes and neutrophils at the SOI, which linked with 
the observed pontamine blue staining in these studies for DDA/TDB:H56. Therefore, this 
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demonstrated an enhanced monocyte infiltration to this site (Figure 7.21E; also see chapters 4 and 
5). This activation of the innate immune system occured due to the presence of the 
immunostimulatory component TDB within the liposome system which was able to activate a non-
TLR pathway (Werninghaus et al., 2009) as opposed to a TLR-based response which acts through the 
Myd88 pathway. Both other cationic formulations tested in this study 
(DDA/TDB/DSPE/Resiquimod:H56 & DDA/TDB/DSPE=Resiquimod:H56) also activated localised 
pontamine blue staining at the injection site (Figure 7.21E). Pontamine blue staining at the injection 
site correlated with the formation of a ‘liposome depot’ at the injection site (Figure 7.21A) which 
suggested that this staining was due to the TDB-induced infiltration of monocytes to the SOI, 
therefore this showed that this formulation may be able to produce a population of circulating 
monocytes and neutrophils at this site. These monocytes were then able to transport liposome 
delivery system (and associated antigen) from the injection site to other areas in the body mainly 
including the draining lymphatics (as described previously in Chapter 4). However the negative 
control formulation used in this study (resiquimod alone) was unable to induce pontamine blue 
staining, which was due to the lack of a delivery system in this formulation hence no liposome depot 
(Figure 7.21E). Therefore these studies suggested that the high cationic charge of the delivery 
system was the key driver in showing monocyte influx, as was demonstrated by high localised 
pontamine blue staining at the SOI for all liposome formulations studied. The inclusion of resiquimod 
within these cationic liposomal adjuvants had no further effect on the intensity of pontamine blue 
staining at this site. 
As a control, the distally located popliteal lymph node (termed the blank lymph node) was processed 
in order to determine the % liposome and agonist dose drainage (Appendix Figures 1 and 2). These 
results showed that only minimal trace levels (< 0.005 %) of the delivered liposome and resiquimod 
TLR agonist were found at this site with no general trend observed over the time period of this study 
between formulations. Therefore this showed that the vaccine was draining to the LN on the same 
leg as injection. The drainage of liposome and TLR agonist to a number of other organs was also 
investigated during this study. Muscle was excised from the uninjected leg, as well as dissection of 
other key organs such as the heart, brain, lung, liver, kidney, small intestine and blood. For these 
organs tested, < 1 % of both the liposome and/or agonist dose was detected. In terms of liposome 
drainage (Appendix, Figure 3), there was no general trend noticed between formulations in terms of 
their drainage to other organs at all experimental time points (days 1, 4 and 8 p.i). Whereas in terms 
of drainage of the TLR agonist resiquimod (Appendix, Figure 4), a slightly higher percentage dose was 
present at the day 1 time point p.i. This indicated more rapid drainage of the TLR agonist to these 
organs studied at earlier time points. 
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Figure 7-21. Liposome (A, C) and agonist dose retention (B, D) at the SOI and PLN respectively following i.m. 
injection of either DDA/TDB/DSPE/Resiquimod, DDA/TDB/DSPE=Resiquimod and DDA/TDB (all adsorbing 
H56 antigen) or resiquimod alone (negative control). (E) shows monocyte influx as indicated by pontamine 
day staining at day 1 p.i following i.m. injection of these liposome vaccine formulations. The proportion of 
3
H 
or 
125
I radionucleotides at the SOI and PLN as a percentage of the initial dose were calculated. Results 
represent the mean ± SD of four mice. Significance between experimental groups and time points was 
measured by one-way ANOVA (*** p<0.001; ** p<0.01; * p<0.05). 
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The biodistribution profile of these vaccine formulations was important due to their subsequent 
ability to initiate immune responses. Therefore, the ability of liposomes to successfully retain 
associated TLR agonist was crucial in order to deliver these components to the same monocyte 
recruiting cells (Korsholm et al., 2007, Kamath et al., 2009, Kamath et al., 2012). Previous literature 
has stated that it was apparent that in order for imidazoquinolines (such as resiquimod) to be both 
safe and effective, that the immune activation at the application site without systemic activation was 
important (Tomai and Vasilakos, 2011). Therefore the results during these studies showed effective 
retention of liposome (with bilayer-conjugated resiquimod) at the SOI, followed by controlled 
drainage of both liposome and resiquimod to the PLN. However, if not conjugated, the liposomes 
were retained at the SOI but the resiquimod was cleared rapidly, which was similar to resiquimod 
administered without liposomes. 
A number of other studies in the previous literature have suggested that conjugation of TLR agonists 
to lipid has a subsequent effect on the maintenance of a ‘reservoir’ of TLR agonist at the injection 
site (Chan et al., 2009, Andrews et al., 2011, Smirnov et al., 2011). Therefore, the retention and 
controlled drainage of liposome and TLR agonist from the SOI to the PLN was hypothesised to be 
advantageous for the induction of immune responses.  
 
7.3.7. Immunisation studies 
 
The aim of these studies was to identify a formulation with the ability to induce strong cell-mediated 
immune (CMI) responses, characterised by cytokine production at the injection site, spleen and 
popliteal lymph node (PLN). Cationic DDA/TDB liposomes were prepared as MLVs combined with the 
H56 TB vaccine, with or without the incorporation of resiquimod; either bilayer incorporated 
(DDA/TDB/DSPE=Resiquimod:H56) or surface attached (DDA/TDB/DSPE/Resiquimod:H56). 
 
7.3.7.1. The effect of resiquimod on antibody response in the blood sera 
 
The ability of H56 vaccine antigen either delivered alone or in combination with DDA/TDB liposomes 
without or with resiquimod (bilayer-incorporated or surface attached) to induce IgG (total), IgG1 and 
IgG2b antibody isotypes was investigated using ELISAs. Mice immunised with resiquimod alone were 
also used as a negative control during this set of studies. Blood was collected on days 13 and 46 and 
mice were injected with vaccines on days 0, 14 and 28. In general, there were a number of noted 
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differences in antibody responses in which liposome-adjuvanted vaccines induced significantly 
enhanced antibody titres at day 46 (P < 0.001) following triple homologous vaccination. At day 13 
(following one immunisation), low and minimal responses were noted for all formulations apart 
from resiquimod which gave no response at all (Figure 7.22). For IgG and IgG1 antibody responses 
(at day 46) all cationic formulations gave rise to similarly high titres (Figures 7.22 A and B), whereas 
in contrast DDA/TDB/DSPE=Resiquimod:H56 liposomes induced significantly higher (p < 0.01) IgG2b 
responses (Figure 7.22C). Therefore, this showed that conjugating resiquimod to the bilayer of the 
vesicles resulted in higher anti-H56 specific IgG2b antibody titres. This indicated that this 
formulation (efficiently incorporating resiquimod) gave rise to increased antibody responses as has 
been suggested in the previous literature (Weeratna et al., 2005, Tomai et al., 2007) for formulations 
that maintained agonist locally at the site of administration. 
 
7.3.7.2. Cytokine Analysis at the Site of Injection 
 
During this investigation there was a need to monitor and study ‘leg immune responses’ at the site 
of injection (SOI). This was in order to monitor the immune response in regards to cytokines 
associated with the inflammasome complex such as interleukin1-beta (IL-1β) as well as interleukin-
18 (IL-18) and interleukin-33 (IL-33) as discussed previously in Chapter 4. Immunisation of mice with 
liposome-adjuvanted H56 vaccines gave rise to significantly increased cytokine production at the 
SOI, in comparison to immunisation with resiquimod or H56 antigen alone (P < 0.001). Interestingly, 
cationic formulations with bilayer-conjugated resiquimod gave rise to further significantly increased 
production (Figure 7.23) for all cytokines tested (IL-1β (p < 0.001), IL-18 (p < 0.05) and       IL-33 (P < 
0.01)) in comparison to the other cationic formulations (DDA/TDB:H56 and 
DDA/TDB/DSPE/Resiquimod:H56 respectively). These results therefore suggested that bilayer 
incorporation of DSPE=Resiquimod within the formulation boosted local innate immune responses 
at the SOI and enhanced the Th1 bias of H56-adsorbed cationic liposomes. This could be due to the 
fact that resiquimod has the potential to bind the endosome-located TLR7 receptor thus initiating 
further cellular immune responses that boost the immune response. These results further concluded 
that proinflammatory cytokine production at the SOI was a result of activation of the inflammasome, 
causing downstream activation of cellular signalling pathways hence this boosted the immune 
response (Ogura et al., 2006, Sharp et al., 2009, Tomai and Vasilakos, 2011). 
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Figure 7-22. H56-antigen specific antibody responses in the blood sera [A: IgG; B: IgG1; C: IgG2b]. Blood was 
collected at days 13 and 46. Results are the mean of five mice ± SD. Significance between experimental groups 
and time points was measured by one-way ANOVA (*** p<0.001). For A and B, significance was measured 
compared to the H56-immunised group. For C, significance was measured compared to all other formulations 
tested. 
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Figure 7-23. IL-1β, IL18 and IL33 production (ng/g tissue) from excised leg muscle from the SOI derived from 
mice immunised with H56 in combination with either DDA/TDB/DSPE/Resiquimod, 
DDA/TDB/DSPE=Resiquimod or DDA/TDB. As negative controls, resiquimod and H56 antigen were injected 
alone. Mice received 3 injections with 2-week intervals; muscle from the SOI was collected at day 49 upon 
termination of the study. Cytokines were measured from muscle supernatants using sandwich ELISAs. Results 
represent the mean of 5 mice per group ± SD. Significance between experimental groups was measured by 
one-way ANOVA (*** p<0.001; ** p<0.01; * p<0.05). 
 
7.3.7.3. Cytokine Analysis from ex vivo restimulated splenocytes 
 
The supernatants of restimulated splenocytes were assayed for the presence of cytokines IFN-γ, IL-
17, IL-2, IL-6, IL-5 and IL-10. H56 antigen  was applied to cells at concentrations of 0.05, 0.5 and 5 
μg/mL, in addition to ConA (2 μg/mL) stimulation as a positive control and media only as a negative 
control. Figure 7.24 gave a conclusive overview of the results derived from each experimental group, 
following restimulation at 5 μg/mL H56. Whilst individual cytokine production in response to media 
(negative control), ConA (positive control) and also H56 (0.05, 0.5 and 5 μg/mL) was shown in the 
Appendix (Figure 5). 
Very low or no responses were measured in the absence of splenocyte restimulation (for all 
cytokines tested in this study; Appendix Figure 5, A to F), which suggested that cytokine production 
was highly-dependent on the activation of splenocytes with previously encountered antigen. Also, as 
a positive control, splenocytes were restimulated with ConA, which caused significantly higher 
cytokine production (for all further cytokines tested) which highlighted the ability of ConA to 
restimulate splenocytes irrespective of the vaccine used to immunise mice (Appendix Figure 5, A to 
F). 
 
The first cytokine investigated was IFN-γ which is a commonly used marker to determine the efficacy 
of tuberculosis vaccines (Agger and Andersen, 2001). Upon re-stimulation of splenocytes with H56, 
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there were significant increases in IFN-γ production for all liposome-injected mice (Figure 7.24); 
resiquimod and free H56 immunised mice only responded in low levels to H56 at any of the 
concentrations added. As discussed previously in Chapter 5, IFN-γ production from splenocytes for 
H56-adsorbing liposomal vaccines was significantly higher than any other cytokine studied during 
this investigation. For liposome-adjuvanted vaccines on average around 13000-18000 pg/mL IFN-γ 
was detected following splenocyte restimulation. Interestingly, mice immunised with cationic 
liposomes with bilayer-conjugated resiquimod gave rise to significantly increased (P < 0.01) IFN-γ 
cytokine production (Figure 7.24) in comparison to cationic DDA/TDB (with or without surface-
adsorbed resiquimod). The presence of increased amounts of resiquimod within the formulation 
resulted in enhanced Th1 immune responses as has been discussed previously for resiquimod and its 
derivatives upon local application (Bishop et al., 2000, Tomai et al., 2000, Wille-Reece et al., 2005, 
Smirnov et al., 2011). However, there were no significant differences between the other two cationic 
DDA/TDB liposome formulations in terms of the production of all cytokines tested, therefore this 
showed that as resiquimod only was only lowly retained by the delivery system (along with the 
inclusion of DSPE), this had no effect on downstream cytokine production. Therefore vaccine design 
in formulating resiquimod to remain at the SOI had important effects for optimal adjuvant activity 
(Tomai et al., 2007). 
 
The following cytokine investigated was interleukin-17 (IL-17), which is able to act as a potent 
mediator in delayed-type reactions by increasing chemokine and cytokine production in order to 
recruit neutrophils and monocytes to the site of inflammation. IL-17 production is stimulated by the 
action of IL-23 on Th17 cells (Cooke, 2006, Schoenen et al., 2010, Kamath et al., 2012). There was a 
significant trend noticed in IL-17 production upon immunisation with H56 antigen-adsorbing 
liposomal vaccines, in comparison to both control groups (free resiquimod and H56); upon 
restimulation of splenocytes at all concentrations tested this leads to enhanced cytokine production. 
As described with IFN-γ, peak IL-17 production (around 6000 pg/mL) was noted by splenocytes 
derived from mice immunised with bilayer-conjugated resiquimod within cationic DDA/TDB 
liposomes (P < 0.05), in comparison to other cationic liposome formulations (Figure 7.24), therefore 
showing the potential of resiquimod to enhance Th17 responses upon inclusion within the 
formulation. 
Interleukin-2 (IL-2) is important in the regulation of the activities of white blood T-cells (leukocytes) 
and also in the maturation of regulatory T-cells (Treg) which modulate the immune system and 
maintain tolerance to self-antigens. In combination with IFN-γ, IL-2 acts in the induction of central 
memory T-cells which possess multifunctional abilities. As noted previously, immunisation with H56 
265 
 
antigen-adsorbing liposomal vaccines, in comparison to both control groups (free resiquimod and 
H56) led to enhanced IL-2 production upon restimulation of splenocytes with previously re-
encountered H56 antigen (5 μg/mL). As described previously with IFN-γ and IL-17, peak IL-2 
production (around 2000 pg/mL) was noted by splenocytes derived from mice immunised with 
(Figure 7.24) cationic DDA/TDB with resiquimod conjugated to the bilayer of vesicles (Figure 7.24), in 
comparison to other liposome formulations (P < 0.01). This suggested that resiquimod enhanced Th1 
immune responses and the combination of liposome, antigen and agonist was important in this 
induction. 
Interleukin-6 (IL-6) is an important cytokine for B cell differentiation towards antibody secreting 
plasma cells. IL-6 also plays a role in the differentiation of T cells to a Th1 or Th2 phenotype so is 
therefore an important cytokine for detection of humoural immune responses as well as cell-
mediated immunity. This pro-inflammatory cytokine is also secreted by T-cells and macrophages in 
order to stimulate the immune response, and IL-6 is also enhanced upon activation of macrophages 
by Toll-like receptor (TLR) agonists within the vaccine formulations. When analysing the results for 
IL-6 production it was observed that splenocytes derived from mice immunised with liposome-
adjuvanted vaccines displayed increased IL-6 cytokine release as has been shown for all other 
cytokines tested (Figure 7.24). Upon splenocyte restimulation with H56 antigen, cationic DDA/TDB 
with bilayer-conjugated resiquimod (DDA/TDB/DSPE=Resiquimod:H56) resulted in significant 
increases in cytokine production, when compared to both other cationic formulations (P < 0.01). 
Interleukin-5 (IL-5) plays a crucial role in activating naïve T cells towards a Th2 phenotype. IL-5 is also 
one of the principle cytokines used to detect immune responses after experimental administration 
of mineral salt adjuvants, such as alum (Noe et al., 2010, Hutchison et al., 2012), due to their Th2 
polarising abilities. When analysing the data for IL-5 cytokine release for H56-liposome adjuvanted 
vaccines it was interesting to note that bilayer conjugation of resiquimod within the formulation 
down-regulated the production of this cytokine upon splenocyte restimulation with H56 antigen 
(Figure 7.24), in comparison to other cationic formulations tested (P < 0.001). In line with this 
finding, work in previous literature has demonstrated that upon inclusion of resiquimod within 
vaccine formulations, this has been shown to inhibit Th2 immune responses (Wagner et al., 1999). 
However levels of IL-5 were relatively low in comparison to other cytokines tested during this study, 
which showed the strong Th1 polarising abilities of these cationic liposomal vaccines (Davidsen et al., 
2005, Perrie et al., 2013). 
The final cytokine of the interleukin family investigated during this immunisation study was 
interleukin-10 (IL-10) which is also known to have dual Th1/Th2 differentiating abilities as well as 
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being involved in establishing humoural immune responses. However this cytokine also down-
regulates the activities of Th1 cytokines, IL2 and IFN-γ (Fiorentino et al., 1989), as well as inhibiting 
cell proliferation (Mocellin et al., 2004). The bilayer conjugation of resiquimod within the cationic 
DDA/TDB (DDA/TDB/DSPE=Resiquimod:H56) led to no difference in the production of IL-10 (Figure 
7.24), compared to both other cationic formulations tested. 
 
Figure 7-24. Cytokine production [IFN-γ, IL-17, IL-2, IL-5, IL-6 and IL-10] from cultured restimulated 
splenocytes derived from mice immunised with resiquimod alone (negative control), H56, either alone or 
combined with DDA/TDB, DDA/TDB/DSPE/Resiquimod (surface attached resiquimod) or 
DDA/TDB/DSPE=Resiquimod (bilayer-incorporated resiquimod). Mice received 3 injections with 2-week 
intervals and splenocytes were obtained 3 weeks post the final immunisation. Splenocytes were restimulated 
for 72 hrs in the presence of H56 (at 5 μg/mL). Cytokines were detected from splenocyte supernatants and 
measured using sandwich ELISAs. Significance between experimental groups was measured by one-way 
ANOVA (*** p<0.001; ** p<0.01; * p<0.05). 
 
7.3.7.4. Cytokine Analysis from ex vivo restimulated popliteal lymph node cells 
 
The supernatants of restimulated popliteal lymph node cells were also assayed for the presence of 
cytokines IFN-γ, IL-17, IL-2, IL-6, IL-5 and IL-10 following restimulation of these cells with H56 antigen 
(Ag85B-ESAT6-Rv2660c) at concentrations of 0.05, 0.5 and 5 μg/mL, in addition to ConA (2 μg/mL) 
stimulation as a positive control. Also as a negative control, cytokine production was measured in 
the absence of splenocyte restimulation (media only). Figure 7.25 gave a conclusive overview of the 
results derived from each experimental group, following restimulation at 5 μg/mL H56. Whilst 
individual cytokine production in response to media (negative control), ConA (positive control) and 
also H56 (0.05, 0.5 and 5 μg/mL) was shown in the Appendix (Figure 6). 
The main results from these studies showed that unstimulated PLN gave rise to background levels of 
all cytokines tested (< 100 pg/mL) during this investigation, which suggested that cytokine 
production was highly-dependent on the activation of splenocytes with previously encountered 
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antigen. Also the restimulation of PLN cells with ConA led to high positive responses of all cytokines 
tested with no hugely significant differences measured between formulation groups (Appendix 
Figure 6, A to F). Also liposome-adjuvanted vaccines gave rise to significantly higher (P < 0.001) 
cytokine production than negative control groups (H56 and resiquimod respectively; Figure 7.25).  
For H56-antigen restimulated splenocytes, IFN-γ production peaked following immunisation with 
DDA/TDB/DSPE=Resiquimod:H56, which was significantly higher than other liposome formulations 
tested (P < 0.05) and negative control groups (P < 0.001). As was noted during in vivo biodistribution 
studies (Section 7.3.6), including DSPE-conjugated resiquimod within the formulation 
(DDA/TDB/DSPE=Resiquimod:H56) resulted in increased retention and controlled release drainage 
to the LN, so higher amounts of TLR agonist drained to the PLN (in combination with liposome 
delivery system), leading to increased cytokine production following PLN restimulation. Similar 
results were described for IL-17 and IL-6 cytokine production (Figure 7.25), in which the general 
trend that cationic liposome formulations with bilayer-conjugated resiquimod enhanced the levels of 
production of these cytokines following PLN restimulation with previously encountered H56 antigen. 
Upon PLN restimulation with H56 antigen (5 μg/mL), this resulted in inhibition of Th2 cytokines 
following immunisation of mice with DDA/TDB/DSPE=Resiquimod:H56 compared to other cationic 
liposomes tested. This suggested that vaccine design to formulate resiquimod to remain at the SOI 
and subsequently drain to the lymph node led to the down-regulation of Th2 cytokine production 
(Tomai et al., 2007). As described previously for IL-5 responses at the spleen, these responses at the 
PLN are also the lowest of all cytokines tested with levels of < 400 pg/mL being measured (Figure 
7.25). As at the spleen, there were no significant differences between the liposome-adjuvanted 
vaccines in terms of the release of IL-10 at the PLN (Figure 7.25) therefore this suggested that 
resiquimod inclusion within the formulation does not affect these responses both at the spleen and 
PLN.  
Therefore, the main findings from the results, in terms of immune responses at the spleen and PLN, 
were that bilayer inclusion of resiquimod (resiquimod conjugation) within the formulation 
(DDA/TDB/DSPE=Resiquimod:H56) resulted in enhanced production of Th1/Th17 cytokines and 
down-regulation of Th2 cytokines from restimulated splenocytes. These results were in comparison 
to other cationic liposome vaccines tested, DDA/TDB/DSPE/Resiquimod:H56 (TLR agonist added 
post-lipid film hydration) and DDA/TDB:H56. Similar trends at both of these sites showed that 
vaccine antigen (in association with liposomal adjuvant) drained to different areas of the body as is 
shown for the biodistribution of these tested vaccine formulations (Section 7.3.6), which was 
especially important for T-cell rich sites associated with the initiation of the immune response.  
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Also all vaccines formulated within liposomal adjuvants gave rise to significantly higher cytokine 
production (for all cytokines tested) than the negative control groups (H56 and resiquimod 
respectively). This showed the importance of formulating sub-unit vaccines, such as H56, with 
delivery system in order to achieve optimal immune responses (Henriksen-Lacey et al., 2010a). 
 
Figure 7-25. Cytokine production [IFN-γ, IL-17, IL-2, IL-5, IL-6 and IL-10] from cultured restimulated popliteal 
lymph node cell derived from mice immunised with resiquimod alone (negative control), H56 (Ag85B-ESAT6-
Rv2660c), either alone or combined with DDA/TDB, DDA/TDB/DSPE/Resiquimod (surface attached 
resiquimod) or DDA/TDB/DSPE=Resiquimod (bilayer-incorporated resiquimod). Mice received 3 injections 
with 2-week intervals and splenocytes were obtained 3 weeks post the final immunisation. Splenocytes were 
restimulated for 72 hrs in the presence of H56 (at 5 μg/mL). Cytokines were detected from splenocyte 
supernatants and measured using sandwich ELISAs. Significance between experimental groups was measured 
by one-way ANOVA (*** p<0.001; ** p<0.01; * p<0.05). 
 
7.4. Conclusions 
 
During these studies, we have been able to design and synthesise a novel conjugate between lipid 
and TLR agonist, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE) and resiquimod, 
respectively. This was a two-step reaction, involving succinylation and esterification, which was 
confirmed by TLC, IR and NMR. Cationic DDA/TDB liposomes, with the inclusion of this 
DSPE=Resiquimod conjugate structure, displayed a vesicle size in the region of 450-500 nm and a 
zeta potential of 65 mV which was similar to previously characterised DDA/TDB (which was shown 
throughout this thesis). Addition of the H56 subunit vaccine antigen led to no further changes in 
vesicle characteristics. It was suggested that the intercalation of the lipid tail of the lipid-TLR 
conjugate into the bilayer of the delivery system resulted in the displaying of the TLR agonist at the 
liposome surface as has been described previously in the literature (Smirnov et al., 2011). 
The high association of resiquimod (when conjugated to DSPE) and/or antigen within the cationic 
liposome formulation, DDA/TDB was confirmed following radiolabelling experiments. As a negative 
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control, resiquimod was added to pre-formed DDA/TDB/DSPE liposomes (also with or without H56 
antigen). There were no measured differences in the vesicle characteristics; however, there was a 
significant (P < 0.001) reduction in resiquimod loading by the liposome formulation thus showing 
that resiquimod was unable to bind to the delivery system through electrostatics and instead 
required to be associated by other means as has been shown through inclusion within the bilayer. 
The biodistribution of these formulations was investigated following dual radiolabelling of the 
liposome delivery system and TLR agonist respectively. The bilayer incorporation of DSPE-conjugated 
resiquimod into DDA/TDB leads to ‘depot formation’ of TLR agonist at the SOI. This was also shown 
to lead to the subsequent controlled release and drainage of resiquimod to the draining popliteal 
lymph node (PLN). In vivo immunisation studies using the latent TB vaccine, H56, concluded that 
bilayer incorporation of lipid-TLR conjugate within the DDA/TDB vaccine formulation resulted in a 
significant increase in release of Th1 cytokines including IFN-γ, IL-2, IL-1β and IL-18 both at the 
spleen, popliteal lymph node and site of injection respectively. Whereas, this formulation was shown 
to down-regulate the production of Th2 cytokines such as IL-5 at both the spleen and PLN.  
In terms of antibody responses in the blood sera, all cationic formulations displayed similar levels of 
H56-specific IgG and IgG1 titres. However, inclusion of resiquimod within the bilayer of the liposome 
adjuvant led to increased anti-H56 IgG2b antibody titres, therefore this showed that resiquimod 
inclusion within the adjuvant strongly enhanced the generated Th1 immune response. Therefore, 
these studies showed that this novel formulation, with resiquimod conjugated within the bilayer of 
the vesicles was able to be delivered with DDA/TDB which has subsequently helped increase the bias 
further towards Th1 immunity. 
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Chapter 8: General Discussion 
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8.1. Optimisation and formulation of liposomal adjuvants 
 
During initial studies we sought to optimise and formulate previously characterised cationic 
DDA/TDB liposomes. This liposome system is currently in phase I clinical trials in combination with 
the TB Ag85B-ESAT6 fusion protein, otherwise known as Hybrid 1 (NCT no: NCT00922363). To 
determine the role of charge in the initial development and formulation of liposomes, the cationic 
lipid DDA was substituted with DSPS therefore giving a high anionic surface charge to the liposomes 
due to the anionic nature of DSPS. These novel liposomes exhibited a fairly similar size to DDA/TDB, 
being in the region of 400 nm, however display a highly anionic surface charge. 
The effect of hydration buffer and dilution buffer was investigated, in which PBS-hydrated liposomes 
tended to aggregate (Yan and Huang, 2009) with this effect being deemed greater for cationic 
DDA/TDB compared to anionic DSPS/TDB liposomes. Upon liposome characterisation, dilution buffer 
also had an effect on vesicle characteristics with this effect being higher for PBS-hydrated liposomes. 
Increasing the concentration of PBS dilution buffer led to slight neutralisation of the surface charge. 
However for Tris-hydrated liposomes, vesicle characteristics remained fairly constant both for vesicle 
size and surface charge which has been addressed during short term stability studies. Therefore as a 
product specification the ideal hydration buffer for formulation of liposomes during these studies 
was Tris (10 mM; pH 7.4) whilst using a weak dilution (of the same buffer) for characterisation 
Further modulation of the liposome surface charge was displayed by increasing the content of the 
neutral lipid DSPC within cationic DDA/TDB and anionic DSPS/TDB liposomes respectively. Through 
increase in the concentration of DSPC within the formulation this resulted in neutralisation of the 
surface charge, with complete DSPC replacement also leading to a significant increase in the vesicle 
size. During this thesis the latency-associated TB subunit vaccine H56 (Ag85B-ESAT6-Rv2660c) has 
been used in initial characterisation and loading studies, as well as immunisation studies. Due to the 
anionic charge of this subunit vaccine, high adsorption was noted for cationic DDA/TDB liposomes 
with observed changes in vesicle characteristics measured.  
 
8.2. The role of liposome surface charge and antigen charge for the depot 
effect and subsequent ability to induce immune responses 
 
It has been hypothesised that cationic liposomes interact with negatively charged serum proteins at 
the injection site, therefore resulting in the formation of a depot of liposome and co-administered 
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antigen (Henriksen-Lacey et al., 2010a). Cationic DDA/TDB and anionic DSPS/TDB liposomes were 
formulated with the H56 subunit vaccine or the cationic model protein lysozyme during initial 
studies. Upon formulation between oppositely charged liposome and antigen components this 
resulted in high antigen loading, due to electrostatic binding at the liposome surface (as shown by 
trypsinisation studies) which led to observed changes in vesicle characteristics. The delivery of 
anionic DSPS/TDB, and co-administered antigen, led to rapid drainage from the injection site. These 
non-depot forming liposome vaccines appeared to drain quickly to the popliteal lymph node which 
was disadvantageous for the generation of Th1 immune responses. In contrast, cationic DDA/TDB 
liposomes (and associated antigen) were efficiently retained at the injection site and displayed more 
controlled release and drainage to the local lymph node. This displayed retention and drainage 
characteristics of cationic DDA/TDB appear to be beneficial in the induction of Th1 cytokines (Perrie 
et al., 2013) at the spleen (IFN-γ and IL-2) and injection site (IL-1β and IL-18) as well as eliciting 
enhanced antibody responses. In terms of splenocyte proliferation, these studies suggested that 
liposome charge had an important role to play in terms of the ability of liposome vaccine 
formulations to deliver antigen to APCs in the spleen with DDA/TDB liposomes being able to induce a 
population of T-cells that could respond upon re-exposure to the disease antigen. The induction of 
cytokine production at the injection site suggested a link with the inflammasome in the generation 
of enhanced immune responses, upon injection of liposome adjuvants such as CAF01 (Sharp et al., 
2009, Schweneker et al., 2013). 
 
8.3. The effect of liposome preparation method; does antigen entrapment 
play a role in the generated immune response? 
 
As it was previously established that a positive (cationic) charge, along with antigen adsorption 
played a role in the biodistribution of liposomal adjuvants, the role of liposome preparation method 
was also investigated. Liposomes have been prepared by the dehydration-rehydration vesicle (DRV) 
method and the double emulsion (DE) method (Nordly et al., 2011c), with the aim of entrapping the 
antigen within the delivery system. As described previously both cationic DDA/TDB and anionic 
DSPS/TDB were co-formulated with either the H56 subunit vaccine or model protein lysozyme. DE 
formulations displayed a reduction in vesicle size, and exhibited lower initial levels of antigen 
loading, in comparison to their respective DRV formulations. However antigen loading was still 
enhanced through addition of oppositely charged vaccine components therefore this showed that 
charge-mediated electrostatics still played a role in this interaction. Trypsin digestion studies have 
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shown that antigen was efficiently entrapped within DRV-formulations, whereas for DE formulations 
antigen was partly entrapped and also surface-adsorbed to the delivery system. 
A similar general trend was observed, in which irrespective of preparation method, anionic 
DSPS/TDB liposomes were removed faster from the injection site compared to their respective 
cationic DDA/TDB formulations. However as described previously the interaction between 
oppositely charged liposome and antigen leads to the formation of an antigen depot at the injection 
site, whereas similarly charged vaccine components lead to low adsorption efficiency and 
subsequent removal from the injection site. In terms of vaccine drainage to the popliteal lymph 
node, non-depot forming anionic DSPS/TDB drained faster to this site irrespective of preparation 
method. Whereas as described in Section 8.2, cationic DDA/TDB (formulated as DRV and DE) have a 
more controlled release drainage pattern which was important for the generation of an immune 
response when formulated with the H56 subunit vaccine. In general, DRV and DE DDA/TDB:H56 
formulations gave rise to similar high release of IFN-γ and IL-17, as well as low release of IL-5, at both 
the spleen and PLN (upon restimulation with previously encountered antigen) thus showing the high 
Th1/Th17 profile of these vaccine adjuvants. However, anionic DRV DSPS/TDB (and not DE) 
liposomes enhanced IL-5 release at both these sites thus this demonstrated the change in bias 
towards Th2-like responses. In terms of antibody production, in general cationic DDA/TDB 
formulations induced higher responses than their anionic counterparts. DRV-formulated vaccines 
enhanced the responses for DDA/TDB:H56 liposomes, when compared to their DE-counterparts, 
with increased IgG2 (a and b) responses noted. Whilst for IgG1, similar responses were measured 
irrespective of the preparation method. These studies have shown that liposome preparation 
method plays a role in antigen presentation to APCs and the subsequent immune response, as 
characterised by cytokine production and antibody responses. 
 
8.4. The inclusion of immunostimulatory TLR agonists within cationic 
liposome adjuvants 
 
The versatile nature of liposomes allows for the inclusion of immunostimulatory molecules within 
the delivery system. With this in mind the TLR3 agonist, polyI:C, was chosen as a candidate molecule 
to include within cationic liposome vaccine adjuvants with the aim of further optimisation of these 
vesicle systems (Milicic et al., 2012). The inclusion of this TLR agonist within liposome vaccine 
adjuvants was shown to increase CD8+ T-cell responses due to the cross-presentation of antigen 
(Zaks et al., 2006, Nordly et al., 2011c). Due to opposing charges, the binding between the cationic 
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liposome surface (of MLV and SUV) and the anionic TLR agonist was mediated through charge-
mediated electrostatic interactions, which at the whole dose concentration was also shown to lead 
to significant dose-dependent changes in vesicle characteristics such as vesicle aggregation. 
However variation in liposome preparation was also used to entrap TLR agonist within the delivery 
system through the use of the DRV method, with less significant changes in vesicle characteristics 
being noted. Through incorporation of antigen within liposome-TLR agonist formulations 
(DDA/TDB/polyI:C) this resulted in no significant changes in initial antigen loading.  
 
8.5. Optimisation of cationic liposome adjuvants with incorporation of TLR 
agonists; stepwise incorporation and high shear mixing 
 
In terms of combined liposome-TLR agonist formulations it was important to maintain constant 
vesicle size and surface charge characteristics in terms of their in vivo mode of action. With this in 
mind, the polyI:C TLR agonist dose could be incorporated step-wise within the formulation, followed 
by either vortexing or high shear mixing. Through stepwise incorporation of polyI:C within the 
formulation (prepared as MLV) this led to slower incorporation and high loading of TLR agonist and 
hence no measured significant changes in vesicle characteristics. Whereas initial formulation of 
cationic DDA/TDB through high shear mixing (HSM), led to a significant reduction in vesicle size with 
no such changes noted for the zeta potential of these systems. Through the introduction of high 
energy forces using HSM this led to the breakdown of the outer layers of the delivery system in 
order to reduce the size of liposomal adjuvants. This process was also used upon stepwise 
incorporation of increasing concentrations of polyI:C, followed by HSM, which led to no further 
significant changes in vesicle characteristics. Therefore through HSM, cationic liposomal adjuvants 
can be formulated with reduced vesicle size which could still incorporate and load high levels of TLR 
agonist, up to the in vivo dose level.  
 
8.6. Investigating the stability of liposome systems 
 
The stability of liposomes was a crucial issue for the use of these vesicles as vaccine delivery 
systems. The storage and handling of these liposomes was extremely important in order to maintain 
their ability to act as vaccine adjuvants and also in being able to transport them to other countries 
for use in vaccination. The handling of these liposomes is very difficult due to their fragility and 
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delicate nature. Liposomes in solution offer a weak chemical and physical stability – therefore 
explaining the reason for only a relatively small number of liposomal-based vaccines being available, 
with several currently in clinical trials. Since most vaccines were thermally unstable, there was an 
important need to create stable vaccine formulations which can be transported to third world 
countries. The distribution of vaccines required “cold-chains” with functional freezers, as well as 
reliable transport links (Christensen et al., 2007a) therefore making vaccine stability a key criteria in 
the development of these delivery systems. Throughout this thesis, the stability of these liposome 
vaccine adjuvants (with and without antigen) was investigated in a number of short 28-day studies, 
as well as longer term 6 month stability trials. These studies were carried out to show the effect of 
hydration buffer, liposome surface charge, liposome preparation method as well as the inclusion of 
immunostimulatory TLR agonists on the stability of the delivery system in terms of measured vesicle 
characteristics. 
Throughout this thesis, vesicles were demonstrated to be relatively stable during short term studies 
(28 days) with storage at the ‘cold chain’ (4 °C) leading to the maintenance of constant vesicle 
characteristics. Storage at 25 °C leads to more slight changes in vesicle characteristics, however 
vesicles remain relatively stable both without and with subunit vaccine antigen (H56). Longer term 
stability trials were carried out for MLV and HSM formulations with the inclusion of 
immunostimulatory polyI:C within the liposome system. Storage of liposomes in accelerated 
conditions (40 °C) led to a general trend for more significant changes in liposome characteristics, 
with liposomes increasing in size due to vesicle aggregation. This suggested vesicle aggregation is 
temperature-dependent, as liposome storage at 4 and 25 °C resulted in lesser changes in 
characteristics for all formulations tested. Therefore, the storage of these liposomes under lower 
temperatures will potentially increase the shelf-life and stability of these vesicles. During liposome 
formulation, the optimisation of the preparation process including the temperature, ionic strength 
of the buffer as well as the addition of stabilising components within the bilayer (including 
cholesterol and immunostimulatory lipids) could lead to increased stability of the delivery system 
also (Grit and Crommelin, 1993, Zuidam et al., 1995, Davidsen et al., 2005). 
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8.7. The inclusion of immunostimulatory resiquimod within cationic 
liposomes; does conjugation with lipid and inclusion within the membrane 
bilayer affect the biodistribution and subsequent immune response? 
 
Resiquimod is an agonist that activates the endosome-located TLR7 receptor. This TLR agonist has 
had mixed success within vaccine formulations due to its ability to very quickly distribute throughout 
the body rather than remain at the site of injection (Tomai et al., 2007). This systemic distribution is 
disadvantageous for the initiation of immune responses. Therefore the formulation of resiquimod to 
remain at the injection site, along with antigen and delivery system, was an important strategy in 
order to overcome this issue. This can be achieved through dermal or topical application, as well as 
formulation within liposome vaccine adjuvants (Tomai et al., 2007, Smirnov et al., 2011). In order to 
incorporate resiquimod within these liposomes, it was hypothesised to formulate a conjugate 
between DSPE lipid and this TLR agonist. This lipid-TLR agonist conjugate was successfully 
incorporated within the bilayer of cationic DDA/TDB liposomes. This has been proven using 
radiolabelling and biodistribution studies. This novel cationic DDA/TDB liposome formulation (with 
bilayer incorporated resiquimod) was strongly retained at the injection site following intramuscular 
administration. In terms of drainage to the PLN, both delivery system and TLR agonist display 
controlled release kinetics (when resiquimod was conjugated to the bilayer of vesicles) in terms of 
movement from the injection site which was also important for increased immune responses due to 
the simultaneous delivery of antigen, agonist and adjuvant (Henriksen-Lacey et al., 2010a, Kamath et 
al., 2012). This was correlated by enhanced Th1/Th17 immune responses both at the spleen and PLN 
as characterised by increased production of IFN-γ, IL-2 and IL-17 as well as the down-regulation of 
Th2 responses (as characterised by a reduction in IL-5 release). In terms of cytokine analysis at the 
SOI, efficient inclusion of resiquimod within the formulation resulted in increased production of IL-
1β, IL-18 and IL-33 which suggested a further role for this liposome formulation (and associated TLR 
agonist) in the activation of the inflammasome in the downstream induction of these immune 
responses. 
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8.8. Final conclusions 
 
To summarise, in relation to initial aims and objectives set in Chapter 1 of the thesis, these studies 
have shown that;  
1. A novel anionic liposome system comprising DSPS and TDB was formulated. 
2. Cationic DDA/TDB liposomes have an advantage over their anionic DSPS/TDB counterparts in 
terms of their ability to promote Th1 immune response, due to the formation of a strong 
‘antigen depot’ at the injection site as well as controlled drainage to the lymph nodes. 
3. Formulation of liposomal adjuvants by the DRV method resulted in higher levels of antigen 
entrapment within the system compared to their respective DE counterparts. This led to no 
significant effect on the Th1-inducing effects of cationic DDA/TDB, however caused elevation 
in the Th2-inducing effects of anionic DSPS/TDB liposomes 
4. The TLR3 agonist, polyI:C, could be efficiently loaded by cationic DDA/TDB liposomes with 
resulting changes in vesicle characteristics being measured including vesicle aggregation, 
neutralisation of the surface charge and greater antigen release however this varied 
depending on the liposome preparation method used. 
5. The vesicle characteristics (size and zeta potential) of polyI:C containing DDA/TDB liposomal 
adjuvants could be maintained through stepwise incorporation of TLR agonist within the 
delivery system, and be further modified through the use of the high shear mixing. 
6. A novel conjugate structure has been synthesised between the TLR7 agonist resiquimod and 
DSPE lipid, which was confirmed through chemical analysis methods. 
7. This conjugate structure was formulated within cationic DDA/TDB liposomes, with this novel 
vaccine adjuvant being shown to significantly increase Th1 responses and down-regulate Th2 
responses (compared to DDA/TDB) at the SOI, spleen and PLN as well as leading to enhanced 
IgG2b antibody titres in the blood sera. 
 
8.9. Future work 
 
With regards to future experiments, the immunogenicity of the non-disease antigen lysozyme could 
be determined following co-formulation with DDA/TDB and DSPS/TDB liposomes prepared by a 
variety of methods. This could be in order to show whether liposome surface charge, liposome-
antigen interactions or the method of antigen attachment plays a more crucial role in stimulating the 
immune response. Part of the mechanism for the mode of action of liposomal adjuvants is termed 
278 
 
the ‘depot effect’ however it may be interesting to elucidate if further factors played a role in this 
process, such as the activation of downstream immune responses. Further optimisation of cationic 
DDA/TDB including TLR agonists and other immunostimulatory molecules might also be an 
interesting route to further understand how these liposomal vaccines function. Future work may 
also focus on the effect of preparation method on the biodistribution of TLR agonists. Also further 
TLR agonists could be included within liposome formulations to see what effect this exerts on the 
mode of action of the vaccine in terms of the immune response. In order to further understand the 
immunogenicity of the formulations studied in this thesis, TB challenge studies could be carried out 
and also larger animal models could be used. 
To finalise, cationic DDA/TDB liposomes have been further described as an ideal platform for the 
delivery of subunit vaccines. The versatile and flexible nature of this vaccine adjuvant system allows 
for the further modification and optimisation with the aim of further stimulating immune responses. 
The results presented within this thesis will further bring forward our understanding of the way 
cationic vaccine adjuvants exert their mode of action. 
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Appendix 
 
 
Figure A-1. DDA/TDB/DSPE/Resiquimod, DDA/TDB/DSPE=Resiquimod and DDA/TDB, all adsorbing H56 
antigen. The proportion of 
3
H radionucleotide at the blank lymph node (BLN) as a percentage of the initial 
dose was calculated. Results represent the mean ± SD of four mice. 
 
Figure A-2. DDA/TDB/DSPE/Resiquimod, DDA/TDB/DSPE=Resiquimod, Resiquimod and DDA/TDB, all 
adsorbing H56 antigen apart from free resiquimod. The proportion of 
125
I radionucleotide at the blank lymph 
node (BLN) as a percentage of the initial dose was calculated. Results represent the mean ± SD of four mice. 
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Figure A-3. A range of tissues were collected at (A) one (B), four and (C) eight days p.i and processed to 
determine the proportion of 
3
H-labelled liposomes. Results represent the mean ± SD of four mice. 
 
 
 
 
 
Figure A-4. A range of tissues were collected at (A) one (B), four and (C) eight days p.i and processed to 
determine the proportion of 
125
I-labelled resiquimod. Results represent the mean ± SD of four mice. 
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Figure A-5. Cytokine production [A: IFN-γ; B: IL-17; C: IL-2; D: IL-5; E: IL-6; F: IL-10] from cultured restimulated 
splenocytes derived from mice immunised with resiquimod alone (negative control), H56 (Ag85B-ESAT6-
Rv2660c), either alone or combined with DDA/TDB, DDA/TDB/DSPE/Resiquimod (surface attached 
resiquimod) or DDA/TDB/DSPE=Resiquimod (bilayer-incorporated resiquimod). Mice received 3 injections 
with 2-week intervals and splenocytes were obtained 3 weeks post the final immunisation. Splenocytes were 
restimulated for 72 hrs in the presence of media alone, H56 at 0.05 μg/mL, 0.5 μg/mL or 5 μg/mL, or in the 
presence of 2 μg/mL ConA to act as a positive control. Cytokines were detected from splenocyte supernatants 
and measured using sandwich ELISAs. 
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Figure A-6. Cytokine production [A: IFN-γ; B: IL-17; C: IL-2; D: IL5; E: IL-6; F: IL-10] from cultured restimulated 
popliteal lymph node cells derived from mice immunised with resiquimod alone (negative control), H56 
(Ag85B-ESAT6-Rv2660c), either alone or combined with DDA:TDB, DDA/TDB/DSPE/Resiquimod (surface 
attached resiquimod) or DDA/TDB/DSPE=Resiquimod (bilayer-incorporated resiquimod). Mice received 3 
injections with 2-week intervals and splenocytes were obtained 3 weeks post the final immunisation. 
Splenocytes were restimulated for 72 hrs in the presence of media alone, H56 at 0.05 μg/mL, 0.5 μg/mL or 5 
μg/mL, or in the presence of 2 μg/mL ConA to act as a positive control. Cytokines were detected from 
splenocyte supernatants and measured using sandwich ELISAs. 
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